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ABSTRACT 
 
Glioblastoma Multiforme (GBM) is the most common lethal brain tumour 
associated with dismal survival rate. GBM is considered to be an incurable 
malignancy as these tumours evade all intricate attempts of therapy and no 
contemporary chemotherapeutic regimen is effective. Although the existence of 
cancer stem cells (CSCs) is still debatable, it is widely accepted that GBM has a 
small population of cells expressing CSC markers (~1%) that are highly 
resistant to chemo-radiation therapy. Recent evidence indicates that hypoxia 
induces cancer stem cell (CSC) phenotypes via epithelial-to-mesenchymal 
transition (EMT) that promote therapeutic resistance in solid tumours. Given 
that GBMs are extensively hypooxygenated heterogenous tumours, 
understanding the molecular relationship between hypoxia, biology of CSCs, 
EMT and chemoresistance would be invaluable for development of drugs that 
can target CSCs. Evidence suggests that hypoxia inducible factors (HIFs), NF-
B and aldehyde dehydrogenase (ALDH) together orchestrate the stemness 
and chemoresistance in hypoxia induced CSCs. But the insights on the 
mechanisms still remain obscure. In this study we used an in vitro GBM CSC 
and hypoxia model along with NF-B-p65 and HIF transfected GBM cell lines to 
investigate the relationship between HIFs, NF-B activation and ALDH activity 
and their role in chemoresistance.  
 
 iv 
 
The findings of this study demonstrated that GBM cells grown as spheres 
consist of a vast proportion of hypoxic cells with elevated CSC and EMT 
markers suggesting hypoxia induced EMT. GBM-CSCs are chemoresistant and 
displayed increased levels of HIFs, NF-B and ALDH activity. It was also 
observed that stable transfection of GBM cells with NF-B-p65 or HIFs induced 
CSC and EMT markers indicating their essential role in maintaining CSC 
phenotypes. The study also highlighted the importance of NF-B and ALDH in 
driving chemoresistance and the potential role of NF-B as the master regulator 
of hypoxia induced stemness in GBM cells. 
 
In this study, we used Disulfiram (DS), an anti-alcoholism drug, in combination 
with copper (Cu) to target the hypoxia-NF-B axis and inhibit ALDH activity to 
reverse chemoresistance in GBM CSCs. We showed that DS/Cu is cytotoxic to 
GBM cells and completely eradicated the resistant CSC population at low 
nanomolar levels in vitro. We also demonstrated that DS/Cu effectively inhibited 
GBM in vivo using newly formulated PLGA-DS nanoparticles. DS is an FDA 
approved drug with low/no toxicity to normal tissues and can freely pass 
through the blood brain barrier (BBB). Further study may lead to quick 
translation of DS into clinical trials. 
 
  
 v 
 
Table of contents 
 
 
Declaration i 
Dedication ii 
Abstract iii 
Table of contents v 
List of Tables xiv 
List of Figures xiv 
Abbreviations xxiii 
Acknowledgements xxix 
  
Chapter 1         Introduction 
 
1 
1.1 Brain Tumours 2 
1.2 Gliomas 3 
1.3 Glioblastoma multiforme (GBM) 4 
1.3.1 Historical Overview of GBM 6 
1.3.2 Epidemiology of Glioblastomas 6 
1.3.3 Etiology of GBM 8 
1.3.4 Biological and morphological features 8 
1.3.5 Molecular subtypes of GBM 10 
1.4 Treatment for GBM 11 
1.4.1 Surgical resection 11 
1.4.2 Radiotherapy 13 
1.4.3 Chemotherapy 14 
1.4.3.1 Temozolomide 15 
1.4.3.2 Gliadel wafers 18 
 vi 
 
1.5  Chemoresistance in GBM 19 
 1.5.1 Drug efflux mechanisms 19 
1.5.1.1 Blood brain barrier 19 
1.5.1.2 P-glycoprotein 20 
1.5.1.3 Multidrug resistance associated protein  21 
1.5.2 DNA damage repair mechanisms 22 
1.5.2.1 MGMT 22 
1.5.2.2 DNA Mismatch repair  23 
1.5.2.3 Base excision repair and PARP-1  24 
1.5.3 Apoptosis resistance 25 
1.6 GBM Cancer stem cells 26 
1.6.1 GBM CSCs and therapeutic resistance 28 
1.6.2 Origin of GBM CSCs 31 
1.6.2.1 Neural stem cells as source of GBM CSCs  31 
1.6.2.2 Epithelial to mesenchymal transition induced GBM 
CSCs 
33 
1.6.2.3 EMT induced by tumour microenvironment 35 
1.7 Hypoxia  36 
1.7.1 Molecular biology of hypoxia inducible factors 37 
1.7.2 Hypoxia induced EMT and CSCs 40 
1.8 Nuclear Factor kappa B (NF-B) 44 
1.8.1 The NF-B activation pathways  46 
1.8.2 NF-B and cancer chemoresistance 47 
1.8.3 Role of NF-B in hypoxia induced EMT 49 
1.9 Disulfiram  51 
1.9.1  Pharmacology of Disulfiram 51 
1.9.2  Disulfiram and treatment  54 
 vii 
 
1.9.2.1 Anti-alcoholism  54 
1.9.2.2 Anti-cancer treatment  54 
1.9.3  Mechanism of Action 55 
1.9.3.1 Role of Reactive Oxygen Species and Copper in anti 
cancer effect of DS 
55 
1.9.3.2 Overriding resistance to chemotherapy 58 
1.10  Targeting CSCs with Disulfiram 59 
1.10.1  Proteasome / NF-B inhibition 59 
1.10.2  ALDH inhibition 60 
1.11 Aims and objectives 62 
  
Chapter 2  Materials and Methods 
 
63 
2.1 Materials  64 
2.1.1 Labware, equipment, reagents, enzymes and kits 65 
2.1.2 Antibodies  68 
2.1.3 Cell lines  69 
2.1.4 Buffers  69 
2.2 Methods  73 
2.2.1 Routine Cell culture (ATT or NOR culture) 73 
2.2.2  Sphere cell culture 76 
2.2.3 Hypoxic Cell culture (HYP culture) 77 
2.2.4  Cytotoxicity assay 78 
2.2.5 SDS-PAGE/Western Blot  81 
2.2.6 Flow Cytometry  87 
2.2.7 Confocal microscopy  89 
2.2.8 Luciferase reporter gene assay  90 
 viii 
 
2.2.9 Molecular biology protocols  92 
2.2.9.1 Preparation of LB plates  92 
2.2.9.2 Transformation of competent bacterial cells  92 
2.2.9.3 Preparation of plasmid DNA  92 
2.2.9.4 Quantification of DNA  94 
2.2.9.5 Digestion of DNA with restriction endonucleases  94 
2.2.9.6 Agarose gel electrophoresis of DNA  94 
2.2.9.7 DNA Purification from agarose gels  95 
2.2.9.8 Ligation of DNA 95 
2.2.9.9 DNA sequencing  95 
2.2.10  Stable transfection of cell lines 96 
2.2.11   Migration assay 97 
2.2.12   Invasion assay 98 
2.2.13  Sphere-formation assay: 6-well plate format 99 
2.3  Statistical Tests 99 
 
 
 
Chapter 3 Characterisation of Spheroids from GBM cell lines 
100 
3.1 Introduction 101 
3.1.1 The GBM CSCs and Sphere cell culture 101 
3.1.2 Identification of GBM CSCs from culture 104 
3.1.2.1  CD133 (Prominin-1) 105 
3.1.2.2 ALDH Activity as a Universal CSC Marker 106 
3.1.2.3 SOX2 107 
3.1.2.4 OCT-4 108 
3.1.2.5 Nanog 109 
 ix 
 
3.1.3 CSCs from cell lines 110 
3.1.4 Rationale and aims of this study 112 
3.2  Experimental design 113 
3.2.1  In vitro neurosphere and suspension sphere culture 113 
3.2.2  Flow cytometric analysis of CSC markers 114 
3.2.3  MTT cytotoxicity assay for GBM monolayer cells 115 
3.2.4  MTT cytotoxicity assay for Sphere cells derived from
 GBMcell lines 
115 
3.2.5 Western blot analysis of stem cell proteins 116 
3.3  Results 117 
3.3.1 High levels of CSC markers are observed in both NS and SUS 
cells 
117 
3.3.2 The NS and SUS cultured cells are highly resistant to anticancer 
drugs 
124 
3.4 Discussion 130 
3.5 Conclusions 136 
  
Chapter 4 Hypoxia drives chemoresistant CSCs in GBM spheres through 
EMT 
137 
4.1 Introduction 138 
4.1.1 Hypoxia 139 
4.1.2 Hypoxia induced EMT 140 
4.1.3  Hypoxia induced EMT in GBM 142 
4.1.4 Hypoxia induced EMT and CSCs 144 
4.1.5 Markers used in this study to identify EMT phenotypes 146 
4.1.5.1 CD44  146 
4.1.5.2 Cadherin Switch  147 
4.1.5.3 Vimentin 148 
 x 
 
4.1.6  Rationale and aims of this study 149 
4.2 Experimental design 150 
4.2.1  Culturing cells under hypoxic conditions 150 
4.2.2  Determining the presence of hypoxia in sphere cells and hypoxic 
cell cultures 
151 
4.2.3  Analysis of EMT markers in sphere and hypoxic cells 152 
4.2.4 Determining mesenchymal properties cells 153 
4.2.5  Analysis of CSC markers in hypoxic cells 154 
4.2.6    MTT cytotoxicity assay for hypoxic cell cultures 154 
4.3 Results 155 
4.3.1 GBM sphere cells contain high proportion of hypoxic cells 155 
4.3.2 GBM sphere cells express EMT markers 158 
4.3.3 The effect of hypoxia on GBM cell lines cultured in monolayer 160 
4.3.4 Hypoxia induces EMT in GBM cell lines 163 
4.3.5 Hypoxic cells shows increased migration and invasion 165 
4.3.6  Hypoxic Cells shows increased CSC characteristics.  168 
4.3.7 Hypoxic cells are highly resistant to anticancer drugs  175 
4.4 Discussion 179 
4.5  Conclusions 184 
  
Chapter 5  The role of hypoxia inducible factors in   
 hypoxia induced EMT and GBM CSCs 
 
185 
5.1 Introduction 186 
5.1.1 The regulatory role of hypoxia and HIF pathway in EMT 187 
5.1.2 The regulatory role of hypoxia and HIFs in CSCs 188 
5.2 Rationale and aims of this study 191 
5.3 Experimental Design  192 
 xi 
 
5.3.1  Stable transfection U373GBM cells with HIF1 and HIF2 192 
5.3.2  Analysis of CSC markers in HIF transfected cells 193 
5.3.3 Determining mesenchymal properties of HIF-transfected clones 194 
5.3.4    MTT cytotoxicity assay for hypoxic cell cultures 195 
5.4  Results 196 
5.4.1 Stable transfection of U373 GBM cell line with HIF1 196 
5.4.2 HIF1 induces CSC characteristics in GBM cells 197 
5.4.3 HIF1 transfected cells displayed mesenchymal   
  properties 
200 
5.4.4 HIF1expression did not induce multidrug resistance in GBM 
  cells. 
204 
5.4.5 Stable transfection of U373 GBM cell line with HIF2 207 
5.4.6 HIF2 induces CSC characteristics in GBM cells 207 
5.4.7 HIF2 transfected cells displayed mesenchymal properties 211 
5.4.8 HIF2 expression did not induce multidrug resistance in GBM 
cells. 
215 
5.5 Discussion 218 
5.6 Conclusions 225 
  
Chapter 6 The role of NF-B in hypoxia induced EMT and GBM 
CSCs 
 
226 
6.1 Introduction 227 
6.1.1 NF-B and EMT 229 
6.1.2 NF-B and HIF signalling 229 
6.2 Rationale and aims of the study 231 
6.3 Experimental Design 232 
6.3.1 Determining NF-B activity in GBM spheres and hypoxic cells 232 
 xii 
 
6.3.2 Stable transfection U373GBM cells with NF-B-p65 233 
6.3.3 Luciferase reporter gene assay for NF-B activity 234 
6.3.4 Analysis of CSC markers in NF-B-p65 transfected cells 234 
6.3.5 Determining mesenchymal properties of NF-B-p65 clones 235 
6.3.6    MTT cytotoxicity assay for NF-B-p65 transfected cells 235 
6.4 Results 236 
6.4.1 High levels of NF-B was observed in both NS and SUS cells 236 
6.4.2 High levels of NF-B was observed in hypoxic cells 237 
6.4.3 Stable transfection of U373 GBM cell line with NF-B-p65 238 
6.4.4 NF-Bp65 transfected clones displayed mesenchymal properties 240 
6.4.5 High NF-B activity induces CSC characteristics in GBM cells 244 
6.4.6 NF-B induced multidrug resistance in GBM cells. 247 
6.5 Interplay between HIFs and NF-B signalling 249 
6.6 Interplay between NF-B and ALDH 252 
6.7 Discussion 260 
6.8 Conclusions 270 
  
Chapter 7  The role of NF-B in hypoxia induced    
 EMT and GBM CSCs 
 
272 
7.1 Introduction 273 
7.1.1 NF-B pathway as a therapeutic target in GBM 273 
7.1.2 Repurposing Disulfiram for GBM treatment 276 
7.2 Rationale and aims of this study 277 
7.3 Experimental Design 280 
7.3.1    MTT cytotoxicity assay  280 
7.3.2 Western blot analysis  281 
 xiii 
 
7.3.3  Sphere formation assay 282 
7.3.4  Cytotoxicity of DS/Cu on a panel of normal cell lines 283 
7.3.5 Preparation of PLGA-DSF nanoparticles 283 
7.3.6 In vitro half-life of Disulfiram 284 
7.3.7 Effect of PLGA-DS nano particles on orthotopic GBM xenograft 
mouse models 
284 
7.4 Results 285 
7.4.1 DS/Cu targets GBM CSCs in vitro 285 
7.4.2 DS/Cu abolished the sphere forming ability of GBM cells 289 
7.4.3 DS/Cu inhibits NF-κB and is cytotoxic to NF-κB and ALDH 
transfected GBM cells 
291 
7.4.4 DS/Cu induces Apoptosis in GBM cells 294 
7.4.5 DS/Cu is less toxic to normal cells 294 
7.4.6 PLGA-DS nanoparticles have increased serum half-life than free 
DS 
296 
7.4.7 PLGA-DS NPs inhibits GBM in orthotopic xenograft mouse 
models 
298 
7.5 Discussion 300 
7.6  Conclusion 306 
Chapter 8   Discussion 307 
References 324 
  
 
 
 
 
 xiv 
 
 
List of tables 
Table 1.1  WHO classifications of gliomas...........................................................5  
Table 2.1  Dilutions ratios for all the primary and secondary antibodies used  
  in the  work...........................................................................................86 
Table 3.1  IC50 values of conventional anticancer drugs on GBM cell lines 
  .............................................................................................................130 
Table 6.1  IC50s of TMZ, VCR, PAC and DOX in ALDH3A1 transfected U373MG 
 cell lines................................................................................................257 
Table 6.2  IC50s of TMZ, VCR, PAC and DOX in ALDH1A3 transfected U373MG 
 cell lines................................................................................................258 
Table 6.3  IC50s of TMZ, VCR, PAC and DOX in ALDH1A1 transfected U373MG 
 cell lines................................................................................................259 
 
List of figures 
Figure 1.1 Distribution of all primary gliomas in the CNS (CBTRUS, 2010)............5 
Figure 1.2 Molecular Subtypes of GBM.................................................................10 
Figure 1.3 Chemotherapy for GBM........................................................................15 
Figure 1.4   Structure of Temozolomide..................................................................17 
Figure 1.5 Normal neural progenitor cells and cancer stem cells..........................30 
Figure 1.6  A) Fate of HIF1under normoxia and hypoxia....................................42 
 xv 
 
Figure 1.6 B) Hypoxia induced EMT as an alternate way of inducing CSCs in 
GBM.......................................................................................................42 
Figure 1.7  Role of NF-B in cancer........................................................................48 
Figure 1.8 Disulfiram forms complex with copper...................................................58 
Figure 3.1 Morphology of GBM spheres................................................................118 
Figure 3.2  High ALDH activity detected in NS and SUS sphere cells....................119 
Figure 3.3  High CD133 expression detected in NS and SUS sphere cells............120 
Figure 3.4  NS and SUS sphere cells express high levels of embryonic CSC marker 
SOX2....................................................................................................121 
Figure 3.5  NS and SUS sphere cells express high levels of embryonic CSC marker 
OCT4....................................................................................................122 
Figure 3.6  NS and SUS sphere cells express high levels of embryonic CSC marker 
NANOG................................................................................................123   
Figure 3.7  Expression of embryonic stem cell markers in NS and SUS cells 
  .............................................................................................................124   
Figure 3.8  Morphology of ATT, NS and SUS cells after treatment with conventional 
anticancer drugs...........................................................................125 / 126   
Figure 3.9  In Vitro Cytotoxicity of conventional anticancer drugs on U87 ATT, NS 
and SUS cells.......................................................................................127 
 xvi 
 
Figure 3.10 In Vitro cytotoxicity of conventional anticancer drugs on U251 ATT, NS 
and SUS cells.......................................................................................128 
Figure 3.11 In Vitro cytotoxicity of conventional anticancer drugs on U373 ATT, NS 
and SUS cells.......................................................................................129 
Figure 4.1  Hypoxic population in GBM sphere cells: Determination of hypoxic status 
in cells by Hypoxyprobe staining and FACS analysis..........................156 
Figure 4.2  In situ detection of hypoxic cells in GBM spheres using Hypoxyprobe 
staining ................................................................................................157 
Figure 4.3  Western blot analysis of HIFs in GBM sphere cells.............................157 
Figure 4.4  High expression of CD44 in GBM cell line-derived NS and SUS 
cells..............................................................................................158 / 159 
Figure 4.5  Western blot analysis of EMT markers in GBM sphere cells..............159  
Figure 4.6  Hypoxic population was detected in hypoxia-cultured GBM cell 
lines......................................................................................................161  
Figure 4.7 Hypoxic cells in hypoxia-cultured GBM cell lines detected by in situ ICC 
Hypoxyprobe staining..........................................................................162 
Figure 4.8  Western blot analysis of HIFs in hypoxia-cultured GBM cell lines 
 ............................................................................................................162 
Figure 4.9  Expression of CD44 in hypoxia-cultured GBM cell lines...........163 / 164  
Figure 4.10 Western blot analysis of EMT markers in hypoxia-cultured GBM cell 
lines....................................................................................................164  
 xvii 
 
Figure 4.11 Hypoxia enhances the migratory potential of hypoxia-cultured GBM cell 
lines....................................................................................................166 
Figure 4.12 Hypoxia enhances the invasive activity of hypoxia-cultured GBM cell 
lines...................................................................................................167 
Figure 4.13 High ALDH activity detected in hypoxia-cultured GBM cell lines.... 
 ...........................................................................................................169 
Figure 4.14 High level of CD133 expression detected in hypoxia-cultured GBM cell 
lines...................................................................................................170 
Figure 4.15 (A) Expression of Embryonic CSC markers in normoxic and hypoxic 
cultures of U87MG............................................................................171 
Figure 4.15 (B) Expression of Embryonic CSC markers in normoxic and hypoxic 
cultures of U251MG..........................................................................172  
Figure 4.15 (C) Expression of Embryonic CSC markers in normoxic and hypoxic 
cultures of U373MG.........................................................................173  
Figure 4.16 Western blot analysis of embryonic stem cell markers in hypoxia-
cultured GBM cell lines....................................................................174   
Figure 4.17 Growth curve for Normoxic and Hypoxic cultures of GBM cell lines. 
....................................................................................................................174 
Figure 4.18 (A) Hypoxia induces chemoresistance in U87MG cells...................176  
Figure 4.18 (B) Hypoxia induces chemoresistance in U251MG cells................177 
Figure 4.18 (C) Hypoxia induces chemoresistance in U373MG cells................178 
 xviii 
 
Figure 5.1  The expression status of HIF1 protein in HIF1 transfected U373MG 
GBM cell lines.....................................................................................196  
Figure 5.2  High ALDH activity and CD133 expression were detected in 
HIF1transfected U373MG cell lines................................................198 
Figure 5.3  Expression of Embryonic CSC markers in HIF1 transfected U373MG 
cell lines.............................................................................................199 
Figure 5.4  Expression of CD44 in HIF1 transfected U373 cell lines.................201 
Figure 5.5  Expression of EMT markers in HIF1transfected U373 cell 
 lines...................................................................................................202  
Figure 5.6  HIF1 enhances the migration potential of U373MG cells in vitro.... 
 .................................................................................................202 / 203  
Figure 5.7  HIF1 enhances the invasive activity of U373MG cells in vitro....... 
 ..................................................................................................203 / 204  
Figure 5.8  In vitro cytotoxicity of TMZ, VCR, PAC and DOX in HIF2 transfected 
U373MG cell lines.....................................................................205 / 206  
Figure 5.9  The expression status of HIF2 protein in HIF2 transfected U373MG 
GBM cell lines...................................................................................208 
Figure 5.10 High ALDH activity and CD133 expression were detected in 
HIF2transfected U373MG cell lines...............................................209 
 xix 
 
Figure 5.11 Expression of Embryonic CSC markers in HIF2 transfected U373MG 
cell lines...............................................................................................210  
Figure 5.12 Western blot analysis of embryonic stem cell markers in HIF2 
transfected U373MG cells...................................................................211   
Figure 5.13 Expression of CD44 in HIF2 transfected U373 GBM cell lines. 
  ............................................................................................................213 
Figure 5.14 Expression of EMT markers in HIF2 transfected U373  
 GBM cell lines.....................................................................................213  
Figure 5.15 HIF2 enhances the migration potential of U373MG  
  cells in vitro.........................................................................................214 
Figure 5.16 HIF2 enhances the invasive activity of U373MG cells in vitro. 
 ............................................................................................................215 
Figure 5.17 In vitro cytotoxicity of TMZ, VCR, PAC and DOX in NF-B transfected 
U373MG cell lines......................................................................217 / 218 
Figure 6.1 Western blot analysis of NF-B in GBM sphere cells.........................237  
Figure 6.2 Western blot analysis of NF-B in hypoxia cultured GBM cell lines. 
 ............................................................................................................238 
Figure 6.3  Expression status of NF-B-p65 protein in p65 transfected U373MG 
GBM cell lines. .................................................................................239  
 xx 
 
Figure 6.4  High NF-B transcriptional activity in NF-Bp65 transfected U373MG 
GBM cell lines......................................................................................239  
Figure 6.5  Expression of CD44 in NF-B transfceted U373 GBM cell lines. 
 .............................................................................................................241 
Figure 6.6  Expression of EMT markers in NF-B transfected U373 GBM cell lines. 
..............................................................................................................242  
Figure 6.7 NFB enhances the migration potential of U373MG cells in vitro. 
 ...................................................................................................242 / 243  
Figure 6.8  NF-B enhances the invasive activity of U373MG cells in vitro. 
 ...................................................................................................243 / 244  
Figure 6.9  High ALDH activity and CD133 expression were detected in NF-B 
transfected U373MG cells....................................................................245  
Figure 6.10 Expression of Embryonic CSC markers in NF-B transfected U373MG 
cells....................................................................................................246  
Figure 6.11 Western blot analysis of embryonic stem cell markers in NF-B 
transfected U373MG cells....................................................................247   
Figure 6.12 In vitro cytotoxicity of TMZ, VCR, PAC and DOX in NF-B transfected 
U373MG cell lines......................................................................248 / 249  
Figure 6.13 NF-B activity in HIF1 and HIF2 transfected GBM cell lines..........251  
 xxi 
 
Figure 6.14 High expression of HIF1and HIF2in NF-B transfected U373MG 
cells. ....................................................................................................252 
Figure 6.15 Expression of different ALDH isoenzymes in GBM sphere 
 cells......................................................................................................253  
Figure 6.16 Expression of different ALDH isoenzymes in NFB transfected GBM 
cells......................................................................................................254  
Figure 6.17 Stable transfection of ALDH isoenzymes in U373 GBM cell line........256  
Figure 6.18 In vitro cytotoxicity of TMZ, VCR, PAC and DOXin ALDH3A1 transfected 
U373MG cell lines................................................................................257  
Figure 6.19 In vitro cytotoxicity of TMZ, VCR, PAC and DOXin ALDH1A3 transfected 
U373MG cell lines...............................................................................258 
 Figure 6.20 In vitro cytotoxicity of TMZ, VCR, PAC and DOXin ALDH1A3 
transfected U373MG cell lines............................................................259 
 Figure 7.1  DS/Cu induced cytotoxicity in GBM cell lines............................286 / 287  
Figure 7.2   In vitro cytotoxicity of DS/Cu on GBM sphere cells.............................288  
Figure 7.3  DS/Cu abolished the sphere forming ability of GBM cells...................290  
Figure 7.4  Expression status of NF-B-p65 protein in DS/Cu treated GBM cell 
lines.....................................................................................................292  
Figure 7.5 In vitro cytotoxicity of DS/Cu on NF-B-p65-transfected GBM cell 
lines.....................................................................................................292  
 xxii 
 
Figure 7.6  In vitro cytotoxicity of DS/Cu on ALDH1A1, ALDH1A3 and ALDH3A1 
transfected GBM cell lines...................................................................293  
Figure 7.7  Western blot analysis of alteration in BAX and BCL-2 in DS/Cu treated 
GBM cell lines.....................................................................................295 
Figure 7.8  DS/Cu is less toxic to normal cells. ...................................................296 
Figure 7.9  Scanning electron micrograph of PLGA-DS Nanoparticles...............297 
Figure 7.10 PLGA-Nanoparticle encapsulation increased the serum half life of 
DS........................................................................................................297  
Figure 7.11 PLGA-DS-NPs inhibited GBM in orthotopic xenograft models.........299  
Figure 7.12 Proposed mechanisms of selective killing of GBM cells  
  by DS/Cu.............................................................................................305 
 
 
 
 
 
 
 
 
 xxiii 
 
Abbreviations 
 IARC  International Agency for Research on Cancer 
TCR   T-Cell Receptor 
AAG Alkyladenine DNA Glycosylase 
ABC ATP-binding cassette 
AGT O6-Alkylguanine-DNA Alkyltransferase 
AHR Aryl hydrocarbon receptor 
AKT3 V-Akt Murine Thymoma Viral Oncogene Homologue 3 
ALDH Aldehyde dehydrogenase 
APS Ammonium persulphate 
ARNT Aryl Hydrocarbon Receptor Nuclear Translocator 
ATM Ataxia-Telangiectasia Mutated Kinases 
ATP Adenosine triphosphate 
ATT-HYP Attached hypoxia culture 
ATT-NOR Attached normoxia culture 
BAX BCL2-associated X protein 
BBB Blood brain barrier 
BCL2 B-cell lymphoma 2 
BCNU bis-chloroethylnitrosourea 
BCR B-Cell Receptor 
BER Base Excision Repair 
BFL1 Bcl-2-related protein A1 
BSA Bovine serum albumin 
CAF Cancer Associated Fibroblast 
 xxiv 
 
CAM Cancer Associated Macrophage 
CD Cluster of differentiation 
cDNA Complementary DNA 
CNS Central Nervous System 
CRUK Cancer Research UK 
CSC Cancer stem cell 
CT Cisplatin and Topotecan 
Ctr1 Copper transporter protein 1 
Cu Copper 
DDC Diethyldithiocarbamic acid 
DER Disulfiram ethanol reaction 
DMEM Dulbecco‟s modified Eagle‟s medium 
DMSO Dimethyl sulphoxide 
DNA Deoxyribonucleic acid 
DOX Doxorubicin 
DS Disulfiram 
DTC Dithiocarbamate 
DTT Dithiothreitol 
EBRT External Beam Radiation Therapy 
ECL Enhanced chemiluminescence 
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
EGFR Epidermal Growth Factor Receptor 
EGTA Ethylene glycol tetraacetic acid 
EMT Epithelial-mesenchymal transition 
 xxv 
 
EPAS1 Endothelial PAS Domain Protein 1 
EPC Endothelial Progenitor Cell 
ERK Extracellular-signal related kinase 
ESC Embryonic stem cell 
FACS Fluorescence-activated cell sorting 
FBS Foetal bovine serum 
FDA Food and Drug Administration 
FITC Fluorescein isothiocyanate 
FLIP FLICE-inhibitory protein 
GBM Glioblastoma multiforme 
GFAP Glial fibrillary acidic protein 
GFP Green fluorescent protein 
H2O2 Hydrogen peroxide 
HA Hyaluronic acid 
HCMV   Human Cytomegalovirus 
HDAC Histone deacetylases 
Poly HEMA Poly(2-hydroxyethyl methacrylate) 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid 
hFGF Human fibroblastic growth factor 
HGF Hepatocyte growth factor 
HIF Hypoxia inducible factor 
HP Hypoxyprobe 
HRE Hypoxia Response Element 
HSCs Haematopoietic stem cells 
IARC  International Agency for Research on Cancer 
 xxvi 
 
ICC Immunocytochemistry 
IKB Nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, alpha 
Ikkβ IκB kinase β 
IL Interleukin 
iPSC Induced pluripotent stem cell 
JNK C-Jun N-Terminal Kinases 
KPS   Karnofsky Performance Scale 
LB medium Luria Bertani medium 
MAPK Mitogen-activated protein kinase 
MDR Multiple drug resistance 
MEK MAPK/ERK kinase 
MET Mesenchymal epithelial transition 
MGMT  O6-Methyl Guanine Methyl Transferase 
miRNA Micro RNA 
mM Milli molar 
MMP Matrix metalloproteinase 
MRP Multi-Drug Resistance Associated Protein 
MTIC   3-Methyl-(Triazen-1-Yl) Imidazole-4-Carboxamide 
MTT 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
NADPH Nicotinamide Adenine Dinucleotide Phosphate 
NANOG Homeobox protein NANOG 
NF-B Nuclear Factor Kappa B 
NHA Normal human astrocytes 
nM Nano molar 
NP Nano particle 
 xxvii 
 
NS Neurosphere 
OCT4 Octamer-binding transcription factor 4 
OD Optical density 
PAC Paclitaxel 
PBS Phosphate-buffered saline 
PVDF Polyvinylidene difluoride  
P-gp P-glycoprotein 
PHD prolyl-hydroxylases 
PI Propidium Iodide 
PLGA Poly(lactic-co-glycolic acid) 
PTEN  Phosphatase and Tensin Homolog 
PTPRD  Protein Tyrosine Phosphatase, Receptor Type, D 
RCT   Randomized Control Trial 
REL A v-rel avian reticuloendotheliosis viral oncogene homolog A 
RHD Rel Homology Domain 
RIPA Radio-Immunoprecipitation Assay 
RLU Relative Luciferase unit 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
RT   Radiotherapy 
RT-PCR Reverse transcription polymerase chain reaction 
SART1  Squamous Cell Carcinoma Antigen Recognized By T Cells 
SDS sodium dodecyl sulphate 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
siRNA Small interfering RNA 
 xxviii 
 
SLC Stem-Like Cell 
SLUG Snail Family Zinc Finger 2 
SNAI1 Snail Family Zinc Finger 1 
SOX2 SRY (sex determining region Y)-box 2 
SUS Suspension 
SVZ Subventricular Zone 
TAE Tris-acetate-EDTA 
TBE Tris/Borate/EDTA 
TBST Tris-buffered saline - Tween 
TCGA The Cancer Genome Atlas 
TEMED Tetramethylethylenediamine 
TF Transcription factor 
TGF Transforming growth factor 
TIC Tumour Initiating Cell 
TLR Toll-Like Receptor 
TM Transmembrane 
TMZ Temozolomide 
TNF Tumour necrosis factor alpha 
TWIST Twist Family bHLH Transcription Factor 
VCR Vincristine 
VEGF Vascular Endothelial Growth Factor 
VHL von Hippel-Lindau 
WHO World Health Organisation 
 
 
 
 xxix 
 
Acknowledgements 
 
First of all, I wholeheartedly thank my supervisor Prof. Weiguang Wang for all 
his contributions of time, ideas, technical guidance, patience and support for the 
successful completion of this work. It has been an honour to be his PhD 
student. His passion and enthusiasm for research was highly motivational for 
me over the last few years. Above all I am grateful to him for teaching me good 
qualities that would shape me into a better person in future. I extend my sincere 
thanks to members of my research group Dr.Peng Liu, Dr.Zhipeng Wang, Dr. 
Sara Brown, Patricia Erebi Tawari, Kate Butcher and Dr. Mohammad Najlah for 
both their contributions to the experiments and for making the lab a great place 
to work. 
 
I am immensely thankful to Dr. Angel Armesilla and Dr. Mark Morris for being 
very friendly and supportive during this project. I have thoroughly enjoyed all the 
insightful discussions with them which have been very inspirational to look at 
my work from different angles. I would like to acknowledge Prof. John Darling, 
for his support throughout my project and for providing me opportunities to 
showcase my research in both national and international conferences during my 
PhD. I wish to extend my thanks to all the staff members of the Research 
Institute in Healthcare Science (RIHS) and School of Applied sciences for their 
kind help and support. My special thanks to Dr.Tracy Warr, Dr.Katherine 
Karakoula, Dr.Farzana Rowther, Dr.Angie Williams and Mr.Keith Holding for 
their support during my study.  
 
 xxx 
 
My time at the University of Wolverhampton was made memorable due to the 
bunch of lovely friends Raj, Sheela, Raji, Hoda, Shawna, Anushree, and 
Lawrence, who constantly showed their love and support to make my PhD 
experience enjoyable and stimulating. Special recognition goes out to 
Sathishkumar, Anitha, Ramkumar, Saravanan, Kalaivanan, Neelakandan, 
Nagappan, Julian Hobson, Jon Yarsley and Oliver Barnfield for always being 
there for me. Words cannot express how grateful I am for your unconditional 
love and support. My sincere appreciation also goes to Mr. Toye Anifalaje, Mrs. 
Victoria, Mr. Amarjit, Mrs. Virinder and Roshan Bains, my friends from Tamil 
people in UK, firends from my cricket team at bronze cricket club, my friends 
back home at PSG College, Dr. Jayan, Dr.Reji and all my project students and 
tuition students.   
 
I would like to thank my parents, my brother Mr.Karthik and his family, Mr.Ram 
Narayanan, Mr.Karumbunathan and Mrs. Valli Karumbunathan for having great 
confidence in me and encouraging me in chasing my dreams. This wouldn‟t 
have been possible without you, thank you. Lastly but most importantly, I truly 
thank my beloved wife Prasanna for her endless love and understanding and for 
standing by my side sharing both good and bad times. 
 
 
 
 
 1 
 
 
Chapter 1 
 
 
 
 
Introduction 
 2 
 
Cancer is a major public health problem and a leading cause of disease in the 
world. It is also the major cause of death worldwide surpassing coronary heart 
disease and stroke (WHO.int, 2015; Ferlay et al., 2014). According to the latest 
World cancer report 2014 published by the World Health Organization‟s 
International Agency for Cancer Research (WHO-IARC), the global burden of 
cancer is growing at an alarming rate with an estimated 14.1 million new cases 
reported in 2012. With the current trend, this figure is expected to increase by 
68% in 2030 to reach 23.6 million new cases every year. Over the same time 
the number of deaths caused by cancer will increase from 8.2 million in 2012 to 
13 million per year (Bray et al., 2012; IARC- World cancer report, 2014; 
IARC.FR, 2015). Lung cancer (13%), breast cancer (11.9%) and bowel cancer 
(9.7%) are the most commonly diagnosed cancers and the majority of cancer 
deaths are due to lung, liver, stomach, colorectal and female breast cancers. 
Most cancer deaths occur in less developed countries due to high population, 
lack of early diagnosis and access to treatment (Gulland, 2014; IARC- World 
cancer report, 2014; CRUK, Cancer Stats, 2015).  
 
1.1 Brain Tumours 
 
Among all the cancers, tumours occurring in the brain and central nervous 
system (CNS) are relatively rare and constitute only 2% of total cancer cases in 
the world (256,000 cases in 2012) (Ferlay et al., 2014). There are more than 
130 different types of tumours that can occur in the brain and other parts of 
CNS. They can be either primary (those which originate in the brain) or 
secondary (other cancers that metastasize to brain) brain tumours (CRUK, 
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Brain, other CNS and intracranial tumours key statistics, 2015). Though small in 
number, they are considered to be the worst type of tumours due to the 
sensitive location, lack of successful therapeutic measures and very high 
mortality rates. Primary brain tumours are those, which develop intracranially 
from the brain parenchyma to its surrounding structures. They are a 
heterogeneous group of benign or malignant tumours that are considered to be 
an important cause of cancer related deaths in adults and children (de Robles 
et al., 2014).  Primary brain tumours account for 2.3% of cancer related deaths 
with an estimated 189,000 reported deaths worldwide in 2012 (CRUK, Cancer 
statistics, 2014; Ferlay et al., 2014).  
 
1.2 Gliomas 
 
Among different histological subtypes of primary brain tumours gliomas are the 
most frequent malignant entities that arise in the glial tissue. Glial cells are the 
most common group of cells in the brain that maintain the blood brain barrier 
and provide the nerve cells with protection, support, energy and nutrients. 
Different glial cells have different functions, for example, astrocytes hold the 
neurons in place and supply them with nutrients, oligodendrocytes provide 
insulation to the neurons, microglia process dead neurons and ependymal cells 
secrete cerebrospinal fluid and line the ventriclular regions (Kandel, 2003). 
Gliomas represent 81% of malignant brain tumours and they develop as 
astrocytomas, oligoastrocytomas, oligodendrocytomas or ependymomas 
depending on the cell type or can be a mix of two cell types. They are classified 
according to the grade of malignancy established by the WHO as grade I-IV. 
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Oligodendrogliomas and oligoastrocytomas fall under grade II and grade III 
respectively. Astrocytomas are of four types: pilocytic, grade I; diffuse, grade II; 
anaplastic, grade III; and glioblastoma multiforme (GBM), grade IV (Louis et al., 
2007). The most common type of gliomas are the astrocytomas which account 
for 76% of all gliomas, the subtype glioblastoma multiforme alone accounting for 
more than 54% of all gliomas. The other less frequent types of gliomas are 
anaplastic astrocytomas (10-15%), anaplastic Oligodendrogliomas and 
anaplastic oligoastrocytomas (10%). The remaining 5% belong to rare glioma 
types, such as anaplastic ependymomas and anaplastic gangliogliomas (Wen 
and Kesari, 2008).  
 
1.3 Glioblastoma multiforme 
   
Glioblastoma multiforme (GBM) is the most common malignant primary brain 
tumour in adults (Dolecek et al., 2012; Filippini, 2012). Glioblastomas consist of 
a heterogeneous group of tumours that differ both genetically and 
phenotypically and are classified as WHO grade IV astrocytomas, the most 
malignant grade. Compared with other gliomas, GBMs are highly invasive, 
proliferative and angiogenic in nature (Karcher et al., 2006). Based on clinical 
presentation GBMs are of two subtypes: i) de novo primary tumours, which 
accounts for more than 85% cases occur commonly in patients older than 60yrs 
and develop by multistep tumourigenesis of normal glial cells ii) The remaining 
10-15% of cases present as secondary GBMs where low grade gliomas like 
diffuse or anaplastic astrocytoma can slowly progress or are transformed to 
GBM over a period of 4-5 years (Tso, 2006). This type of GBM is quite rare and 
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is very common in patients below the age of 45. Despite remarkable 
achievements in oncology in recent years, treatment and management of GBM 
patients still remain very challenging.  
 
 
 
 
 
 
 
 
 
 
Table 1.1 WHO classifications of gliomas (Louis et al., 2007). 
 
 
 
 
 
 
 
 
 
Fig 1.1 Distribution of all primary gliomas in the CNS (Adamson et al., 2009)  
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1.3.1 Historical Overview of Glioblastoma multiforme 
 
Glioblastomas were originally known as „fungus medullare‟ during the 1800s. 
GBM was first identified as tumours originating from glial cells through 
macroscopic and microscopic observations done by Dr. Rudolf Virchow in 1863 
and hence he coined the term „glioma‟. Later in 1920, Dr. Walter Dandy 
reported the differences between GBM and other gliomas by observing the 
extensive infiltrative nature of GBM and named it as „spongioblastoma‟ 
(Fleming, 1926). In 1926 two neurosurgeon/neuropathologists Bailey and 
Cushing thoroughly studied the microscopic features and clinical history of over 
400 glioma samples.  Cushing introduced the term glioblastoma multiforme in 
the second half of the nineteenth century. The term „multiforme‟ reflects the 
heterogeneous nature in clinical presentation, genetic characteristics, pathology 
and responsiveness to treatment of this type of tumour (Bailey and Cushing, 
1926).   
 
1.3.2 Epidemiology of Glioblastomas 
 
Cancer registry data from Europe and North America show that the number of 
recorded GBM cases is 3.1 per 100 000 adults each year, and is more common 
in men in comparison to women at the ratio of 1.26: 1 (Crocetti et al., 2012; 
Jemal et al., 2010; Omuro, 2013). Around 87% of the cases occur in adults at a 
median age of 65yrs at diagnosis. Though GBM is less common in children, it 
contributes to 15% of all childhood brain tumours (Arora et al., 2008). There are 
no differences in morphology or histology between adult and childhood GBM. It 
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is also reported that GBM is more common in the Caucasian population than in 
other ethnic origins (Filippini, 2012; Wen and Kesari, 2008). Despite aggressive 
treatment like surgery, radiotherapy and chemotherapy the median survival 
period for GBM patients is only 14.6 months (Stupp et al., 2005; Darefsky et al., 
2011). Population based studies show that only less than 30% of newly 
diagnosed GBM patients live for more than 1 year and only 3-5% of GBM 
patients live for more than 2 years. This is one of the worst survival rates among 
all cancers (Ostrom et al., 2014; Sant et al., 2011; Jung et al., 2012; Lamborn et 
al., 2008; Arrigo et al., 2011; Mirimanoff et al., 2007). Recurrent GBMs have 
much worse prognosis with a median survival between 3-5 months. Childhood 
GBMs have a very poor prognosis. Secondary GBMs in women are known for 
thier worse median survival rate (Krex et al., 2007; Henriksson et al., 2011).  
 
Age is an important prognostic factor in GBM where the survival rate is clearly 
higher for younger patients while elderly patients have a median survival rate of 
only 4.5 months (Reardon and Arvold, 2014; Iwamoto et al., 2008). 
Epidemiological data suggest that GBM incidence rates are rapidly increasing 
especially with patients aged over 65 years (Reardon and Arvold, 2014). Among 
this age cohort the incidence rate has doubled from 5.1 per 100,000 in the 
1970s to 11 per 100,000 in the 2000s. No contemporary treatment regimen is 
shown to improve the survival rates despite 3 decades of advancements in 
oncology and long term survival for GBM patients is exceptional (Perez-Larraya 
et al., 2011; Wick et al., 2012). 
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1.3.3 Etiology of Glioblastoma multiforme 
The etiology of GBM has not been fully elucidated and the predisposing factors 
are poorly understood.  Although various risk factors like ionizing radiation, 
pesticides, polycyclic aromatic compounds, solvents, rubber industry, 
petrochemical industry and electromagnetic fields are described in medical 
history, GBM is widely considered to be a spontaneous tumour (Spinelli et al., 
2010). About 1% of GBM patients represent familial aggregations; however, the 
genetic background for development of this type of GBM is different from 
spontaneous ones (Karim et al., 2011). Some genetic diseases like tuberous 
sclerosis, Turcot syndrome, and other genetic disturbances like the loss of 
genetic material in chromosome 10q, amplification of genes like EGFR, FGFR2, 
IRS2, AKT3 and mutations in genes like PTEN, TP16, TP53, PARK2, PTPRD 
and NF1 are also attributed to the development of GBM (McLendon et al., 2008; 
Urbańska et al., 2014). Recently, investigators believe that human 
cytomegalovirus (HCMV), is also among the etiologic agents for the 
development of GBM. Although various contributing factors and risk factors for 
GBM are mentioned in the literature, the true etiologic agent is still 
undetermined. 
 
1.3.4 Biological and morphological features 
GBM mainly form in the hemispheres of the brain or very rarely in subtentorial 
brain stem or cerebellum. It is characterized by infiltrating growth and typically 
contains a mix of tumour cells and stromal cells, therefore it is difficult to clearly 
distinguish tumour mass from the normal tissue. The tumour consists of 
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signature characteristics like poorly differentiated neoplastic astrocytes with 
brisk mitotic activity, polymorphism, anisokaryosis, neoangiogenesis and 
necrosis (Robson, 2001). GBM cells also show nuclear pleomorphism 
(increased nuclear to cytoplasmic ratio) and intranuclear inclusions (Schultz et 
al., 2005). Neovascularization is a characteristic feature of GBM that 
distinguishes it from low grade gliomas and contain irregular layer of pericytes 
and have vascular thrombosis (Rojiani and Dorovini-Zis, 1996; Di Ieva et al., 
2011). Presence of necrotic foci is one of the most distinctive characteristics of 
GBM. Histologically, two types of necrosis have been observed in GBM 
(Robson, 2001). The first type has a large central necrotic region in the tumour, 
which is formed because of insufficient blood supply, and the second type 
contains multiple, small, irregular pseudopalisading necrotic foci, which are 
created by radially, oriented glial cells. The zone of pseudopalisades contains 
the rapidly dividing neoplastic cells that have undergone central necrosis; a 
population resistant to apoptosis; inflammatory cells around these necrotic 
regions; migratory cells and stem like cells (Brat, 2004). This is the reason why 
GBMs are inherently aggressive and resistant tumours with increased 
malignancy and infiltration that makes it almost impossible to remove, treat or 
cure this malignancy.  Despite the aggressive and proangiogenic nature of 
GBM, metastasis of this neoplasm outside CNS is extremely rare.  It is 
assumed that the barrier created by cerebral meninges, absence of lymphatic 
vessels and short life span of patients are key reasons behind the low 
metastatic potential of GBM (Lun et al., 2011; Robert and Wastie, 2008).  
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1.3.5 Molecular subtypes of GBM 
Recent insights into the genomic profiling of GBM have allowed clinicians to 
categorize GBM in to four subtypes based on distinguishing genetic alterations 
and molecular profiles. Using integrated genomic approach researchers 
described an expression‑based molecular classification of GBM into classical, 
mesenchymal, proneural, and neural with specific molecular signature for each 
subtypes as shown in the figure below (Verhaak et al., 2010; Brennan et al., 
2009; Network, 2013; Phillips et al., 2006).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Molecular Subtypes of GBM. (A) Genetic and chromosomal alterations in 
primary and secondary GBM. (B) Recent sub classification of primary GBM in four further 
distinct subtypes through integrated genomic analysis. (Adapted from Agnihotri et al., 2013).   
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1.4 Treatment for GBM 
Treatment of GBM has a very challenging and a long history with more than a 
hundred different types of clinical trials reported in the literature even dating 
back to 1960s. This was mainly attributed to the brain itself as a sensitive organ 
controlling multiple functions; hence, any damage caused to it by the tumour or 
treatment strategies would lead to poor quality of life and very short survival 
period.  Over many years, the challenges in developing effective treatment for 
GBM were met only by numerous Phase III randomized control trials (RCTs). 
The current standard therapy for newly diagnosed GBM includes maximal safe 
surgical resection, followed by parallel radiation therapy to the resection site 
and chemotherapy with adjuvant Temozolomide (Stupp et al., 2005). This 
procedure which is also known as Stupp protocol emerged as the standard of 
care for GBM after the seminal work done by Stupp and colleagues that 
increased the survival rate from 12.1 months to 14.6 months.  
1.4.1 Surgical resection 
Surgery remains a cornerstone in the treatment of GBM. The primary aim of 
surgery is to achieve gross total resection of the tumour without affecting 
neurological functions (Anton et al., 2012). In addition to cytoreduction, surgery 
provides samples for histological and molecular analysis to confirm the 
diagnosis and to identify the subtypes that lays foundation for further treatments 
and prognosis (Ryken et al., 2014). Surgery is also considered as a therapeutic 
measure to reduce the intracranial pressure thereby leading to recovery of lost 
neurological function. However, on the other hand cytoreductive surgery leads 
to loss of vital brain tissue that will further cause immediate neurological deficits. 
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Hence, many neurosurgeons argue against surgery as a treatment attempt 
because of the anticipated worst quality of life (Ryken et al., 2014).  However, it 
has to be noted that many retrospective studies and RCTs in the past has 
shown that a safe maximal surgical resection of the tumour >98% will 
significantly improve the survival rate helps patients respond better to 
radiotherapy and chemotherapy after surgery (Lacroix et al., 2001). In contrast, 
elderly patients above the age of 70 have no benefit from surgery as the overall 
median survival rate is increased only by a month (from 4.5 months to 5.7 
months) with the additional burden of poor quality of life (Harter et al., 2014; 
Ryken et al., 2014). GBM is diffuse, highly invasive, infiltrates adjacent tissue 
and have ill-defined borders, so a complete resection is impossible. In addition, 
involvement of eloquent structures or both hemispheres will make it a very 
difficult decision for the neurosurgeon to call for surgery. When the tumour is 
reduced partially, the residual tumour behaves in a very aggressive and 
malignant manner with massive oedema and acute neurological effects. The 
Surgeons generally avoid surgery strictly if the patients have a poor 
performance status (Karnofsky performance scale [KPS] <70), very old age, 
complicated location or involvement of both cerebral hemispheres (Harter et al., 
2014). Advanced surgical imaging techniques like intraoperative magnetic 
resonance imaging (MRI), diffusion tensor imaging, awake craniotomy, cortical 
mapping, stereotactic guidance, and fluorescent guided resection, have made it 
easier for neurosurgeons to visualize a defined border for the tumour for 
maximal resection (Hoover et al., 2010). However with all these advancements 
surgery appears to improve survival only for a short term and there is no 
change in the 2 years disease free survival (Ryken et al.,2014).  
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1.4.2 Radiotherapy 
 
The use of adjuvant radiotherapy (RT) following surgical resection has been a 
historical gold standard for management of GBM patients. The current standard 
for RT in GBM is postoperative fractionated focal external beam radiation 
therapy (EBRT). About 60Gy of RT is administered as 30 fractions 
(2Gy/fraction) over a period of 6 weeks to the surgical resection cavity and 2cm 
ring of surrounding tissue beyond the rim of the cavity. Dose higher than 60Gy 
has no survival benefit due to increased toxicity. RT is usually given after 2 
weeks of surgery to provide adequate time for wound healing. In some cases 
like multifocal GBM, whole brain RT is used (Leibel and Sheline, 1987). Phase 
III RCTs have shown that RT clearly doubles survival rates after surgery from 4-
5 months to 9-10 months. RT is shown to be the best treatment choice for 
elderly patients aged over 70yrs where surgery is not an available option for 
them. Given that RT along with supportive care alone provides a survival 
advantage in elderly patients, RCTs are now being carried out to analyse 
whether modifying the conventional RT strategy with hypofractionated, or low 
dose whole brain RT will provide extra survival benefit for these patients (Ryu et 
al., 2014; Adamson et al., 2009). Ionizing radiation induces single and double 
strand breaks in the DNA of dividing cells and hence it is obvious that it will 
have a significant deleterious effect on normal brain tissue as well. In addition, 
radiation causes various side effects like headaches, vomiting, cognitive 
disturbances, memory loss, worsening neurological deficits and damage to BBB 
leading to oedema (Adamson et al., 2009; Harter et al., 2014).   
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1.4.3 Chemotherapy 
 
Chemotherapy for GBM has been the most varied and disappointing strategy in 
the history of cancer therapeutics, with numerous laboratory research and 
RCTs dating back to 1970s (Walker et al., 1978). The benefits offered by 
chemotherapy for GBM patients have been questioned for many decades but 
various RCTs involving different chemotherapeutic regimen shows that patients 
receiving chemotherapy along with radiation have a significant survival benefit 
when compared with patients receiving radiation alone (Anton, 2012; Cairncross 
et al., 1998). Certain patients are reported to have remarkable and prolonged 
responses to chemotherapy and new agents are being developed that targets 
molecular markers which are promising and may extend the efficacy of 
chemotherapy (Olson et al., 2014). Chemotherapy can be applied at different 
stages during treatment. Neoadjuvant CT- after diagnosis before surgery or any 
other treatment; Concurrent CT– in parallel with radiation; Adjuvant CT– after 
surgery/radiation as a follow up treatment; Recurrent CT – At the time of tumour 
relapse (Figure 1.4) (Parney and Chang, 2003). Chemotherapeutic agents are 
of two types - Cytotoxic agents cause cell death in tumour mass by damaging 
DNA or other cellular contents thereby inducing apoptosis or Cytostatic agents 
that alter biological mechanisms of tumour like proliferation, invasion, 
angiogenesis, etc., that inhibits tumour growth. They can be used on their own 
or in combination with other agents. For example, the use of cytostatic agents 
used along with cytotoxic agents can block biological mechanisms like 
resistance or growth factor pathways that help the cytotoxic agents to work 
better (Parney and Chang, 2003). 
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Figure 1.3 Chemotherapy for GBM (A) Different time points for administration of 
chemotherapeutic drugs to GBM patients.  (B) Classification of GBM chemotherapeutic drugs 
based on their mode of action. Adapted from Parney and Chang, 2003. 
 
 
1.4.3.1 Temozolomide 
 
A breakthrough study in 2005 by Stupp and colleagues demonstrated that a 
regimen of parallel doses Temozolomide (TMZ) with surgery and radiation 
followed by adjuvant TMZ improved the overall survival, progression free 
survival and two-year survival rates of GBM patients significantly (Stupp et al., 
2005). Since then Stupp protocol became the standard therapy for GBM 
patients with or without modifications. Temozolomide (TMZ), a second-
generation imidazotetrazine derivative is a drug of interest since 1990s and is at 
present the first line chemotherapeutic agent for treating GBM following surgery 
and radiation (Villano et al., 2009). Being lipid soluble, TMZ is rapidly absorbed 
with a nearly 100% bioavailability including the CNS and it readily crosses the 
blood-brain barrier achieving high concentrations in the cerebrospinal fluid. TMZ 
is an oral alkylating agent that degrades at physiological pH to 3-methyl-
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(triazen-1-yl) imidazole-4-carboxamide (MTIC) that methylates the DNA at O6 
position of guanine residue resulting in DNA lesions. During subsequent 
replication, the methylated guanine adducts pair with thymdine instead of 
cytidine that activates ineffective mismatch repair and eventually leads to 
apoptosis (Villano et al., 2009; Malcolm et al., 2002; Roos et al., 2006).  
 
However, DNA damage caused by TMZ could be corrected by DNA excision 
repair enzyme O6 methyl guanine DNA methyl transferase encoded by the gene 
MGMT that leads to resistance to TMZ and other alkylating drugs (Sarkaria et 
al., 2008).  It is also shown that patients have different levels of MGMT for DNA 
repair mechanisms. Treatment with TMZ saturates the existing enzyme activity 
and results in further DNA damage. However, MGMT positive GBM patients 
have a high expression of the enzyme that works beyond the saturation point 
(Nagane et al., 2007; Hegi et al., 2008). The current regimen for TMZ when 
given in combination with RT is 75 mg/m2/day for 6 weeks. Following 
completion of RT, patients receive adjuvant TMZ at a dose of 150 mg/ m2/day 
for 5 days followed by 23 days rest. This 4 weeks cycle is repeated for at least 6 
cycles. However, because of MGMT mediated resistance and recurrence of 
GBM, the median PFS time is only 7months and the 2-year survival rate is only 
27%. In those cases, increasing the dose of TMZ (Dose Dense- DD –TMZ 
regimen) to a level that would saturate the enzymatic activity of MGMT would 
benefit the MGMT positive patients as well as patients with recurrent GBMs.  
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B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.4 (A) Structure of Temozolomide (B) Mechanism of action and repair of 
Temozolomide induced DNA damage (Adapted from Liu et al., 2006). 
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In addition to MGMT, recent understanding of the diverse mechanisms 
responsible for resistance and the role played by various subtypes of GBM has 
resulted in the evaluation of new therapies in combination with TMZ (Sarkaria et 
al., 2008; Tentori and Graziani, 2002). Various clinical trials are being 
conducted at different phases to verify the effectiveness of TMZ in combination 
with other drugs like protein tyrosine/serine-threonine kinase inhibitors, 
interferons, conventional drugs, EGFR and VEGF inhibitors, etc.,. So far, none 
of them showed realistic benefits compared to temozolomide treatment alone 
(Ren et al., 2009). Thus, TMZ has shown a remarkable improvement in patient 
survival; however TMZ simply does not have the answer for GBM. 
 
1.4.3.2  Gliadel wafers 
 
Gliadel wafers are biodegradable polymers loaded with carmustine, designed to 
deliver local chemotherapy in the peritumoural surgical bed. The wafer consists 
of a biodegradable polymer disc that measures 1mm in thickness, 200mg in 
weight and 1cm in diameter and carries 3.85% BCNU by weight (Brem et al., 
1995). The wafers are implanted in the surgical cavity and as the polymer 
degrades, the drug is slowly released resulting in local concentrations 100 times 
higher than systemic administration (Panigrahi et al., 2011).  Gliadel is currently 
approved for treating recurrent glioblastoma and as an adjunct for surgery and 
radiation in newly diagnosed GBM patients (Panigrahi et al., 2011; Aoki et al., 
2007). Patients treated with carmustine wafers after surgery and radiation 
showed a significant increase in median survival rate and follow up studies for 
2-3years demonstrated a survival advantage in these patients compared to a 
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placebo group (Westphal et al., 2003). From the encouraging preliminary 
results, many ongoing studies adopted a multimodality approach to use BCNU 
wafers in combination with other drugs (McGirt et al., 2009). A multicentered, 
phase III double, blind study that combined the use of Gliadel wafer with 
temozolomide increased the median survival of GBM patients to 21 months 
(McGirt et al., 2009). Although more than 20,000 procedures with carmustine 
wafers have been carried out since 1997, the use of gliadel wafers for 
intracranial treatment is limited by fatal cerebral oedema, seizures, infections 
and the cost of wafers (Gallego et al., 2007; Weber & Goebel, 2005). 
 
1.5 Chemoresistance in GBM 
1.5.1 Drug efflux mechanisms 
1.5.1.1 Blood brain barrier  
Although significant development has been made in the development of drugs 
against specific targets, no progress has been made in the treatment outcomes 
of chemotherapy for GBM mainly because most of the drugs discovered are 
unable to cross the BBB (Sugiyama et al., 1999). BBB is a complex network 
made up of endothelial cells, pericytes and astroglia that lines the vessels of the 
central nervous system (CNS). BBB isolates the CNS from systemic circulation 
by regulating the passage of materials between the brain intravascular 
compartment and the cellular compartment. Since brain is a delicate organ BBB 
protects the brain from bacteria, toxic substances and large molecules that are 
present outside the CNS and provide selective access to molecules that are 
needed for normal functioning of CNS (Schlosshauer, 1993; Bentivoglio and 
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Kristensson, 2014). This property of the BBB also restricts the entry of most 
pharmaceutical agents into the brain and this is therefore a major obstacle in 
chemotherapy of GBM. In general, any drugs or small molecules, which are 
water soluble or lipophilic in nature and less than 400Da, can readily cross the 
BBB by passive transport. However, 98% of molecules greater than 200Da are 
prevented from crossing the BBB (Ricci et al., 2006). The pharmaceutical 
agents also face additional barriers present in the BBB which are the efflux 
pumps like P-glycoprotein (P-gp) and multi-drug resistance associated protein 
family (MRP) that transport these molecules actively back to the vascular 
compartment (Kusuhara and Sugiyama, 2001).  
 
1.5.1.2 P-glycoprotein 
 
P-gp plays important physiological roles in a wide range of tissues like BBB, 
capillaries, brain, kidney, liver, intestine and adrenal glands. Among all gliomas, 
GBM cells are reported to have high levels of P-gp that contributes to the 
intrinsic resistance of GBM (Ling, 1995).  P-gp is a 170-kDa membrane protein 
encoded by the ABCB1 gene and belongs to the ATP binding cassette super 
family (ABC) transporters (Gros, et al., 1986). P-gp aids in transport of neutral 
and cationic hydrophobic compounds, natural product anticancer agents, 
including vinca alkaloids, anthracyclines,and taxanes such as vincristine, 
paclitaxel, doxorubicin, epirubicin, cepharanthine, cytarabine, bisantrene, 
etoposide, vinblastine, actinomycin, etc., (Gottesman et al., 2002). The 
transport of drug is coupled with two step hydrolysis of ATP. The first hydrolysis 
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of ATP to ADP is needed to bring about a conformational change to form a 
transition state intermediate of P-gp complex followed by the extrusion of drug. 
The second hydrolysis ensures that ADP bound to P-gp is dissociated and the 
conformation of P-gp is restored to its original state (Leonessa 2003, Ambudkar, 
2003; Sarkadi, 2006). Despite 30 years of research in P-gp, no clear therapeutic 
strategy has been identified to tackle the drug efflux pump in tumours. 
 
1.5.1.3 Multidrug resistance associated protein (MRP) 
 
The MRP family of transporter proteins are organic ion transporters found in 
many mammalian tissues and consists of 9 members, MRP 1-9. Some of the 
family members especially MRP1 is shown to be expressed in brain capillaries. 
They carry anionic substances such as methotrexate and neutral drugs in 
association with acidic ligands like sulphate, glucoronide or glutathione. MRP1 
is a 190-kDa protein that has 17 transmembrane domains (TMDs) and has a 
core similar to the P-gp. The range of resistance conferred by MRP 1 extends to 
anthracyclines, antifolates, vinca alkaloids but MRP cannot resist taxanes, 
mitoxantrone or cisplatin (Tanaka et al., 1999). MRP 1 expression is thought to 
be significantly affected by chemotherapy where a higher expression rate is 
observed in samples after chemotherapy. Other members of the family MRP 2-
6 have been correlated with resistance to variety of drugs in different 
mechanisms but their relevance with GBM is not well established (Rudas et al, 
2003; Leonard, 2003; Konig et al, 2005). 
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1.5.2 DNA damage repair mechanisms 
 
1.5.2.1 MGMT 
The DNA repair enzyme MGMT also known as O6-alkylguanine-DNA 
alkyltransferase (AGT), plays an important role in resistance to TMZ and other 
alkylating agents. The chemoresistant activity of MGMT has been shown in 
several cell culture and xenograft studies. The DNA damage induced by 
addition of methylated adducts by TMZ and other alkylating agents can undergo 
single-step error free reversal in the presence of MGMT (Esteller et al., 2000). 
MGMT forms a covalent bond between the alkylated bases and an internal 
cysteine residue within its active site. It then directly transfers the alkyl group 
from the DNA to the cysteine thereby restoring the structural integrity of 
methylated bases in the DNA (Payne et al., 2005). Thus, MGMT can confer 
resistance to the cytotoxicity induced by alkylating agents and increased MGMT 
expression is associated with in vitro and in vivo GBM resistance to first line 
drug TMZ, other nitrosoureas and alkylating drugs (Dolan et al., 1990). 
However, in this process, MGMT undergoes self degradation through the 
ubiquitin-proteasome pathway after binding alkyl groups from DNA and hence 
the cells have to re-synthesize MGMT molecule (Chen et al., 1998; Esteller and 
Herman, 2004). Research has shown that the expression levels of MGMT are 
not the same in all patients and differ with individuals as well as with the grade 
and aggressiveness of the tumour. Epigenetic inactivation of MGMT gene by 
promoter hypermethylation results in low or no MGMT expression and lowers 
cellular ability to carry out DNA repair (Esteller and Herman, 2004).  Hence, 
GBM patients lacking tumour MGMT expression benefit from treatment with 
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alkylating drugs and show prolonged survival compared to MGMT-positive GBM 
patients. For example in the case of first line drug TMZ, a median survival of 
21.7 months was seen among patients with a methylated promoter who 
received TMZ + radiotherapy compared to patients with a unmethylated 
promoter who had a median survival of just 12.7 months with the same 
treatment. Therefore, MGMT promoter methylation status has been shown to 
predict clinical response to alkylating agents (Hegi et al., 2005). The above facts 
suggested that inactivation of MGMT using inhibitors could improve treatment 
outcomes and made MGMT a suitable target for intervention. An inhibitor like 
O6-benzylguanine (O6-BG) that irreversibly inactivates MGMT is shown to 
enhance BCNU and TMZ cytotoxicity in MGMT-positive glioma cells both in 
vitro and in vivo but the therapeutic potential of adding O6-BG to TMZ-treatment 
has so far also been discouraging (Jaeckle et al., 1998).  
 
1.5.2.2 DNA Mismatch repair  
 
The second important mechanism of resistance against chemotherapy is the 
DNA mismatch repair mechanism (MMR). MMR is a normal DNA repair 
pathway that maintains genomic integrity by correcting replication errors, which 
escape the DNA polymerase proof reading process (Hickman and Samson, 
1999). MMR acts as direct sensors to DNA damage signalling through ATR 
checkpoint and this property is therefore considered as an important tumour 
suppressor mechanism. Absence of a functional MMR system due to mutations 
in the protein complexes results in unnoted drug-induced DNA damage that 
contribute to further mutagenesis and reduced anti-tumour activity of 
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methylating anticancer drugs (Fink et al., 1998). For example in the case of 
TMZ treatment DNA polymerase mispairs O6-meG with thymine (instead of C 
opposite) and a normal MMR system should recognise base pair by MutS a 
heterodimeric complex made of two MMR proteins HMSH2 and HMSH6. This in 
turn will interact with MutL to excise the damaged strand of DNA.  However, 
O6- meG remains and binds with another thymine thereby activating multiple 
cycles of MMR.  Futile cycling of MMR, continuous DNA re-synthesis and failure 
to get past O6- meG halts DNA replication and leads to checkpoint activation 
finally causing breaks in DNA strand (Taverna et al., 2000). Thus, cytotoxicity 
induced by TMZ largely depends on functional MMR and MMR mutated or 
deficient cells are shown to be more than 100-fold more resistant to alkylating 
agents like TMZ. 
 
1.5.2.3 Base excision repair and PARP-1  
 
Endogeneous DNA damage resulting from methylation, deamination, 
hydroxylation and ROS are repaired by the DNA base excision repair system 
(BER).  The BER pathway also repairs DNA base lesions induced by drugs like 
TMZ and other alkylating agents (Frosina, 2000). Apart from O6-meG, several 
other DNA adducts as N7-methylguanine, O3-methyladenine and N3-
alkyladenine are produced by drugs.  These alkylated adenine or guanine 
bases are repaired by the BER pathway in two steps. Firstly a lesion specific 
DNA repair enzyme alkyladenine DNA glycosylase (AAG) removes those bases 
from the DNA strand leavng single nucleotide gaps known as AP sites since 
they are either apurinic (devoid of A or G) or apyrimidinic (devoid of C or T). In 
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the second step the AP site is recognised by an AP-endonuclease (APE1) that 
makes an incision in the strand and fills the single nucleotide gap by DNA 
polymerase- (pol-)-mediated DNA synthesis and DNA ligase that seals the 
nick in the strand (Trivedi, 2005; Frosina, 2000). Poly-ADP-ribose polymerase-1 
(PARP1) is an important enzyme in the BER pathway with zinc finger DNA 
binding nuclease activity and acts as a sensor of DNA damage. It facilitates 
repair of single stranded or double stranded breaks in the DNA by coordinating 
with other pathways like BER and MMR (de Murcia et al., 1997). Inhibition of 
PARP is shown to suppress the function of BER pathway and significantly 
enhance the cytotoxicity of alkylating drugs in GBM cells (Tentori et al., 2002). 
In addition, it is also shown that most GBM specimens have very high basal 
levels of PARP expression especially after treatment with TMZ (Wharton et al., 
2000; Cheng, 2005). Both BER and PARP expression are correlated to 
suppression of MMR activity that further worsens chemoresistance. 
 
1.5.3 Apoptosis resistance 
 
Dysregulation of apoptosis is an additional chemoresistance mechanism in 
GBM. An apoptotic response to DNA damage induced by chemotherapeutic 
drugs can be disrupted by various apoptosis- interrupting mechanisms like loss 
of p53 function, overexpression of Bcl-2 or Bcl-XL, or upregulation of EGFR. 
p53 is well known for its central role in mediating apoptosis by detecting DNA 
damage and acting as a transcription factor that regulates the genes involved in 
pro-apoptotic signaling pathways (Fels et al., 2000; Karmakar et al., 2006). 
Additionally cytoplasmic p53 is known to regulate mitochondrial membrane 
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permeability by acting as a pro-apoptotic BH3 domain protein that releases 
cytochrome c and eventually inducing caspases for cell death (Willis and 
Adams, 2005). Target genes of p53 include BCL2, BAX, EGFR, MDM2 and 
BIM. Although p53 plays a central role, the resistance mechanism is largely 
mediated by increased expression of Bcl-2 family members that suppress the 
drug-induced apoptosis. The BCL-2 family consist of both pro apoptotic proteins 
like Bax, Bak and Bcl-Xs and anti apoptotic proteins such as Bcl-2 and Bcl-XL. 
Increased expression of Bcl2 and Bcl-XL due to p53 dysregulation will inhibit 
Bax and Bak thereby inhibiting the intrinsic apoptosis pathway. Hence, the 
balance between the level of pro and anti apoptotic BCL2 family members plays 
a vital role in apoptosis. Based on the analysis of patient tumour samples it was 
reported earlier that, inactivation of p53 occurs in 87% of GBMs, associated 
with the upregulation of Bcl-2 and suggested to be an important mechanism in 
the pathogenesis and resistance of GBM (Newcomb et al., 1997).  
 
1.6 GBM Cancer stem cells 
 
Among the several challenges for successful treatment of GBM, difficulty in 
combating the resistant cancer stem cell population has been the prime focus of 
many researchers in recent years. It is well established that most solid tumours 
have heterogeneous group of cancer cells in addition to vasculatures, 
inflammatory cells and other stromal components (Hanahan and Weinberg, 
2011). As discussed earlier GBM shows remarkable hierarchy and 
heterogeneity in both morphological and differentiation statuses of the cells. 
Traditionally heterogeneity is believed to be a result of regional variations in the 
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subpopulations of the tumour microenvironment or due to progressive genetic 
and epigenetic alterations. This was known as stochastic model of GBM where 
it was considered that GBM has multiple clones of cells (Nowell, 1976). The 
strongest clone continually grows and surpasses other clones while the 
heterogeneous nature was attributed to the residual weaker clones (Nowell, 
1976).  
 
For many years parallelism existed between tumour biology and stem cell 
biology because of several reports highlighting the importance of stem cell 
genes and their roles in cancer. Rudolf Virchow, also known as the father of 
pathology, suggested in 1858 that cancer is a disease of embryonic like tissue. 
Evidence accumulated in the last decade from studies on haematopoietic and 
solid cancers like breast, brain, colorectal, prostate and lung has suggested the 
existence of a small subpopulation of cancer cells known as cancer stem cells 
(CSCs) (Lapidot et al., 1994; Bonnet and Dick, 1997; Al-Hajj et al., 2003; 
Hemmati et al., 2003; Singh et al., 2004; Galli et al., 2004; Dalerba et al., 2007; 
Schatton et al., 2008). They were named so because of their ability to 
differentiate into other types of cells in the tumour as well as the ability to self 
renew giving rise to more CSCs. They share similarities with normal stem cells 
in critical characteristics such as cell surface markers and embryonic signalling 
mechanisms (Reya et al., 2001; Vescovi et al., 2006; Bao et al., 2006; Rosen 
and Jordan, 2009; Park and rich, 2009; Heddleston et al., 2010; Frank et al., 
2010). Aggressive tumours like GBM are well recognized for the presence of 
poorly differentiated cells and hence their names contain the term „blastoma‟. 
Similar to other malignancies the existence of such small population of cells in 
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GBM called GBM cancer stem cells (GBM CSCs) were identified and 
characterized by several groups beginning from 2003. GBM CSCs are 
functionally able to self-renew, differentiate in vitro into cells of CNS and display 
high tumourigenic potential in vivo when compared with non-stem tumour 
population (Hemmati et al., 2003; Galli et al., 2004; Singh et al., 2004; Bao et 
al., 2006; Lee et al., 2006). So far, it has been identified that these GBM CSCs 
exhibit a wide range of NSC markers such as CD133, CD44, CD90, the 
intermediate filament NESTIN, transcription factors SOX2, OCT4, NANOG and 
BMI1, increased aldehyde dehydrogense activity (ALDH) and the RNA binding 
protein MUSASHI. There are many controversies concerning the 
characterization of GBM CSCs, their origin, markers and their exact role in GBM 
pathogenesis and hence they are referred to as „Stem-like cells‟ (SLCs) by 
some researchers. Much of the ongoing research in GBM is focussed on 
establishing the crucial role of GBM CSCs in initiation, progression, and 
angiogenesis, resistance to therapy and systematic relapse of GBM and 
developing GBM CSCs as potential targets for treatment. 
 
1.6.1 GBM CSCs and therapeutic resistance 
 
Despite maximal resection, GBMs are extremely resistant to conventional 
radiotherapy and chemotherapy with rapid recurrence (Furnari et al., 2007; Wen 
and Kesari, 2008). Although there is a controversy between the hierarchical 
relationship of CSC population and the entire mass of tumour cells, it is widely 
accepted that CSCs contribute to the repopulation of tumour after conventional 
therapies (Park et al., 2010). By far radiotherapy is considered the most efficient 
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non-surgical therapeutic measure for GBMs, but it is quite disappointing that 
these CSC populations are widely resistant to radiation. It has been 
demonstrated that CD133+ CSCs are more resistant to radiation when 
compared to the parental population (Bao et al., 2006). GBM CSCs are shown 
to preferentially activate DNA damage checkpoint response like ataxia-
telengectasia mutated kinases (ATM), Rad17, Chk1and Chk2 kinases in 
response to DNA damage induced by radiation (Bao et al., 2006). Checkpoint 
activation enables CSCs to rapidly repair damaged DNA and recover from 
genotoxic stress. More recently another essential CSC factor BMI1 was shown 
to interact with these checkpoint proteins and non-homologous end joining 
(NHEJ) repair proteins to achieve efficient recruitment of DNA damage 
response machinery during radiation.  Various other signalling pathways like 
Notch, Wnt/β-catenin signalling, ROS/MAPK has been linked to decreased 
radiosensitivity of CSCs (Diehn et al., 2009; Woodward et al., 2007).  Treatment 
for GBMs also includes adjuvant chemotherapy with primary chemotherapeutic 
molecule TMZ an oral methylating agent (Stupp et al., 2005; Wen and Kesari, 
2008). The mechanism of TMZ induced cytotoxicity, MGMT mediated 
resistance to TMZ, and involvement of promoter methylation has been 
described earlier. Resistance to TMZ and invariable tumour recurrence 
regardless of MGMT status indicates the presence of a TMZ-resistant 
population in GBM. Various findings suggest that GBM CSCs can induce 
resistance to TMZ in a MGMT dependent and MGMT independent mechanism. 
For example in a genetically engineered GBM mouse model exposure to TMZ 
significantly enriched a population with CSC properties (Bleau et al., 2009). In 
addition, in vitro exposure of GBM NS cultures to TMZ showed that the CD133+ 
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population is significantly resistant to TMZ and other drugs. On the contrary, 
other researchers have also shown that TMZ preferentially depletes CSCs in 
sphere cultures and inhibits their tumourigecity. However, it was also found that 
TMZ can eliminate only the MGMT- CSC population. MGMT expressing CSCs 
were not inhibited by TMZ.  (Liu et al., 2006; Bleau et al., 2009; Beier et al., 
2007; Clement et al., 2007). CSCs are known to have several other potential 
mechanisms like expression of multidrug resistance genes such as MDR1, 
BCRP1 and ABCG2. CD133+ CSCs express high levels of drug transporters, 
antiapoptotic genes including FLIP, BCL-2 and BCL-XL compared to CD133− 
cells (Hirschmann-Jax et al., 2004; Schatton et al., 2008). Consequently, CSCs 
are resistant to TMZ, carboplatin, VP16 and Taxol drugs. Future design of 
chemotherapy and other treatment procedures largely depends on a better 
understanding of GBM CSCs resistance mechanisms. 
 
 
 
 
 
 
 
 
 
 
Fig 1.5 Normal neural progenitor cells and cancer stem cells. Neural stem/progenitor cells 
that harbour mutations can give rise to resistant GBM CSCs, which act as the source for cancer 
recurrence. (Figure adapted from Zhang et al., 2009). 
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1.6.2 Origin of GBM CSCs 
In an effort to understand the GBM CSCs and their roles in GBM, it is necessary 
to understand the source of these GBM CSCs. Many theories have been 
proposed and evidenced in recent years and great progress has been made in 
the understanding of GBM and the origin of CSCs. Due to their striking 
similarities with normal neural stem cells (NSCs) it was believed that GBM 
CSCs might have resulted from genetic and epigenetic changes in neural 
stem/progenitor cells (Sanai et al., 2005; Safa et al., 2015). Although a definitive 
proof is still lacking, GBM CSCs were also named as tumour initiating cells 
(TICs) or glioma initiating cells (GICs) due to the belief that GBM tumour may 
be initiated and maintained by these uncommitted self-renewing population of 
cells (Safa et al., 2015).  
1.6.2.1 Neural stem cells as source of GBM CSCs  
The search for GBM cells with stem like properties is based upon the 
knowledge gained from the normal neural stem cells (NSCs) in the brain. NSCs 
are multipotent self renewing cells found in the sub ventricular zone, dentate 
gyrus or subcorticular zone of brain that generate differentiated cells of the brain 
(Doetsch et al., 1999). They can be grown in vitro as suspended cell aggregates 
called neurospheres (NS) using a serum free media supplemented with stem 
cell growth factors. When they are exposed to serum, they generate all types of 
differentiated cells of the brain (Nunes et al., 2003). Since GBM CSCs isolated 
from GBM samples and grown in a similar manner share very definitive 
characteristics with NSCs and faithfully reproduced the tumour in xenograft 
models it was considered that an altered NSC could be the cell of origin for 
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GBM. This was also because NSCs survive indefinitely and reproduce over a 
longer period making them suitable candidates that can accumulate mutations 
and lead to the first GIC (Rao et al., 1998; Sanai et al., 2005). In addition, the 
GBM CSC model also follows a hierarchical organization similar to the normal 
tissue generation and turnover where the number of stem cells would be very 
low. This was true with GBM as the amount of CSCs in GBM were only less 
than 1% of the total population (Lee et al., 2006). In an effort to establish the 
fact whether GBM or a first GBM CSC or TIC may arise from altered NSCs, 
researchers developed murine models of gliomagenesis. The first and most 
genetically faithful models were the xenograft models (Singh et al., 2004). Early 
studies used CD133 positive GBM CSC population as side-population method 
and considered them as pure CSCs. It was found that as few as 100 CD133+ 
cells could faithfully recapitulate the parent tumour in immunodeficient mice 
whereas more than a million CD133- cells cannot induce tumours (Beier et al., 
2007). These studies initially proved that GBM CSCs could be the likely source 
of giomagenesis and NSCs could be the source of tumour initiating GBM CSC. 
However, subsequent studies proved that gliomagenesis could also happen 
with CD133- cell population, which clearly highlighted the need for better 
markers and further studies (Wang et al., 2008).   
Many researchers focussed on the subventricular zone (SVZ) and other stem 
cell niches in murine models. Genetic studies involving NSCs in the SVZ like 
p53 mutations, KRAS and Akt mutants, PDGFR alterations, PTEN/p53 
recombination, EGFR amplification, infecting NSCs with oncogenic viruses, 
HCMV infection, etc have clearly given rise to GBM (Sanai et al., 2005). A 
number of radiographic studies in patients revealed that GBM formation occurs 
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near the periventricular areas in majority of the cases. Other GBMS that are 
present supratentorially can be attributed to the migration of TIC before 
establishing the tumour (Jackson et al., 2006). Therefore, it seems reasonable 
that NSCs or transiently dividing neural progenitors located in the SVZ regions 
are likely candidates for cellular origin of GBM and hence selective targeting of 
these altered NSCs/GBM CSCs will effectively reverse chemoresistance and 
provide therapeutic benefit in GBM treatment.  
 
1.6.2.2 Epithelial to mesenchymal transition induced GBM CSCs 
 
Epithelial-to-mesenchymal transition (EMT) is an evolutionarily conserved 
cellular process that has multifunctional roles in embryogenesis, tissue repair 
and wound healing. The epithelial cells are normally immobile due to their 
polarized organization and adherence to the basement membrane. During EMT 
process the polarity and cell to cell junctions of the epithelial cells are lost which 
results in cytoskeletal rearrangement and change of shape leading to the 
acquisition of mesenchymal phenotype. These cells are characterized by 
increased proliferation, increased cell migration, invasion and synthesis of 
components that can degrade the basement membrane. Increasing evidence 
suggest that progression of most cancers is associated with acquisition of the 
mesenchymal phenotype which enable the cells to infiltrate surrounding tissue 
and migrate to distant sites leading to metastasis and also lead to the 
acquisition of stem cell characteristics (Kalluri et al., 2009; Acloque., 2009). 
Milestone studies in GBM, breast cancer, pancreatic cancer and colon cancer 
suggest that mesenchymal cells produced by EMT inside the tumour 
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microenvironment account for the stem cell phenotypes in solid tumours and 
thus can explain the heterogeneity, hierarchical nature of CSCs and clonal 
evolution in tumours.  These studies also highlighted that EMT is a major 
molecular event that is required for progression of early stage benign tumour 
into a malignant phenotype that has invasive and metastatic capabilities 
(Brabletz et al., 2001). EMT can be readily observed by the loss of epithelial 
markers like E-cadherin, cytokeratins and tight junction proteins such as 
claudins and occludins. On the other hand EMT phenotypes show increase in 
markers like N-cadherin, vimentin, matrix metalloproteinases, fibronectin, etc., 
(Lee, 2006). In addition to these markers EMT phenotypes also show markers 
like ALDH, CD133 and nestin that are originally thought to be specific for NSCs 
or GBM CSCs. Various stem cell developmental pathways and transcription 
factors like Wnt, Notch, Hedgehog, SOX2, OCT4, NANOG and -catenin are 
also observed in the EMT phenotypes in addition to suppression of p53 
mediated apoptosis and expression of resistance proteins such as ABC, P-gp 
and MRP.   
Recent reports in GBM research also seem to link this phenomenon to GBM 
progression, invasion and intrinsic resistance. Members of Twist, Snail, ZEB 
and other EMT activators are shown to augment GBM motility and invasion both 
in vitro from patient samples and in vivo using animal models (Mikheeva et al., 
2010; Qi et al., 2012; Kahlert et al., 2013). The recent addition of a 
mesenchymal subgroup to GBM classification also supports this phenomenon 
and highlights the clinical importance of EMT (Louis et al., 2007). Patients with 
mesenchymal subtype of GBM have significantly low overall and event free 
survival rates (Verhaak et al., 2010). Tumours in these patients are 
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characterized by enormous motility, aggressive invasion, increased distribution 
and multifocal presentation in addition to intrinsic resistance to chemoradiation 
treatments. Mesenchymal cells themselves are pluripotent cells with stemness 
and also can grow as spheres like NSCs that have the ability to differentiate into 
different types of cells of the CNS (Li et al., 2015). Hence some researchers 
believe that the mesenchymal population is the CSC population in tumours as 
they are dedifferentiated from cancer cells. But on the other hand, evidences for 
NSC origin of GBM CSCSs are quite strong. The existence of CSCs in the 
proneural subtype of GBM and their origins from progenitors of NSCs are well 
established (Lei et al., 2011). Hence some researchers refer to the 
mesenchymal group as „stem-like cells‟ but not true CSCs.  
1.6.2.3 EMT induced by tumour microenvironment 
EMT and the resulting mesenchymal phenotype displaying all the CSC features 
are thought to be induced, supported and maintained by the tumour 
microenvironment. The tumour cells in the microenvironment are provided a 
supportive framework by several factors like ECM, hypoxia, acidity, cancer 
associated fibroblasts (CAFs), cancer associated macrophages (CAMs), 
endothelial progenitor cells (EPCs), stromal cells, soluble growth factors, 
numerous cytokines, and nutritional gradients and modified metabolism 
(Vaupel, 2004; Ariztia et al., 2006). The multiple signals received from the 
neighbouring cancer cells and stromal cells trigger expression of transcription 
factors like TGF-, HIF1, HIF2, NF-B, EGF, WNT, NOTCH and -catenin 
that initiates EMT pathways leading to invasion, quiescence, progression, 
metastasis and chemoresistance (Polyak and Weinberg, 2009).  
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1.7 Hypoxia  
 
The concentration of oxygen is tightly regulated in cells and tissues due to its 
essential role in different biological processes. Low levels of oxygen in cells or 
tissues, referred to as hypoxia results in extensive transcriptional effects 
involving multiple downstream signalling leading to pro-apoptosis or pro-
angiogenesis pathways. Hypoxia is the most common feature in solid tumours 
and one of the most pervasive microenvironmental stresses associated with 
tumour progression, invasion, angiogenesis, metabolic alterations and 
resistance to therapy (Favaro et al., 2011).  Usually when the tumour size 
reaches above 2mm3 the ever expanding cancer cells experience poor oxygen 
diffusion, chaotic vasculature and irregular blood resulting in a flux in the 
oxygen tension (Carmeliet and Jain, 2011).  It is estimated that hypoxia (1% or 
less O2) or anoxia (<0.01% or no detectable O2) is a predominant feature in 
more than 60% of locally advanced solid tumours which clinically contributes to 
high risk of metastasis, tumour recurrence, reduced overall survival rate and 
high mortality (Carmeliet and Jain, 2011; Evans, 2004).  
 
Compared to normal cells, neoplastic cells employ various abnormal oxygen 
sensitive mechanisms to control transcriptional and post-transcriptional changes 
in gene expression that allows them to adapt to a hostile, hypoxic environment 
for survival. These can be done by either engaging specific metabolic 
reprogramming to survive under hypoxia, by producing an environment 
favouring de novo angiogenesis or by activating a motility program such as 
EMT to escape the hostile environment and colonize in a different environment 
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(metastasis). This clearly explains the contribution of hypoxia to the malignant 
and aggressive behaviour of extensively hypoxygenated tumours like GBM. The 
normal physiological O2 concentration in a healthy brain ranges between 12.5% 
and 2.5%. However majority of GBM tumours displayed either mild hypoxia 
ranging from 2.5% to 0.5% or severe hypoxia with O2 concentrations reduced 
upto 0.1% (Evans, 2004; Pistollato et al., 2010).  
 
1.7.1 Molecular biology of hypoxia inducible factors 
 
Cellular responses to hypoxic conditions are controlled by a family of oxygen 
sensitive proteins known as hypoxia inducible factors (HIFs) which are one of 
the most critical transcriptional regulators that help tumour cells to adapt to a 
hypoxic microenvironment.  So far three different HIFs are identified in humans 
namely HIF1, HIF2 and HIF3 however HIF1is the most commonly 
reported transcription factor involved in hypoxic response (Majmundar et al., 
2010). HIFs are known as master regulators under hypoxia because of their 
extreme ability to undergo conformational changes to varying oxygen 
concentrations. HIFs are heterodimeric transcription factors that consist of an 
oxygen sensitive HIF- subunit and a constitutively expressed HIF- subunit. 
The functional HIF is produced when the  and  subunits are assembled 
together by post transcriptional modifications which largely depend on 
stabilization of oxygen dependant subunit that is well studied in the case of 
HIF1(Philip et al., 2013). In the presence of oxygen the HIF1 subunit is 
hydroxylated on proline positions of the polypeptide by a group of enzymes 
called prolyl-hydroxylases (PHDs) namely PHD1, PHD2 and PHD3. The 
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hydroxylation of HIF1 subunit by PHDs is an oxygen requiring reaction, which 
also needs a-ketoglutarate as substrate. Hydroxylated HIF-1 is ubiquitinated 
by another enzyme called von Hippel-Lindau (VHL) tumour suppressor ubiquitin 
ligase. Ubiquitination of HIF subunit will mark this protein ubiquitin dependant 
protein degradation and therefore prevents the  subunit to form a functional 
dimer with  subunit. In addition to the proline hydroxylation by PHDs another 
oxygen dependant hydroxylation mechanism mediated by the factor-inhibiting 
HIF1 (FIH) can hydroxylate the aspartine803 that prevents the interaction 
between HIF1 and its transcriptional co-activator (Kallio et al., 1999). The HIF-
1 subunit is an aryl hydrocarbon receptor nuclear translocator (ARNT) which is 
constitutively in the nucleus of many cell types (Kallio et al., 1999). Under 
hypoxic conditions, the hydroxylation reaction cannot happen effectively and 
leads to the stabilization of HIF-1subunit. it is then translocated into the 
nucleus where it forms an active transcription factor heterodimer with HIF-
1The dimer of HIF1- with the help of p300/CREB binding protein (CBP) 
coactivators will bind to transcriptional enhancer elements normally known as 
hypoxia response element (HRE) which are identical sequences (5‟-RCGTG-3‟; 
R=A or G) present in the promoter/enhancer regions of target genes. This in 
turn enhances transcription of target genes involved in cellular adaptations to 
hypoxia (Philip et al., 2013; Majmundar, et al., 2010).  
 
HIF-2α, which is also known as endothelial PAS domain protein 1, EPAS1 due 
to its restricted expression in endothelial cells is also an oxygen regulated 
transcription factor that has been shown to share several transcriptional target 
genes with HIF-1α. This includes genes like VEGF, TE-1, Tie2, Ang-2 and Flt-1 
 39 
 
with promoter/enhancer regions that has homologous DNA-binding sequence 
binding sites for both HIF-1α and HIF-2α mediated HREs (Holmquist-
Mengelbier et al., 2006). Despite their similarities, the restriction of HIF-2α 
expression in vasculature highlights the dominant role played by HIF-2α in the 
induction of tumour organs. In addition HIF-2α is known to have several unique 
transcriptional targets such as Oct4 and transforming growth factor-α (TGF-α) 
which are different from the canonical pro-angiogenic hypoxic response 
suggests an important and specific role for HIF-2α in the regulation of  stem cell 
pathways.  Multiple recent experimental studies have revealed that high 
expression of HIF2α important is required for maintaining the CSC phenotype 
and tumourigenesis in GBM, neuroblastoma, renal cancer, and non-small cell 
lung cancer (Li et al., 2009; Mazumdar et al., 2010; Helczynska et al., 2008). 
However the role of HIF2α is still not fully elucidated.  
 
The third HIF isoform is HIF-3α and very little is known about its function and 
regulation. A small number of studies have shown that HIF-3α has a limited 
expression pattern in eyes, kidneys, lung and cerebellum and some studies 
have described several splice variants of HIF-3α. These variants are thought to 
be dominant-negative regulators of HIF-1α and 2α isoforms and potentially 
direct transcriptional targets of HIF-1α under hypoxia (Gu et al., 1997). Over 
expression of HIF-3α isoforms in vascular cells is shown to decrease VEGF 
expression under hypoxia, which confirms the regulatory function of HIF-3α in 
HIF signalling pathway (Heidbreder et al., 2007; Augstein et al., 2010). 
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1.7.2 Hypoxia induced EMT and CSCs 
 
Hypoxia has been well known as a factor that regulates and maintains the stem 
cell sub-population in normal tissues during development (Dunwoodie, 2009). 
Recent experimental evidences indicate that hypoxia and HIF signalling also 
plays a pivotal role in    phenotype and function of CSCs by enhancing the self-
renewal capacity and maintenance of undifferentiated state of CSCs. CSCs 
maintained under hypoxic conditions retain the undifferentiated phenotype 
whereas those exposed to normoxia readily undergo differentiation (Ezashi, et 
al., 2005; Zeng et al., 2011). It has been shown that hypoxia is able to achieve 
this by activating signalling pathways that are associated with normal stem 
cells, including Sox2, Oct4 and Notch-1 signalling. This activation of the 
signature stem cell genes in CSCs may be the important reason for the 
association of hypoxia with increased tumour aggressiveness resulting in poor 
clinical outcomes. This is also consistent with recent findings in glioma CSCs 
where hypoxia promotes CSC phenotypes and contributes to tumour 
aggressiveness. It is also now understood that hypoxic areas or necrosis within 
the solid tumours like GBM may act as a niche where CSCs can reside 
(McCord et al., 2009). Therefore, it is likely that tumours may originate and 
develop from mutation acquired by normal stem cells or from non-stem cell 
population due to hypoxic microenvironment. In fact, there is substantial 
evidence showing that CSCs may arise from epithelial cells through hypoxia 
induced EMT especially in breast cancer (Jiang, Tang and Liang, 2011). But the 
precise mechanism involved by which hypoxia mediates the EMT-CSC 
phenotype is not fully understood. It has been documented that hypoxia-
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mediated CSC phenotypes are regulated by HIF proteins, especially HIF-1α- 
and HIF-2α- signalling pathways that activates Sox2, Oct4, Nanog, cMyc, 
Notch-1, CD133, CD44 and other CSC markers. But in the very initial stages of 
hypoxia survival becomes the priority for cells experiencing hypoxic stress and 
cannot carry out aerobic respiration (Heddleston et al., 2010). It is HIF-1α which 
helps these stressed cells to switch primarily to glycolysis rather than oxidative 
metabolism and adapt to that environment. HIF-1α mediated expression of 
pyruvate dehydrogenase kinase completely blocks decarboxylation of pyruvate 
to acetyl coA. HIF1 also mediates expression of GLUT transporters to enhance 
the uptake of glutamine which can be converted to isocitric acid and to -
ketoglutarate by IDH1/IDH2 pathways. -ketoglutarate is a strong inhibitor of 
PHDs that keeps the HIF-1α signalling active (Lisy and Peet, 2008). HIF1 
signalling effectively communicates with stromal cells and CAFs to help the 
starving tumour cells by producing and uploading lactate in the 
microenvironment through Warburg metabolism which is used by cancer cells to 
protein and energy production. Although HIF-1α induces angiogenesis and 
finally achieves supply of oxygen and nutrients the cells still seem to adhere to 
Warburg metabolism and is thought to contribute to mimic persistent hypoxia 
activation and hypoxia induced metaplastic switch (Semenza, 2003).  On the 
other hand HIF-2α is shown to be highly expressed in CSCs unlike HIF-1α 
which is expressed both in stem and non stem cell populations (Skuli et al., 
2009). Recent investigations show that conditional loss of HIF-2α is shown to 
affect the self-renewal capacity of CSCs and suppress EMT. Meanwhile forced 
expression of HIF-2α in non stem cell population is shown to activate various 
stem cell features like Oct4, Nanog, CD44, CD133, Sox2 and c-Myc with  
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Figure 1.6 A) Fate of HIF1under normoxia and hypoxia (Carroll et al., 2005). B) Hypoxia 
induced EMT as an alternate way of inducing CSCs in GBM. 
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increased tumourigenicity (Heddleston et al., 2010). These facts collectively 
underscore the role of HIF-1α and HIF-2α in adaptation of cancers under 
hypoxia. However if the metabolic switch is not sufficient, additional adaptations 
are activated by HIF-1α to promote the escape of cancer cells from the primary 
tumour through EMT program. Multiple studies demonstrate that hypoxia 
induces EMT characteristics in a variety of cells and EMT is tightly regulated by 
HIF-signalling pathways. A complex molecular crosstalk between hypoxia-
induced pathway and EMT has not yet fully understood. During the acquisition 
of EMT phenotype, several transcription factors such as ZEB1, ZEB2, Snail1, 
Slug, Twist1 and TCF3 are shown to be critical mediators of EMT program and 
the activation of HIF-1α and HIF-2α can induce these transcription factors. In 
addition hypoxia and HIF signalling could increase the expression of EMT-
associated inflammatory cytokines such as TNF-α and interleukins and activate 
other EMT-associated signalling pathways such as TGF-β, Notch, NF-B, 
Wnt/β-catenin, and Hedgehog (Jiang et al., 2011; Graham et al., 2008). HIFs 
are also shown to facilitate motility and invasion through direct or indirect 
regulation of cell-matrix interactions and genes such as LOX, Hey1, Hes1 and 
MMPs (Chen et al., 2010). Unlike HIF-1α, HIF-2α can operate under moderate 
hypoxic levels or even under physiological oxygen concentrations and seems to 
participate in acidity induced CSC phenotypes. It is postulated that HIF-1α is 
required during acute or transient hypoxia whereas HIF-2α may play a 
significant role during prolonged or chronic hypoxia. It is evident from certain 
cancers that during chronic hypoxia they switch from HIF-1α metabolism to HIF-
2α by degrading HIF-1α using an E3 ubiquitin ligase known as SART1 (Koh et 
al., 2011; Koh et al., 2008). This switch enables the cells to acquire more 
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mesenchymal features and motility in addition to expression of EMT related 
genes. Thus the differential expression of HIF-1α and HIF-2α on stem cell and 
non-stem cell population coupled with duration of hypoxia in the 
microenvironment could be the deciding factor in CSC population and tumour 
aggression (Koh et al.,2011).  
 
1.8 Nuclear Factor kappa B (NF-B) 
 
NF-B is a family of structurally related transcription factors that regulates a 
large number of normal cellular processes such as immune and inflammatory 
responses, growth and apoptosis. Over three decades of research has 
demonstrated that NF-B is ubiquitously expressed in almost all cell types and 
tissues. NF-B is thought to play a pivotal role in multiple physiological and 
pathological processes by regulating variety of genes that has NF-B binding 
sites in their promoters or enhancer regions (Oeckinghaus et al., 2009). Due to 
its ability to induce gene expression in numerous genes the activity of NF-B is 
tightly regulated at multiple levels.  
 
The NF-B family consists of five structurally related and evolutionarily 
conserved proteins namely RelA (p65), RelB, c-Rel, NF-B1 (p50/p105), and 
NF-B2 (p52/p100) (Chen and Ghosh, 1999). All components share a highly 
conserved amino terminal Rel homology domain (RHD) which is a sequence 
made up of 300 amino acids  that is responsible for DNA binding, dimerization, 
and interaction with IkB. NF-B proteins are divided into two classes based on 
the synthesis and transactivation properties of sequences from C-terminal to the 
 45 
 
RHD. The class I NF-B proteins include NF-B1 and NF-B2 which are 
synthesized as large precursors p105 and p100 respectively. Both the proteins 
contain an N-terminal RHD and a long C-terminal transactivating domain with a 
series of ankyrin repeats. Both p105 and p100 is converted to mature DNA 
binding proteins p50 and p52 respectively by removing transactivating part of 
the C-terminal domain with the help of ubiquitin/proteasome pathway. The class 
II NF-B proteins include RelA (p65), RelB and c-Rel, which are synthesized in 
their mature forms and no processing is required. Their C-terminal contains 
transactivating domain but it does not have the inhibitory ankyrin repeats (Karin 
et al., 2002). All these 5 different NF-B proteins can form homodimers within 
themselves or heterodimers with other members (Barkett and Gilmore, 1999). 
These homodimers or heterodimers start transcription when they bind 
specifically to DNA sites which are called κB sites which are made up of 9-10 
base pairs with the base sequence 5'-GGGRNNYYCC-3'; where R= purine; Y= 
pyrimidine; N= any nucleotide (Nishikori, 2005). This distinct ability of REL/NF-
B proteins to form dimers enables them to bind to different kB sites or to the 
inhibitor proteins like IKBThe heterodimer made up of p50/RELA is known as 
the prototypical NF-B complex. NF-B dimers are held in the cytoplasm in an 
inactive form by members of another family of proteins called IκB (inhibitors of 
κB) that prevents the nuclear translocation of the dimers (Karin et al., 2002). 
The IκB inhibitory protein family contains seven members namely IBα, IBβ, 
IκBε, IκBγ, Bcl-3, and the carboxyl-terminal regions of NF-B1 (p105) and NF-
B2 (p100). The IκB proteins have multiple ankyrin repeats at their C-terminal 
domains through which they associate with the RHD of NF-B proteins and 
retain them in the cytoplasm (Nishikori, 2005).  
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1.8.1 The NF-B activation pathways  
Under normal conditions of cells, the activation of NF-B is a tightly regulated 
process that depends on degradation of IB through specific phosphorylation 
mediated by IB kinase (IKK) (Ghosh et al., 2002). The IKK complex plays an 
important role upstream of NF-B signal transduction cascade. The IKKs 
complex is comprised of two catalytic kinase subunits, IKKα (IKK1) and IKKβ 
(IKK2) and a regulatory element IKKγ also known as NF-B essential modulator 
(NEMO) (Ghosh et al., 2002). The IKK-dependent activation of NF-B can take 
place in two ways: classical (canonical) pathway and the alternative (non-
canonical) pathway. The classical NF-B pathway is triggered when the cells 
are stimulated by inducers such as TNFα, T-cell receptors (TCR), B-cell 
receptors (BCR), Toll-like receptor (TLR) or interleukin-1 receptors (IL-1R) 
(Karin et al., 2000). IBα is phosphorylated at specific sites Ser32 and Ser36 by 
IKKβ of the IKB kinase complex. The role of IKKα in the classical pathway is not 
confirmed, but recent studies suggest prior activation of IKK complex depends 
largely on IKK specifically the phosphorylation and activation of IKKβ. (Karin et 
al., 2000). Phosphorylation of IBα triggers rapid polyubiquitination at Lys21 
and Lys22 sites of IκBα and stimulates subsequent degradation of this 
cytoplasmic inhibitor by 26S proteasome complex, that liberates NF-B 
(RelA/p50) and unveils the nuclear localization signal present on RelA 
promoting the nuclear translocation of NF-B dimers to the nucleus (Karin et al., 
2000). The alternative pathway involves the inducible proteolytic processing of 
p100. The p100 protein binds to N‟-terminal of RHD of RelB and holds the dimer 
inactive in the cytoplasm. Signal from NF-B inducers like LTβ and lymphotoxin 
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B and B cell activating factor (BAFF) and CD40L via NF-B inducing kinase 
(NIK) results in the phosphorylation of p100 by IKKα. This results in 
ubiquitylation and partial proteolytic degradation of p100 by 26S proteasome 
resulting in p52. This generates RelB/p52 heterodimers that is translocated into 
the nucleus as transcription factors (Bonizzi et al., 2004).  
 
1.8.2  NF-B and cancer chemoresistance 
 
NF-B is an important transcription factor associated with many hallmarks of 
cancer development like proliferation independent of any growth factors, 
inhibition of apoptosis, never-ending replication, invasion and metastasis 
(Baldwin et al, 2001; Karin, 2002). NF-B is also known to play important role in 
tumour initiating cells. NF-B is constitutively activated in a variety of 
hematologic and solid tumours, by multiple mechanisms including mutations in 
upstream regulatory components of this pathway. It has been shown that 
cytokines such as TNFα, IL-1, IL-6, and IL-8 mediates constitutive activation of 
NF-B that maintains the chronic inflammation in these tumours (Ghosh et al., 
2002; Chen et al., 2004). NF-B plays an instrumental role in regulating the 
expression of anti-apoptotic proteins as well as suppression of multiple 
apoptotic or proapoptotic proteins (Patel et al., 2000; Arlt et al., 2001). The anti-
apoptotic proteins regulated by NF-B are inhibitor of apoptosis proteins IAPs, 
FLICE, cFLIP, Bcl-XL, Bfl-1, TRAF1 and TRAF2. IAPs (c-IAP1, c-IAP2, and 
XIAP) inhibit effector caspases and suppress both extrinsic and intrinsic 
pathways of apoptosis (Deveraux and Reed, 1999). c-FLIP associates with  
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Figure 1.7 Role of NF-B in cancer. NF-B activation pathways and important functions of NF-
B target genes in promoting cancer cell survival and chemoresisatcne (Adapted from Viennois 
et al., 2013).   
 
TNFR to block caspase 8 activation. Anti-apoptotic members of the bcl-2 family 
(Bcl-XL, A1) stop the release of cytochrome-c and inhibit caspase-9 activity 
(Cheng et al., 2000). TRAF proteins are known to obstruct the caspase cascade 
at the TNFR1 level through amplification of NF-B activation. Another 
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mechanism by which NF-B blocks apoptosis is by inhibiting JNK activation and 
accumulation of ROS (De Smaele et al., 2001).  In some tumours, cells 
exposed to radiation or treated with chemotherapeutic drugs enhance the NF-
B activation which inhibits the apoptosis induced by treatment and subsequent 
acquisition of chemo and radioresistance. This drug or radiation induced 
activation of NF-B combined with inherent increased NF-B activity prior to 
treatment in tumour cells could be a significant obstacle to effective cancer 
therapy (Brach et al., 1991). In addition, recent studies have demonstrated that 
drug resistance genes like MDR1, P-gp, MGMT and BCRP have NF-B binding 
sites in their promoter regions confirming the role of NF-B in chemoresistance 
(Wang et al., 1999). 
 
1.8.3  Role of NF-B in hypoxia induced EMT 
 
Although HIF signalling is important for cellular response under hypoxia, more 
than 20 different transcription factors are functional in the interplay between 
hypoxia, EMT and CSC phenotypes to induce resistance and metastasis. 
Among them, NF-B is thought to play a crucial role in inducing CSC population 
under hypoxic conditions by functioning as an important transcription factor that 
activates various EMT and metastasis promoting genes (Chua et al., 2007; 
Connelly et al., 2007). For cancer epithelial cells to undergo EMT several 
developmental transcription factors together have to repress epithelial gene 
expression. For example E-cadherin gene transcription is thought to be 
suppressed by Snail and Slug. Two other transcription factors ZEB1 and ZEB2 
together with Twist and SMAD are also known to regulate E-cadherin and EMT 
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programme. Multiple lines of evidence suggest all these transcription factors are 
controlled upstream by NF-B signalling (Nieto, 2002; Culleres et al., 2006; 
Kajita et al., 2004; Chua et al., 2007; Yang et al., 2004; Sosic et al., 2003). It 
has been shown that the region between -194 and -78 of SNAI1 promoter is 
activated by GSK3 inhibition stimulating the transcription of Snail in a NF-B 
dependant fashion (Min et al., 2008). Slug downregulates the expression of 
epithelial E-cadherin, claudins and occludins and it is thought be controlled by 
an aryl hydrocarbon receptor (AhR) (Zhang et al., 2006). AhRs are known to 
transactivate a variety of environment responsive genes including Slug, which in 
turn is shown to be regulated by c-REL of NF-B family.  ZEB family of proteins 
are known for their role in EMT by disintegrating cell-cell junctions in epithelial 
cells and induction of mesenchymal markers. Studies from various cancers 
suggest that p65 subunit of NF-B directly regulates ZEB family which are very 
important mediators of NF-B signalling during EMT. Twist is another EMT 
gene that helps the cancer cells to undergo intravasation to systemic circulation 
and hence promoting invasion and metastasis. Twist is a direct transcritptional 
target of NF-B and is shown to be evolutionarily conserved in this way. It has 
also been shown that Twist expression and activation induced by 
chemotherapeutic agents in certain cancers largely depended on p65 and c-
REL containing NF-B complexes (Yang et al., 2004). In addition to above 
factors NF-B dependant expression is also observed in mesenchymal 
cytoskeletal protein Vimentin, invasive collagenases MMP2 and MMP9 which 
are important elements of EMT phenotypes (Kang and Massague, 2004).  
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HIFs regulate more than150 genes including NF-B and many studies have 
indicated that hypoxia resulted in enhanced NF-B signalling pathway in cancer 
cells (Melvin et al., 2011; Devries et al., 2010). NF-B is primarily required as an 
anti apoptotic machinery to enable a hypoxic cell to survive. On the other hand, 
multiple experimental evidences suggest that NF-B regulates HIFs owing to 
the presence of NF-B binding site in their promoter regions (Cockman et al., 
2006). Together HIF and NF-B signalling pathways orchestrate EMT and 
maintain the stem cell phenotype in tumour microenvironment. Further 
experiments and validations are required to precisely understand the interplay 
between hypoxia, HIFs, NF-B, EMT, CSC phenotypes and cancer 
chemoresistance. However, it is reasonable to hypothesize that hypoxia 
induced NF-B could be the key in maintenance of CSCs during the 
development and progression of tumours. The pivotal role of the NF-B 
pathway and the fact that NF-B is constitutively activated in a large number of 
malignancies, strongly imply that inhibiting NF-B would be a promising strategy 
in cancer therapy. 
 
1.9  Disulfiram  
1.9.1  Pharmacology of Disulfiram 
Disulfiram (DS) also known as tetraethylthiuram disulfide was developed from 
thiocarbamide by a German chemist, M. Grodzki in the year 1881 (Grodzki et 
al., 1881). DS was first used as a catalyst in the rubber industries to accelerate 
the vulcanization of rubber and other synthetic rubber products (Eneanya et al, 
1981). DS was introduced in the clinics in early 1940s by two British physicians 
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as a drug to tackle scabies (Gordon et al., 1942). Two Danish physicians Hald 
and Jacobsen reported in 1945 that ingestion of alcohol after treatment with DS 
would lead to highly unpleasant reactions, which led to the use of DS as an 
antialcoholism drug (Eneanyn et al, 1981). Clinically DS is shown to be a very 
safe drug with very less toxic effects (even after high doses of 300 to 500 
milligrams a day) an excellent bioavailability where 20% of the administered 
drug remains in the body for up to two weeks (Sauna et al., 2005). Structurally 
DS is made up of two molecules of diethyldithiocarbamate molecules attached 
together by a disulfide bridge. It has a low molecular weight of 296Da (Sauna et 
al., 2005). When DS is metabolized, the breakdown of disulfide bridge by a 
rapid reduction reaction converts DS into its respective thiol groups namely 
diethyldithiocarbamate (DDC). If administered orally DS is rapidly absorbed 
from the gastrointestinal tract. More than 80% of oral dose is generally 
absorbed but a little amount of this is reduced in the stomach and DDC is 
liberated which is less stable in stomach acid and decomposes to diethylamine 
and carbon disulphide. However DDC is a strong chelating agent of metals and 
rapidly forms complex with metal ions like cupric ions to yield DDC-copper 
(Cu(DDC)2). Cu(DDC)2 is more stable in stomach acid that allows its absorption 
in the upper intestinal tract. Hence a combination of copper with DS is thought 
to improve the bioavailability of the parent drug. After crossing the intestinal 
mucosa into the blood stream, DS rapidly disappears below the limit of 
detection. This process is very quick and can happen within 4minutes in vitro 
(Cobby et al., 1977). In vivo the glutathione reductase system in RBCs can 
readily reduce DS, which causes the rapid disappearance of DS from blood 
stream. 
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The DDC formed could be metabolised further by four different reactions 
namely glucuronidation, nonenzymatic degradation, methylation, and oxidation.  
Glucuronidation is the main detoxification mechanism of DS where DDC is 
conjugated with glucuronic acid in mammals and about half of the given dose of 
DS is excreted in the urine as glucuronide metabolite. Nonenzymatic 
degradation DDC is a pH dependent mechanism where DDC is rapidly 
decomposed to diethylamine and carbon disulphide in an acidic environment 
(Stromme et al., 1966). The resulting diethylamine may be further degraded to 
simpler compounds such as ammonia and acetaldehyde. About 0.05% of the 
given dose of DS and its DDC form can be methylated to form a methyl ester of 
DDC (MeDDC). Another type of methylation of DDC observed was the S-
methylation, which accounted for about 27% of metabolism of the given dose 
(Cobby et al., 1977., Gessner et al., 1972). Enzymes such as esterases targets 
MeDDC derivative to generate a methyl mercaptan which is further oxidized to 
sulfate and formaldehyde. Since production of sulfate from other thioester 
compounds is a rapid process the S-methyl compound oxidation to produce 
inorganic sulfate by cleavage of methyl mercaptan (Canellakis et al., 1953., 
Maw et al., 1954). Oxidation reaction involving DDC under atmospheric oxygen 
condition, results in the reoxidation of DDC back to DS. However it is rare 
process that accounts for only about 4% of DDC and can be frequently affected 
by oxidases in the body (Strume, 1965).  
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1.9.2  Disulfiram and treatment  
1.9.2.1 Anti-alcoholism  
DS has been used for treating alcoholism for more than 60 years (Kampman, 
2009). In healthy adults, ethanol is eliminated in the liver by a group of enzymes 
known as alcohol dehydrogenases that results in the formation of acetaldehyde. 
Acetaldehyde is an extremely toxic compound which is instantly converted to 
less toxic acetate by the enzyme ALDH. DS and its metabolites such as Me-
DDC irreversibly inhibit the enzyme ALDH1 by oxidation of sulfhydryl groups to 
form irreversible internal S-S bonds (Vallari et al, 1982). Alcohol consumption 
after taking DS results in a dramatic increase of acetaldehyde in the plasma, 
which mediates histamine release and leads to distressing physical symptoms 
collectively known as disulfiram ethanol reaction (DER).  Typical DER will result 
in tachycardia, hypotension, nausea, vomiting, flushing of the skin owing to 
cutaneous vasodilatation particularly on the trunk, tachypnoea, palpitations, 
anxiety and headache. DS was sold under the trade name Antabuse that was 
prescribed to well-motivated alcoholics who wished to quit heavy drinking. It 
was a well-tolerated drug but produced extreme adverse effects beyond safety 
levels if alcohol was ingested during antabuse treatment.  
1.9.2.2 Anti-cancer treatment  
Repurposing old drugs for new uses is an established shortcut between the lab 
and clinics. The anticancer activity of DS is long known. The use of DS for 
anticancer treatment gained attention after a case report by Lewison in 1977 
about an alcoholic breast cancer (BC) patient with multiple bone metastases 
showed spontaneous regression after the use of Antabuse-DS for her alcohol 
 55 
 
addiction. Earlier in vivo studies showed that oral administration of 
Benzo[]pyrene induced tumours in 90% of animals, but animals with 1% DS 
was added to their diet did not develop tumours even after 30 weeks. Another 
experiment in Wistar rats showed that administration of DS in the diet in parallel 
with N-n-butyl-N-(4hydroxybutyl) nitrosamine (BHBN) significantly reduced the 
induction of urinary bladder cancer by BHBN. A phase II clinical trial with 5 year 
follow up study that used DDC as an adjuvant in 64 late stage BC patients 
reported 13 relapses and 12 deaths in control group, whereas only 6 relapses 
and 5 deaths were reported in DDC group. The OS at 6 years was 81% in DDC 
group with 76% disease free survival rate while the OS in the control group was 
only 55%. A single case study of a patient with ocular melanoma and hepatic 
metastasis reported that a combination of oral DS and zinc gluconate induced 
reduction in hepatic metastases and produced clinical remission. She also 
continued the dose of DS therapy for 53 months with negligible side effects. 
Moreover various high-throughput cell-based screening studies of known drugs 
and drug like small molecules have identified DS as a potential therapeutic 
agent for prostate cancer, triple negative breast cancer and GBM.  
1.9.3  Mechanism of Action 
1.9.3.1 Role of Reactive Oxygen Species and Copper in anti cancer 
  effect of DS  
Reactive oxygen species (ROS) are biologically essential highly reactive 
species of partially reduced unpaired electrons of oxygen such as superoxide 
(O2-), hydrogen peroxide (H2O2), hydroxyl radical, and peroxynitrite. ROS are 
generated mainly from superoxides that are formed in mitochondria by reaction 
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of O2 with electrons leaked out from the respiratory chain (Schafer et al., 2001). 
ROS can also be generated by reactions involving NADPH oxidase complexes 
or from biochemical reactions in peroxisomes and cytochromes (Perry et al., 
2000). A small increase in intracellular ROS levels will promote cell proliferation 
and differentiation. However massive increase in the amounts of ROS will result 
in irreversible damage to lipids, proteins and DNA, leading to apoptosis 
(Boonstra et al., 2004; Schafer et al., 2001; Perry et al., 2000). ROS could 
induce DNA lesions through oxidized bases, strand breaks or by adding 
adducts (Randerath et al., 1996; Lloyd et al., 1997). Excessive ROS is known to 
damage the mitochondrial membrane and release cytochrome c eventually 
activating the apoptotic cascade of proteins such as caspases to induce cell 
death (Hensley et al., 2000). Therefore, the levels of ROS are kept under 
balance by ROS-scavenging systems such as superoxide dismutases (SOD1, 
SOD2, and SOD3), glutathione peroxidase, peroxiredoxins, glutaredoxin, 
thioredoxin and catalase (Boonstra et al., 2004). Cancer cells are known to 
have high intracellular ROS levels because of their high metabolic activity and 
increased oxidative stress. Under such increased ROS stress, cancer cells are 
known to adapt by increasing the expression of cell survival proteins, 
modification of protein structures, enhancing transcription factors and activate 
genes that control cell growth and differentiation (Davies et al., 1999). For 
example, up-regulation of the expression of antioxidant enzymes such as SOD, 
catalase and peroxidases and activation of the glutathione system 
(GSSG/2GSH) and thioredoxin system has been reported as adaptive 
mechanisms in cancer cells to maintain cellular redox balance (Schafer et al., 
2001; Sasada et al., 1996). Another mechanism is to activate the transcription 
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factors like NF-B, HIF1α, HIF2 and other cell signalling molecules such as 
MAPK and JNK to modulate cell growth and survival (Martindale et al., 2002). 
Therefore further increase in ROS levels after exposure to anti-cancer drugs will 
lead cancer cells to apoptosis.  
Cu is an essential trace element in humans and plays important roles in 
respiratory and metabolic reactions. The redox potential of Cu makes it an 
useful element as biological cofactor, but also can react with oxidizing agents to 
undergo Fenton‟s reaction and generate ROS mediated toxicity that can 
irreversibly damage cellular components including lipids, proteins, DNA 
resulting in cell death. The movement of Cu in and out of the cells is tightly 
regulated by a Cu transporting integral termed Ctr1. DS is a strong chelator of 
divalent metal ions such as Cu, iron (Fe), nickel (Ni), zinc (Zn), gold (Au), 
cadmium (Cd), etc (Morrison et al., 2010). Described as a Cu ionophore, DS 
binds primarily to Cu and can increase the cellular deposition of Cu leading to 
cytotoxic effects, a mode of action known as Cu overload. Cu can exist in cells 
only as protein bound forms and hence Cu overload disrupts the functions of 
proteins. In addition, Cu bound with DS is also a well established cytotoxic 
complex on its own, reported to induce apoptosis in many cancer cells by 
several mechanisms.   
According to the Cu overload theory the excess Cu mediates cytotoxicity 
through various mechanisms. As mentioned earlier, cancer cells have high ROS 
levels due to higher metabolic activity. They also accumulate Cu to meet their 
metabolic demands, which result in greater intracellular Cu concentration than 
non-malignant cells.  Cu interferes with the ROS withstanding glutathione 
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system of tumour cells and depletes the antioxidant defences in them. In the 
presence ROS in cancer cells Cu ions can cycle between two ionic forms, Cu(II) 
and Cu(III), to induce further ROS by the Fenton reaction. High Cu levels within 
tumour cells also activate NF-B, triggering anti-apoptotic factors which 
decrease this effect but the DS/Cu complex both increases ROS and inhibits 
NF-B, so the overall effect seems that Cu can push the oxidative stress in 
cancer cells beyond the threshold limit leading to cell damage or sensitise them 
to other anticancer drugs. This loophole can also be used as a selective target 
mechanism because chelation of excess Cu in cancer cells by DS itself will be 
toxic to cancer cells than normal cells. (Guo et al., 2009; Liu et al., 2012; Yip et 
al., 2011).  
 
 
Fig 1.8 Disulfiram forms complex with Cu (Cvek and Dvorak, 2008) 
 
1.9.3.2 Overriding resistance to chemotherapy 
DS was shown to inhibit P-glycoprotein (P-gp) mediated drug efflux of 
vinblastine and colchicine in vitro by modifying thiol groups in cysteine residues 
of P-gp.  Another finding suggests that the multidrug transporter-mediated 
resistance in Candida albicans is reversed by DS using the same mechanism. 
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Furthermore, metabolites of DS, such as DDC, MeDDC-sufoxide and MeDDC-
sulfone, inhibited the ATPase activity of P-gp stimulated verapamil treatment. 
Progression of a primary tumour largely depends on angiogenesis. DS 
demonstrates extensive antiangiogenic activity both in vitro and in vivo resulting 
in suppression of gliomas and Lewis lung carcinoma tumours that further led to 
clinical trials of DS in lung cancer (ClinicalTrials. gov Identifier NCT00312819). 
Another work using chicken embryos revealed that DS/Zn complex interacts 
with MMP2 and MMP9 to inhibit angiogenesis. DS is shown to downregulate the 
release of MMP2, MMP9, VEGF and TNFin osteosarcoma cells.  Tumour 
angiogenesis like normal angiogenesis requires VEGF and FGF to use Cu as a 
co factor. Addition of any Cu chelators like penicillamine has been shown to 
inhibit angiogenesis. It was hypothesised that DS also acts in a similar fashion 
to remove Cu from blood vessels during tumour vascularization. A recent 
finding in GBM reported the effect of DS/Cu complex on the DNA repair enzyme 
MGMT that confers resistance to alkylating agents like TMZ. It was found that 
DS modified Cys145, a critical cysteine site for DNA repair leading to the loss of 
MGMT from tumour cells through ubiquitin proteasome pathway in a dose 
dependant manner.   
 
1.10  Targeting CSCs with Disulfiram  
1.10.1  Proteasome / NF-B inhibition 
The ubiquitin proteasome pathway is the principle mechanism for controlled 
degradation of proteins in the cell. The proteasome enables rapid clearance of 
proteins, which is a critical process in tightly regulated mechanisms like cell 
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cycle, inflammation, apoptosis, transcriptional activation, and ageing. This 
breakdown of proteins is also critical for recycling the raw materials for new 
protein synthesis. Thus, the proteasome system helps to maintain the circadian 
rhythm and homeostasis of the cell. As mentioned in detail in section 1.8 the 
proteasome pathway plays an important role in the activation of NF-B, which is 
a predominant transcription factor activated in many malignant tumours. The 
inactive form of NF-κB is held in the cytoplasm by its inhibitor IB until any 
external stimuli triggers the phosphorylation of IκB. Phosphorylated IB is poly-
ubiquitinated by ubiquitin ligases, which is recognised by the proteasome and 
finally degraded. This releases NF-κB, which is then translocated to the nucleus 
and binds to its target genes in order to drive their transcription. NF-B is known 
to play multiple roles in cancer chemoresistance and considered to be one of 
the prime targets for anticancer drug development.  DS/Cu complex is a potent 
inhibitor of NF-B pathway primarily by its proteasome inhibitory action. To be 
more specific DS/Cu inhibits the E3 ubiquitin ligase of the proteasome system 
and impeding the breakdown of IB, eventually stopping NF-B release and 
translocation to the nucleus. DS/Cu is also known to interact with sulfhydryl 
groups of REL homology domain to inhibit NF-B independent of the 
proteasome system.    
1.10.2  ALDH inhibition 
In recent years, CSCs have become an attractive target to improve treatment 
outcomes in resistant tumours. ALDH has been identified as a functional marker 
of CSCs and known for its role in chemoresistance in wide range of cancers. 
ALDH is a superfamily containing 19 functional isoenzymes in 11 families and 4 
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subfamilies. They are NADH dependant enzymes involved in detoxification of 
exogenous and endogenous aldehydes as well as xenobiotics like 
cyclophosphamide.  Overexpression of ALDH isoenzymes in cancer cell lines 
can induce chemoresistance to a wide range of conventional anticancer drugs 
in vitro. Also knocking down ALDH genes has been shown to inhibit the growth 
of cancer cell lines and sensitizes CSCs to anticancer drugs. None of the 
available detection methods is specific for a particular ALDH isoenzyme 
because of the overlap of the same substrates for different ALDH isoenzymes. 
ALDHs also act as ROS scavengers thereby reducing the drug or radiation 
induced oxidative stress which could explain the high amounts of ALDH in 
CSCs and their resistant nature. Different ALDH isoenzymes are reported to be 
expressed for different cancer types. It is hypothesized that multiple ALDH 
isoenzymes are coexpressed in the CSCs derived from the same cancers. 
Therefore targeting an individual ALDH subtype may not be efficient in 
eliminating the CSC population within a tumour. DS is a pan- ALDH inhibiting 
molecule that targets ALDH enzyme activity rather than ALDH isoenzyme and 
thus could be an ideal agent to target CSCs. Therefore, inhibition of ALDHs by 
DS/Cu will result in ROS accumulation and ROS related cytotoxicity in CSCs. 
Although ALDH is one of the potential targets of DS, several other mechanisms 
are still not understood.  
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1.11 AIMS and OBJECTIVES 
 
Resistance to chemotherapy is a major obstacle in improving the therapeutic 
outcome of GBM patients. The majority of drugs do not cross the BBB which 
results in poor bioavailability of anticancer drugs in the brain. In addition to 
various intrinsic resistance mechanisms, GBM contains a very small population 
of cancer cells expressing CSC markers that promote therapeutic resistance. It 
is still unclear whether GBM CSCs are derived from neural progenitor cells or 
differentiated cells.  Many recent studies have elucidated that intra-tumoural 
hypoxia induces CSC phenotypes in tumour via epithelial-to-mesenchymal 
transition (EMT). Hypoxia inducible factors (HIFs) are master transcriptional 
regulators under hypoxic conditions. However NF-B, another key transcription 
factor, is also highly up-regulated in hypoxia induced CSCs and is proved to 
play an important role in cancer chemoresistance. There are no clear insights 
on how HIFs and NF-B together orchestrate the anti-apoptotic signalling, 
chemo-radiation resistance and maintenance of stemness in GBM CSC 
phenotypes. GBM is resistant to all available anticancer drugs and GBM CSCs 
play a major role in chemoresistance of GBM. Therefore, development of drugs 
that cross BBB, targets GBM CSCs in addition to eliminating non-CSC tumour 
population is of significant clinical importance. The ultimate aim of my study is to 
determine the anticancer efficacy of Disulfiram and copper in vitro and in vivo.  
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This project was designed to meet the following objectives: 
 To understand the relationship between CSCs and chemoresistance in 
GBM CSC cultures and to investigate the nature and origin of CSCs 
isolated from cell lines. 
  
 To determine whether hypoxia and its underlying mechanisms can 
induce CSCs in GBM and lead to resistance. 
 
 To understand the role of HIFs and NF-B, in bridging hypoxia and CSC-
related chemoresistance in GBM cells. 
 
 To examine the cytotoxic effect of DS and Cu on GBM cell lines, especially 
on GBM CSCs and to investigate the molecular anticancer mechanisms of 
DS/Cu in vitro.  
 
 To examine the tumour inhibiting effect of newly developed formulation of 
DS using orthotopic xenograft GBM mouse models.  
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Chapter 2 
 
 
 
 
 
 
 
 
Materials and Methods 
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2.1 Materials  
 
2.1.1 Labware, equipment, reagents, enzymes and kits  
 
10, 25, 50 and 100 mL polystyrene tubes, 6-well, 24 well and 96-well flat-
bottom tissue culture plates with lids, Tissue culture Cell+ flasks with PE 
ventilation caps (T25, T75, T175), Filtropur V50.0.2 Vacuum Filter (500 mL), 
Cell scrapper, 1.5mL and 0.5mL eppendorf tubes, sterile disposable pipettes, 
(5mL, 10mL, 25mL), (Sarstedt Ltd., Leicester, UK). 
AccuGel 40% (19:1 acrylamide:bis), 30% acrylamide:bis-acrylamide (37.5:1), 
10× Electrophoresis buffer - Tris/Glycine/SDS, 10× Transfer buffer - 
Tris/Glycine, 10×TAE buffer, 10XTBE buffer, EZ-ECL chemiluminescence 
detection kit for horse radish peroxidise solution A and B (GeneFlow, UK-
National Diagnostics, Yorkshire, UK).  
 NuPAGE ® LDS Sample Buffer (4x), SeeBlue plus 2 pre-stained protein 
markers, Geneticin (G418), N2® supplement (100x), B-27® supplement 
(50x), Trizol, Optimem, Lipofectamine transfection reagent (Life technologies-
Invitrogen Ltd., Paisley, UK)  
Boyden chamber assay kit (Cell biolabs inc. San Diego, USA) 
Basic fibroblast growth factor- human (hFGF) (R&D systems, Albingdon, UK) 
Matrigel (BD biosciences, Oxford, UK) 
Boyden chambers, BD Falcon Chamber slides, BD Falcon tissue culture 
dishes, Corning 24 well plates for transwell inserts (Corning, MA, USA – 
distributed by VWR, Sussex, UK) 
 Confocal microscope (Carl Zeiss Laser Scanning Systems LSM 510), 
Inverted light microscope (Nikon, Japan) 
Clean air laminar flow hood (Telstar, Netherlands) 
CO2 incubator (Sanyo, Japan) 
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Micropipettes – BiopetteTM Auotclavable pipettes (Labnet international inc., 
USA) and PipetmanTM autoclavable pipettes (Gilson inc., Luton, UK) 
Micropipette tips refill cartridges (1mL, 200μL)  and Nucleasefree filtered tips 
(1mL, 10μL, 40μL, 200μL) (Alpha laboratories, Eastleigh, UK) 
Amersham Hybond ™ - P (PVDF membrane), Amersham Hybond TM - N+ 
(GE Healthcare, Buckinghamshire, UK)  
ADLH-ALDEFLUOR assay kit, Hypoxia incubator chamber (Stem cell 
technologies, Cambridge , UK) 
BamH I and Hind III enzymes and associated buffers (New England Biolabs). 
BD FACSCalibur™ Flow Cytometer, CellQuest™ Pro, Cell wash, FACS 
Clean, FACS Rinse, BD Falcon FACS tubes (BD Biosciences, Oxford, UK). 
Mini-protean western blot tank with lid and gel plate adapters, 1.0mm and 
1.5mm glass plates, 15 well and 10 well combs, gel cutter, buffer dam 
(balance plate for running single gel), Bio-Rad protein assay kit II, Power 
pack for electrophoresis (Bio-Rad Laboratories, Hertfordshire, UK). 
Complete easy packs-Protease inhibitor cocktail tablets, phospho-stop 
phosphotase inhibitor tablets, Annexin-V apoptosis kit, Rapid Ligation kit 
(Roche Diagnostics Ltd., East Sussex, UK)  
Dulbecco‟s Modified Eagle Medium (DMEM) with 4.5 g/L glucose, Foetal Calf 
Serum (FCS), L-Glutamate (200 mM), Penicillin-Streptomycin (10,000U/mL 
penicillin and 10,000U/mL Streptomycin), 10xTrypsin, Sterile Phosphate 
Buffer Saline (PBS) (0.0067M PO4), DNase and RNase free Ultrapure water 
(BioWhittaker® Lonza, Walkersville, USA - Lonza, Slough, UK). 
Enhanced Chemiluminescence Western Blot Signal Detection Kit (Amersham 
Biosciences, UK). 
EZ-ECL chemiluminescence detection kit for horse radish peroxidases 
solution A and B (Thermo fisher scientific, UK). 
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Fuji Medical X-Ray Film Super RX (13x18) (Fujifilm UK Ltd., Bedfordshire, 
UK)  
Special Gas (1%O2, 5%CO2 in Nitrogen) – (BOC gases, UK) 
Heraeus Multifuge 3SR laboratory centrifuge with microtitre carrier plate 
adapter max 4 plates (Thermo Fischer scientific, Longborough, UK) 
HypoxyprobeTM-1 Plus Kit supplied by Hypoxyprobe Inc (Burlington, MA, 
USA) 
Marvel dried milk (Marvel, Dublin, Ireland) 
Microscope slide (ERIE SCIENTIFIC Company Portsmouth.N.H., US). 
Nalgene Cryoware™ Cryogenic vials (Labware, Roskilde, Denmark)  
Polylysine-coated slides (VWR, Lutterworth, UK) 
Qiaquick gel extraction kit, plasmid maxiprep kit, plasmid miniprep kit 
(Qiagen, West Sussex, UK) 
Restriction enzymes and associated buffers, pfu polymerase, Luciferase 
assay kit, Gel shifting assay kit, 1Kb DNA ladder, 100Kb DNA ladder, Dual 
Luciferase Assay reagents, Access RT-PCR system (Promega UK Ltd., 
Southampton, UK)  
RNase A (100 mg/mL) (Qiagen Ltd., West Sussex, UK)  
Semi-dry transfer unit (Hoefer, Inc., Holliston, USA)  
Semi-dry transfer unit (Amersham Biosciences, UK)  
Sigma 1-15k refrigerated microtube centrifuge (Sigma Laborzentrifugen 
GmbH, Germany)  
Stuart® 3 block heater (Bibby Scientific Ltd., Straffordshire, UK). 
Insulin (10mg/mL), 45% D-Glucose, human EGF, Heparin, poly-HEMA, 
Disulfiram, Cu Chloride (CuCl2), Vincristine (VCR), Paclitaxel (PAC) , 
Doxorubicin (DOX), Temozolomide (TMZ), minisart plus (0.20 μm) filter, 
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99.9% Dimethylsulfoxide (DMSO), Tris HCl, Tris Base, Tween 20, EDTA, 
Hygromycin B, Ammonium persulfate (APS), Sodium Dodecyl Sulfate (SDS, 
98.5% GC grade), Methanol, Isopropanol, Glycine, HEPES, Sodium Chloride 
(NaCl), Thymidine, KH2PO4, Sodium hydroxide (NaOH), Nonident p40, 
Ethidium Bromide, LB broth, polydIdC (PdIdC), Triton X-100, Agarose, 3MM 
filter paper, Propidium iodide (powder), Tetramethylethylenediamine 
(TEMED), fixer/replenisher, developer/replenisher, Kodak medical X-ray film, 
DL-dithiothreitol (DTT) solution (1 M in H2O) (Sigma Aldrich Company Ltd., 
Dorset, UK)  
Multiskan Ascent and Multidrop 384 (Thermo Fisher Scientific Inc., 
Leicestershire, UK)  
 
2.1.2 Antibodies  
 
MACS- Flow cytometry CD133-PE conjugated antibody, (Miltenyi Biotec Ltd, 
Surrey, UK) 
BD FACS CD44-FITC conjugated antibody (BD biosciences, UK) 
p-p65 (S276) antibody (Abcam, Cambridge, UK)  
Horse radish peroxidase conjugated secondary anti-mouse and anti-goat 
antibodies (Amersham Biosciences, UK)  
Sox2, Oct4, Nanog, Vimentin, N-Cadherin (Cell Signalling, Herts, UK)  
Enhanced ChemiLuminescence (ECL) ™ anti-mouse antibody (Ab), ECL ™ 
anti-rabbit antibody (GE Healthcare, Buckinghamshire, UK)  
HIF2α antibody (Novus Biologicals, CO, USA)  
p65, BCL-2, BAX, E-Cadherin, Nucleolin, ALDH1A1, ALDH3A1, HIF1α, IκBα, 
MDR1 antibodies (Santa Cruz Biotechnology Inc., Heidelberg, Germany)  
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ALDH2, ALDH1A3, Anti-vinculin monoclonal antibody, Anti-tubulin 
monoclonal antibody, FITC-conjugated anti-mouse IgG antibody (Sigma 
Aldrich Company Ltd., Dorset, UK) 
 
 2.1.3 Cell lines  
 
Human Glioblastoma multiforme cell lines: U87MG, U251MG and U373MG 
(Prof John Darling, BTUK neurooncology lab, University of Wolverhampton, 
UK)  
Human normal breast epithelial cell line: MCF10A (American Tissue Culture 
Collection, Rockville, USA)  
Normal Human Astrocytes (Dr.Tracy Warr, BTUK neurooncology lab, 
University of Wolverhampton, UK)  
Normal human vascular endothelial cells, HeCV (Prof Wenguo Jiang, 
University of Cardiff, UK) 
Human endothelial cell line: EAhy926 (Dr Angel Armesilla, University of 
Wolverhampton, UK)  
WI38 –Lung fibroblasts (Dr Weiguang Wang, University of Wolverhampton, 
UK) 
 
2.1.4 Buffers  
 
Complete protease inhibitor  
A (25x) complete protease inhibitor (Roche Diagnostics Limited, West 
Sussex, UK) was prepared by dissolving 1 tablet of complete protease 
inhibitor in 25 mL of distilled water, and stored at -20°C until use.  
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Sorensen’s Glycine Buffer  
Glycine buffer solution (500 mL) was prepared by dissolving 3.75 g glycine 
and 2.92g NaCl in distilled water. The pH of the glycine buffer was adjusted 
to pH 10.5 using 5 M NaOH. The glycine buffer solution was stored in room 
temperature until use.  
 
RIPA Buffer for Whole Protein Extraction  
10x RIPA Buffer was prepared by the list below (pH 7.4), and RIPA Buffer 
was stored in -20°C until use. 
Chemicals    Conc.    W/100 mL 
 Tris Hcl   25 mM    395 mg 
 SDS    0.1%    0.1g 
 Triton X-100   1%    1 mL 
 Sodium deoxycholate  0.5%    0.5 g 
 NaCl    0.15 M    0.88g 
 EDTA    1 mM    37.2 mg 
 Sodium orthovanadate 1 mM    18.4 mg 
 Leupeptin   1 µM (1 - 10 µg/mL)  1 mg   
 Aprotinin   1 µM (1 - 10 µg/mL)  1 mg 
 PMSF    1 mM    17.4 mg 
 
 
Separating buffer  
Separating buffer was prepared using the following recipe and the pH was 
adjusted to 8.8 and stored in room temperature until use.  
 Tris base 45.4 g 
 SDS 1g  
 Add 250 mL distilled water  
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Stacking buffer  
Stacking buffer was prepared using the following recipe and the pH was 
adjusted to 6.8 and stored in room temperature until use.  
 Tris base 15 g 
 SDS 1 g 
 Add 250 mL distilled water  
 
Running buffer  
Running buffer was prepared by mixing 100 mL of 10X stock solution with 
900 mL distilled water.  
 
Buffer A for Nuclear Protein Extraction  
Buffer A was prepared using the following recipe and stored at -20°C until 
use.       Final Conc. Stock solution 
 10 mM hepes       500 mM  200 L 
 10 mM KCl     2M   50 L 
 0.1 mM EGTA (pH 8.0)  500 mM  2 L 
 0.1 mM EDTA (pH 8.0)  500 mM  2 L 
 1 mM DTT      0.5 M   20 L 
 Protease inhibitor cocktail   25    500 L 
 Distilled water    9.2 mL 
 
Buffer C for Nuclear Protein Extraction  
Buffer C was prepared using the following recipe and stored at -20°C until 
use.     Final Conc.  Stock Solution 
 20 mM hepes    500 mM  60 L 
 0.4 M NaCl    5 M   120 L 
 1 mM EGTA    500 mM  3 L 
 1 mM EDTA    500 mM  3 L 
 1 mM DTT    0.5 M   3 L 
 Protease inhibitor   25    75 L 
 5% glycerol (v/v)  100%   75 L 
 Distilled water     1161 L 
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Tris-buffered saline Tween-20 (TBS-T) –Wash Buffer 
A stock (10x) TBS-T solution was prepared as given below and the pH was 
adjusted to 7.4 
 12.11 g Tris base  
 81.8 g NaCl  
 1 litre of distilled water  
 
The (1x) TBS-T buffer was then prepared by mixing100 mL (10x) TBS-T, 900 
mL distilled water and 500μL of Tween-20.  
 
Transfer buffer  
Transfer buffer was prepared by mixing 100 mL of 10 x stock solution, 200mL 
of methanol and 700mL distilled water. This solution was stored at room 
temperature until use.  
 
Blocking buffer for western blot 
For western blot the blocking buffer used was 5% (w/v) milk prepared by 
dissolving 5g Marvel milk powder in 100 mL of (1x) TBS-T. 2%BSA (w/v) in 
TBST was used as blocking buffer for phosphorylated antibodies. 
 
Blocking buffer for Flow cytometry and ICC 
For flow cytometry procedure involving staining of live cells 4%FBS in PBS 
was used as blocking buffer. For procedures involving fixed cells and to 
increase cell permeability PBS containing 1%BSA (w/v) and 0.01% (v/v) 
Triton-X 100 was used as blocking buffer.  
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2.2 Methods  
2.2.1 Routine Cell culture (ATT or NOR culture) 
Serum-containing medium  
Serum-containing medium consists of DMEM medium with 1% (v/v) L-
glutamine, 1% (v/v) penicillin-streptomycin and 10% Foetal Calf Serum 
(BioWhittaker® Lonza, Walkersville, USA)  
Serum-free medium  
Serum-free medium consists of DMEM medium with 1% (v/v) L-glutamine, 
1% (v/v) penicillin-streptomycin (BioWhittaker® Lonza, Walkersville, USA). 
Trypsin  
Working solution of trypsin (1x) was prepared by diluting stock solution of 
trypsin (10x) in sterile PBS (BioWhittaker® Lonza, Walkersville, USA)  
Neurosphere medium 
The selective medium for isolating neurospheres or neural stem cells consist 
of DMEM F-12 medium (500mL) with 1%v/v L-glutamine, % (v/v) penicillin-
streptomycin, 5mL N-2 Supplement, 10mL B-27 Supplement, 10ng/mL 
hEGF, 10ng/mL hFGF, 20ug/mL Insulin, 20ug/mL heparin, 3.1mL 45% D-
Glucose. The media was filter sterilised and stored at 4oC until use. However 
the media was not stored for extended periods due to its less stable 
ingredients.  
Freezing Medium for cryogenic storage of cell samples  
Freezing medium was prepared by mixing 90% foetal calf serum with 10% 
DMSO and stored at 4°C until use.  
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Recovering Cell Lines from Liquid Nitrogen Storage  
Cells were recovered from liquid nitrogen storage, rapidly defrosted in 37°C 
water bath, and then transferring the 1 mL content of the cryovial into a 75 
cm2 tissue culture flask containing 19 mL of serum-containing medium. The 
cells were incubated at 37oC and allowed to attach and recover overnight. 
The following day media was changed to get rid of any unattached or dead 
cells and to ensure that there is no DMSO in the culture.  
 
Trypsinization of Adherent Cell Lines  
Any spent cell culture medium was removed from the tissue culture flask, 
rinsed with 5 mL of sterile PBS, and 2 mL of trypsin was added and spread 
evenly to cover the adherent cells. Cells with trypsin were incubated at 37oC 
in incubator, gently tapped in between and checked regularly under the 
microscope for detachment. When the cells were completely detached, 2 mL 
of serum-containing medium was added to neutralize the trypsin and the cells 
were re-suspended thoroughly by pipetting the 4 mL volume up and down. 
The contents were transferred in to a tube and cells were suspended for 
culture by centrifugation at 880g for 5 minutes.  
 
General Cell Line Maintenance  
 
Cell cultures were regularly checked under the microscope (2-3 times a 
week) for cell density, and changes in the colour of the medium. When there 
is a change in the colour of the medium but the cell density is low, (defined 
as adhered cells are spread out and very few cells are touching each other), 
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the medium was removed and replaced with fresh serum-containing medium. 
When there was a change in the colour of the medium and the cells were 
confluent, (defined as cells are fully grown and only very few gaps are left 
between the cells), cells were sub-cultured. Sub-culturing was done by 
trypsinizing the cells. The cell pellet collected after trypsinization and 
centrifugation was re-suspended thoroughly in 5 mL of fresh serum-
containing medium. 1 mL of this cell suspension was then added to two 75 
cm2 tissue culture flasks with 19 mL of serum-containing medium incubated 
at 37°C with 5% CO2, with the tissue culture flask lying down. When they are 
fully grown again, the same process of subculture was applied. The cells can 
be enlarged in a number of flasks based on requirements or used for 
experiments or collected and stored at -20oC as pellets.  
 
Preparing Cell Lines for Liquid Nitrogen Storage  
 
Cells were trypsinised and the cell pellet was collected by spinning down for 
3minutes at 800 g. The cell pellet was then re-suspended in freezing medium 
and aliquot into 1 mL/labelled-cryovial. Each cryovial was then wrapped in 
tissue paper, put into a disposable labelled-glove and placed in -80°C 
overnight. The following day, the cryovials were removed from the gloves and 
tissue papers, and transferred into liquid nitrogen (-180°C) for long-term 
storage. The locations of the samples stored in liquid nitrogen are recorded in 
the liquid nitrogen storage log.  
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2.2.2 Sphere cell culture 
 
Poly-HEMA coating for sphere cell culture 
The poly HEMA crystals were dissolved overnight (poly HEMA (poly-2-
hydroxyethyl methacrylate Sigma ref P3932) under agitation at 10 mg/mL 
in 95% ethanol (100% EtOH doesn‟t work). The solution was filter sterilized 
and stored at 4°C for several months. The following volumes were used for 
coating the plates and flasks  
 4 mL for  T75 
 2 mL for  T25 
 0.4 mL 6 wells 
 0.3 mL 24 wells 
 30 µl 96 wells 
The coated plates/flasks were then dried in a 50-60°C incubator and can be 
kept at RT for several months. Before using those coated flasks/plates for 
culturing the cells they were thoroughly rinsed twice with sterile water or PBS 
(critical step as trace of free poly HEMA can be toxic). 
 
Growing cells as Neurospheres (NS culture) 
 
The U87MG, U251MG and U373 MG cells were trypsinised from an adherent 
culture flask and counted using haemocytometer. For neurosphere cultures, 
10,000 cells/ mL were grown in selective NS medium with all growth factors. 
The cells were cultured in low adherence flasks or multi-well plates provided 
by Corning, USA. Alternatively the cells can also be grown in poly-HEMA 
coated low adherence flasks or plates that are prepared in our lab using the 
above protocol. The cells were incubated for 5-7 days and allowed to form 
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spheres with intermittent replacement of fresh media. After incubation the 
cells were photographed and observed for sphere formation and used for 
further stem cell experiments.  
 
Growing cells as spheres with serum containing medium (SUS culture) 
 
Alternatively to the NS culture with serum free selective medium we tried to 
grow the U87MG, U251MG and U373 MG cells as suspension cultures in 
serum containing medium. The cells were trypsinised from an adherent 
culture flask and counted using haemocytometer. About 10,000 cells/ mL 
were grown in normal DMEM serum containing medium without any growth 
factors in low adherence flasks or multi-well plates. The cells were incubated 
for 5-7 days and allowed to form spheres with intermittent replacement of 
fresh media. The cells were later photographed and observed for any 
evidence of sphere formation under non-selective medium.  
 
2.2.3 Hypoxic Cell culture (HYP culture) 
 
All three GBM cell lines U87, U251 and U373 grown in adhered condition 
(ATT) were subcultured and the flasks were placed under hypoxic conditions 
to grow the cells as HYP cultures. This method was a simple adaptation of 
normal cell culture using a tightly sealed chamber that contains low O2 levels 
and can be placed inside the 37oC incubator. The cells were cultured in 
dishes, flasks or plates and placed inside this chamber. The gasket and seals 
were tightly secured and hypoxia special gas mixture (1%O2, 5%CO2 and 
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rest N2) was passed into the chamber through inlet tube. The outlet tube was 
left open was at least 2-3minutes in order to flush out the normal O2 
containing air inside the chamber. The reduction in O2 was measured using 
an O2 meter placed inside the chamber. The outlet is closed tightly using the 
clamps provided. After ensuring that the special gas has filled the chamber 
and the inlet was also quickly secured using the clamps. The chamber was 
now placed in a non-CO2 incubator at 37
oC for 5-7 days. Intermittent feeding 
of the cells was done every 2-3days and the flasks were flushed with gas to 
remove any O2 introduced from the replaced medium before placing them 
back to the chamber. The cells grown in these conditions were processed 
quickly during experiments to ensure maximum reliability. In addition all these 
ATT-HYP cells were compared with cells grown under normoxia for 5-7days 
in parallel with same initial cell number (ATT-NOR) for experiments. The 
chambers were also monitored for any leaks and gassed everyday to ensure 
that there is proper induction of hypoxic conditions. 
 
2.2.4 Cytotoxicity assay  
 
Stock MTT solution 
5 mg/mL MTT solution (500 mL) was prepared by adding 2.5 g of 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide in 500 mL of sterile 
PBS, mixed to dissolve using a magnetic stirrer, with the bottle wrapped in 
foil to protect the MTT from direct light. This MTT solution was then filtered 
sterilized, wrapped in foil and stored at 4°C until use.  
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MTT assay 
MTT assay is one of the widely used methods to evaluate the effect of anti-
cancer drugs on cell viability. Cells were cultured in 96-well plates (1 × 
104/well) and left overnight at 37°C. Cells were exposed to different 
concentrations of anti-cancer drugs like VCR, TMZ, PAC, DOX, DS/Cu 
prepared by a two-fold serial dilution using culture medium i.e. 10 μM, 5 μM, 
2.5 μM, 1.25 μM, 0.625 μM, 0.3125 μM. One column of cells was used as 
negative control and other column was used as carrier control for carriers like 
DMSO. After removing the spent media from the wells, the medium (200 μL) 
with different concentrations of drug was distributed in each well. The plates 
were then incubated at 37oC for desired time. Normally there are 3 wells with 
the same drug concentration and cell type in each plate and the experiment 
was done with triplicate plates at the same time.  
 
The experiment was repeated three times with triplicate plates to calculate 
the standard deviation. After incubation time, 50 μL of MTT solution was 
added to the wells and the plates were wrapped in the aluminium foil and 
incubated for 3-4hrs at 37°C. The solution was removed after incubation and 
80μL of 99.9% DMSO and 20μL glycine buffer was added. The OD values of 
each well in the plates were read by a multi-well plate reader 
spectrophotometer at a wavelength of 540 nm. The readings were tabulated 
and %viability can be calculated in order to determine the IC50 values for 
each drug and each cell line. 
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 MTT assay for sphere cells (NS and SUS) 
 
Since the NS and SUS cells were suspended they get washed away while 
dosing with drug containing medium or removing spent medium following 
addition of MTT. Hence we followed a modified MTT method for these sphere 
cells. The sphere cells NS and SUS from all three GBM cell lines used were 
trypsinised and dissociated into individual cells. They were then reseeded in 
poly HEMA coated 96 well flat bottom plates in their corresponding culture 
medium at a cell density of 5000 cells/well and cultured overnight. They are 
grown overnight at a volume of 100 L/ well. They were then dosed with drug 
containing medium (2X concentration to compensate already present 100L) 
on top with another 100L with appropriate drugs under study. The cells 
were treated for 120 hours and MTT reagent was added to the wells. After 
incubation with MTT reagent, the plates were spun down at 800 rpm for 5 
mins in a plate centrifuge and media is discarded. The spheres which appear 
like purple crystals are dissolved by adding DMSO and the OD is measured 
using a plate reader. The % viability and corresponding IC50 values for each 
drug was calculated. 
 
MTT assay for Hypoxic cells 
MTT assay for hypoxic cultures were carried out very similar to that of ATT 
NOR cells. Prior to seeding in 96 well plates the cells were grown under HYP 
for 5 days. These HYP cells were quickly trypsinised and seeded at a cell 
density of 1000 cells per well and incubated for another 48hrs before dosing 
with drugs. ATT- NOR cells grown in parallel was used as control. After 
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treatment with drugs for desired time the cells were subjected to MTT assay 
as mentioned above and the cell viability was calculated in order to 
determine any difference in IC50 values of HYP cultures.  
 
2.2.5 SDS-PAGE / Western Blot  
 
10% Ammonium Persulphate (APS)  
10% Ammonium Persulfate (APS) (Sigma Aldrich Company Ltd., Dorset, UK) 
was prepared by dissolving 0.1 g APS in 1 mL of distilled water. This was 
prepared fresh before use.  
Preparation of Separating Gel  
Separating gel was prepared by following the recipe below 
Separating Gel: (normally use 10% gel.) 
      10% 8% 7.5% 6.5% 6% 
1) 30% 19:1 Acrylamide:bis 
 
Separating buffer    5.5 mL 5.5 mL 5.5 mL 5.5 mL 5.5 mL 
30% 19:1 acrylamide:bis   5.9 mL 4.3 mL 4.0 mL 3.4 mL 3.2 mL 
H2O      5.0 mL 6.2 mL 6.4 mL 7.0 mL 7.2 mL 
10% (w/v) ammonium persulphate (L) 120 120 120 120 120 
TEMED (added before pouring gel) (L) 15 15 15 15 15 
 
2) 40% 19:1 Acrylamide:bis 
 
Separating buffer    5.5 mL 5.5 mL 5.5 mL 5.5 mL 5.5 mL 
40% 19:1 acrylamide:bis   4.4 mL 4.3 mL 4 mL 3.4 mL 3.2 mL 
H2O      6.5 mL 6.2 mL 6.4 mL 7.0 mL 7.2 mL 
10% (w/v) ammonium persulphate (L) 120 120 120 120 120 
TEMED (added before pouring gel) (L) 15 15 15 15 15 
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About 4.5mL was used for one gel with 1.0mm spacer plates and 7mL was 
used for 1.5mm spacer plates. After adding the gel a small amount of 
isopropanol (200L) was added to cover the top of the separating gel 
solution, was added on top of the separating gel to get rid of air bubbles and 
form a flat layer. The gel was left to set for 20 mins. 
 
Preparation of Stacking Gel  
Stacking gel was prepared by following the recipe below 
4% Stacking gel: 
      Volume 
Stacking Buffer    4.2 mL 
30% (19:1) acrylamide   1.6 mL 
H2O      6.2 mL 
10% ammonium persulphate   250 μL 
TEMED     20 μL  
When the gel was set the isopropanol from the separating gel was removed 
and washed with distilled water. The stacking gel mix was added above the 
separating gel and a comb was immediately inserted on the top of the 
stacking gel, to form wells for protein loading. Care must be taken to avoid air 
bubbles and the gel was left to set before removing the comb.  
 
Collection of whole cell lysates and proteins 
Whole cell proteins were collected from the cells by washing the cell pellets 
with PBS and adding 100-200μL (less or more depending on the size of 
pellet) of RIPA buffer with protease and phosphatise inhibitors to the pellet. 
The cells were thoroughly suspended and completely lysed using the RIPA 
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buffer and then centrifuged for 20mins at 4oC at 14000rpm.  The supernatant 
collected is the whole protein extract and they were stored in clearly labelled 
tubes at -80oC until use. 
 
Cytoplasmic and Nuclear Protein Extraction  
Nuclear protein extracts were prepared by washing the cells in PBS and 
resuspending them in 100μL of buffer A. The mixture was left on ice for 15 
minutes, to which, 25 μL 10% NP-40 (Sigma Aldrich Company Ltd., Dorset, 
UK) was added and then centrifuged for 30secs at 10,000rpm. The 
supernatant was collected (cytoplasmic protein) and the pellet was re-
suspended in 500 μL buffer A to completely wash any cytoplasmic proteins, 
centrifuged again for 30secs at 10,000rpm, and the supernatant was 
removed. The pellet was then re-suspended in 50-100 μL of buffer C, left to 
spin on a rotator at 4°C for 1 hour, then centrifuged for 5 minutes at 
14,000rpm and the supernatant was collected as nuclear protein and stored 
in clearly labelled tubes at -80oC until use.  
 
Protein Concentration Measurement  
A serial standard using BSA protein was prepared by serially diluting the 
3.0mg/mL BSA solution in RIPA buffer to the following concentrations: 
3.0mg/mL, 1.5 mg/mL, 1.0 mg/mL, 0.75 mg/mL, 0.50 mg/mL, 0.25 mg/mL 
and 0mg/mL (30μL RIPA buffer). The BioRad protein estimation reagent mix 
A/S was prepared by adding 20μL of reagent S to every 1mL of reagent A 
and mixed using vortex mixer. 5μL of the BSA standards (duplicates) and the 
5μL of protein samples were pipetted into a 96-well flat-bottomed plate, in 
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triplicates, to which 25μL of A/S reagent mix was added. 200μL of reagent B 
was then added and incubated at room temperature for 10 minutes. The 
absorbance was read at 650nm using a multiwall plate reader 
spectrophotometer and protein concentration of the samples was calculated 
from plotting the absorbance versus protein concentration of the BSA serial 
standard.  
 
SDS-PAGE Electrophoresis  
The previously prepared SDS-PAGE gels were assembled into the 
electrophoresis tank using the cassette adapter and soaked in the tank 
loaded with 1 x running buffer. The protein samples were prepared by mixing 
50-100μg of quantified protein extracts with loading buffer (4x), 1μL of 1M 
DTT and distilled water to make up a final volume of 30 μL in a 0.5 mL 
eppendorf. The samples were heated using a PCR block heater at 96°C for 
10 minutes then centrifuged quickly at 10,000g for 10 seconds and stored on 
ice until use. The wells were washed to remove any debris and the samples 
were loaded into the wells. 10μL of pre-stained protein was loaded as a 
control in one well. The gel was then run at 200V for 1 hour until the protein 
marker clearly separates. 
 
Blotting  
3MM blotting paper was cut into 9 x 10cm size and soaked in transfer buffer. 
PVDF membrane was cut into 8 x 4.5 cm size and briefly dipped in methanol 
and soaked in transfer buffer. A sandwich of SDS-PAGE gel on top of the 
PVDF membrane between 3 layers of the wet blotting papers was setup in 
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the semi-dry transferring unit. Protein was transferred from the SDS-PAGE 
gel to the PVDF membrane by apply 20V and 200mA current for 1 hour and 
30 minutes.  
 
Blocking of the membrane  
5% fat-free milk in 1x TBS-T solution was used to block the protein-
containing PVDF membrane for 1 hour on a rocker in order to prevent non-
specific binding of primary and secondary antibodies to the protein free areas 
of PVDF membrane.  
 
Antibody Staining  
5 mL of primary antibody according to the dilutions given in Table 2.1 was 
prepared in the blocking buffer. After blocking the PVDF membrane with 
blocking buffer for at least 1 hour, the membrane was placed in a clean 
plastic bag and sealed around the corners using a heat sealer. The primary 
antibody was poured into the bag, sealed, and left overnight at 4°C on a 
shaker. Care was taken to ensure that the antibody solution completely 
covers the surface of the membrane and there were no air bubbles inside the 
bag. The following day, the primary antibody was removed for reuse from the 
bag and the PVDF membrane was washed twice with TBST (1x) for 10 
minutes each. The PVDF membrane was then placed face up in a tray 
containing 10mL of secondary antibody (diluted as in Table 2.1) and 
incubated at room temperature for at least 1 hour on a shaker. The PVDF 
membrane was then washed twice with TBS-T (1x) for 10 minutes. The 
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membrane was immediately transferred to a prepared x-ray film exposure 
cassette and processed for signal detection. 
Antibody Dilution  Supplier 
p-p65 (S276) 1:1000 Abcam 
Sox2 1:1000 Cell signalling technology 
Oct4 1:1000 Cell signalling technology 
Nanog 1:500 Cell signalling technology 
HIF2α 1:500 Novus biologicals 
HIF1α 1:1000 Santa cruz biotechnology 
p65 1:1000 Santa cruz biotechnology 
BCL-2 1:1000 Santa cruz biotechnology 
BAX 1:1000 Santa cruz biotechnology 
ALDH1A1 1:500 Santa cruz biotechnology 
ALDH2 1:1000 Sigma 
ALDH1A3 1:2000 Sigma 
ALDH3A1 1:1000 Santa cruz biotechnology 
IκBα 1:1000 Santa cruz biotechnology 
E-Cadherin 1:1000 Santa cruz biotechnology 
N-Cadherin 1:500 Cell signalling technology 
Vimentin 1:2000 Cell signalling technology 
Tubulin 1:8000 Sigma 
Nucleolin 1:1000 Santa cruz biotechnology 
Secondary Anti-Rabbit 1:5000 Amersham 
Secondary Anti-Mouse 1:5000 Amersham 
Secondary Anti-Goat 1:2000 Amersham 
 
Table 2.1 Dilutions ratios for all the primary and secondary antibodies used in the work given 
in L. The antibodies were prepared in 5% (w/v) fat free milk. 5% (w/v) BSA  was used for 
antibodies against phosphorylated proteins. 
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Signal detection  
The membrane after washing was placed in a cassette layered with cling film 
paper. In the dark room, about 2-3mL of EZ-ECL solution was prepared by 
mixing solution A with solution B at a 1:1 ratio and added to PVDF 
membrane. PVDF membrane in the A/B mixture solution was left for 3-5 
minutes and then any excess solution was removed using a tissue paper. 
The PVDF membrane was then wrapped in cling film and then exposed to a 
Fuji medical x-ray film in complete dark conditions. The length of exposure 
depends on the strength of the signal. The film after exposure was developed 
in a tray containing developer solution and briefly rinsed in water and then 
fixed in a tray containing fixer solution. The bands were seen as dark spots 
due to chemiluminescent light affecting the x-ray film. Intensities of bands 
indirectly represent the protein content in the wells. This will implicate the 
expression level of protein under study.  
 
2.2.6 Flow Cytometry  
 
Flow cytometry for fixed cells  
70% ethanol was prepared by diluting absolute ethanol in PBS or water. Any 
ATT, HYP, NS and SUS cells under study were trypsinised and pelleted by 
centrifugation at 800 g for 5 minutes. The supernatant was removed and the 
cells were washed with 5mL of sterile PBS for at least two times. The final 
cell pellet was re-suspended in 200μL of sterile PBS. While placing the tubes 
on a vortex mixer 2 mL of 70% ethanol was slowly added to the cell 
suspension, and fixed for 10 minutes. After 10 minutes the fixed cells were 
pelleted by centrifugation at 800 g for 5 minutes, the ethanol was removed 
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and the cell pellet was washed with sterile PBS. Following this process the 
fixed cells were permeabilized, blocked, stained and analysed according to 
ICC protocol.  For FACS analysis involving intracellular proteins like Sox2, 
Oct4 and Nanog the collected cells were fixed with ethanol and 
permeabilized using FACS blocking buffer containing tritonX100 and BSA. 
The primary antibody was diluted at 1:500 in blocking buffer and incubated 
overnight at 4oC. The following day cells were washed with PBS to remove 
any unbound primary antibody and then incubated with fluorescent tagged 
secondary antibody prepared in blocking buffer at the dilution 1:1000 for 1 
hour in room temperature. After incubation the cells were washed and 
resuspended in flow buffer and analysed using FACS. 
 
Hypoxyprobe assay 
HP assay was performed using fixed cells. Full instructions are available in 
the kit. The cells grown as ATT, HYP, NS or SUS were treated with 
hypoxyprobe reagent for 2-4hrs. The cells were then trypsinised, fixed with 
ethanol, blocked and stained with anti-HP FITC conjugated monoclonal 
antibody prepared in blocking buffer. The cells were then washed with PBS, 
resuspended in flow buffer and analysed using FACS.  
 
Flow cytometry for live cells  
Alternative to the use of fixed cells the cells can also be used as live cells. 
After collecting the cells by trypsinising, the cells were stained with antibodies 
prepared in flow buffer. Flow buffer contains serum and hence helps to 
maintain live cells. We have used live cell staining method for CD133 and 
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CD44. Cells were collected, resuspended in flow buffer containing the CD133 
or CD44 antibody and incubated in 4oC for 15 minutes. After incubation the 
cells were washed with fresh flow buffer and analysed by FACS. The CD133 
is a PE conjugated antibody and hence analysed using FL2 red range filter in 
the FACS machine. The CD44 is a FITC conjugated antibody and hence FL1 
was used as filter for green range. The stained cells should be analysed 
quickly to avoid any non specific binding.  
 
ALDEFLUOR assay 
The ALDH- ALDEFLUOR reagent was prepared according to the instruction 
in the kit. The cells collected after trypsinising were stained with the reagent 
suspended in assay buffer and incubated at 37oC for 30 mins. The cells were 
washed and analysed using FL1-green filter in FACS. 
 
2.2.7 Confocal microscopy  
 
Fluorescence labelling of sphere cells  
Sphere cells were washed twice with PBS gently and trypsinised to individual 
cells. The cells were subjected to cytospin at 800rpm for 3mins using a 
funnel attachment in the poly-lysine coated slides.  The cells attached to the 
slides were fixed with 70% ethanol or methanol acetone (50:50) mix. Fixed 
cells were washed twice with PBS, and then the cells were blocked with 5% 
BSA containing triton X 100 for 30 minutes at room temperature to block non-
specific binding of immunoglobulin. The cells were incubated with the primary 
antibodies for 1 hour at room temperature, washed three times with PBS and 
then labelled with the secondary antibodies for 1 hour in the dark, then the 
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cells were washed three times in PBS. For HP the direct conjugated antibody 
was used to bind to HP. Cover slips were mounted onto slides using anti-
fade mounting medium. Images were captured using laser-scanning 
microscope.  
 
Fluorescence labelling of ATT cells  
Cells from flasks were harvested by trypsinization and 0.5x104 cells were 
seeded on a sterile 8-well chamber slide over night at 37°C for 
immumofluorencence experiment. For HP experiment the cells were 
incubated with HP reagent for 2 hours before fixing the slides. The staining 
protocol is very similar to that of sphere cells but the cells don‟t have to go 
through cytospin step as they are grown in chamber slides. The chamber 
walls are carefully removed with forceps and the cells were then fixed, 
permeabilized and stained with appropriate antibodies. Images were taken 
after mounting the slides with a cover slips and mounting medium. 
 
2.2.8 Luciferase reporter gene assay  
 
Cell culture  
Cells were seeded at a density of 5 x 104/100 μL of medium/well on to 96 
well flat bottom white opaque plates and allowed to grow overnight at 37°C.  
 
Lipofectamine Transfections  
The following day, two sets of transfection solutions were prepared as 
described below which contains the control pGL3-Basic vector in one tube 
and the test luciferase reporter gene vectors in another. Both solutions 
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contain an internal control which is pRL-SV40- renilla.  The cells wer 
transfected using these vectors prepared in Lipofectamine 2000. Solution I: 
According to requirements in total number of wells, 0.2 μg/well of Luciferase 
reporter plasmid DNA and 0.002 μg/well pRL-SV40 (Renilla) DNA was 
diluted in 25 μL/well of opti-MEM medium without serum. Solution II: 10μL of 
lipofectamine 2000 was diluted in 250μL of opti-MEM for each plasmid vector 
and incubated at room temperature for 5 minutes. Solution I and solution II 
were mixed in equal amounts and incubated at room temperature for 20 
minutes. After incubation the mix was aliquoted equally to all the wells with 
cells and the plates were incubated at 37°C, 5% CO2 for 48hours. Luciferase 
test was carried out after incubation time. 
  
Luciferase assay test & analysis  
The medium was removed after 48 hours, and the wells were washed with 1 
x PBS. 100 μL of 1 x lysate buffer was added to each well and incubated at 
room temperature for 10 minutes on a rocker followed by the addition of 30μL  
Luciferase assay reagent II and read in a luminometer. The reading taken 
corresponds to the firefly luciferase activity. This was followed by the addition 
of 30 μL Stop & Glo reagent and read again which corresponds to renilla 
activity. The readings of the luciferase activity in each well were normalized 
using the pRL-SV40 Renilla value using the formula: Ln = L/R where Ln: 
normalised luciferase activity; L: value of luciferase activity and R: value of 
Renilla activity. Finally Ln was further standardized by transcriptional activity 
of the control (pGL3-Basic), using the formula: RLU = Ln/pGL3-basic (RLU: 
relative luciferase unit).  
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2.2.9  Molecular biology protocols  
 
2.2.9.1 Preparation of LB plates  
25 g LB broth powder and 20 g agar was added to 1 L of deionised water to 
prepare LB agar medium. The medium was autoclaved and allowed to cool 
to 50°C.  50 μg/mL ampicillin was added to the medium and mixed well. 
Approximately 15 mL/ plate were poured into 10 cm2 Petri dishes and were 
allowed to set at room temperature. The plates can be stored at 4°C.  
 
2.2.9.2 Transformation of competent bacterial cells  
DH5α component E.Coli bacteria was purchased from invitrogen and stored 
as 50μL aliquots at -80°C. An aliquot of DH5α cells was thawed on ice and 
500ng of DNA was added and incubated on ice for another 15 minutes. The 
cells were subjected to heat shock for 90 seconds at 42°C and replaced on 
ice for 2 minutes. After this 1 mL of SOC medium was added to the cells and 
incubated at 37°C for 1 hour in a shaking incubator. 100l of this bacterial 
culture was spread using an L-rod onto prepared LB plate and incubated 
overnight at 37°C. The next day plates a single colony of positively selected 
cells was transferred to LB broth for plasmid preparation.  
 
2.2.9.3 Preparation of plasmid DNA  
Mini-preps 
QIAfilter miniprep kit was used to do mini-prep purification following the 
manufacturer‟s instructions. Cells were collected by centrifugation at 12,000g 
for 5 minutes and re-suspended in 100μL of re-suspension buffer I (50 mM 
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Tris-HCl, 10 mM EDTA, pH 8.0 containing 100 μg/mL RNase A). 100μL of 
lysis buffer II (200 mM NaOH, 1% (w/v) SDS) was added to the cells, mixed 
and incubated for 5 minutes with gently up and down. 100μL of neutralisation 
buffer III (3 mM potassium acetate, pH 5.5) was then added to stop lysis. 
Following centrifugation for 10 minutes at 12,000 g, the supernatant was 
transferred to mini-prep columns. The columns were spun for 1 minute at 
12,000 g and washed two times with 750 μL wash buffer (1.0 mM NaCl, 50 
mM Tris-HCl, pH 7.0, 15% (v/v) isopropanol). The bound DNA was then 
eluted into a clean 1.5 mL eppendorf tube with 100 μL DNase, RNase-free 
H2O.  
 
Maxi-preps  
Plasmid DNA was extracted on a larger scale using the Qiagen QIAfilter kit 
following manufacturer‟s instructions. 350 mL of transformed bacterial culture 
was centrifuged for 15 minutes at 6,000 g at 4°C. The cell pellet was re-
suspended in 10 mL of pre-cold buffer P1 (50 mM Tris-HCL pH 8.0, 10mM 
EDTA, 100 μg/μL Rnase A). 10 mL buffer P2 (200 mM NaOH, 1% (w/v) SDS) 
was added to the cells, mixed well by inverting the tube few times and 
incubated for 10 minutes at room temperature. Buffer P3 (3.0 M potassium 
acetate pH 5.5) was added to neutralise the reaction. The solution was 
quiclky applied to a QIAfilter cartridge and left for 10 minutes at room 
temperature. Meanwhile, a Qiagen tip 500 was equilibrated by the addition of 
buffer QBT (750 mM NaCl, 50 mM MOPS pH 7.0, 15% (v/v) isopropanol).  
The lysed cells were added onto the equilibrated tip and allowed to pass 
through the filter. 60 mL of buffer QC (1.0 M NaCl, 50 mM MOPS pH 7.0, 
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15% (v/v) isopropanol) was used to wash the column. 15 mL of buffer QF 
(1.25 M NaCl, 50 mM Tris-HCl pH 8.5, 15% (v/v) isopropanol) was added to 
elute the DNA which was finally precipitated by adding 10.5 mL isopropanol 
followed by centrifugation at 12,000 g for 30 minutes at 4°C. 5 mL of room 
temperature 70% (volume ratio) ethanol was added to the pelleted DNA and 
centrifuged for 15 minutes at 12,000 g at 4°C. The supernatant was carefully 
discarded and the pellet was air-dried before re-suspension in 0.5-1 mL of 
DNase, RNase-free H2O.  
2.2.9.4 Quantification of DNA  
DNA was quantified by checking the absorbance of a 1:40 dilution of the 
sample at 260 nm. 1 unit of absorbance at this wavelength was taken to 
correspond to 50 μg/mL of double stranded DNA. The final concentration of 
the sample could be determined using the formula: 
 Sample concentration = OD 260 x dilution factor (40) x 50 μg/mL.  
2.2.9.5 Digestion of DNA with restriction endonucleases  
Depending on the manufacturer, 1-2 units of restriction endonuclease 
enzyme was added to 1 μg of DNA along with the specified buffer for the 
optimum activity of the enzyme in use, making the final volume of reaction to 
be 20 μL. The mixture was incubated at 37°C for a minimum of 2 hours.  
2.2.9.6 Agarose gel electrophoresis of DNA  
The digested DNA samples were diluted in 5 × DNA loading buffer.  They 
were run on 1.0% (w/v) agarose gel prepared by dissolving 100g of agarose 
in 100mL 1 × TAE buffer 5ul of 2.5 mg/mL ethidium bromide and allowed to 
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set in a horizontal gel tank. Samples were loaded along with 10ul of 1kb DNA 
ladder and the gel was run at 100V for 1 hour. The DNA fragments were 
visualized under ultraviolet light. The size of each fragment was assessed by 
comparing with the molecular weight of different fragments of the DNA 
ladder. 
2.2.9.7 DNA Purification from agarose gels  
The desired DNA fragments were cut from the gel with a sterile disposable 
scalpel blade inside the UV transilluminator hood. Excised gel fragments 
were then transferred to a sterile tube and purified using the QIAQuick gel 
extraction kit according to the manufacturer‟s instructions. The fragments 
were dissolved in buffer QG followed by the addition of isopropanol at 37°C. 
The solution was transferred onto a purification column and centrifuged. 20-
30 μL of sterile water was used to elute the bound DNA from the purification 
column. 
 
2.2.9.8 Ligation of DNA  
The digested PCR or DNA fragments were ligated onto the digested vector 
DNA using a Rapid DNA ligation kit. A molar ratio of 1:3 to 1:8 (vector to PCR 
product/DNA fragment) was used in a reaction volume of 10 μL containing 1 
unit of ligase and the supplied buffer. The mixture was incubated at room 
temperature for 1 hour or alternatively at 4°C overnight.  
 
2.2.9.9 DNA sequencing  
DNA sequencing analysis was done using the Sequencing Service at the 
School of Life Sciences, University of Dundee, Scotland. 
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2.2.10 Stable transfection of cell lines 
 
About 0.5x106 cells/well were cultured in 6 well-plates with 2 mL medium and 
incubated overnight. In a tube containing 250L of OPTI-MEM, 10ul of 
lipofectamine 2000 was added and incubated for 5mins at RT. To another 
tube containing 250L of OPTI-MEM, 10 μg of plasmid DNA was added. 
After incubation both the solutions were mixed together and incubated for 
another 20mins at RT. The mix was added to cells in corresponding wells 
and incubated at 37oC for 24 hours and then sub-cultured in cell culture 
dishes with fresh DMEM medium containing 250 μg/mL G418 or/and 50 
μg/mL hygromycin as selection agent. The cells were allowed to grow for 10-
15 days for selection of positive clones. They were routinely checked and fed 
with fresh selection medium every two days. When the positive cells form 
colonies of more than 50 cells, the colonies were picked up by trypsinizing 
using colony cloning cylinders and the single colony was transferred to 24 
well plates. Once the cells establish themselves in 24-well plates they were 
transferred to 25cm2 flasks containing a selective medium to enlarge the 
population and screened by western blot for expression of target gene 
product. In total about 50-72 clones were picked up for every transfection and 
the two clones confirmed with best expression was chosen for further 
experiments. 
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2.2.11 Migration assay 
Scratch or wound healing assay is a popular cheap assay that can be used 
to study migration of cells. A confluent plate generated from initial seeding of 
0.5x106 cells in  6 well plates of any type of attached cells NOR or HYP is 
„„wounded‟‟ by scraping off a thin straight line area of cells using a 200 L 
plastic pipette tip. Pictures of the scratch area were taken at 0hr, 24hrs and 
48 hrs. Cell migration can be monitored microscopically, as cells travel from 
the undamaged regions into the scratched region. %migration can be 
calculated by measuring the decrease of the uncovered region at different 
time points until the „„wound‟‟ is closed using the image J software. Cell 
migration can be observed as single cells or loosely connected population 
(mesenchymal cells) or as sheets of cells (epithelial cells).  
 
Calculation using image J software: 
 
The images were converted to same size and resolution on a single sheet 
using MS powerpoint and loaded as Jpeg file. The pixels of the uncovered 
regions were calculated in the 0hr picture drawing an outline manually 
around the scratch seen in the picture and a numerical value is obtained (A). 
The pixels for 24hr picture is also calculated by manually drawing free form 
lines around the uncovered regions and a sum of all the numerical values for 
uncovered region is taken. The value of uncovered region at 24hr (B) is 
subtracted from the 0hr value (A) to give the value of region that has been 
covered by migration of cells (C). The percentage migration can be then 
calculated using the formula below 
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A=Total cell free region at 0hr 
B=Total cell free region at 24hr 
Total migrated region C = A-B 
Percentage Migration =   C / A x 100% 
 
2.2.12 Invasion assay 
 
300 ul of warm, serum-free media was added to the cell culture inserts and 
incubated at room temperature for 1 hour in order to rehydrate the basement 
membrane layer of the insert. The media was carefully removed after the 
incubation period. 300 L of cell suspension with 0.5-1x106 cells/mL in 
serum-free media was added to the inside of each insert. 500 L of media 
with 10% fetal bovine serum was added to the lower well of the plate. After 
incubation for 48 hours, media was carefully aspirated from the insert. Using 
wet cotton-tipped swabs, cells were removed from the interior of the insert. 
The insert was then dipped in a well containing 400 L of cell stain solution 
and incubated for 10 minutes at room temperature. After several times of 
gentle washing in a beaker of water, the inserts were allowed to air dry. The 
inserts were then transferred to a well with 200 L of Extraction Solution and 
incubated for 10 minutes in an orbital shaker. 100 L from each sample was 
transferred to a 96-well plate and OD was measured at 560nm. The OD 
values are presented as invasion index. The OD for control is taken as 100% 
and the relative increase or decrease in invasion of the sample is given by 
calculating the percentage difference in invasion.  
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2.2.13 Sphere-formation assay: 6-well plate format 
Cells were collected from spheres or attached cells by trypsinization and 
were counted using a haemocytometer. For each group, 1000 cells were 
mixed in 2mL medium in a 15mL tube. Drug was added into each tube and 
cells were treated for the designed time period. Cells were centrifuged and 
medium discarded. Cells were then washed with 1xPBS once and 
resuspended into 6mL of fresh medium. Cells were seeded into HEMA-
coated and 2-times water rinsed 6-well plate (2mL/well). Cells were cultured 
for 7 days and the total number of spheres in all wells was counted. 
 
2.3 Statistical Tests  
 
Microsoft Excel 2010 data analysis tools were used to perform all statistical 
data analysis. The cut-off chosen for statistical significance between samples 
was p=0.05. Values less than 0.05 indicate that the difference between the 
samples is statistically significant. P- value <0.001 denotes that the 
difference between the samples is extremely significant, and p≥0.05 defines 
that the difference between the two samples is not statistically significant. 
The statistical test‟s- t-test: paired two samples for means‟ was used to 
determine the statistical significance between GBM cell lines that were tested 
under same conditions. The statistical test “Anova: single factor” was used to 
determine the statistical significance of the same GBM cell line that was 
tested under varying conditions. 
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Chapter 3 
 
 
 
 
Characterisation of Spheroids from 
GBM cell lines 
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3.1 Introduction 
 
3.1.1  The GBM CSCs and Sphere cell culture 
 
Tumours like GBM are complex tissues that comprise a heterogeneous 
collection of cells associated with the neoplastic compartment, vasculature, 
inflammation, stroma and ECM (Furnari et al., 2007). This heterogeneity can be 
explained by the CSC hypothesis which proposes that tumours contain a small 
subset of CSCs that are able to undergo asymmetric division that generates a 
cellular hierarchy representing the tumour bulk while maintaining the CSC 
population itself (Ward and Dirks 2007). CSCs have been isolated from a 
variety of cancers including many gliomas such as GBM (Li et al., 2007; Al-Hajj 
et at., 2003; Singh et al., 2004).  Accumulated evidence suggests that these 
GBM CSCs play important roles in GBM initiation, angiogenesis, maintenance, 
invasion, aggression and resistance to chemo and radiation therapy. Targeting 
these GBM CSCs in addition to treatments that eliminate the tumour bulk will be 
a better strategy to improve the survival rates in GBM patients. GBM CSCs 
have been mentioned in numerous studies with different terminologies like 
glioma stem cells, glioma initiating cells, glioma propagating cells, stem-like 
cells, resistant GBM subpopulation, multipotent glioma cells, transdifferentiated 
cells, etc. The terminology used raises confusion regarding the cell of origin and 
their specific function (Eyler and Rich, 2008; Bao et al., 2006; Liu et al., 2006).  
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In order to study and understand the biology and role of CSCs in GBM, 
researchers needed a system, where they can be propagated. The earliest 
known system was developed by Reynolds and Weiss in 1992 to isolate neural 
stem cells from mouse that were able to grow as neurospheres in a serum-free 
culture medium supplemented with growth factors like EGF and bFGF. When 
the neurospheres were dissociated and re-plated as single cells they developed 
new neurospheres. It was observed that most differentiating and differentiated 
cells died under these serum-free conditions, whereas the neural stem cells 
were enriched by the growth factors (Vescovi et al., 2006). When the CSC 
theories stepped in to GBM research, methods to culture and enlarge the stem 
cell-like population was adopted from the methods that were originally used to 
culture normal neural stem cells. This is because the discovery of neural stem 
cells has influenced the thought among scientists that brain tumours originate 
from transformed neural stem or progenitor cells (Reynolds and Weiss, 1992; 
Singh et al., 2004). Applying the same conditions as that of NSC culture, a 
population of cells that formed tumour spheres were isolated from human GBM 
cells. These cells are capable of differentiation into neural and glial lineages in 
addition to self-renewal capacities (Galli et al., 2004; Ignatova et al., 2002; Lee 
et al., 2006; Singh et al., 2004). Furthermore, the cells from the tumour spheres 
faithfully reproduced the primary tumour when injected into the brains of 
immunodeficient mice which imply the stem-like and tumour initiating abilities of 
these cells. Similar kinds of sphere culture models were established in a variety 
of cancers such as leukemia, breast cancer, colon cancer, prostate cancer, 
ovarian cancer and pancreatic cancer (Bonnet and Dick, 1997; Al-Hajj et al., 
2003; Tang et al., 2009).  
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Therefore, when culturing putative tumour stem cells from GBM, the clonogenic 
spheroid models known as “Neurosphere assay” are often used for preserving 
tumour stem-like cells in serum-free medium (Lee et al., 2006). The GBM cells 
are grown in suspension in a culturing medium that has to be serum-free. It is 
known from normal NSC culture that serum causes irreversible differentiation of 
neural stem cells (Gage et al., 1995). This serum-free medium should contain 
neurobasal medium with added EGF and bFGF which are growth factors that 
induces proliferation and selection of multipotent, self-renewing, expandable 
stem-like cells from tumours (Galli et al., 2004; Ignatova et al., 2002; Lee et al., 
2006). In the study by Lee et al., (Lee et al., 2006) it was observed that 
dissociated GBM cells from short term cultures grown as suspension in NS 
medium, successfully selected CSCs and formed neurospheres expressing 
stem cell markers. But when they cultured those selected cells in serum 
containing medium, they noted irreversible differentiation of the CSCs into 
neural and glial cell lineages which is very similar to the irreversible 
differentiation observed in NSCs under the serum conditions (Gage et al., 
1995). Thus the sphere culture system employed to grow NSCs and CSCs 
attempts to avoid differentiation by reducing the secretion of differentiation 
factors and evading adherence mediated stimulation of differentiation. NS 
cultures are excellent models to study CSCs since they enrich the population 
with pathological signature and retain the genetic profile of actual tumour (Miki 
and Rhim, 2007). 
 
 
 
 104 
 
3.1.2 Identification of GBM CSCs from culture 
 
Although self-renewal, differentiation, and tumorigenicity of a population is used 
as a signature identity for CSCs they are usually identified precisely by their cell 
surface markers. With the discovery of fluorescence-activated cell sorting and 
magnetic bead isolation of cells based on surface markers a lot of research has 
focussed on identification and validation of CSC markers in many types of 
tumours.  Nowadays a wide range of stem cell markers are used to identify 
CSCs and they differ based on tumour types. CD133, CD44, ABC transporter, 
CD90, etc are commonly used for many tumours (Zhu et al., 2009; Hwang-
Verslues et al., 2009; Ho et al., 2007). For example CD44hi/CD24low pattern 
and ESA are used in breast cancer, while MDR1, CD166 and CD44 are used 
for prostate cancer CSCs (Fillmore and Kuperwasser, 2008). Currently 
leukaemias are the only malignancies known to have the universally accepted 
panel of CSC markers (Gilbert and Ross, 2009).  
 
Several markers are hypothesised as unique for GBM CSCs /Glioma stem cells 
which are mostly based on NSCs. Nestin expressed in NSCs was thought to be 
a valuable marker but is a cytoplasmic protein, which makes it difficult to use for 
sorting the CSC population (Lendahl et al., 1990; Ehrmann et al., 2005). 
Although Nestin, CD133, CD90, ALDH, Notch, Sox2, Bmi1, Musashi1, A2B5, 
Oct4 and Nanog are used for identification of GBM CSCs, currently there is no 
universally accepted panel of CSC markers for isolation and purification of a 
GBM CSC population (Strojnik et al., 2007; Uchida et al., 2000; Ying et al., 
2011; Singh et al., 2004). In this study we used ALDH, CD133, Sox2, Oct4 and 
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Nanog as markers of pluripotency and stem cell characteristics shown by cells 
cultured as spheres in comparison to adhered GBM cell lines.  
 
3.1.2.1  CD133 (Prominin-1) 
 
CD133 is a glycosylated transmembrane protein, with five transmembrane (TM) 
domains and 2 extended extracellular loops expressed in a variety of non 
pathogenic tissue including brain with unknown function. CD133 was initially 
used as a marker for haematopoietic stem cells and later identified as a surface 
marker for NSCs (Miraglia et al., 1997; Uchida et al., 2000). Subsequently 
CD133 was applied to GBM CSCs to isolate populations with enhanced stem 
cell characteristics from different CNS tumours (Singh et al., 2003; Singh et al., 
2004). CD133+ cells from GBMs have high capacity to undergo multilineage 
differentiation, form neurospheres in culture, and express high levels of NSC 
genes similar to signalling pathways in normal NSCs (Liu et al., 2006). CD133+ 
cells show elevated expression of embryonic genes nestin, Msi-1, Notch, Oct4, 
Sox2 and have the ability to reproduce a tumour that resembles the patient‟s 
tumour in animal models (Ma et al., 2008; Miki et al., 2007). These tumours 
initiated by CD133+ GBM can be serially transplanted into NOD-SCID mice and 
faithfully reproduce the tumour. It was noted that, injecting as less as 100 
CD133+ cells resulted in tumour formation while over 100,000 CD133− injected 
cells did not produce any tumours (Singh et al.,2004). Recent reports reveal 
that CD133− cells still exhibit CSC characteristics like self-renewal, multilineage 
differentiation, and tumour formation in xenograft models (Beier et al., 2007; 
Jaksch et al., 2008). Moreover it is now known that CD133 was not expressed 
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in about 40% of freshly isolated GBM tumours (Beier et al., 2007) which 
underlines the limitation of using CD133 for selecting GBM CSCs (Son et al., 
2009). Although CD133 is still used as a means of isolating cell population with 
enhanced stem cell properties, it is not considered to be a universal GBM CSC 
marker. 
 
3.1.2.2 ALDH Activity as a Universal CSC Marker 
 
In addition to using cell surface markers for CSC identification, certain functional 
characteristics of stem cells were used for CSC detection and isolation.  In 
2007, groundbreaking studies by Cheung et al., (2007) and Ginestier et al 
(2007) showed that increased aldehyde dehydrogenase (ALDH) activity 
measured by the ALDEFLUOR assay, originally used for the isolation of 
hematopoietic stem cells, can be used for the isolation of CSCs from leukaemia 
and breast cancer. They demonstrated the potential applicability of quantifying 
ALDH activity using ALDEFLUOR in solid tumours. Cells isolated based on 
increased ALDH activity had tumourigenic and self-renewal properties of CSCs 
(Ginestier et al., 2007).  
 
In the following years, reports from various researchers established the 
successful use of ALDH activity as a CSC marker in many cancers like lung, 
liver, brain, colon, cervical, pancreatic, skin, prostate, head and neck, bone, 
bladder and thyroid cancers and it was suggested that ALDH activity can be 
used as a universal CSC marker (Boonyaratanakornkit et al., 2010; Basak et 
al., 2009; Carpentino et al., 2009; Chu et al., 2009; Clay et al., 2010; Deng et 
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al., 2010; Li et al., 2009; Ma et al., 2008; Wang et al., 2010; Su et al., 2010; 
Todaro et al., 2010; van den Hoogen et al., 2010). In addition ALDH is 
considered to play an important role in chemoresistance of CSCs by detoxifying 
drugs and maintaining quiescence and low ROS levels that minimizes therapy 
induced ROS-DNA damage. However the ALDH activity measured by 
ALDEFLUOR in various tissues may differ and identification of specific ALDH 
isoforms from a family of 19 enzymes is difficult to correlate with the increased 
activity found in various solid tumours (Black and Vasiliou, 2009). 
 
3.1.2.3 SOX2 
 
Sox [SRY (sex determining region Y)-box] 2 belongs to the Sox family of high 
mobility group domain-containing transcription factors that are expressed in 
many tissues during development. Sox-encoding genes are highly expressed in 
the developing nervous system especially Sox2 which is expressed in 
undifferentiated neural precursor cells functions as a specific marker for neural 
development (Pevny and Nicolis, 2010). Sox2 is highly expressed in embryonic 
and adult neural stem cells present in the subventricular zone or in the 
subgranular layer and its expression persists until the cells differentiate into 
mature neural or glial cells. These stem cells with high expression of Sox2 are 
characterized by self-renewal and multipotency along with the expression of the 
neural stem cell marker nestin and glial marker GFAP (Tanaka et al., 2004). In 
addition to stem cells in the nervous system, Sox2 is also a bona fide marker of 
stem and progenitor cells of the stomach, breast, cervix, liver, bone marrow, 
testes, and several glands (Arnold et al., 2011). Sox2 is also well-known for its 
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role as an important transcription factor unique to embryonic stem cells and 
foetal progenitor cells found in the developing embryo. Several animal model 
studies with forced expression of Sox2 reveal that Sox2 is very important for 
preventing neuronal development and maintenance of stem cell state (Favaro et 
al., 2009; Ferri, 2004).  
 
3.1.2.4 OCT-4   
 
Oct4 (Oct3/4 or POU5F1) belongs to the POU family of transcription factors and 
plays a crucial role in the maintenance of self-renewal and pluripotency in 
ESCs. Oct4 is commonly found in unfertilized oocytes, blastocysts, germ cells, 
embryonic carcinoma cells and embryonic germ cells (Nichols et al., 1998) 
Studies have demonstrated that high expression of Oct4 sustains a pluripotent 
undifferentiated stem cell state and a further two-fold increase in Oct4 will push 
the cells to very primitive endoderm and mesoderm-like cells. On the other hand 
even a 50% loss of Oct4 induces stem cells to undergo differentiation, 
producing a heterogenous population (Nichols et al., 1998; Niwa et al., 2000). 
This suggests that Oct4 is regulated at a precise level to maintain lineage-
specific ESC differentiation. Moreover Oct4 is an important transcription factor 
involved in the recent research area of reprogramming differentiated somatic 
fibroblasts into embryonic pluripotent cells known as inducible pluripotent stem 
cells (iPSC). Oct4 is the only transcription factor shown to be required 
exogenously among the several combinations of transcription factors needed to 
make iPSCs. This indicates that Oct4 may act as a „gatekeeper‟ of pluripotency 
in differentiated cells (Stefanovic and Pucéat, 2007). Expression of Oct4 is seen 
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in number of cancers and its expression has been correlated with aggressive 
tumour grade and decreased survival rates (He, 2012; Chen et al., 2012). It has 
been demonstrated that ectopic expression of Oct4 in normal breast cells leads 
to the generation of cells showing features of CSCs with tumour-initiating and 
colonization abilities in mouse models of breast cancer (Beltran et al., 2011). 
Presence of Oct4 in CD133- lung cancer cells attributes them to CSC properties 
and increases the sub population of CD133+ cells (Chen et al., 2008). In 
addition to this Oct4 is also shown to be expressed in acquired EMT 
phenotypes which enhanced tumourigenicity and drug resistance of prostate 
cancer (Kong et al., 2010). 
 
3.1.2.5 Nanog 
 
Nanog is a homeodomain-containing transcription factor that plays a major role 
in the maintenance of pluripotency and self-renewal in embryonic stem (ES) 
cells (Chambers et al., 2003) (Pan and Thomson, 2007). Along with Oct4 and 
Sox2, Nanog is also one of the key transcription factors that have the ability to 
reprogram human somatic fibroblast cells into pluripotent embryonic stem cell-
like cells known as iPSCs (Park et al., 2007). The expression of Nanog is 
regulated at transcriptional level by Oct4/Sox2 heterodimers (Kuroda et al., 
2005). Although the Oct4/Sox2 heterodimers are positioned at a higher level in 
the regulatory network of ES cell hierarchy, Nanog possesses unique properties 
that regulate key stemness-associated transcriptional factors and hence is 
considered to be indispensable to maintain ES cell identity and biology 
(Chambers et al., 2003). Higher Nanog expression is observed in cancer stem 
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cells than in non-stem cancer population of several germ cell tumours and other 
solid tumours, including breast, lung, brain, cervix, prostate, kidney, colon, oral 
and ovarian cancers  (Lee et al., 2011; Ibrahim et al., 2012; Bussolati et al., 
2008; Niu, 2011). Several correlation studies indicate that Nanog-positive 
cancer stem cells also express high levels of the CSC surface marker and 
represent only <2% of the total cancer cell population (Ibrahim et al., 2012). For 
example, a high level of Nanog expression is observed in CD133+ or CD44+ 
cancer cells than CD133− or CD44- ones (Xu et al., 2012). It was also shown in 
prostate cancer cells that increased Nanog results in upregulation of CD133 
and ALDH1. In addition, many functional studies through ectopic 
overexpression of Nanog have demonstrated that Nanog is not only a CSC 
marker, but also functions to drive a subpopulation of cells to adopt a stem like 
phenotype with clonal growth and tumour regenerative capacity, thereby 
promoting CSC-like characteristics in several cancers (Jeter et al., 2011; 
Ibrahim et al., 2012).  
 
3.1.3 CSCs from cell lines 
 
In addition to the isolation of CSCs from tumour tissues and primary cultures, it 
is also now evident that CSCs can be isolated from established tumour cell 
lines. Generally, the cells growing as cell lines containing vigorously dividing 
tumour cells are considered to be terminally differentiated cells.  Additionally 
these cell lines were cultured in serum containing medium as monolayers for a 
very long time (haematopoietic malignancies are exceptions). These cell lines 
are used in various studies for decades and they have undergone various 
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genetic, epigenetic and morphological changes in order to adapt to the in vitro 
culture conditions. Li et al., (2008) reported that although established gliomas 
cell lines conserved some features of primary tumour, they had significantly 
higher number of recurrent aberrations which are not found in primary tumours.  
Therefore cultured cell lines are very unlikely to contain CSC population. Recent 
validated studies report the isolation of CSCs from established tumour cell lines 
of breast cancer (Fillmore and Kuperwasser, 2008), prostate cancer (Luk et al., 
2011), ovarian cancer (Shi et al., 2010), melanoma (Chandrasekaran and 
DeLouise, 2011), colon cancer (Fan et al., 2011), brain tumour (Qiang et al., 
2009) and the list seems to be expanding further. All the above studies used 
sphere cell culture and specialised stem cell selection media with growth factors 
to enrich the CSC phenotypes growing as spheres. However, the differentiation 
potential of the CSCs derived from cell lines is not well established. Although it 
is unclear how CSCs can be extracted from cell lines, the presence of CSCs or 
stem like cells in these sphere cultures is unquestionable. This is based on the 
fact that cells from these sphere cultures also express very high levels of CSC 
markers equivalent to the spheres isolated from primary tumours or short term 
cultures. In addition they are also shown to express various proteins and 
transcription factors involved in embryonic signalling and stem cell survival 
pathways. These cell lines based on CSCs are very much comparable to CSCs 
from primary sources since they also show high tumourigenic capacity in animal 
models (Fehlauer et al., 2006).  
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3.1.4 Rationale and aims of this study 
 
The above findings stating the isolation of CSCs from cell lines have led to 
interesting questions and uncertain solutions. Can CSCs be re-induced from 
tumour cells cultured for a long-term under in vitro conditions? Does the sphere 
culture system serve as a selection media or induce CSCs from non-stem cells? 
Why CSCs are found in some cancer cell lines and not in others?  
 
It is not known whether some residual CSCs exist in cell lines or the culture 
condition in selective medium enhanced the enrichment of CSC phenotypes. It 
is also not known whether growing these cells as spheres in suspension results 
in cellular aggregation and subsequent activation of dedifferentiation pathways 
to convert differentiated cells back to stem-like phenotype.  Recent evidence 
suggest that overcrowding in solid tumours caused by bulk tumour cells and 
resultant hypoxic and microenvironmental conditions leads to EMT pathways 
and induces stem cell phenotypes (Polyak and Weinberg, 2009). Some studies 
also mentioned that sphere culture conditions mimic the tumour 
microenvironment by inducing mesenchymal cells under low oxygen conditions 
(due to hypoxic core in sphere cell aggregates) and mediate CSCs and 
resistance phenotypes in tumour models (Bjerkvig et al., 1990). There are 
various correlations between hypoxia induced stem cells and chemoresistance 
nature of the tumours that leads to failure of therapy and relapse. If EMT is the 
answer for CSC phenotypes in cell lines, then we have to know the true role of 
the selection medium in CSC sphere culture.  
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The main goal of this study is to understand whether the sphere culture can 
mimic the actual CSCs found in GBM which are known to be the utmost 
contributors of therapy resistance in GBM. To address this, we cultured the 
established glioblastoma cell lines as spheres in two different culture conditions. 
On one hand the cells were grown as neurospheres with neural CSC selection 
medium without serum, containing all the growth factors. On the other hand 
cells were grown as suspension in normal complete medium as used for 
monolayer cultures with serum. We examined the expression of generally 
accepted CSC markers in these sphere cells and compared their 
chemoresistance ability to that of adherent monolayer cultures by cytotoxicity 
assays using conventional anticancer drugs used for GBM therapy.  
 
3.2  Experimental design 
Detailed information on materials, products, manufacturers and methodologies 
used for the entire study has been described in chapter 2. The following are 
specific experimental designs and methods used for this part of the study. 
 
3.2.1 In vitro neurosphere and suspension sphere culture 
 
Three established GBM monolayer cell lines U87 MG, U251MG and U373MG 
were used in this study. Routine subculture methods were followed for the 
maintenance of the attached monolayer cultures. Two individual groups of three 
GBM cell lines U87 MG, U251MG and U373MG were cultured in ultra low 
adherence poly-HEMA coated T75 flasks at a cell density of 10,000 cells/mL. 
One group was grown in conventional stem cell enrichment medium without and 
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with growth factors. The other group was cultured in normal DMEM with 
10%serum. The cells were incubated at 37oC for 7 days with necessary media 
replacement every 3 days. The cells were allowed to form spheres and 
subjected to further experiments after trypsinisation and dissociation of spheres. 
The cells grown as monolayer are labelled as attached (ATT), spheres grown 
suspended in selective medium are labelled neurosphere cultures (NS) and 
spheres grown suspended in serum containing medium are labelled as 
suspension cultures (SUS). The sphere cells were photographed and can be 
trypsinised and reseeded for further passage or collected at the end of 7 days. 
Since they are derived from cell lines the sphere cells can be generated from 
adherent cells at any time.  
 
3.2.2 Flow cytometric analysis of CSC markers 
 
Cells from all three types of culture conditions ATT, NS and SUS from all three 
cell lines were trypsinised and dissociated into single cells. The cells were 
counted and 2.5x105 cells were analysed with corresponding CSC markers. 
ALDH activity was measured by staining with ALDH substrate and assay buffer 
for 30 mins at 37oC and analysed according to the instructions provided with the 
ALDEFLUOR kit.  For detection of CD133 cell surface marker the cells were 
incubated with anti-CD133-PE conjugated antibody for 15-20 mins and then 
analysed. For intracellular embryonic stem cell marker proteins like Sox2, Oct4 
and Nanog about 1x106 cells were fixed with 100% ethanol and blocked using 
FACS blocking buffer that includes TritonX100 to make the cells permeable to 
the antibody. The cells were then stained with the corresponding primary 
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antibody diluted (1 in 1000) in blocking buffer and left overnight. The primary 
antibody was washed and the cells were incubated with appropriate FITC 
tagged secondary antibody (1 in 5000) diluted in blocking buffer. All cells were 
washed with PBS after incubation and re-suspended in corresponding buffers 
and examined using BD FACS Calibur and Cell Quest ProTM Software (BD 
bioscience). An increase in the expression of CSC markers is quantified by 
measuring increase in fluorescence.  
 
3.2.3 MTT cytotoxicity assay for GBM monolayer cells 
 
Three GBM cells lines U87 MG, U251MG and U373MG were cultured overnight 
in flat bottomed 96 well plates at a cell density of 5000 cells/well in triplicates. 
These ATT cells were then exposed to first line GBM drug TMZ and other 
conventional anticancer drugs VCR, PAC and DOX in the following 
concentrations (conc). TMZ (highest conc- 500M serially diluted down to 
3.9M); VCR (highest conc- 50nM serially diluted down to 0.39nM); PAC 
(highest conc- 50nM serially diluted down to 0.39nM); DOX (highest conc-
250nM serially diluted down to 1.9nM). The cells were treated for 120 hours and 
subjected to MTT analysis. The % cell viability at different concentrations was 
calculated and the corresponding IC50 values were calculated for each drug. 
 
3.2.4 MTT cytotoxicity assay for Sphere cells derived from GBM cell lines 
 
The sphere cells NS and SUS from all three GBM cell lines used were 
trypsinised and dissociated into individual cells. They were then reseeded in 
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poly HEMA-coated 96-well flat bottom plates in their corresponding culture 
medium at a cell density of 5000 cells/well and cultured overnight. Since the 
cells were suspended they were grown overnight at a volume of 100 L/ well. 
They were then dosed with drug containing medium on top with another 100L 
with appropriate drugs under study as follows: TMZ (highest conc- 500M 
serially diluted down to 3.9M); VCR (highest conc- 50nM serially diluted down 
to 0.39nM); PAC (highest conc- 50nM serially diluted down to 0.39nM); DOX 
(highest conc-250nM serially diluted down to 1.9nM). The cells were treated for 
120 hours and MTT reagent was added to the wells. After incubation with MTT 
reagent, the plates were spun down at 800 rpm for 5 mins in a plate centrifuge 
and media is discarded. The spheres which appear like purple crystals were 
dissolved by adding DMSO and the OD was measured using a plate reader. 
The % viability and corresponding IC50 values for each drug were calculated. 
 
3.2.5 Western blot analysis of stem cell proteins 
 
ATT, NS and SUS cells from all three cell lines were trypsinised and collected 
as pellets. The whole cell protein in the cells were extracted with RIPA buffer, 
quantified and separated by SDS PAGE. The expression levels of embryonic 
CSC markers like Oct4, Sox2 and Nanog were analysed using appropriate 
primary and secondary antibodies as mentioned in the western blot section of 
chapter 2. 
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3.3  Results 
 
3.3.1 High levels of CSC markers are observed in both NS and SUS cells 
 
When compared to the ATT monolayer culture, both the NS cells and SUS cells 
isolated from all three GBM cell lines used in this study showed remarkable 
increase in all the CSC markers tested. Figure 3.1 shows the general 
morphology of ATT, NS and SUS cells from U87 MG, U251MG and U373MG. It 
can be observed that SUS grown with serum formed bigger and tighter spheres 
than the cells grown in NS medium. This may be because, in the presence of 
serum the cells dividing outside formed a healthy tighter shell outlining the cells 
inside similar to the tumour microenvironment. The results of FACS analysis are 
shown in Figure 3.2. The measurement of ALDH activity by ALDEFLUOR assay 
showed statistically significant increase in ALDH activity in the NS and SUS 
population of all three cell lines (Figure 3.2). Similarly expression of the cell 
surface marker CD133 increased significantly in NS and SUS population as 
shown in Figure 3.3. Although the function and reliability of CD133 marker is still 
uncertain, it is arguable that most neural progenitor cells have characteristic 
expression of CD133 on their surface. Both ALDH and CD133 in sphere cells 
indicates that the CSC phenotypes present in the NS and SUS population is 
similar to neural progenitor cells. Embryonic stem cell proteins such as Sox2, 
Oct4 and Nanog are important transcriptional factors that play a major role in 
regulation of stemness, pluripotency and stem cell renewal pathways. The 
expression of these proteins is usually restricted to embryonic stem cells and 
other progenitor cells as they are known to be switched off after differentiation. 
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SUSNSATT
Our results clearly indicated increased expressions of Sox2, Oct4 and Nanog in 
NS and SUS cells in comparison to ATT cells as shown in Figure 3.4, 3.5 and 
3.6 respectively. Furthermore Western blot analysis confirmed the presence of 
high levels of these proteins in NS and SUS cells derived from all three GBM 
cell lines (Figure 3.7). The in vitro culture of sphere cells using expensive 
selective medium is basically adopted from normal neural stem cell culture. The 
cells grown in this system known as Neurospheres (NS) were thought to be 
CSCs selected by the special medium. But our results showed that the cells 
grown with serum in normal culture medium also can select or support the 
growth of GBM CSC like cells. We did not observe any significant difference in 
the CSC characteristics between the NS and SUS cultures, thus questioning the 
use of expensive media for growing CSCs.  
 
 
 
 
 
 
 
 
 
 
 
Fig 3.1 Morphology of GBM spheres. All three GBM cell lines grown as ATT, NS and SUS 
cultures. Cells grown as suspensions in low attachment conditions using both selective NS 
medium and normal DMEM with serum formed spheroids. Images taken after 7 days of culture 
(x40 magnification).  
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Fig 3.2 High ALDH activity detected in NS and SUS sphere cells. ALDH activity measured 
by ALDEFLUOR assay using FACS analysis. The bar chart displays the percentage of ALDH 
cell populations. n= 9, **p<0.01  
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Fig 3.3 High CD133 expression detected in NS and SUS sphere cells.  CD133 
immunostaining using PE conjugated anti-CD133 measured by FACS analysis.  The bar chart 
displays the percentage of CD133 cell populations. n= 9, **p<0.01  
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Fig 3.4 NS and SUS sphere cells express high levels of embryonic CSC marker SOX2.  
Expression of SOX2 determined by immunostaining using SOX2 antibody and FITC conjugated 
secondary antibody and measured by FACS analysis.  The bar chart displays the percentage of 
SOX2 expressing cell populations. n= 9, *p<0.05;  **p<0.01  
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Fig 3.5 NS and SUS sphere cells express high levels of embryonic CSC marker OCT4.  
Expression of OCT4 determined by immunostaining using OCT4 antibody and FITC conjugated 
secondary antibody and measured by FACS analysis.  The bar chart displays the percentage of 
OCT4 expressing cell populations. n= 9, **p<0.01  
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Fig 3.6 NS and SUS sphere cells express high levels of embryonic CSC marker NANOG.  
Expression of NANOG determined by immunostaining using NANOG antibody and FITC 
conjugated secondary antibody and measured by FACS analysis.  The bar chart displays the 
percentage of NANOG expressing cell populations. n= 9, **p<0.01  
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Fig 3.7 Expression of embryonic stem cell markers in NS and SUS cells.  Western blot 
analysis of embryonic stem cell proteins Sox2, Oct4 and Nanog in ATT, NS and SUS cells from 
all three GBM cells. Tubulin was used as a loading control. 
 
3.3.2 The NS and SUS cultured cells are highly resistant to anticancer 
drugs 
 
Although the NS and SUS cells displayed several CSC characteristics, we were 
not certain whether these cells play a role in chemoresistance of GBM like the 
CSCs present in vivo which are well known for their intrinsic chemoresistance.  
GBM CSCs evade the damage caused by chemotherapeutic agents through 
various mechanisms like drug efflux, quiescence, anti-apoptosis and enhanced 
DNA repair and leads to recurrence and poor survival rates in patients. In this 
study we tested the first line drug TMZ and three other conventional anticancer 
drugs VCR, PAC and DOX on both monolayer ATT and sphere cells NS and 
SUS population. We hypothesized that if the cells that display GBM CSC 
characteristics are resistant to multiple drugs, we can use the CSCs isolated 
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U87 ATT
U251 ATT
U373 ATT
Doxorubicin
50nM
Paclitaxel
50nM
Vincristine
50nM
-VE Temozolomide
500uM
from established cell lines to study chemoresistance mechanisms and develop 
targets. Our MTT cytotoxicity results show that both NS and SUS cultures are 
extremely resistant to first line drug TMZ even at very high concentrations used 
in this study (500M) while the non stem ATT cells are comfortably killed by 
TMZ. Similar results were observed on treatment with other drugs like VCR, 
PAC and DOX where the ATT cells were killed at low concentrations and NS 
and SUS survived at high concentrations. Figure 3.8 A,B and C shows the 
morphology of cells ATT, NS and SUS from all three cell lines respectively after 
drug exposure. Figure 3.9 A, B and C which displays the results of U87, U251 
and U373 cell lines respectively shows the cell viability curves of ATT, NS and 
SUS for different drugs in comparison to each other. There is a clear difference 
between the curves of ATT and NS or SUS which explains the low IC50 values 
for ATT cells and increased IC50 values of NS and SUS cells mentioned in 
Table 3.1  
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Fig 3.8 Morphology of ATT, NS and SUS cells after treatment with conventional 
anticancer drugs.  (A) Attached monolayer cultures are effectively killed by all drugs whereas 
(B) NS and (C) SUS cultures survived even under very high concentrations of drugs. Cells were 
exposed to drugs for 120 hours and images were taken at 40X magnification. 
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Fig 3.9  In Vitro Cytotoxicity of conventional anticancer drugs on U87 ATT, NS and SUS 
cells. The cells were exposed to different drugs for 120 hours and subjected to MTT cytotoxicity 
assay. The cell viability curves clearly show a significant difference in the dose response 
between ATT and Sphere cells. 
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Fig 3.10  In Vitro cytotoxicity of conventional anticancer drugs on U251 ATT, NS and SUS 
cells. The cells were exposed to different drugs for 120 hours and subjected to MTT cytotoxicity 
assay. The cell viability curves clearly show a significant difference in the dose response 
between ATT and Sphere cells. 
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Fig 3.11  In Vitro cytotoxicity of conventional anticancer drugs on U373 ATT, NS and SUS 
cells. The cells were exposed to different drugs for 120 hours and subjected to MTT cytotoxicity 
assay. The cell viability curves clearly show a significant difference in the dose response 
between ATT and Sphere cells. 
 
 130 
 
Table 3.1  IC50 values of conventional anticancer drugs on GBM cell lines. 
 
The values n the table indicates the IC50s for different drugs on GBM cells. SD is given in 
parenthesis. n=9 **p<0.01. 
 
3.4 Discussion 
 
Stem cells possess two unique features: pluripotency and self-renewal, and it 
has been revealed that all tissues contain tissue-specific stem cells which 
continuously produce differentiated counterparts of the tissue to maintain its 
structure and function. The discovery of cancer stem cells that behaved in a 
similar manner to normal stem cells turned out to be a breakthrough in the area 
of cancer resistance and relapse (Dick et al., 2008). GBM was the first solid 
tumour from where self-renewing, multipotent, tumourigenic CSCs were isolated 
(Singh et al., 2003).  It is clearly understood from various studies that GBM 
Table 3.1 VCR (nM) PAC (nM) DOX (nM) TMZ (uM)
U87 att 2.50 (0.76) 3.02 (1.41) 36.83 (7.7) 15.69 (1.81)
U87 NS >50** >50** >2000** >500**
U87 Sus >50** >50** 892.3 (14.8) ** >500**
U251 att 2.52 (0.74) 2.77 (1.27) 41.92 (7.99) 13.3 (0.64)
U251 NS >50** >50** >2000** >500**
U251 Sus >50** >50** 958.72 (32.4) ** >500**
U373 Att 2.71 (0.43) 2.04 (0.2) 46.51 (6.26) 40.45 (11.21)
U373 NS >50** >50** >2000** >500**
U373 Sus >50** >50** >2000** >500**
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CSCs are responsible for the invasive growth and GBM recurrence due to their 
chemoresistant nature. In an effort to study and target the therapeutic 
resistance of GBM CSCs the CSC culture system was used to isolate CSCs 
from patient tumour samples or short term cultures. 
 
The GBM CSC culture system is adapted from the normal neural stem cell 
culture system. The growth factor-supplemented serum-free spheroid culture is 
widely accepted as a gold standard method to keep the CSCs in an 
undifferentiated state under in vitro conditions. It is also referred that serum free 
conditions will purge the differentiated progenies, and selectively enrich the 
CSC population (Lee et al., 2006). The major drawback of the serum-free 
enrichment system is that it is very expensive (approx. £150 for a 500mL 
bottle). Additionally this system does not exactly mimic the physiological 
conditions and there is no clear information on the origin/source of the CSCs 
growing in sphere culture. Another paradox for the NS system is the belief that 
CSCs once exposed to serum will differentiate irreversibly in to their progenies. 
So people supporting this selection hypothesis do not use established cell lines 
as a source for CSCs. They consider the cell lines to be fully differentiated cells 
grown for many years under serum containing culture conditions. On the 
contrary there are several reports on isolating CSCs from established cell lines.  
They show all CSC characteristics including initiation of tumour in animal 
models.  
 
Our results also indicate that when the cells from established GBM cell lines 
such as U87, U251 and U373 are grown as NS in selective media they form 
 132 
 
spheres and exhibit several CSC characteristics like CD133, ALDH, Sox2, Oct4, 
and Nanog. If this is the case it appears like most of the established cell lines 
have a residual population of CSCs that can be enriched and activated by this 
growth factor enriched medium and proper culture conditions. But on the other 
hand growing the cell lines as spheres in normal DMEM+10% serum conditions 
also induces better spheres and enhanced all the above mentioned CSC 
characteristics. Therefore from the results of our study and information from 
literature we can be definite that stemness in GBM CSCs is not determined by 
the culture medium. Also we can be sure that the serum free culture system is 
not mandatory for GBM CSC culture.  
 
Therefore there must be another common factor in this culture method that 
induces and maintains the CSC phenotypes from established cell lines. The 
most important feature of this culture system is growing the cells in low 
adherence conditions that allow the cells to grow as spheres. It is well known 
that cells grown in suspension are more likely to aggregate with each other and 
form clumps. No matter how low the cell number is, unless they are grown as 
single cell suspension, the aggregation of the suspended cells is inevitable 
(Jensen et al., 2011).  In our experiments we followed the standard NSC culture 
methods and therefore we used a cell density of 10,000 cells/mL. The cells 
aggregate together and form clumps which eventually become sphere-shaped 
in about 5-7 days after which the CSC populations become apparent. If the 
culture media does not induce GBM CSCs the other possible mechanism could 
be a stress- induced phenotype change that occurs in the spheres. If we have a 
closer look at the sphere cells they clearly have a hypoxic core and a necrotic 
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region surrounded by healthy cells. The cells in the centre of the sphere may 
have been subjected to severe hypoxia and nutrient deprivation that causes 
necrosis in the middle. This matches very closely with in vivo GBM tumour 
conditions where there is extensive hypoxia and necrosis due to lack of 
nutrients and oxygen in the centre of rapidly growing tumour mass (Jensen et 
al., 2011).  
 
There are several recent evidence indicate that hypoxia can induce a pathway 
known as EMT which allows the fully differentiated cells to dedifferentiate to 
mesenchymal cells that shows CSC characteristics. If this is true, then it is very 
likely that all sphere cultures will eventually result in hypoxic core due to 
aggregation which will induce CSCs/mesenchymal cells through EMT program. 
This could be the possible reason why both serum and non serum GBM sphere 
cultures can show CSC phenotypes in them. Even if cells are grown as single 
cell suspension, the same scenario will apply to it after the cells divide and join 
together to form spheres. Under physiological conditions tumour cells under 
hypoxia reprogram to mesenchymal cells to facilitate migration, metastasis or to 
produce growth factors to initiate angiogenesis. Unlike the NSCs, the 
monolayer-cultured non-CSCs and sphere-cultured CSCs are interconvertible 
by oxygen concentrations. Hypoxia induces EMT and the cells can migrate out 
of the tumour and follow another program called MET where the mesenchymal 
cells become differentiated epithelial cells. This could be the reason why when 
grown as spheres, established cell lines get converted to mesenchymal 
phenotype and revert back to epithelial when they are adhered back to 
monolayer culture. We also had a question how some researchers isolated NS 
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CSCs from fresh samples or by growing them as single cell suspension. This is 
probably because they are enriching the mesenchymal or CSC phenotypes 
induced by physiological hypoxia in the primary tumour. A detailed analysis of 
how hypoxia can induce CSCs in GBM cell line derived spheres is given in 
chapter 4. 
 
Despite optimal therapies GBM remains to be a fatal malignancy mainly due to 
their resistance towards conventional therapy and recurrence (Furnari et al., 
2007). Studies from our group and many others have confirmed that GBM 
CSCs promote therapeutic resistance and relapse (Liu et al., 2012; Bao et al., 
2006; Johannessen et al., 2009; Liu et al., 2006). In this study we also 
established that cell line-derived NS and SUS GBM CSCs show high level of 
chemoresistance compared to the ATT non-stem cell population. The exact 
mechanisms of GBM CSC chemoresistance are unknown, but probably due to 
a combination of slow cell cycle kinetics, resistance to oxidative damage, DNA 
repair mechanisms, avoiding apoptosis, hypoxia activated mechanisms and 
multidrug resistance proteins (Diehn et al., 2009; Bao et al., 2006; Liu et al., 
2006). GBM CSCs probably remain in a quiescent state and may be more 
resistant to anticancer drugs that target rapidly dividing cells. It is found that cell 
cycle profiles of human breast CSCs had an extended G2 phase and hence 
more resistance to induction of apoptosis (Harper et al., 2010). The current 
standard chemotherapeutic agent known to improve survival in newly 
diagnosed GBM is TMZ, an oral methylating agent that induces DNA damage 
by methylated guanine adducts (Stupp et al., 2005). But invariable tumour 
recurrence after TMZ therapy point towards the presence of TMZ-resistant 
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subpopulation in GBM that express the repair enzyme MGMT which removes 
the DNA adduct. It is reported that MGMT is expressed in GBM sphere cultures 
isolated from patient samples so GBM CSCs also contribute to the 
chemoresistance to TMZ (Johannessen et al., 2009; Liu et al., 2006; Paranjpe 
et al., 2013). So we hypothesised that the expression of MGMT is elevated after 
growing the monolayer into spheres that results in resistance of NS and SUS to 
TMZ. But even after several experiments with positive controls we were not able 
to identify any MGMT expression in both NS and SUS GBM CSCs. This 
indicates that probably there are MGMT independent mechanisms present in 
GBM CSCs that renders the drug ineffective both in vitro and in vivo. This could 
be the possible reason why many MGMT negative GBM patients also develop 
resistance to TMZ and end up in tumour relapse.  
 
GBM CSCs also express multidrug resistance proteins like P-gp, BCRP and 
ABCG2, whose drug efflux functions aid survival of GBM CSCs. When 
compared with autologous CD133− cells, GBM CSCs that are CD133+ are 
shown to express an array of anti-apoptotic proteins including FLIP, BCL-2 and 
BCL-XL that helps in survival after treatment (Liu et al., 2009). In addition to 
MGMT and other resistance proteins, GBM CSCs may have various other 
mechanisms like enhanced DNA repair, ALDH activity, oxidative stress balance, 
etc that can drive multidrug resistance to cytotoxics such as TMZ, BCNU, 
CCNU, carboplatin, Vincristine, Palitaxel, Docetaxel, Doxodubicin, VP16 and 
other drugs. Another mechanism of resistance in NS and SUS is thought to be 
hypoxia induced by cell aggregation and sphere formation. Hypoxia is widely 
acknowledged as a contributing factor in chemoresistance of solid tumours. 
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Some studies highlight that hypoxia induced EMT can drive chemoresistance 
(Harris, 2002). Other studies point out that the chemoresistant effects of CSCs 
are largely mediated by hypoxia inducible factors (HIFs) and other transcription 
factors highly expressed in GBM CSCs (Tanase et al., 2013). Our findings also 
indicate a means through which oxygen tension in NS and SUS culture systems 
could affect GBMs responsiveness to drugs. We have explained these facts in 
detail in the chapter 4.  
 
3.5 Conclusions 
 
To conclude, the CSC-like cells in GBM cell lines are probably induced by 
spheroid cultures. The culture medium or the source of initial GBM does not 
affect the formation of GBM CSCs in sphere cultures. The isolated GBM CSCs 
were resistant to chemotherapeutic drugs. It may be hypoxia that drives these 
CSC phenotypes by epithelial cell dedifferentiation. The NS and SUS cultures 
can mimic the physiological conditions in the tumour and possibly provide us 
with various insights on how hypoxia could drive CSCs. It appears like the GBM 
CSCs acquire resistance through a number of potential mechanisms that may 
vary between individuals and cancer types. A better understanding of these 
mechanisms will improve our existing knowledge about GBM CSCs and guide 
us towards future therapeutic targets. 
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Chapter 4 
 
 
 
 
Hypoxia drives chemoresistant CSCs 
in GBM spheres through EMT 
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4.1 Introduction 
In the previous chapter (chapter 3) the existence of a subpopulation of cancer 
stem-like cells in spheroid-cultured (NS and SUS) GBM cell lines has been 
demonstrated.  The most widely used method for identifying CSCs like surface 
markers and embryonic markers tested on these NS and SUS cells provide 
definitive evidences that they closely resemble normal neural stem cells and are 
capable of self-renewal. It is also apparent that they are resistant to various 
drugs and could be the possible sources of tumour relapse. However, the 
reliability of these markers and their relationship to the phenotype of CSCs from 
our study and many others is still questioned mainly because several reports 
show that these cells comprise as many as 25% of the total population disputing 
the idea that CSCs are very rare populations (Kelly et al., 2007; Quintana et al., 
2008).  On the other hand there are several questions to be answered about 
using serum containing medium and isolating CSCs from established cell lines 
(Lee et al., 2006). We compared the growth of spheres in media with serum and 
without serum and suggested that the sphere cells form as a result of cell 
aggregation rather than CSC selection by the medium. We hypothesised that 
due to aggregation there is a nutrient deficient hypoxic condition in the middle of 
the spheres that could possibly drive these epithelial cells to reprogram into 
CSC/stem like phenotype that bring about these CSC characteristics. We also 
proposed that an established process called “hypoxia induced EMT” could 
coordinate the entire reprogramming events occurring in the sphere cells. In this 
chapter I will discuss the possible mechanisms of how hypoxia can drive EMT 
and analyse the possibilities of these mechanisms in our NS and SUS CSCs 
from GBM cell lines.   
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4.1.1 Hypoxia 
Cancer cells undergo numerous genetic and epigenetic changes that allow 
them to acquire various features that help them adapt to environmental 
changes. It is becoming increasingly clear that the interdependent interactions 
between the tumour and its microenvironment play a key role in the initiation 
and progression of tumours. One such aspect of the tumour milieu that 
modulates behaviour of tumour cells is oxygen. The progression of a tumour is 
normally maintained by enough supply of O2 and nutrients through tumour 
associated vasculature. As most tumours proliferate rapidly and grow bigger in 
size, they undergo episodes of aberrant vasculature which then fail to meet the 
metabolic requirements of the growing tumour. Especially hypoxia, a condition 
of O2 deprivation that compromises normal cellular function, is a common 
phenomenon experienced by many malignancies, particularly the fast growing 
tumours (Hulleman & Helin, 2005; Louis et al., 2007; Preusser et al., 2006). 
Hypoxic tumours activate angiogenic pathways that results in improper neo-
vascularisation which forms immature, leaky and dilated blood vessels with 
blind ends, intravascular shunts and excessive branches (Bar, 2010). Hence the 
growing tumour is subjected to repetitive cycles of hypoxic stress which push 
them to undergo epigenetic, metabolic, morphological and functional 
modifications and eventually change their phenotype. As a survival mechanism 
these altered cells escape and move away from the stressful environment 
through invasion, migration and metastasis. Thus hypoxia is a well known 
contributing factor for tumour invasion and metastasis, resistance to radiation 
and chemotherapy and often associated with poor survival rate in patients (Bar, 
2010; Li et al., 2009; Mashiko et al., 2011).  
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4.1.2 Hypoxia Induced EMT 
 
The poor patient outcome associated with hypoxia is probably due to the 
phenotypic change of cells induced by hypoxia in order to escape the hostile 
environment. Recent evidence suggest that hypoxia induced EMT could 
possibly be the mechanism through which the distressed differentiated cells in 
the tumour microenvironment can escape the tumour. They achieve this by 
switching themselves through the EMT program to an early stage mesenchymal 
phenotype which has more motility and multipotent properties. Following this 
change these cells can move out through leaky vasculature of tumours and 
spread locally or carried as circulating tumour cells to distant metastatic sites. 
EMT is a complex cellular programme by which epithelial cells get rid of their 
differentiated features like cell–cell adhesion, apical–basal polarity and immotile 
nature, and alternatively acquire mesenchymal features like motility, 
invasiveness and increased resistance to apoptosis. EMT is characterized by 
various signature features like down-regulation of E-cadherin, relocation of 
zonula occludens-1 (ZO-1), down-regulation and nuclear translocation of β-
catenin and up-regulation of mesenchymal markers such as vimentin, 
fibronectin and N-cadherin (Gregory et al., 2008; Thiery, 2002; Lee, 2006; Hugo 
et al., 2007). Although the idea of EMT was initially met with scepticism, 
increasing evidence has demonstrated its vital role in cancer progression and 
metastasis (Brabletz et al., 2001; Christiansen, 2006). Tumour cells with 
mesenchymal phenotype that escapes the primary tumour are believed to 
undergo reverse transition at the site of metastasis to regain the pathology of 
epithelial cells through another controlled process known as Mesenchymal-to-
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Epithelial Transition (MET).  MET is a crucial step by which metastatic tumour 
cells grow and establish at the secondary site. This return to an epithelial state 
involved the formation of cell–cell interactions between normal cells and the 
migrated cancer cells, allegedly mediated by E-cadherin bridges formed 
between them (Christiansen, 2006). It is still unknown whether any specific 
growth factors or cytokines present in the normal tissues are ever involved in 
actively inducing MET. Another possible way MET could happen is due to the 
absence of signals, cytokines and growth factors similar to that of primary 
tumours like those induced by hypoxia, tumour stromal cells and inflammation 
that helped them to maintain the EMT phenotype.  Metastatic cancer cells may 
simply fall back to an epithelial state as a consequence of reversion in 
epigenetic transcriptional mechanism (Moustakas and Heldin, 2007; Fischer et 
al., 2006; Strutz et al., 2002). Under normal processes like embryogenesis, 
EMT is strictly controlled by time and space to ensure accurate homing and 
prevents abnormal development by reversion of cells to non-invasive 
phenotypes after migration to an intended location (Hay, 1995; Oft et al., 1998; 
Brabletz et al., 2001). But cancer cells undergoing EMT does not have intended 
target location and induce independent autocrine loops of growth signals to 
avoid apoptosis which leads to pathological conditions (Gotzmann, 2004). EMT 
is regulated by many transcriptional repressors like Snail, Slug, TWIST and the 
ZEB family which repress expression of E-cadherin and the key signalling 
pathways which induce EMT include the TGF-β, Wnt, and Notch signalling 
pathways that control the above transcription factors (Batlle et al., 2000; Yee et 
al., 2010). However the EMT and MET pathways in cancer biology is still not 
completely elucidated. 
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4.1.3  Hypoxia induced EMT in GBM 
 
GBM is one such malignancy in which hypoxic regions, hypoxia-induced 
necrosis and neovascularization are very common and are thought to play an 
important role in pathological diagnosis. Indeed hypoxic necrotic foci associated 
with pseudopalasading cells is a WHO recommended classification feature for 
GBM. The physiological O2 concentration in the brain ranges from 0.5% to 7% 
(Bar et al., 2010). Using the method of EF5 binding and Eppendorf needle 
electrodes, Evans and colleagues measured O2 levels in gliomas. They noted 
that the hypoxia levels varied drastically between patients and they grouped 
them as mild hypoxia (0.5% to 2.5% O2), moderate hypoxia (0.1% to 0.5% O2) 
and severe hypoxia/anoxia (0.1% O2 or less). They noted that the patients with 
moderate hypoxia had reduced survival while the patients with severe hypoxic 
gliomas had the worst outcome among all (Evans et al., 2008).  Many other 
studies also showed that increased levels of hypoxic regions are associated 
with invasive, resistant phenotype of GBM that has very poor patient survival 
(Sathornsumetee et al., 2008; Vaupel and Mayer, 2007).  
 
Although hypoxia or microenvironment induced EMT is considered as a major 
modulator of metastasis formation in many epithelial solid tumours, there are 
only very few reports on EMT process occurring in neuroepithelial environment 
or in CNS tumours. In spite of being extensively hypoxygenated tumours, there 
is no robust evidence for the existence of EMT process or its role in invasion or 
progression in the case of GBMs. Recent analysis of The Cancer Genome Atlas 
(TCGA) data by Cheng and colleagues, demonstrated that GBM has a strong 
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association between an EMT expression signature and the expression of the 
CSC markers and early recurrence following initial treatment (Cheng et al., 
2012). The activity of EMT transcription factors like SNAI1, TWIST1, ZEB2 are 
reported to be significantly elevated in GBM tissue compared to normal brain 
and positively correlate with tumour grading. These TFs are thought to promote 
invasion and proliferation in GBM by modulating genes such as MMPs, HGF, 
FGF, Wnt and -catenin (Yang et al., 2010; Mikheeva et al., 2010). These TFs 
are known to suppress the epithelial marker E-cadherin and in parallel increase 
the mesenchymal markers like N-cadherin, vimentin and cadherin-11. But E-
cadherin expression is very rare in both normal and glioma tissues of the brain 
(Motta et al., 2008). On the other hand, N-cadherin and cadherin-11 are 
frequently expressed at a low level in normal brain tissue and their expression is 
elevated in malignant gliomas (Asano et al., 2004). The loss of E-cadherin and 
its correlation with glioma‟s grade was reported in only two studies and 
therefore there is no definitive evidence for classical cadherin switch in 
malignant gliomas, except in some specific cases (Motta et al., 2008; Lewis-
Tuffin et al., 2010). However, Lu and colleagues recently reported an alternative 
cadherin switch in GBMS, different from the classic E-cadherin-to-N-cadherin 
switch (Lu et al., 2012). They observed that another atypical member of the 
cadherin family called T-cadherin was downregulated when Snail and N-
cadherin increased in GBM cells.  T-cadherin expression is absent in most high 
grade gliomas including invasive GBMs and is also associated with a poorer 
prognosis (Andreeva and Kutuzov, 2010).  Zeb-1 has been shown to suppress 
T-cadherin to aid the acquisition of EMT phenotype and it has been 
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demonstrated that ectopic overexpression of T-cadherin in GBM cells inhibits 
proliferation, migration and invasion (Huang et al., 2003).  
 
It is becoming increasingly evident that EMT plays an important role in 
regulating GBM CSCs, GBM invasion and its intrinsic resistance but a large part 
of it remains unexplored due to complex feedback loop systems and missing 
links between them. It is likely that the elevation of mesenchymal signature 
genes in GBM could be due to an ongoing EMT process due to hypoxia or 
could be the reminiscent of an earlier mesenchymal shift during gliomagenesis. 
Due to the remarkable comprehensive analysis of TCGA data by Philips and 
colleagues, the WHO classification system has added the mesenchymal like 
GBM as another subtype of GBM owing to the solid evidences of EMT in GBM 
(Phillips et al., 2006; Louis et al., 2007). Given the established role in 
progression of other hypoxygenated solid tumours, signalling pathways like NF-
κB, HIFs, notch, hedgehog-GLI, WNT/β-catenin, EGFR, RTKs and PI3K-AKT 
may play important roles in hypoxia induced EMT program of GBM. All these 
facts together indicate that GBM share several features with EMT but more 
research and perfect evidence are required to propose this as a therapeutic 
target in GBM. 
 
4.1.4 Hypoxia induced EMT and CSCs 
 
It is interesting to know that hypoxia induced EMT mesenchymal cells carry 
molecular characteristics similar to progenitor or stem cells and are thought to 
initiate or propagate tumour acting as seeds for relapse of tumour after therapy. 
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Multiple evidence from researchers working on various solid tumours argue that 
the CSC phenotypes inside a tumour are probably these EMT induced 
mesenchymal cells.  EMT phenotypes are often confused with cancer initiating 
mutated progenitor cells and hence are referred to as tumour initiating cells or 
cancer stem like cells. Joo et al., (2008) showed that a mesenchymal subtype 
genetic signature was seen specifically in CD133-negative GBM CSCs when 
compared with CD133-positive GBM CSCs and they initiated tumours with an 
invasive growth. Similarly, Lottaz et al., (2010) demonstrated that GBM CSCs 
which are positive for the EMT marker CD44 carry a mesenchymal gene 
signature and produced enhanced invasive growth in vitro and in vivo compared 
with CD44 negative cells regardless of CD133 expression. 
 
Many researchers still believe that a mutated progenitor cell could become a 
CSC and establish a tumour, while other believe that the EMT phenotypes are 
resistant stem like population or metastasis initiating cells induced by 
microenvironment and may not be the actual CSCs that initiated the tumours. 
Regardless of whether CSCs arise from progenitors or are induced by an EMT 
program, it is well established that hypoxia supports the survival and 
maintenance of these CSCs. A hypoxic niche is well known for its role in 
maintaining normal NSCs in the CNS. This raises the possibility that if CSCs 
are present in GBM, the intra-tumoural hypoxia provides the hypoxic niche for 
these cells along with cytokines and growth factors from the tumour stroma to 
maintain their undifferentiated state (Panchision, 2009). 
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4.1.5 Markers used in this study to identify EMT phenotypes 
 
4.1.5.1 CD44:  
 
CD44 is a principal transmembrane cell surface glycoprotein that acts as a 
receptor for hyaluronan (HA). CD44 plays a vital role in alteration and 
degradation of HA which leads to migration and invasion of cancer cells and 
consequently metastasis (Rodgers, 2006; Nagano and Saya, 2004). Under 
hypoxic conditions HA is degraded into smaller subunits by enzymes called 
hyaluronidases. HA fragments promote angiogenesis and also can bind with 
CD44. The binding of HA-CD44 activates the cytoplasmic tail of CD44 and 
interact with actin cytoskeleton through a group of linked proteins called ezrin-
radixin-moesin (ERM) proteins.  Interactions between CD44 and cytoskeletal 
components modulate the adhesion of cancer cells to each other as well as to 
endothelial cells and increase the migratory potential of the cells (Mori et al., 
2008). CD44-HA binding is also known to activate EMT program through TGF- 
pathway and by activation of Rho-GTPases and protein kinase C and 
subsequently various CSC genes like Nanog, OCT4, Wnt and -catenin. CD44 
also interacts with MMPs and increases the activity of MMP-dependant 
degradation of ECM thereby promoting invasion and metastasis (Chetty et al., 
2012). The expression of CD44 has been associated with more metastatic and 
resistant phenotypes of hepatocellular carcinoma, breast cancer, colorectal 
cancer, pancreatic cancer, head and neck cancer and ovarian cancer. The 
significance of CD44 in GBM CSCs has not been studied clearly but it is 
thought that EMT phenotypes expressing high levels of CD44 could be the 
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potential reason behind aggressive nature of GBM. Thus CD44 has been 
suggested as an important differentiator of epithelial versus mesenchymal 
characteristics (Mani et al., 2008). 
 
4.1.5.2 Cadherin Switch 
 
Cadherins are a superfamily of adhesion molecules that play vital roles in 
embryogenesis, tissue recognition and maintaining epithelial structure and 
tissue architecture. E-cadherin is a calcium-dependent cell adhesion molecule 
that mediates cell-cell adhesion, one of the hallmarks of epithelial cells. Another 
well-characterized cadherin is N-Cadherin which is expressed in many cells and 
predominantly in mesenchymal cells. The interaction between cadherins results 
in stable and strong adhesive forces between cells and is thought to be 
regulated by environmental signals, growth factors and cytokines. Accumulating 
evidence from many epithelial cancers suggests that multiple changes in 
cadherin expression occur during tumour growth that results in tumour 
progression. Particularly a phenomenon known as “cadherin switching” play a 
critical role during the process of EMT where E-cadherin is switched off and N-
cadherin is switched on resulting in the conversion of nascent tumour cells from 
an epithelial to a mesenchymal phenotype. The loss of E-cadherin has been 
proved to be an important reason for the disruption of tight cell-cell contact 
during EMT leading to an invasive/ metastatic state (Maeda, 2005; Baum, 
Settleman and Quinlan, 2008; Nieman, 1999). In addition, the mesenchymal N-
cadherin becomes upregulated that promotes a motile state in cancer cells 
allowing the dissociation of individual cells from primary tumour and their 
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interaction with endothelial cells. This enhances migration and extravasation of 
tumour cells to a distant metastatic site through circulation. Therefore the switch 
between the classic E and N cadherins is used as a hallmark of EMT and the 
acquisition of mesenchymal phenotype (Hazan et al., 2004).  
 
4.1.5.3 Vimentin 
 
Vimentin is a major constituent of intermediate filaments that comprise the 
cytoskeletal proteins along with tubulin and actin microtubules. Vimentin is 
predominantly expressed in mesenchymal cells and are often used as a marker 
of cells undergoing EMT or cells derived from the mesenchymal origin (Satelli 
and Li, 2011). It is a major cytoskeletal component of mesenchymal cells 
because of its dynamic nature and its ability to offer flexibility in shape of cells 
thereby increasing their mobility (Satelli and Li, 2011). Moderate to strong 
vimentin expression was found in normal human brain especially in the 
ependymal cells, meninges and choroid plexus (Yamada et al., 1992). 
Expression of vimentin in GBM cells was shown to be dependent on the cellular 
density and chemo/radio treatment and is shown to mediate integrin trafficking 
which is vital for propelling GBM malignancy (Fortin et al., 2010). In other CNS 
tumours like meningiomas, schwannomas and neurofibromas vimentin 
expression was associated with the migration potential and infiltrative/invasive 
nature of these tumours (Bouamrani et al., 2010; Kawahara et al., 1988). 
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4.1.6  Rationale and aims of this study 
 
The conventional sphere culture system is based on the above mentioned fact 
that GBM CSCs are preserved in the tumour microenvironment by hypoxia and 
hence can be isolated, enriched and studied using suitable serum-free selective 
medium. But we believe that when the cells grown in sphere culture system the 
aggregation of cells will first induce hypoxia and activate hypoxia mediated EMT 
in vitro that results in mesenchymal-CSC phenotypes. These cells are further 
maintained and protected by self renewal and embryonic signalling pathways 
activated under hypoxic environment. The main goal of this study is to show 
that CSC phenotypes induced in NS and SUS cultures of GBM cell lines are 
due to hypoxia induced EMT. Although the spheres are grown under normal O2 
conditions, spheroids of larger size become hypoxic due to diffusion gradient 
(Lee et al., 2006).  We aim to prove that any established cell lines grown under 
sphere culture method will have the same effect and result in CSCs which are 
mesenchymal cells. By this way we would like to implicate that the GBM CSCs 
that are chemoresistant in actual primary tumour could possibly be 
mesenchymal cells and also establish the fact that hypoxia is the key target.  
 
If hypoxia is the problem, we would like to know whether hypoxia can induce 
EMT and CSCs while the cells are grown as attached monolayer. We aim to do 
this by culturing monolayer of GBM cell lines under normoxic and hypoxic 
conditions and determine whether there are any signs of EMT or CSC 
characteristics under hypoxic conditions. If there are mesenchymal changes 
observed we also would like to examine whether these cells are resistant to 
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anticancer drugs. By this way we can be sure whether or not the hypoxia 
induced mesenchymal cells are the true culprits in GBM chemoresistance. In 
this chapter we will discuss the possible mechanisms of how hypoxia can drive 
EMT and analyse the possibilities of these mechanisms in our NS and SUS 
CSCs from GBM cell lines.   
 
4.2 Experimental design 
 
Detailed information on materials, products, manufacturers and methodologies 
used for the entire study has been described in chapter 2. The following are 
specific experimental designs and methods used for this part of the study. 
 
4.2.1 Culturing cells under hypoxic conditions 
 
The ATT monolayer cells of all three GBM cell lines U87, U251 and U373 were 
grown under hypoxic conditions using STEMCELL Technologies Hypoxia 
incubator chamber gassed with mixture of 1%O2, 5%CO2 and remaining N2 
from a custom made BOC gas cylinder. The cells for culture were placed in the 
chamber and sealed after purging the O2 in the chamber with the above 
mentioned low O2 gas for 4 minutes. Cells were grown for 5-7 days depending 
on growth rate before subjecting to experiments. The cells were fed with fresh 
media every 2-3 days and to make sure the residual O2 in the media doesn‟t 
affect the experiment, the media in the flask was gassed before closing and 
then placed in the chamber to continue hypoxic conditions. An O2 meter was 
always inside the chamber to monitor any leaks or increase in O2 levels during 
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the process. Any processing or handling of the hypoxic cells during culture or 
for experiments was done quickly every time to achieve maximum reliable 
results. The cells grown under hypoxia will be referred in this study as ATT-HYP 
while the normoxic cells will be referred as ATT-NOR. For example –U373 ATT-
HYP or U373 ATT-NOR. 
 
4.2.2 Determining the presence of hypoxia in sphere cells and hypoxic cell 
cultures 
 
The presence of hypoxic status in the cells was determined using the 
HypoxyprobeTM-1 plus Kit supplied by Hypoxyprobe Inc (Burlington, MA, USA) 
following the supplier‟s instruction. The kit was used for both 
immunocytochemistry (ICC) assay as well as quantification using flow cytometry 
(FACS). The NS and SUS cells were cultured for 7 days and treated with 
Hypoxyprobe (HP) reagent for 24 hours. Since the sphere cells are suspension 
cultures they were spun at 800 g for 3 minutes to spread the spheres onto 
Polylysine-coated slides. The cells were fixed with methanol and stained with 
FITC conjugated monoclonal antibody against HP for 1 hour, washed, mounted 
and then images were taken using a confocal microscope. The measurement of 
hypoxia status in ATT-HYP culture was done similarly to that of NS and SUS 
cells using the Hypoxyprobe kit. But the cells were cultured in 8-well chamber 
slides at ATT-NOR/HYP conditions and labelled with HP for 24 hours. For flow 
cytometric analysis, the NOR, HYP, NS and SUS cells were grown in 25cm2 
flasks and after treatment with HP reagent were trypsinized, counted, fixed with 
methanol and stained with the FITC anti-HP antibody. The hypoxic population 
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was detected using a FACS Calibur flow cytometer with 488 nm blue laser and 
standard FITC 530/30 nm bandpass filter. Any experiments involving HYP cell 
culture, NS or SUS was compared with ATT normoxia cells grown in parallel 
with same initial cell number and incubation periods. In both the cases of ICC or 
FACS, cells without HP but stained with FITC antibody were used as suitable 
negative and staining controls.  
 
Additional confirmation for hypoxia status can be done by western blot analysis 
of HIFs. HIFs are highly oxygen sensitive proteins and their degradation by 
PHDs is immediately stopped as a response to low O2 levels, hence the 
functional HIF proteins will translocate to nucleus of the cells. If hypoxia is 
present in cells grown as NS and SUS, there will be an increased expression 
and nuclear translocation of HIF1 and HIF2 in these cells. The same 
phenomenon applies to cells grown under hypoxia.  ATT-NOR, ATT-HYP, NS 
and SUS cultures of all three GBM cell lines were harvested and the nuclear 
protein in the cells was extracted by following the protocol for nuclear protein 
extraction, quantified and separated by SDS PAGE. The expression of HIF1 
and HIF2 was analysed using appropriate primary and secondary antibodies 
as mentioned in the western blot section of chapter 2.  
 
4.2.3 Analysis of EMT markers in sphere and hypoxic cells 
 
To establish the fact that hypoxia induces EMT three important EMT markers 
such as CD44, vimentin and E-Cadherin to N-cadherin switching were tested for 
ATT-HYP, NS and SUS cells with ATT-NOR cells as control. CD44 cell surface 
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marker expression was analysed using FACS flow cytometry protocol. The 
other markers vimentin, E-cadherin and N-cadherin were analyzed by western 
blot to detect protein level expression. If EMT was happening under hypoxic 
conditions and sphere cell cultures, we expect an increase in the expression of 
CD44, N-cadherin and vimentin and a decrease in the level of E-cadherin 
expression.  
 
4.2.4 Determining mesenchymal properties cells 
 
Cells that have undergone EMT and acquired a mesenchymal phenotype 
display increased migratory and invasive characteristics. To confirm if the cells 
grown under hypoxia are truly mesenchymal in nature we planned to carry out 
in vitro wound healing assay (scratch assay) for migration and transwell 
invasion assay (Boyden chamber assay) to determine invasion.  But 
unfortunately the cells grown under hypoxia divided very slowly and hence a 
confluent tightly packed monolayer was not achieved in order to carry out a 
scratch assay. Hence we performed the migration assay using Boyden chamber 
without matrigel. The cells grown under  NOR and HYP in 25cm2 flasks for 6 
days were quickly subjected to Boyden chamber migration assay according to 
the manufacturer‟s recommended protocol and instructions in chapter 2. The 
cells under NOR and HYP were subjected in vitro cell invasion assay as 
described in chapter 2 using 8.0M pore size transwell filter inserts coated with 
matrigel in 24 well plates. Briefly, the invasion rate of HYP and NOR cells that 
invaded through matrigel basement matrix was assessed according to the 
manufacturer‟s recommended protocol. 
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4.2.5 Analysis of CSC markers in hypoxic cells 
 
We already established the fact that NS and SUS cells have increased CSC 
characteristics in chapter 3. If hypoxia-induced EMT resulted in CSCs in sphere 
cells and if EMT happened in the cells grown under hypoxic conditions, we 
expect that there should be an increase in the CSC characteristics of the ATT-
HYP cells. So we examined all CSC markers tested for NS and SUS cells like 
ALDH, CD133, Sox2, Oct4 and Nanog using immunofluorescence protocol for 
FACS as mentioned in chapter 2. An increase in expression of CSC markers is 
quantified by measuring increase in fluorescence. Additional confirmation for 
the expression of Sox2, Oct4 and Nanog embryonic CSC markers was done by 
western blot analysis. ATT-NOR and ATT-HYP cells of all three GBM cell lines 
were compared for their expression of the above markers. If hypoxia induced 
any phenotypic changes in cells grown as monolayers and generated any cells 
with CSC characteristics, then we can implicate that hypoxia in the NS and SUS 
cells is the true reason behind CSC characteristics in sphere cultures. 
 
4.2.6   MTT cytotoxicity assay for hypoxic cell cultures 
 
Although we assumed that hypoxic conditions can induce CSCs through EMT, 
the true aspect we are interested in is the chemoresistance induced by CSCs. If 
cells grown under hypoxia showed CSC characteristics, we aim to assess 
whether they mimic the chemoresistant nature of CSCs. To determine the effect 
of hypoxia on drug sensitivity, the cells were cultured in 1% oxygen condition at 
a cell density of 1x103 cells/well in 96-well plate for 4 days and exposed to 
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anticancer drugs for another 120 hours before MTT assay. TMZ and other 
conventional anticancer drugs VCR, PAC and DOX were used in the same 
concentrations as used for NS and SUS MTT assay. A parallel MTT assay was 
performed for cells under normoxic condition. 
 
4.3 Results 
4.3.1 GBM sphere cells contain high proportion of hypoxic cells 
Hypoxyprobe analysis reveals that a high proportion of hypoxic cells are present 
in both NS and SUS cells in comparison to the ATT monolayer culture. This was 
true for NS and SUS from all three GBM cell lines (Figure 4.1). The 
quantification by FACS analysis shows a statistically significant increase in the 
hypoxic population in sphere cells and there was no significant difference 
between NS and SUS cells (4.1 bar chart). A closer look at the FACS results 
also show that NS and SUS cells have two populations probably the outer 
normoxic cells and inner hypoxic cells. ICC and confocal imaging of cells 
treated with hypoxyprobe stained with anti HP-FITC antibody and propidium 
iodide counter stain clearly show bright green cytoplasmic staining (Figure 4.2) 
indicating hypoxia in majority of the cells. Furthermore western blot results 
showed a significant increase in the nuclear translocation of HIF1and 
HIF2in NS and SUS cells whereas no increase was observed in ATT cells 
(Figure 4.3). These results clearly indicate that hypoxia is an important 
characteristic of sphere cell culture due to aggregation of cells and also there 
are no differences between the cells grown as spheres using expensive special 
medium or with normal medium.  
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Fig 4.1 Hypoxic population in GBM sphere cells: Determination of hypoxic status in cells by 
Hypoxyprobe staining and FACS analysis. The bar chart displays the presence of statistically 
significant number of hypoxic cells in NS and SUS than ATT cells (n=6; **p<0.01)  
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Fig 4.2 In situ detection of hypoxic cells in GBM spheres using Hypoxyprobe staining. 
ICC staining of ATT, NS and SUS cells from all three GBM cell lines using Hypoxyprobe kit 
shows that the sphere cells have increased proportion of hypoxic cells (Green+FITC) in 
comparison to the ATT cells.  PI-(Red) was used as nuclear counter stain. (x40 magnification). 
 
 
 
 
 
 
 
Fig 4.3 Western blot analysis of HIFs in GBM sphere cells: Western blot analysis shows that 
the sphere cells have increased expression and nuclear translocation of both hypoxia inducible 
factors (HIF1 and HIF2) in comparison to the ATT cells.  Nucleolin was used as loading 
control.  
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4.3.2 GBM sphere cells express EMT markers 
 
FACS analysis for expression of CD44 cell surface marker show that NS and 
SUS cells from all three GBM cell lines had increased level of CD44 expression 
when compared to ATT cells (Figure 4.4). CD44 is an important cell surface 
marker in EMT activated cells and mesenchymal cells. We further used western 
blot analysis to determine the expression of other EMT markers like vimentin 
and cadherin switching. Our results (Figure 4.5) show that NS and SUS have 
increased expression of mesenchymal markers vimentin and N-cadherin in 
comparison to the ATT cells which clearly indicates the presence of 
mesenchymal population in the sphere cells. On the other hand there was a 
significant loss of the epithelial marker E-cadherin in both NS and SUS cells 
which further confirms the phenotype change to mesenchymal origin. The ATT 
cells retained E-cadherin and no increase in vimentin or N-cadherin was 
observed in them.  
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Fig 4.4 High expression of CD44 in GBM cell line-derived NS and SUS cells. The 
expression of CD44 in ATT and GBM spheres was detected using CD44-FITC conjugated 
antibody in FACS analysis. The bar chart above displays statistically significant increase in the 
CD44 expression in GBM spheres than ATT cells. n=9; **p<0.01 
 
 
 
 
 
 
 
 
 
Fig 4.5 Western blot analysis of EMT markers in GBM sphere cells. Western blot analysis 
using whole cell lysates of ATT and sphere cells clearly displays that the sphere cells have 
decreased expression of epithelial marker E-cadherin and increased expression of 
mesenchymal markers (N-cadherin and vimentin) in comparison to the ATT cells indicating EMT 
activation in these cells.  Tubulin was used as loading control. 
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4.3.3 The effect of hypoxia on GBM cell lines cultured in monolayer 
 
The attached monolayer cultures of all three GBM cell lines grown under 
hypoxic conditions was compared with attached monolayer grown under 
normoxia using the hypoxyprobe analysis. The results obtained through FACS 
analysis quantification showed significant increase in proportion of hypoxic cells 
in ATT-HYP cultures than ATT-NOR cells (Figure 4.7). The HP results from ICC 
shows clear increase of hypoxic population in ATT-HYP cells with bright green 
HP-FITC staining and PI counter staining (Figure 4.6). The normoxic cells have 
a clear cytoplasm with prominent nucleus that stained red with PI.  
 
Although HP can detect hypoxic conditions the true background of the study 
was to induce hypoxia mediated activation of cellular pathways. This is 
indicated by the expression of various hypoxia dependant factors in the 
nucleus. Further analysis for the confirmation of hypoxia through nuclear 
translocation of HIFs was done by western blot and the results indicate a clear 
increase in the translocation of HIFs in ATT-HYP cells compared to that of ATT-
NOR cells which is shown in Figure 4.8. These results confirms the successful 
generation of hypoxia in ATT-HYP cells by growing them in hypoxic chamber 
with 1%O2 and any results obtained from hypoxic cell cultures are comparable 
to that of hypoxic population in the NS and SUS cultures.  
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Fig 4.6 Hypoxic population was detected in hypoxia-cultured GBM cell lines. The  hypoxic 
cells were detected by Hypoxyprobe staining and FACS analysis. The bar chart displays the 
presence of statistically significant number of hypoxic cells in GBM cells cultured under hypoxia 
than normoxia (n=6; **p<0.01) 
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Fig 4.7 Hypoxic cells in hypoxia-cultured GBM cell lines detected by in situ ICC 
Hypoxyprobe staining. ICC staining using Hypoxyprobe kit shows that all three  GBM cell lines 
grown under Hypoxic conditions (less than 1 % O2) have increased proportion of hypoxic cells 
(Green+FITC) in comparison to the cells grown under Normoxic conditions cells. PI-(Red) was 
used as nuclear counter stain. 
 
 
 
 
 
 
 
 
 
Fig 4.8 Western blot analysis of HIFs in hypoxia-cultured GBM cell lines. Western blot 
analysis of nuclear extracts from ATT-NOR and ATT-HYP cells of all three GBM cell lines 
shows that the hypoxic cultures have increased expression and nuclear translocation of HIF1 
and HIF2 in comparison to the normoxic cells. Nucleolin was used as loading control. 
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4.3.4 Hypoxia induces EMT in GBM cell lines 
We hypothesized that hypoxia induces EMT to give rise to CSC characteristics 
in tumour cells. Cells grown as ATT-HYP are tested for the expression of 
mesenchymal cell surface marker CD44 and other EMT markers. FACS 
analysis shows a statistically significant increase in the expression of CD44 in 
ATT-HYP (Figure 4.9). In addition western blot results in Figure 4. 10 shows the 
increased expression of other mesenchymal proteins like N-cadherin and 
vimentin in ATT-HYP cells. Very similar to that of sphere cells the ATT-HYP 
cells lost the epithelial marker E-cadherin. Whereas in cells grown under 
normoxia there was no loss of E-cadherin and hence they remain epithelial in 
nature. These results indicate that if hypoxia can transform the cells into a more 
mesenchymal phenotype and can be reversed to epithelial nature if the cells 
were returned back to normoxia. This also indicates that accumulated hypoxia 
due to aggregation of cells is probably the reason behind the acquisition of EMT 
phenotypes leading to CSC characteristics in NS and SUS cells. 
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Fig 4.9 Expression of CD44 in hypoxia-cultured GBM cell lines. FACS analysis using CD44-
FITC conjugated antibody shows increased expression of CD44 cell surface marker in all three 
hypoxic GBM cell lines in comparison with their normoxic counterparts. n=6, **p<0.01 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.10 Western blot analysis of EMT markers in hypoxia-cultured GBM cell lines. The 
results clearly displays that in comparison with their NOR counterparts the HYP cells have 
decreased expression of E-cadherin and increased expression of N-cadherin and vimentin 
indicating EMT activation in the HYP cells. Tubulin was used as loading control. 
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4.3.5 Hypoxic cells show increased migration and invasion 
 
Further confirmation of hypoxia-induced EMT and transformation of cells into 
mesenchymal phenotype was done by analysing the migratory potential of cells 
under hypoxia. The images taken using the inverted microscope for Boyden 
chamber migration assay and the OD measured from the experiment enable us 
to calculate the %migration between ATT-NOR and ATT-HYP cells. Results 
from the above analysis (Figure 4.11 A and B) showed significant increase in 
the migratory potential of cells grown under hypoxic conditions. Mesenchymal 
phenotypes are also known to have increased invasion potential that can be 
measured by transwell matrigel invasion assay. Cells with mesenchymal 
characteristics have the potential to produce MMPs that can digest the ECM or 
substance like matrigel that enables them to invade the gel and move out of the 
matrix towards chemoattractants like serum or growth factors. The cells that 
invaded, crossed the matrix and moved out of the pores in transwell were fixed 
and stained while attached to the filter. Images taken from the above 
experiment shown in Figure 4.12A indicate a remarkable increase in the 
invasion potential of cells grown under hypoxia. We also lysed the stained cells 
according to the protocol and measured the OD at 540nm using a multiwell 
plate reader. The results given as % invasion (Figure 4.12B) confirm the 
increased invasion potential of hypoxic cell cultures which is statistically 
significant.   
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Fig 4.11 Hypoxia enhances the migratory potential of hypoxia-cultured GBM cell lines. 
Migration ability was determined using Boyden chamber migration assay. A) Images show 
migration of cells through the pores in transwell membrane (x40 magnification) indicating EMT.  
B) Migration index shows statistically significant increase in the migratory potential of HYP 
cultures in comparison to their respective NOR counterparts.  n=4; **p<0.01 
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Fig 4.12 Hypoxia enhances the invasive activity of hypoxia-cultured GBM cell lines. 
A)Images from matrigel invasion assay showing penetration of cells through matrigel coated 
membrane indicating EMT (x 40 magnification). B) Invasive index shows statistically significant 
increase in the invasive potential of cells grown under hypoxic conditions in comparison to that 
of Normoxic cells. n=6; **p<0.01 
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4.3.6 Hypoxic Cells show increased CSC characteristics.  
 
To show that hypoxia induced EMT and the mesenchymal phenotypes are the 
driving force behind CSC characteristics in GBM sphere cells, we tested the 
ATT-HYP cultures for the presence of CSC markers. For all the results below 
we have compared ATT-HYP cells with ATT-NOR cells grown in parallel. Our 
results from FACS analysis confirmed that all three GBM cell lines U87, U251 
and U373 grown as ATT-HYP show statistically significant increase in the 
universal stem cell marker ALDH and neural progenitor marker CD133 (Figure 
4.13 and 4.14). The expression of embryonic stem cell proteins like Sox2, Oct4 
and Nanog that regulate stemness, self-renewal and pluripotency are also 
significantly increased which is evident from FACS data of HYP cultures from all 
three GBM cell lines (Figure 4.15 A, B and C). The expression of these proteins 
is restricted to progenitor cells and they are switched off in fully differentiated 
cells. In addition, results from western blot analysis confirm the protein level 
increase in the expression of these embryonic markers (Figure 4.16). In addition 
to stem cell markers, results from growth curve experiments for cells grown 
under hypoxia (Figure 4.17) showed significant decrease in growth rate and 
doubling time indicating quiescence which is an important stem cell feature. 
These results confirm the fact that an increased hypoxic stress can induce EMT 
program to convert a subpopulation of cells into mesenchymal phenotypes that 
display all stem cell like characteristics which are interpreted as CSCs when 
they arise from tumour cells. This implicates that although NS and SUS are 
grown under normal O2 conditions developed hypoxia and resulted in CSC like 
cells which are more likely to be mesenchymal cells. 
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Fig 4.13 High ALDH activity detected in hypoxia-cultured GBM cell lines. ALDH activity 
was measured by ALDEFLUOR assay using FACS analysis.  The bar chart displays the 
statistically significant increase in the ALDH activity in HYP cells in comparison to their 
respective NOR counterparts. n=9; **p<0.01 
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 Fig 4.14 High level of CD133 expression detected in hypoxia-cultured GBM cell lines. 
Expression of CD133 was measured by CD133 immunostaining using FACS analysis.  The bar 
chart displays the statistically significant increase in the expression of CD133 in HYP cells in 
comparison to their respective NOR counterparts. n=9; **p<0.01 
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Fig 4.15 (A) Expression of Embryonic CSC markers in normoxic and hypoxic cultures of 
U87MG. Embryonic CSC markers measured by ICC using FACS analysis. The bar chart below 
displays all three embryonic CSC markers e.g. SOX2, OCT4 and NANOG are increased in HYP 
cultures in comparison to the NOR counterparts. n=6, **p<0.01 
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Fig 4.15 (B) Expression of Embryonic CSC markers in normoxic and hypoxic cultures of 
U251MG. Embryonic CSC markers measured by ICC using FACS analysis. The bar chart below 
displays all three embryonic CSC markers e.g. SOX2, OCT4 and NANOG are increased in HYP 
cultures in comparison to the NOR counterparts. n=6,**p<0.01 
 173 
 
O
C
T
4
S
O
X
2
N
A
N
O
G
U373 MG
ATT-Normoxia ATT-Hypoxia
1.81(0.98) 63.06(4.8)
2.17(0.76) 15.78(2.3)
1.7(0.66) 11.52(2.7)
Embryonic CSC Markers
S
id
e
 S
ca
tt
e
r
0
10
20
30
40
50
60
70
80
SOX2 OCT 4 NANOG
%
C
e
lls
U373 MG-Nor Vs Hyp 
Embryonic CSC markers
U373 MG NOR
U373 MG HYP
**
**
**
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.15 (C) Expression of Embryonic CSC markers in normoxic and hypoxic cultures of 
U373MG. Embryonic CSC markers measured by ICC using FACS analysis. The bar chart below 
displays all three embryonic CSC markers e.g. SOX2, OCT4 and NANOG are increased in HYP 
cultures in comparison to the NOR counterparts. n=6,**p<0.01 
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Fig 4.16 Western blot analysis of embryonic stem cell markers in hypoxia-cultured GBM 
cell lines.  Western blot analysis of embryonic stem cell proteins Sox2, Oct4 and Nanog in 
NOR and HYP cells from all three GBM cells. Tubulin was used as a loading control. 
 
 
 
 
 
 
 
 
 
Fig 4.17 Growth curve for Normoxic and Hypoxic cultures of GBM cell lines. Growth curve 
experiment using U251 and U373 GBM cell lines show very slow growth rate under hypoxic 
conditions in comparison to their respective NOR cultures.  
 
Days Days 
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4.3.7 Hypoxic cells are highly resistant to anticancer drugs  
 
GBM CSCs are very well known to be the reason behind chemoresistance of 
GBM. Although hypoxia induces EMT and increases CSC marker expression in 
GBM cells, we need to know whether those cells are chemoresistant like the 
CSCs isolated from NS and SUS. In this study we tested the first line drug TMZ 
and other three conventional anticancer drugs VCR, PAC and DOX on both 
ATT-NOR and ATT-HYP cells from all three GBM cell lines.  We hypothesized 
that if the cells that display GBM CSC characteristics are resistant to multiple 
drugs, we can confirm that hypoxia induced EMT is the true reason in driving 
GBM CSCs and therefore can be potential treatment targets. Our MTT 
cytotoxicity results show that ATT-HYP cells are extremely resistant to first line 
drug TMZ even at very high concentration used in this study (500M) while the 
ATT-NOR cells are comfortably killed by TMZ. Similar results were observed on 
treatment with other drugs like VCR, PAC and DOX where the ATT-NOR cells 
were killed at low concentrations and ATT-HYP survived up to high 
concentrations. Figure 4.18 A, B and C displays the cell viability curves results 
of U87, U251 and U373 cell lines respectively under ATT-NOR in comparison to 
ATT-HYP for different drugs in comparison to each other. There is not a clear 
difference between the curves of two conditions in all three cell lines which 
explains the low IC50 values for ATT-NOR cells and increased IC50 values of 
ATT-HYP cells as mentioned in Table 4.1 and bar charts below the viability 
curves. 
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Fig 4.18 (A) Hypoxia induces chemoresistance in U87MG cells. The ATT-Normoxia and 
ATT-Hypoxia cells were analysed by MTT assay after exposure to TMZ, VCR, PAC and DOX. 
The cell viability curves clearly show significant difference in the dose response between the 
Normoxia and Hypoxia cultures. The bar chart below shows the elevated IC50 values for HYP 
cells indicating increased drug resistance of the cells grown under hypoxic conditions. (n=9 
**p<0.001) 
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Fig 4.18 (B) Hypoxia induces chemoresistance in U251MG cells. The ATT-Normoxia and 
ATT-Hypoxia cells were analysed by MTT assay after exposure to TMZ, VCR, PAC and DOX. 
The cell viability curves clearly show significant difference in the dose response between the 
Normoxia and Hypoxia cultures. The bar chart below shows the elevated IC50 values for HYP 
cells indicating increased drug resistance of the cells grown under hypoxic conditions. (n=9 
**p<0.001) 
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Fig 4.18 (C) Hypoxia induces chemoresistance in U373MG cells. The ATT-Normoxia and 
ATT-Hypoxia cells were analysed by MTT assay after exposure to TMZ, VCR, PAC and DOX. 
The cell viability curves clearly show significant difference in the dose response between the 
Normoxia and Hypoxia cultures. The bar chart below shows the elevated IC50 values for HYP 
cells indicating increased drug resistance of the cells grown under hypoxic conditions. (n=9 
**p<0.001) 
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4.4 Discussion 
CSCs have been found in a variety of different cancers such as leukaemia 
(Bonnet & Dick, 1997), colon cancer (Zhang et al., 2004), breast cancer (Al-Hajj 
et al., 2003) and brain cancer (Singh et al., 2004). With the discovery of the 
neural stem cells (Reynolds & Weiss, 1992) it also became plausible that brain 
tumours could be derived from the transformation of neural stem cells or 
progenitor cells (Singh et al., 2004). When culturing putative tumour stem cells, 
spheroid models are often used especially in a selective serum free 
neurosphere medium and the cells grew as neurospheres. Under these serum-
free conditions most differentiating and differentiated cells died, whereas the 
GBM CSCs are protected. But studies from our group and several others 
showed that CSCs can be isolated from fully differentiated GBM cell lines. Our 
results from chapter 3 also indicated that GBM cell lines grown as spheres in 
normal serum containing culture medium can also produce CSCs with no 
significant differences from that of NS cells. Several studies associate tumour 
hypoxia with poor patient outcome and resistance to therapies (Bar, 2011; Li et 
al., 2009; Mashiko et al., 2011). In line with this, one of the hallmarks of GBMs 
is the presence of necrosis, occurring as a consequence of poor oxygenation 
and nutrition because of rapid tumour growth and formation of vessel 
thrombosis (Hulleman & Helin, 2005; Louis et al., 2007; Preusser et al., 2006). 
The role of hypoxia in normal stem cell biology is well established. 
Hematopoietic stem cells, for example, colonize hypoxic niches within the bone 
marrow, where they are maintained quiescent by hypoxia-induced proteins such 
as osteopontin (Stier et al., 2005; Nilsson et al., 2005). Severe hypoxia inhibits 
the differentiation of normal NSCs (Santlli et al., 2010). Also, hypoxic conditions 
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reduce differentiation in human embryonic stem cell cultures while not affecting 
their proliferation (Ezashi et al., 2005). Hypoxia is also known to improve the 
generation of induced pluripotent stem (IPS) cells (Yoshida et al., 2009). 
With above facts in mind we hypothesized that the only common factor between 
the NS and SUS is hypoxia due to cell aggregation and proliferation. Hypoxia 
can drive CSCs as shown in other cancers through a mechanism known as 
EMT. We analysed our NS and SUS cells from GBM cell lines for presence of 
hypoxia using HP. HP contains pimonidazole hydrochloride which is reductively 
activated in hypoxic cells. The activated intermediate forms stable covalent 
adducts with thiol (sulphydryl) groups in proteins, peptides and amino acids. 
The antibody reagent MAb1 binds to these adducts allowing their detection by 
immunochemical means. The results obtained showed a remarkable increase in 
hypoxic cell populations in both NS and SUS. Furthermore cellular responses to 
O2 concentrations are tightly regulated by PHDs that degrade HIFsubunits of 
HIF transcription factors under normal O2 concentrations. PHDs become 
inactive under hypoxia thereby releasing HIF subunits to join with HIF 
subunits and translocate into the nucleus to form functional HIF TFs that 
activates hypoxia responsive genes. Analysing our NS and SUS with their 
nuclear protein by western blot has shown increased nuclear translocation of 
HIF1 and HIF2 TFs. This is a very strong evidence for the presence of 
hypoxic status in sphere cells.   
 
EMT is a collection of trans-differentiation program that occur during 
embryogenesis and cancer cells exploit the same principle to drive invasive and 
aggressive tumour that results in poor patient outcome. Hypoxia is one of the 
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physiological mechanisms that can induce EMTs in tumours through multiple 
distinct mechanisms. Hypoxia-induced EMT has been reported in a wide range 
of solid tumours recently but evidences in GBM are still not solid. These facts 
pushed us to find out if hypoxia induced EMT can occur in GBM cells giving rise 
to CSC traits. With the confirmation of hypoxic status of GBM spheres we 
wanted to determine if there is any hypoxia driven EMT mediated phenotypic 
change occurring to those cells. Our results clearly established that cells under 
NS and SUS conditions display an increased vimentin and N-cadherin 
expression indicating switching to a mesenchymal phenotype while losing E-
cadherin which is a hallmark of epithelial phenotype. With these results we 
confirmed that hypoxia induced EMT is probably the reason behind CSC 
characteristics of cell line-derived GBM spheres. But this was not settled 
completely because if hypoxia is the key player, we wanted to know if inducing 
hypoxia to any cells grown as attached monolayer will have the same EMT and 
CSC effect that eventually drives resistance to anticancer drugs.  
To study this we grew cells under hypoxia as attached monolayer cultures and 
compared it with normoxia in parallel. We confirmed the successful induction of 
hypoxia in our hypoxic cultures by performing HP analysis and subsequent 
confirmation of HIFs nuclear translocation. With successfully grown hypoxic 
cultures we searched for evidence of EMT by analysing all the EMT markers. 
We found significant increase in EMT when cells are grown under hypoxia 
indicating a true change to a mesenchymal phenotype. We further confirmed 
the mesenchymal characteristics through increased invasion and migration 
properties of hypoxic cell cultures. Although we established that hypoxia can 
certainly drive EMT to induce mesenchymal phenotype, we wanted to know 
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whether these are the cells responsible for CSC characteristics in sphere cells. 
Our results for analysis of CSC markers clearly established that hypoxic cell 
cultures undergoing EMT show increased stemness. In addition to cell surface 
CSC markers, embryonic signalling pathways and quiescent behaviour of these 
cells were also evident from the expression of embryonic stem cell proteins and 
a much slower proliferation rate under hypoxia.   
However the main aim of our work was to understand the molecular 
mechanisms behind CSC induced chemoresistance to anticancer drugs. GBM 
normally recurs intracranially and tumour recurrence happens due to several 
reasons including chemoresistance. Hypoxia induced EMT driving the invasive 
and migratory phenotype may help the tumour cells to penetrate the nearby 
tissue and escape the hostile environment leading to tumour recurrence. So we 
wanted to know if hypoxia induced EMT mediated CSCs are the true culprits 
driving recurrence and resistance to drugs in order to develop effective methods 
to target them for therapy. The MTT analysis results showed significant 
increase in the resistance of hypoxic cells to all four drugs tested. Hence it can 
be confirmed that in NS and SUS cells the CSCs are induced by hypoxia which 
play an important role in chemoresistant nature of GBM CSCs. If this is the case 
in actual GBM in patients the same phenomenon can happen where GBM 
CSCs can develop in the hypoxic niche of the tumours. Several studies relate 
hypoxic nature of GBM as prognostic factor for response to therapy. In addition 
several correlation studies also highlighted that extensively hypoxygenated 
nature of GBM could be the reason behind increased invasive and aggressive 
nature of GBM tumours. This could be possibly due to the mesenchymal 
characteristics acquired by GBM during progression and evidences are 
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emerging to support the EMT nature of GBM. A good example is the inclusion 
of an additional mesenchymal subtype in the classification of GBM by WHO. 
Under in vitro conditions culturing of cells is usually performed at 21 % O2 as 
attached monolayer. But when cells are grown as spheroids of large sizes they 
become hypoxic even if cultured in normoxia because of a diffusion gradient 
(Fehlauer et al., 2005). Low oxygen levels in different tumour types are believed 
to increase the population of CSCs and to promote a stem-like state (Bar et al., 
2010; Heddleston et al., 2009; Saigusa et al., 2011; Soeda et al., 2009; Wang et 
al., 2011; Xing et al., 2011; Yeung et al., 2011). This is similar to results 
obtained for embryonic stem cells showing that low oxygen levels promote 
maintenance of pluripotent potential, and maintenance of the cells in an 
undifferentiated stem cell state (Ezashi et al., 2005; Heddleston et al., 2009). 
The existence of tumour stem cells has been suggested to be restricted to 
perivascular niches and hypoxic areas within the tumour (Heddleston et al., 
2009) explaining the poor outcome and therapeutic resistance seen in these 
hypoxic tumours. In addition to obtaining a more in vivo like metabolic milieu 
when culturing cells in hypoxic conditions, hypoxia also seems to promote the 
existence and propagation of tumour stem cells (Heddleston et al., 2009; 
McCord et al., 2009; Soeda et al., 2009). Several studies thus reported an 
increase in spheroid diameter, cell proliferation and number of spheroids 
(Heddleston et al., 2009; McCord et al., 2009; Soeda et al., 2009) when 
culturing spheroids in hypoxic compared to normoxic conditions. In a study from 
Kolenda et al., spheroids obtained from a glioblastoma short term culture and 
the commercial glioblastoma cell line U87MG were cultured in both normoxia 
and hypoxia (Kolenda et al., 2010). Interestingly, a significant increase in the 
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expression of the proposed stem cell markers CD133, Podoplanin and Bmi-1 
was found in both types of spheroids when cultured in hypoxia. Furthermore, a 
study by Heddelston et al. (Heddleston et al., 2009) proposed that a phenotypic 
shift from non-stem to stem-like cells was obtained when culturing tumour cells 
in hypoxia. On the more mechanistic level, the spheroid formation in hypoxia 
has been shown to be affected by the hypoxia inducible factors as shown in 
studies by Li et al. (Li et al., 2009) and Méndez et al. (Mendez et al., 2010). 
Knockdown of HIF altered spheroid formation in glioma spheroids, resulting in 
smaller and fewer spheroids.  
4.5 Conclusions 
To conclude, GBM CSCs in NS and SUS are induced by hypoxia resulting from 
their growth as suspended spheres. The culture medium or the source of initial 
GBM does not affect the formation of GBM CSCs in sphere cultures. 
Development of CSCs in NS and SUS is due to the dedifferentiation of epithelial 
to mesenchymal phenotypes by hypoxia-induced EMT process.  This is evident 
from hypoxic cultures acquiring mesenchymal phenotype and eventually CSC 
properties without growing them as spheres. Transition into CSC like 
phenotypes also leads to resistance which indicates that accumulated hypoxia 
could be the key reason behind chemoresistance in GBM. Overall these 
findings suggest that culturing of cells as spheroids provides important in vivo 
like hypoxia conditions that are optimal when studying the stem cell biology and 
chemoresistance of brain tumours. Further understanding of the mechanisms of 
hypoxia-induced EMT will guide us towards therapeutic targets. 
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Chapter 5 
 
 
 
 
The role of hypoxia inducible factors in 
hypoxia induced EMT and GBM CSCs 
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5.1 Introduction 
 
Hypoxia is one of the basic biological phenomena that has an intricate 
association with the development and progression of a variety of solid tumours. 
Hypoxia can activate the EMT program in tumours through several mechanisms 
mediated by HIFs, HGF, SNAI1, TWIST, Notch or NF-κB pathways, and 
induction of other epigenetic DNA modifications (Vooijs et al., 2008). Although 
several factors are reported to be important for hypoxia induced EMT, Hypoxia-
inducible factors (HIFs) are widely recognized to function as the primary and 
master transcription factors in regulating hypoxia responsive genes. HIFs are 
known to play critical roles in tumour invasion, cell proliferation, metastasis, 
angiogenesis, chemo-radio resistance, stem cell maintenance and survival 
(Bruick, 2001).  Hypoxia activates self-reinforcing positive-feedback loops 
involving HIFs and various other signalling pathways that stabilize the 
expression of EMT-inducing transcription factors in the nucleus in order to 
maintain the mesenchymal state (Radisky et al., 2005).  
 
Although both EMT and hypoxia on their own are considered as crucial 
processes that favours invasion and metastasis of cancer cells, the two events 
are long known to have some molecular mechanisms in common. Increasing 
amount of evidence reveals that, alterations of oxygen level in the tumour 
microenvironment and subsequent activation of hypoxic signalling through HIFs 
acts as important triggers and modulators of the EMT, which is now believed to 
be the convergence point between hypoxia and cancer.  
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5.1.1 The regulatory role of hypoxia and HIF pathway in EMT  
 
The acquisition of EMT during tumour progression is known to modulate cell 
adhesion capacity, which leads to increased cell migration and invasion, 
resulting in tumour aggressiveness (Hugo et al., 2007). In the process of EMT, 
several TFs such as ZEB1, ZEB2, Snail1, Snail2 (also known as Slug), Twist1 
and E47 are shown to be critical mediators of various EMT inducers in different 
cell lines including cancer cells (Jiang et al., 2011). The hypoxia-induced EMT is 
tightly mediated by HIFs which are TFs that activates of E-cadherin transcription 
repressors and hence reprograms epithelial cells to a more mesenchymal 
phenotype, leading to the promotion of invasive potential in tumours (Chang et 
al., 2011). This complex molecular crosstalk between hypoxia-induced 
pathways and EMT has not been fully understood. Several aspects of potential 
molecular mechanisms are still being studied, as reviewed recently by Jiang et 
al., in 2011. One proposed mechanism is that the activation of HIF-1 and 2 can 
up-regulate EMT associated TFs or repressors such as Twist, Snail, Slug, and 
SIP1/ZEB2 as observed in many carcinomas (Sun et al., 2009; Welford et al., 
2011; Katoh et al., 2009). Another possible mechanism is that hypoxia and HIF 
pathway activate further downstream signalling pathways related to EMT such 
as TGF-β, Notch, NF-κB, Wnt/β-catenin, and Hedgehog (Zavadil et al., 2004; 
Yang et al., 2006; Vincent et al., 2009). Other proposed mechanisms like the 
regulation of EMT-associated inflammatory cytokines by hypoxia and HIF 
pathway such as increased expression of TNF-α, IL-6 and IL-1β are shown to 
play positive roles in inducing EMT phenotype or characteristics (Sullivan et al., 
2009). Finally, hypoxia and HIF pathway is also shown to interact directly or 
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indirectly with proteins and enzymes that mediate communications between 
cells and ECM to facilitate motility and invasion and induce EMT. This also can 
be mediated through the regulation of LOX/LOX2, Hey1, Hes1, and uPA 
expression (Erler et al., 2006). Recent data also suggest that other signalling 
pathways such as VEGF and epigenetic regulators also play central roles in 
hypoxia-induced EMT of cancer cells. For example, hypoxia or HIF can induce 
HDCA3 which is reported to be an important requirement for EMT program 
(Yang et al., 2006; Wu et al., 2011). In addition to various citations of HIF1 
pathway in regulating EMT, one in vitro and in vivo study in non-small cell lung 
showed that HIF-2α can also promote the expression of EMT genes such as 
ZEB1, Snail, SIP1, and vimentin and enhance tumour growth in xenograft 
mouse models (Kim et al., 2009). There is increasing evidence for an important 
role of HIF-2α in pathological conditions. Therefore, targeting both HIF1 and 
HIF2 pathway along with inhibitors of EMT could provide a therapeutic benefit in 
the future. 
 
5.1.2 The regulatory role of hypoxia and HIFs in CSCs 
 
When hypoxia induced EMT results in CSC phenotypes in the tumour 
population, it is also the responsibility of hypoxia to maintain the CSC 
phenotypes. Several studies have provided robust evidence that hypoxia and 
HIF signalling pathway play crucial roles in the regulating the function of CSCs, 
contributing to tumour aggressiveness and chemoresistance (Hermann et al., 
2010; Creighton et al., 2010). It has been widely recognized that hypoxia is an 
important factor that regulates and maintains the normal stem cell population in 
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the normal tissues or during embryonic and adult development (Dunwoodie, 
2009). Emerging experimental evidence indicates that the same function of 
hypoxia is also applicable for GBM CSC phenotypes, where hypoxia enhances 
the self-renewal capacity and helps in the maintenance of undifferentiated state 
of CSCs. This is further confirmed by experiments involving CSCs under 
normoxic and hypoxic conditions where it is shown that hypoxic CSCs robustly 
retained the undifferentiated phenotype, whereas normoxic CSCs entered the 
differentiated state. Hence CSC phenotypes induced by hypoxia are reversible 
when they re-grow under normoxic conditions, a process consistent with the 
EMT-MET changes that occur after tumour seeding at a distant metastatic site 
(Li et al., 2010).  
 
This activation of signature CSC genes by hypoxia or HIF signalling may be one 
of the major reasons behind the CSC supporting function of hypoxia. Emerging 
evidence suggests that hypoxic areas within a tumour or the areas of necrosis 
behave as a niche where CSCs reside (Li et al., 2010). 
 
It is recognized that HIF proteins, specifically HIF-1α and HIF-2α participates in 
the transcriptional activation and regulation of HIF targets, such as Oct4 and 
other CSC markers thereby mediating signalling pathways leading to hypoxia 
induced CSC phenotypes (Heddleston et al., 2009). Experiments in 
neuroblastomas has shown that hypoxia is able to maintain the stem-like 
phenotypes by activating signalling pathways that are associated with 
undifferentiated phenotypes of normal stem cells, including Sox2, Oct4, Nanog 
and Notch-1 signalling (Bao et al., 2006). Recent studies have demonstrated 
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that HIF-1α have several target genes such as Oct4, Nanog, c-Myc, Notch-1, 
and CD133, in various cancer cells including GBM CSCs (Covello et al., 2006; 
Mathieu el al., 2011) whereas knock-down of HIF-1α attenuates the hypoxia-
induced CD133+ CSCs (Wang et al., 2011). These results collectively suggest 
the central role of HIF-1α as a primary hypoxia responsive factor that is required 
for the maintenance of the CSC phenotypes.  
 
Several other recent investigations are also focused on the role of HIF-2α in the 
regulation of CSCs. It has been shown that HIF-2α is highly expressed in CSCs 
of neuroblastoma, glioblastoma, renal cell carcinoma, and breast carcinoma 
(Pietras et al., 2008; Pietras et al., 2010). The expression of HIF-2α also 
increased expression of CD133 (Bar, 2010) and the tumorigenic capacity of 
GBM CSCs (Li et al., 2009). Conditional loss of HIF-2α resulted in vessel 
abnormalities, decreased proliferation and reduced self-renewal of CSCs 
resulting in suppression of tumour growth and metastasis (Skuli et al., 2009). 
Ectopic over-expression of HIF-2α induces CSC markers such as Oct4, Nanog, 
Sox2, and c-Myc, and augments the tumorigenic potential of the non-CSC 
population (Heddleston et al., 2009). It is interesting to note that HIF-2α are 
highly active in low pH environments and function in an oxygen-independent 
manner and regulate CSCs (Hjelmeland et al., 2010). These findings strongly 
suggest that HIF-2α may be the pathological HIF required for the phenotype 
and function of CSCs while HIF1 could be the primary responsive factor for 
hypoxia.  
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5.2 Rationale and aims of this study 
 
From the findings of chapter 3 and chapter 4 we established the fact that 
isolation of GBM CSCs does not require special culture medium because they 
are not selected CSCs, but instead are induced by hypoxia through EMT when 
grown as sphere cultures. We also confirmed that CSCs induced by hypoxia are 
the real culprits in chemoresistant nature of GBM CSCs. If this is the case 
according to literature HIFs should play a predominant role in inducing 
stemness in our NS and SUS cultures. But in recent years there has been a lot 
of debate over the primary HIF involved in CSCs. This is due to the following 
findings of differential expression and role of HIF-1α and HIF-2α between non-
stem cells and CSCs. HIF-2α has attracted the attention of researchers in 
recent years and has also been shown to be significantly present in the 
population of CSCs, and remarkably induced by hypoxia (Li et al., 2009). In 
comparison, HIF-1α is found in both stem and non-stem tumour cells and is only 
stabilized and activated under severe hypoxic conditions. It is hypothesised that 
HIF-1α is involved in the adaptation to acute/transient hypoxia and HIF-2α to 
chronic/prolonged hypoxia (Li et al., 2009).  Recent experimental data has 
shows that cancer cells highly expressed E3 ubiquitin ligase factor known as 
hypoxia associated factor (HAF) which decreases during acute hypoxia, but 
increased following prolonged hypoxia. HAF is shown to inhibit HIF-1α activity 
by directly binding to HIF-1α protein and marking it for degradation by 
ubiquitination in an O2 and pVHL-independent mechanism. Whereas binding of 
HAF to HIF-2α, increases HIF-2α transactivation without causing its 
degradation. Thus, HAF switches the hypoxic response of the cancer cells from 
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HIF-1α dependent to HIF2α -dependent transcription and activates CSC and 
EMT related genes. This switch to HIF-2α-dependent gene expression 
mediated by HAF also promotes highly aggressive and rapidly expanding 
tumour stem cell population, resulting in increased tumourigenic potential in vivo 
(Koh et al, 2008; Koh et al, 2011). However, the exact molecular mechanisms of 
interplay between HIF-1α and HIF-2α in regulation of CSC require further in-
depth investigation. 
 
Thus in this study we were interested to establish the role of HIF1α and HIF2α 
in hypoxia induced EMT and related stemness and to find out whether HIF1α or 
HIF2α functions as the driving force behind chemoresistant GBM CSCs. We 
also would like to ascertain whether HIF1α or HIF2α could be the ultimate target 
to reverse chemoresistance in GBM.  
 
5.3 Experimental Design  
Detailed information on materials, products, manufacturers and methodologies 
used for the entire study has been described in chapter 2. The following are 
specific experimental designs and methods used for this part of the study. 
Although we studied the CSC and hypoxic characteristics using all three GBM 
cell lines U87, U251 and U373, due to the limitations of time, funding and 
resources we used only the U373MG GBM cell line in this study.  
 
5.3.1 Stable transfection U373GBM cells with HIF1 and HIF2
HIFs are tightly regulated by O2 concentrations and are active only under 
hypoxia. We aimed to carry out ectopic overexpression of both HIF1 and 
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HIF2 in GBM cell lines in order to compete with the action of PHDs and 
thereby achieving high nuclear translocation of HIFs under normoxic conditions 
and eventually driving the HIF target genes. cDNA for HIF1 and HIF2 were 
obtained from Origene, (Cambridge, UK) and recombinant vectors were 
constructed by inserting the cDNA into pCMV6/Neo mammalian expression 
vector. U373 GBM cells were cultured (1x106 cells/well) in 6 well plates without 
antibiotics overnight. 4ug of empty vector pCMV6 and recombinant vector with 
HIF1 or HIF2 were introduced into the cells separately using LipofectamineTM 
2000 reagent. The transfected cells were incubated at 37oC for 24 hours 
selected for 7-10 days in a selective medium containing G418 250ug/mL. 
Colonies of cells were picked up, enlarged and screened for over-expression of 
target gene in comparison with mock transfected clones using western blot. For 
the overexpression of HIF1 and HIF2 confirmation was done by analysing 
the nuclear translocation of HIFs using western blot from nuclear extract of 
transfected cells. At least two positive clones with high nuclear translocation of 
HIFs were selected for each gene and subjected to further analysis. The mock 
transfected cells containing empty pCMV6 vector was grown in parallel for all 
experiments and used as controls for HIFs expression. All cells were grown 
under the selecting medium containing G418 throughout culturing time.  
 
5.3.2 Analysis of CSC markers in HIF transfected cells 
We already established the fact that NS, SUS and HYP cells have increased 
CSC characteristics in chapter 3. If these CSC characteristics are driven by 
either HIF1 or HIF2 then we expect that there should be an increase in the 
CSC characteristics of the cells with increased expression of HIFs. So we 
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examined all CSC markers tested in previous experiments like ALDH, CD133, 
Sox2, Oct4 and Nanog using immuno-fluoresecence protocol for FACS as 
mentioned in chapter 2. An increase in expression of CSC markers is quantified 
by measuring increase in fluorescence. Additional confirmation for the 
expression of Sox2, Oct4 and Nanog embryonic CSC markers was done by 
western blot analysis. The HIF1 or HIF2 expressing clones were compared 
for their expression of the above markers with mock cells. If either of HIFs 
increased CSC characteristics, then we can implicate that they are the key TF 
in driving the stemness in the NS, SUS and HYP cells. 
 
5.3.3 Determining mesenchymal properties of HIF-transfected clones 
 If HIF1 or HIF2 truly drives EMT signalling pathways and results in an EMT 
program, the positive clones should express high EMT markers. In other words 
the positive clones should be growing as mesenchymal phenotypes. In order to 
determine the mesenchymal properties and to determine which HIF induces 
EMT three important EMT markers like CD44, Vimentin and E-Cadherin to N-
cadherin switching were tested for both HIF1 and HIF2 positive clones with 
Mock cells as control. CD44 cells surface marker expression was analysed 
using FACS flow cytometry protocol. The rest of the markers vimentin, E-
cadherin and N-cadherin were analyzed by western blot to detect protein level 
expression. In addition cells that have undergone EMT and acquired a 
mesenchymal phenotype should display increased migratory and invasive 
characteristics. To confirm if the HIF positive clones are truly mesenchymal in 
nature we carried out in vitro wound healing assay (scratch assay) for migration 
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and transwell invasion assay (Boyden chamber assay) to determine invasion.  
For scratch assay cells were grown in a 6 well plate and incubated for 24h. The 
cells were serum starved for 24h and a scratch wound was made using a 200 µl 
pipette tip to create a cell-free linear uniform gap. The progress of cell migration 
into the scratch was photographed at regular intervals following the protocol 
mentioned in chapter 2. The HIF transfected cells were subjected in vitro cell 
invasion assay as described in chapter 2 using 8.0uM pore size transwell filter 
inserts coated with matrigel in 24 well plates. Briefly, the invasion rate of Mock 
and HIF transfected cells that invaded through matrigel basement matrix was 
assessed according to the manufacturer‟s recommended protocol. 
 
5.3.4   MTT cytotoxicity assay for hypoxic cell cultures 
The true aspect we are interested in for our study is the chemoresistance 
induced by CSCs. If cells transfected with HIFs activated EMT and resulted in 
CSC phenotypes they should also show the chemoresistant characteristics of 
CSCs. We aim to assess whether the cells with increased HIF expression could 
mimic the chemoresistant nature of CSCs. To determine the drug sensitivity, the 
cells were cultured in at a cell density of 2.5 x 103 cells/well in 96-well plate for 
overnight and exposed to anticancer drugs for another 120 hours before MTT 
assay. TMZ and other conventional anticancer drugs VCR, PAC and DOX were 
used in the same concentrations as used for sphere cell MTT assay and 
hypoxic conditions MTT assay. A parallel MTT assay was performed for mock 
transfected cells. 
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5.4  Results 
5.4.1 Stable transfection of U373 GBM cell line with HIF1 
U373 GBM cell lines were transfected with pCMV6/ HIF1 recombinant vector 
and empty pCMV6 vectors and clones were selected and enlarged in media 
containing 250ug/mL G418. The selected clones were screened for 
overexpression of HIF1 protein by western blot analysis in the cytoplasmic 
level using the mock transfected cells as control. Positive clones were selected 
enlarged and screened once again to select cells with high level of nuclear 
translocation of HIF1 functional transcription factor using the nuclear extracts 
of selected cells.  Western blot results in Figure 5.1 shows the cytoplasmic and 
nuclear level HIF1 protein expression. As seen in the figure, when compared 
to mock two clones namely C10 and C17 had the highest HIF1 expression 
levels and were selected for further experiments.  
 
 
 
 
 
 
 
Fig 5.1 Expression status of HIF1 protein in HIF1 transfected U373MG GBM cell lines. 
Western blot analysis shows increased expression and nuclear translocation of HIF1 under 
normoxia conditions in selected clones C-10 and C-17 in comparison to that of Mock 
transfected cells. Tubulin and Nucleolin was used as loading control. 
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5.4.2 HIF1 induces CSC characteristics in GBM cells 
 
In order to analyse if HIF1 can play role in inducing CSC traits we tested the 
presence of CSC characteristics in U373/pCMV6/HIF1 positive clones C10 
and C17. For all the results below we used U373/pCMV6/Mock as a control 
which was grown along in parallel along with the HIF1 clones C10 and C17. 
As seen from the FACS analysis data in figure 5.2 HIF1 expressing clones 
showed statistically significant increase in the expression level of universal CSC 
marker ALDH which was detected by ALDEFLUOR activity. In addition to ALDH 
the expression of another cell surface CSC marker CD133 which is specific to 
neural progenitor cells was analysed by FACS using PE-conjugated CD133 
antibody. The results as shown in figure 5.2 displays an increased expression of 
CD133 in HIF1 clones C-10 and C-17 in comparison to the mock transfected 
cells. In addition the expression of embryonic CSC markers namely Sox2, Oct4 
and Nanog also increased remarkably in the HIF1 expressing clones than the 
mock cells (Figure 5.3). These proteins which are restricted to progenitor cells 
are important for stem cell maintenance, renewal and pluripotency. Our results 
indicate that all CSC characteristics are increased just by a simple 
overexpression of HIF1 protein under normoxia, implying that HIF1 may play 
a pivotal role in driving these CSC related proteins and thereby induce CSC 
characteristics in cells when they are subjected to hypoxic conditions.  
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Fig 5.2 High ALDH activity and CD133 expression were detected in HIF1transfected 
U373MG cell lines. ALDH activity and expression of CD133 were measured by ALDEFLUOR 
assay and CD133 immunostaining using FACS analysis, respectively. The bar chart displays 
the percentage of ALDH and CD133 cell populations. n= 9, **p<0.01 
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Fig 5.3 Expression of Embryonic CSC markers in HIF1 transfected U373MG cell lines. 
CSC markers were measured using FACS analysis. The bar chart below displays the 
statistically significant increase in all three embryonic CSC markers like SOX2, OCT4 and 
NANOG in HIF1positive clones. n=6 **p<0.01 
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5.4.3 HIF1 transfected cells displayed mesenchymal properties 
 
To establish the role of HIF1 and EMT we analysed all the EMT markers and 
invasive and migratory properties of U373/pCMV6/HIF1 positive clones C10 
and C17 in comparison to the mock transfected cells. FACS analysis for the 
EMT cell surface marker CD44 showed an increased expression of CD44 in 
C10 and C17 clones with high HIF1 (Figure 5.4). In addition, expression of 
other mesenchymal proteins like N-cadherin and vimentin also increased in 
HIF1 clones which is evident from the western blot results shown in Figure 5.5. 
Very similar to that of sphere cells and ATT-HYP cells with increased HIF1 lost 
the epithelial marker E-cadherin. Whereas in control mock transfected cells 
there was no loss of E-cadherin and hence they remain epithelial in nature. 
These results indicate that high levels of HIF1 can transform the cells into a 
more mesenchymal phenotype which could be the reason behind EMT 
phenotypes leading to CSC characteristics. 
 
Further confirmation for the role of HIF1 signalling in inducing EMT 
phenotypes was done by analysing the mesenchymal based migration and 
invasion potential of these HIF1 positive clones (Figure 5.6A). The images 
taken using the inverted microscope for wound healing scratch assay were 
analysed using Image J software. This program measures the migratory 
distance and calculates the area and pixels for regions with no migrations as 
numerical value which enables us to calculate the %migration between HIF1 
clones and Mock cells. Results from the above analysis (Figure 5.6B) showed 
significant increase in the migratory potential of cells when there is high HIF1 
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expression. Invasion potential of these cells measured by matrigel invasion 
assay and the images taken from that experiment is shown in Figure 5.7A. 
There is a clear increase in the invasion potential of HIF1 clones C10 and C17 
in comparison to the mock cells. We also lysed the stained cells according to 
the protocol and measured the OD at 540nm using a multiwall plate reader. The 
results were given as % invasion (Figure 5.7B) confirms the increased invasion 
potential of cells with high HIF1 expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.4 Expression of CD44 in HIF1 transfected U373 cell lines: FACS analysis using 
CD44-FITC conjugated antibody show increased expression of CD44 cell surface marker in 
HIF1 positive clones C10 and C17 in comparison to Mock transfected cells.  n=9 **p<0.01 
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Fig 5.5 Expression of EMT markers in HIF1transfected U373 cell lines. EMT markers 
were detected from whole cell lysates of HIF1transfected clones and mock cells using western 
blotting assay. Tubulin was used as loading control. 
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Fig 5.6 HIF1 enhances the migration potential of U373MG cells in vitro. A) Migration 
ability of HIF1 transfected U373 GBM cell line determined by the images from (x100 
magnification) wound healing assay. The images show increased migration of HIF1 clones into 
the scratch when compared to the mock cells. B) Rate of migration (%) determined by analysis 
of wound healing assay images using image J software shows statistically significant increase 
in the migratory potential of HIF1 clones when compared to the mock cells.  n=6, **p=<0.01 
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Fig 5.7 HIF1 enhances the invasive activity of U373MG cells in vitro. The invasive activity 
of GBM cells was detected using matrigel Invasion assay. A) Morphology of the membrane 
penetrated GBM cells (40 magnification). B) Invasive index shows statistically significant 
increase in the invasive potential of HIF1 transfected cells in comparison to mock cells. n=6; 
**p<0.01 
 
5.4.4 HIF1expression did not induce multidrug resistance in GBM cells. 
From above results we know that HIF1 expression can definitely induce EMT 
and results in CSCS characteristics. So we speculated that high HIF1 
expression plays an important role in promoting chemoresistant GBM CSCs. To 
determine this we measured the drug sensitivity of HIF1 positive clones 
compared to that of Mock cells using MTT analysis. Although HIF1 cells 
displayed increased CSC properties they did not show any significant increase 
in resistance to any of the four drugs tested.  As seen from the results shown in 
Figure 5.8 there was no real difference between the drug sensitivity curves and 
the IC50 values of HIF1 clones and Mock cells are shown in the corresponding 
bar charts Figure 5.8B. The HIF1 transfected clones treated with the first line 
drug TMZ showed a slight increase in the IC 50 for C17 and also a very minor 
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resistance trend. But at higher doses the cell viability curve dropped even below 
the mock. The slight variation seen in IC50 values for TMZ was not statistically 
significant due to an increased standard deviation. However the IC50 of HIF1 
transfected cells to other drugs namely DOX, VCR and PAC was even lower 
than the mock cells. The curves also indicated that cells with HIF1 were more 
sensitive to these drugs contradictory to that of various literature resources as 
well as resistance shown by cells grown under hypoxic conditions. These 
results indicate that HIF1 may play a role in inducing CSC features through 
HIF1 mediated signalling pathways but do not play a role in chemoresistance 
in hypoxia induced EMT.  
5.8A) 
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Fig 5.8 In vitro cytotoxicity of TMZ, VCR, PAC and DOX in HIF2 transfected U373MG cell 
lines. (A). Cell viability curves after the cells were exposed to different drugs for 120 hours and 
subjected to MTT cytotoxicity assay. B) The bar charts display the IC50s of different drugs in the 
transfected cells. n=9 **p=<0.01 
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5.4.5 Stable transfection of U373 GBM cell line with HIF2 
 
U373 GBM cell lines were transfected with pCMV6/ HIF2 recombinant vector 
and empty pCMV6 vectors and clones were selected and enlarged in media 
containing 250ug/mL G418. The selected clones were screened for 
overexpression of HIF2 protein by western blot analysis in the cytoplasmic 
level using the mock transfected cells as control. Positive clones were selected 
enlarged and screened once again to select cells with high level of nuclear 
translocation of HIF2 functional transcription factor using the nuclear extracts 
of selected cells.  Western blot results in Figure 5.9 shows the cytoplasmic and 
nuclear level HIF2 protein expression. As seen in the figure, when compared 
to mock two clones namely C14 and C26 had the highest HIF2 expression 
levels and were selected for further experiments.  
 
5.4.6 HIF2 induces CSC characteristics in GBM cells 
 
We already established the fact that HIF1 can drive an EMT program and 
result in mesenchymal phenotypes with increased CSC characteristics. But 
HIF1 was not able to mimic the chemoresistant characteristic of the CSCs. 
Under hypoxic conditions HIF2 is also known to induce EMT. Hence we 
hypothesised that HIF2 could be another possible transcription factor that can 
result in CSC phenotypes with chemoresistance characteristics. In order to 
analyse if HIF2 can play role in inducing CSC traits we tested the presence of 
CSC characteristics in U373/pCMV6/HIF2 positive clones C14 and C26. For 
all the results below we used U373/pCMV6/Mock as a control which was grown 
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along in parallel along with the HIF2 clones C14 and C26. As seen from the 
FACS analysis data in Figure 5.10 HIF2 clones C14 and C26 showed 
statistically significant increase in the expression level of universal CSC marker 
ALDH and neural progenitor marker CD133 in comparison to the mock 
transfected cells. In addition the HIF2 transfection also induced the induced 
the expression of embryonic CSC markers namely Sox2, Oct4 and Nanog 
increased remarkably in the HIF2 expressing clones than the mock cells 
(Figure 5.11). These proteins which are restricted to progenitor cells are 
important for stem cell maintenance, renewal and pluripotency. Results from 
western blot analysis for in Figure 5.12 also confirm the protein level expression 
of these embryonic markers.  
 
 
 
 
 
 
 
 
 
Fig 5.9 Expression status of HIF2 protein in HIF2 transfected U373MG GBM cell lines. 
Western blot analysis shows increased expression and nuclear translocation of HIF2 under 
normoxia conditions in selected clones C-14 and C-26 in comparison to that of Mock 
transfected cells. Tubulin and Nucleolin was used as loading control. 
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Fig 5.10 High ALDH activity and CD133 expression were detected in HIF2transfected 
U373MG cell lines. ALDH activity and expression of CD133 were measured by ALDEFLUOR 
assay and CD133 immunostaining using FACS analysis, respectively. The bar chart displays 
the percentage of ALDH and CD133 cell populations. n= 9, **p<0.01 
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Fig 5.11 Expression of Embryonic CSC markers in HIF2 transfected U373MG cell lines. 
The CSC markers were measured using FACS analysis. The bar chart below displays the 
statistically significant increase in all three embryonic CSC markers like SOX2, OCT4 and 
NANOG in HIF2positive clones. n=6 **p=<0.01 
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Fig 5.12  Western blot analysis of embryonic stem cell markers in HIF2 transfected 
U373MG cells.  Western blot analysis shows increased expression of embryonic stem cell 
proteins Sox2, Oct4 and Nanog in HIF2 transfected clones C14 and C26 in comparison to 
Mock. Tubulin was used as a loading control. 
 
 
5.4.7 HIF2 transfected cells displayed mesenchymal properties 
 
To establish the role of HIF2 and EMT we analysed all the EMT markers and 
invasive and migratory properties of U373/pCMV6/HIF2 positive clones C14 
and C26 in comparison to the mock transfected cells. FACS analysis for the 
EMT cell surface marker CD44 showed an increased expression of CD44 in 
C14 and C26 clones with high HIF2 expression (Figure 5.13). In addition 
expression of other mesenchymal proteins like N-cadherin and Vimentin also 
increased in HIF2 clones which is evident from the western blot results shown 
in Figure 5.14. Very similar to that of sphere cells and ATT-HYP cells with 
increased HIF2 expression lost the epithelial marker E-cadherin. Whereas in 
control mock transfected cells there was no loss of E-cadherin and hence they 
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remain epithelial in nature. These results indicate that if HIF2 expression can 
transform the cells into a more mesenchymal phenotype which could be the 
reason behind EMT phenotypes leading to CSC characteristics. 
 
Further confirmation for the role of HIF2 signalling in inducing EMT 
phenotypes was done by analysing the mesenchymal based migration and 
invasion potential of these HIF2 positive clones. The images taken using the 
inverted microscope for wound healing scratch assay (Figure 5.15A) were 
analysed using Image J software. This program measures the migratory 
distance and calculates the area and pixels for regions with no migrations as 
numerical value which enables us to calculate the %migration between HIF2 
clones and Mock cells. Results from the above analysis (Figure 5.15B) showed 
significant increase in the migratory potential of cells when there is high HIF2 
expression. Invasion potential of these cells measured by matrigel invasion 
assay and the images taken from that experiment is shown in Figure 5.16A. 
There is a clear increase in the invasion potential of HIF2 clones C14 and C26 
in comparison to the mock cells. We also lysed the stained cells according to 
the protocol and measured the OD at 540nm using a multiwall plate reader. The 
results were given as invasion index (Figure 5.16B) which confirms the 
increased invasion potential of cells with high HIF2 expression. 
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Fig 5.13 Expression of CD44 in HIF2 transfected U373 GBM cell lines. FACS analysis 
using CD44-FITC conjugated antibody shows increased expression of CD44 cell surface 
marker in HIF2 transfected clones C14 and C26 in comparison with mock cells. n=6, **p<0.01  
 
 
 
 
 
 
 
 
 
 
Fig 5.14 Expression of EMT markers in HIF2 transfected U373 GBM cell lines. The EMT 
markers were detected from whole cell lysates of HIF2 transfected clones and mock cells 
using Western blotting assay. Tubulin was used as loading control. 
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Fig 5.15 HIF2 enhances the migration potential of U373MG cells in vitro. A) Migration 
ability of HIF2 transfected U373 GBM cell line determined from the images (x100 
magnification) of wound healing assay. The images show increased migration of HIF2  clones 
into the scratch when compared to the mock cells. B) Rate of migration (%)determined by 
analysis of wound healing assay images using image J software shows statistically significant 
clear increase in the migratory potential of HIF2 clones when compared to the mock cells.  
n=8, **p=<0.01 
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Fig 5.16 HIF2 enhances the invasive activity of U373MG cells in vitro. The invasive 
activity of the GBM cells was detected using matrigel Invasion assay. A) Morphology of the 
membrane penetrated GBM cells (40 magnification). B) Invasive index shows statistically 
significant increase in the invasive potential of HIF2transfected clones in comparison to that of 
mock cells. n=6; **p<0.01 
 
 
5.4.8 HIF2 expression did not induce multidrug resistance in GBM cells. 
 
From above results we know that HIF2 expression can definitely induce EMT 
and results in CSCS characteristics. So we speculated that high HIF2 
expression plays an important role in promoting chemoresistant GBM CSCs. To 
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determine this we measured the drug sensitivity of HIF2 positive clones 
compared to that of Mock cells using MTT analysis. The expression of HIF2 in 
these cells induced a significant resistance to the first line drug TMZ. Many 
studies in TMZ mediated resistance refers to the activation of resistance gene 
MGMT that confers resistance to alkylating agents, specifically to TMZ. MGMT 
is one of the major reasons for chemotherapy failure in GBM at present 
because TMZ is the only drug known to improve the survival rate in GBM by a 
few months. We were interested to study whether HIF2 can drive the 
activation of MGMT gene. But after several trials we did not detect any MGMT 
increase in these HIF2 positive clones. This could be an important finding 
because in some cases of GBM nowadays MGMT independent resistant nature 
has been reported in patients. Possibly HIF2 could be one of the reasons 
behind this phenomena according to our results. But HIF2 did not increase the 
resistance for other three drugs tested namely PAC, VCR and DOX. Although 
HIF2 cells displayed increased CSC properties they did not show any 
significant increase in resistance to any of the four drugs tested.  As seen from 
the results shown in Figure 5.17 there was no real difference between the drug 
sensitivity curves and the IC50 values of HIF2 clones and Mock cells shown in 
the corresponding bar charts. These results indicate that HIF2 may play a role 
in inducing CSC features through HIF2 mediated signalling pathways but do 
not play a role in chemoresistance in hypoxia induced EMT. 
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Fig 5.17 In vitro cytotoxicity of TMZ, VCR, PAC and DOX in NFB transfected U373MG cell 
lines. (A). Cell viability curves the cells were exposed to different drugs for 120 hours and 
subjected to MTT cytotoxicity assay. B) The bar charts display IC50s of different drugs in the 
transfected cells. n=9 **p=<0.01 
 
5.5 Discussion 
 
Hypoxia is one of the physiological mechanisms that can induce EMTs in 
tumours through multiple distinct mechanisms. In the previous chapter we had 
shown that both HIF1 and HIF2 nuclear translocation increased in both 
hypoxic and sphere cell cultures. With above facts in mind we hypothesized that 
either HIF1 or HIF2 could be the possible driving factor behind hypoxia EMT 
leading to chemoresistance. We studied the EMT and CSC inducing abilities of 
HIF1 and HIF2 individually through ectopic overexpression of these TFs by 
stable transfection of U373MG GBM cell line. Cellular responses to O2 
concentrations are tightly regulated by PHDs that degrades HIF subunits of 
HIF transcription factors under normal O2 concentrations. PHDs are extremely 
O2 sensitive and allow the binding of HIF subunits with HIF subunits only 
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under severe O2 deprivation. But stable transfected clones of GBM cells 
overexpressed significant amount of HIF1 and HIF2 under normoxic 
conditions so that they can outcompete the amount of PHDs and translocate 
into the nucleus to form functional HIF TFs that activates hypoxia responsive 
genes. We had picked about 48 clones for each successful transfection and 
screened them to select two clones with the highest expression and nuclear 
translocation of HIFs. Two positive clones and one mock transfected clone was 
analysed for both HIF1 and HIF2 separately.  Confirmation for the nuclear 
translocation of HIFs in the selected clones was determined with their nuclear 
protein by western blot.  Several studies have previously shown that HIFs 
modulates the process of EMT by regulating the expression of MET associated 
TFs such as TWIST, SNAIL, SLUG and ZEB. Constitutive expression of HIFs 
was shown to induce EMT in various cell lines by increasing their invasive and 
migratory potential. However, there is no solid evidence for EMT in GBM which 
encouraged us to find out if hypoxia induced EMT can occur in GBM cells giving 
rise to CSC traits via HIF regulated EMT. With confirmation of higher HIF1 
nuclear translocation in clones compared to mock, we wanted to determine if 
there is any EMT mediated phenotypic change occurring to those HIF1 clones. 
Our results clearly established that cells with elevated HIF1 display an 
increased CD44, vimentin and N-cadherin expression indicating switching to a 
mesenchymal phenotype while losing E-cadherin which is a hallmark of 
epithelial phenotype. Along with these results we also confirmed through the 
migration and invasion assays that these cells have increased migratory and 
invasion potential which is another trademark characteristic of mesenchymal 
phenotypes. We finally confirmed the CSC characteristics of these cells by 
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increased expression of CSC markers like ALDH, CD133, SOX2, Nanog and 
Oct4. Bar et al., (2010) reported that they could recapitulate the hypoxia-
dependent increase in CD133-positive population under normoxic conditions 
simply by over expressing an oxygen stable form of HIF-1 thus suggesting that 
HIF-1 is sufficient to mediate EMT. Yang et al (2008) reported that HIF1 
directly activates TWIST which in turn represses E-cadherin. They mentioned 
that reduced HIF1 could revert these cells to a pre-hypoxic status where all the 
mesenchymal markers are replaced with epithelial markers. Chen et al., (2010) 
showed that HIF1 could activate SNAIL, SIP1 and SLUG in order to repress E-
cadherin and activates MMPs that leads to cell migration and breakdown of 
ECM.  
 
Sahlgren et al., (2008) reported the effects of constitutively activated HIF1 
pathway in cervical, colon, GBM, ovarian and breast cancer cell lines. They 
reported the activation of Notch signalling by HIF1 which is a known activator 
of SNAIL, LOX and ZEB EMT TFs leading to increased motility and 
invasiveness of the tumour cells. In addition to Notch, HIF1 target genes 
include other CSC factors like oct4, c-Myc, Nanog and CD133. Several 
consistent studies with various cell lines and CSCs has shown the CSC 
enhancing effects of HIF1 and on the other hand several evidences are also 
presented for attenuation of CSC phenotypes with conditional knock down of 
HIF1 (Chen et al., 2007; Soeda et al., 2009; Li et al., 2010., Mathieu et al., 
2011; Covello et al., 2006; Gordan et al., 2008).  All these studies along with our 
obtained results suggest that HIF1 is required for the activation of EMT and 
subsequent maintenance of the CSC phenotypes.  But this was not settled 
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completely, because the main aim of our work was to understand the molecular 
mechanisms behind CSC induced chemoresistance to anticancer drugs. Many 
studies in recent years, demonstrated the contribution of HIF-1 to drug 
resistance in a range of neoplastic cells (Sullivan et al., 2008; Brown et al., 
2006; Hao et al., 2008; Liu et al., 2008; Sasabe et al., 2007;). One of the 
earliest observations of HIF1 and drug resistance was done by Wenger and 
colleagues where the efficacy of carboplatin and etoposide was enhanced by 
inactivation of HIF-1 in mouse embryonic fibroblasts (Unruh et al., 2003). Most 
of these studies focused mainly on the reversal of hypoxia-induced drug 
resistance by targeting HIF-1 through RNA interference or inhibitors. However 
some studies in neuroblastoma and lung adenocarcinoma cells could not 
reproduce the fact that inactivation of HIF-1 had positive effect on drug 
response (Chang et al., 2006; Hussein et al., 2006). Meanwhile some studies in 
fibrosarcoma, gastric cancer or breast carcinoma cells reported that inhibiting 
HIF-1 even under normoxic conditions had positively enhanced the sensitivity 
of chemotherapeutic agents showing the resistance-mediating effect of HIF-1 
under normoxia (Brown et al., 2006; Li et al., 2006; Liu et al., 2008; Rohwer et 
al., 2010). 
 
Our results indicated that none of the HIF1 positive clones showed resistance 
to anticancer drugs which was completely contradictory to our results obtained 
from HYP and sphere cells. Despite the fact that HIF1 induced significant 
changes to activate CSC phenotypes it failed to trigger any drug resistance 
which is a clinically significant hallmark characteristic of CSCs. From the above 
facts reported by several groups the overall conclusion of these observations is 
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that HIF-1 has the ability to promote drug resistance in cancer cells through 
various reported mechanisms like drug efflux, defective apoptosis, DNA 
damage inhibition and reduced ROS activation. However, there are some 
reports that indicated that HIFs are not necessary for inducing drug resistance. 
We even observed that some of the HIF1 clones were even more sensitive to 
the drugs that were tested. This could be probably due to the variations in the 
tumour cell types and limitations of cell line models for transfection experiments. 
There are even some contradictory reports indicating that the expression of 
HIF1 could enhance the susceptibility of tumour cells to chemotherapy. A 
recent study by Evens et al. (2010) showed that increased HIF-1 expression in 
patients with diffuse large B-cell lymphoma treated with rituximab and 
anthracyclines had improved progression-free survival and overall survival rates 
(Evens et al., 2010). This indicates that HIF1 may not be the only factor 
responsible for chemoresistance mediated by CSCs and hence targeting 
HIF1necessarily reverse chemoresistance in GBM CSCs.  
 
The above findings pushed us to understand the status of other HIF increased 
under hypoxia which is HIF2. Although both HIF1 and HIF2TFs activate the 
HRE-dependant gene expression, there is considerable difference in their trans-
activation domains that indicates the requirement of distinct transcriptional co-
activators and unique targets for each of them. But unlike the well studied 
HIF1, the role of HIF2 in hypoxia mediated signalling pathways is not well 
established. We wanted to know if our HIF2 transfected clones will have the 
same EMT and CSC effect that eventually drives resistance to anticancer 
drugs. In our results we found that HIF2 overexpression led to a decrease in 
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the expression of epithelial marker E-cadherin and an increase in the 
expression of EMT markers like CD44, Vimentin and N-cadherin indicating the 
switching of HIF2 positive clones to a mesenchymal phenotype. Many studies 
reported that HIF2 in addition to HIF1 or independently can also activate the 
target genes involved in EMT like TWIST, ZEB, SNAIL and SIP1 (Kim et al., 
2009). In addition we also observed that the HIF2 positive clones had 
increased CSC characteristics evident by the presence of markers like CD133, 
ALDH, Sox2, Oct4 and Nanog. Heddleston et al used a similar approach with 
oxygen stable form of HIF-2 and found an increased percentage of CD133-
positive cells with HIF2 whereas CD133-negative cells did not express HIF2. 
This HIF-2 expression also resulted in increased expression of CSC factors 
like cMyc, Nanog and Oct4 (Heddleston et al., 2010). Multiple recent studies in 
CSC isolated from GBM, neuroblastoma, renal cancer and non-small lung 
cancer show that HIF2 is required for the maintenance of the CSC phenotype 
and its functions (Kim et al., 2009; Li et al., 2009; McCord et al 2009; Pietras et 
al., 2008). Li et al., (2009) examined the expression of HIF2 mRNA in cells 
extracted from primary GBM patients and xenografts of GBM cell lines and 
showed that HIF-2 mRNA is expressed highly in CD133-positive cells than in 
CD133-negative cells, whereas HIF-1 mRNA was uniformly present in both 
CD133-positive and CD133-negative cells. They also showed that HIF-2 
mRNA levels increased significantly in response to hypoxia in CD133-positive 
cells, and its levels were stable even after return to normoxia. Similar findings 
were made by McCord et al., where HIF-2 protein was present even under 
physiological O2 levels (7%). whereas HIF-1 was barely detected. This 
indicates that CD133-positive GBM cells can maintain their CSC signature even 
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at physiologic oxygen levels due to enhanced activation of HIF-2. Seidel et al., 
(2010) showed that the presence of HIF-2 but not HIF-1 can significantly 
induce the expression CSC panel of genes generating a side population.  
 
In contrast to numerous reports on the well-established role of HIF-1 in 
anticancer therapy, the significance of HIF-2 in chemoresistance is remarkably 
understudied and poorly understood. One of the earlier studies in head-and-
neck cancer samples by Harris et al., in 2002 threw light on the role of HIF2 in 
response to anti-proliferative therapy. The expression of HIF-2 highly 
correlated with an incomplete response to chemoradiotherapy of these cancers 
(Koukourakis et al., 2002). But various recent studies analyzed the role of 
HIF2 on a functional level. Bertout et al., used human clear cell renal cell 
carcinoma (ccRCC) cells that expressed HIF-2 under normoxia but lacks VHL- 
and HIF-1 to show that functional inhibition of HIF- 2 significantly enhanced 
the sensitivity of these cells (Bertout et al., 2009). It was also shown that 
inhibition of HIF-2 promoted p53-mediated apoptosis by ROS accumulation in 
these cells (Rohwer et al., 2010). In our experiments with HIF2 transfected 
GBM clones, we observed HIF2 can significantly increase the resistance to the 
first line drug TMZ. However we did not observe multidrug resistance in these 
HIF2 clones like the CSCs. These cells were in fact sensitive to the drugs like 
DOX, VCR and PAC. These results were similar to that of HIF1clones, 
indicating that HIF2 might be an important factor in activating EMT and CSC 
characteristics, but does not play a significant role in hypoxia induced 
chemoresistance. The possible explanation for our observations could be the 
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fact that there may be another important resistance factor equally important as 
that of HIFs which is activated under hypoxia. ALDH which is a universal CSC 
marker could be one of the possible factors in chemoresistance that can be 
thought of, due to several reports made in literature regarding the role of ALDH 
in chemoresistance. In our experiments both HIF1 and HIF2 transfected cells 
carried significantly enhanced ALDH activity, but still no resistance was 
observed. So there must be other TFs like NF-B, TGF-beta, TNF-, etc, that 
could possibly link up to the resistance induced under hypoxia. Further studies 
are required to confirm these facts. 
 
5.6 Conclusions 
Therefore, the overall conclusion from this study could be that when there is 
reduced oxygen environment for a given cell type, both HIF-1 and HIF-2 will 
be activated which directly or indirectly activates the expression of hundred of 
genes. Some of these targets overlap between these two factors due to the 
similar DNA binding sequence due to structural homology. Therefore the 
biological consequences of hypoxia in cells largely depend on which HIF is 
active at any given time and what targets are being regulated by them. While 
HIF-2 protein is more stable and widely expressed range of O2 levels, HIF-1 
is tightly regulated by O2 levels and is expressed in cells experiencing moderate 
hypoxia. Despite these differences and not playing important role in 
chemoresistance in GBM cells tested, we cannot deny the fact that both HIF-1 
and HIF-2 are crucial for EMT, CSCs, tumour motility and invasion suggesting 
that pharmacological inhibition of these factors in addition to suppression of 
chemoresistance factors holds great promise in targeting GBM CSCs. 
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Chapter 6 
 
 
 
 
The role of NF-B in hypoxia induced 
EMT and GBM CSCs 
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6.1 Introduction 
 
Our findings from chapter 5 about the role of primary hypoxia response genes 
HIF1α and HIF2α in hypoxia induced EMT and CSCs has revealed that HIF1 
and HIF2α play a central role in altering the epithelial phenotype of cells to more 
mesenchymal phenotype. We also showed that HIF1α and HIF2α mediated 
phenotype alteration leads to CSC characteristics in cells indicating the possible 
role of these signalling pathways in hypoxia induced CSCs of GBM. Although 
they expressed CSC markers and had invasive characters, these cells failed to 
induce significant amount of chemoresistance or multidrug resistance, which is 
an important feature of CSCs. Although several literature findings supported the 
role of HIF1α and HIF2α in inducing chemoresistance and projected them as 
important targets to improve GBM therapy, we did not find convincing evidence 
from our in vitro model. Additionally, these findings do not match with the 
findings from NS, SUS and HYP cells that displayed both resistance and CSC 
traits, indicating that there are some other factors involved in regulating the 
responsiveness to drugs. Since chemoresistance of GBM CSCs is the aspect 
we are interested in for our study we had to search for another possiblefactor 
that should be regulated by hypoxia but must be independent of HIF1α or HIF2α 
signalling. This could possibly be another transcription factor that is expressed 
in parallel to HIFs at a higher level than HIFs. There are more than 20 different 
transcription factors involved directly or indirectly in hypoxic sensitivity and one 
suitable TF candidate could be NF-B which is a common TF reported to be 
upregulated in several types of cancers.  
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The activation of NF-B by hypoxia has been known for more than a decade in 
a wide variety of cells (Koong et al., 1994). Several studies have suggested that 
hypoxia could activate NF-B signalling pathway in a wide range of cancer 
cells. The NF-B is well-known for its function as a critical transcription factor in 
a wide range of cancers that regulates the expression of several genes involved 
in cancer cell survival, proliferation, invasion, migration, angiogenesis and 
tumour metastasis, leading to resistance to chemo-radiotherapy, tumour relapse 
and poor prognosis (Baldwin, 2001). Additionally, emerging data hint that NF-B 
may also play an important role in EMT and CSCs, contributing to 
aggressiveness of tumours. Hence it is reasonable to speculate that hypoxia 
induced NF-B activation may contribute to the maintenance of CSCs and EMT 
during the development and progression of tumours especially because NF-B 
signalling pathways are well-studied chemoresistant factors and are known to 
enhance the induction of EMT phenotype and maintenance of stem cell 
phenotype. NF-B is a structurally conserved family of heterodimeric 
transcription regulators which play important roles in large number of normal 
cellular processes namely immune response, inflammation, cellular growth and 
apoptosis. They are typically activated following stimulation of cells with pro-
inflammatory cytokines such as TNF-α and IL-1β, antigens, bacterial 
liposaccharides, growth factors, UV light, and ROS (Ghosh et al., 2002; Chen 
and Greene, 2004). Since NF-B is a primary regulator of inflammatory and 
anti-apoptotic gene expression it is speculated that NF-B activation is very 
essential for a hypoxic cell to inhibit apoptosis that enable them to survive 
through the period of hypoxic insult (Koong et al., 1994). Moreover, hypoxic 
activation of NF-B signalling pathway is mediated by the regulation of gene 
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expression of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β, 
adhesion molecules, enzymes, and pro-inflammatory enzymes which finally 
result in a hypoxic inflammatory response (Taylor et al., 2008).  
 
6.1.1.1 NF-B and EMT 
Multiple evidencefrom literature point out that NF-B is a master transcriptional 
regulator of several other developmentally important EMT inducing transcription 
factors. These factors like Snail, Slug, ZEB and Twist are part of the growing list 
of genes that are recognised to be direct transcriptional targets of NF-B which 
upon activation lead to suppression of various epithelial genes like cadherins, 
claudins, occludins and muc1 (Nieto, 2002; Culleres et al., 2006; Kajita et al., 
2004;Chua et al., 2007; Yang et al., 2004;Wang et al., 1997; Kanegae et al., 
1998; Takeda et al., 1999; Sosic et al., 2003). Additionally NF-B is also known 
to directly regulate end stage mesenchymal genes such as Vimentin and MMPs 
(Lilienbaum et al., 1990; Chua et al., 2007; Himelstein et al., 1997; Connelly et 
al., 2007).  
 
6.1.1.2  NF-B and HIF signalling 
It has been shown previously by many researchers that HIF-1α is required for 
the activation of NF-B, which suggest HIF-mediated regulation of canonical 
NF-B signalling by directly binding to the promoter region of NF-B (Cockman 
et al., 2006). Some of the earlier findings also support that hypoxia regulates 
the NF-B pathway through activation of IKK, specifically via IKK-β (Melvin et 
al., 2011; Cockman et al., 2006; Devries et al., 2010).The activation of NF-B 
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mediated by HIF-1α has been shown to coincide with cancer cell survival, 
invasion, and tumour progression and therefore shown to be very important in 
the modulation of hypoxic tumour microenvironment (Scortegagna et al., 2008; 
Nam et al., 2011; Yeramian et al., 2011). Besides HIF-mediated activation of 
NF-B, evidences from large number of experimental studies indicate that NF- 
B could directly regulate HIF pathway in tumourigenesis. NF-B could control 
the expression of HIFs and its downstream signalling pathways within the 
tumour microenvironment because the promoter region of HIF1α gene contains 
active NF-B binding site at position−178/−188 (Belaiba et al., 2007; Bonello et 
al., 2007; Van et al., 2008). It is speculated that NF-B drives HIF-1 signalling 
pathway to maintain the basal levels of HIF-1α under normoxia condition, and 
further increase the levels of HIF-1α under hypoxia (Cockman et al., 2006). 
Unlike the well studied interaction between HIF-1α and NF-B, the link between 
NF-B in HIF-2 still remains largely unexplored. In one study by Bracken et al., 
(2005) it was found that NF-B interact with IKK- which leads to the 
transcritptional activation of HIF-2. It was also shown that NF-B could 
modulate HIF-2 protein levels indirectly by inducing HIF-1 mRNA levels.  
Saito et al., (2010) studied skeletal growth and osteoarthritis, where they found 
HIF-2 as a central transactivator in the ossification of chondrocytes and 
skeletal muscle development. They performed a screening for various TFs that 
could regulate the upstream of HIF-2 and found that NF-B is the most potent 
activator of HIF-2 in the majority of the cells. They also identified an NF-B 
motif in the promoter region of EPAS1 (HIF-2 gene) which is particularly found 
to be regulated by RelA. He et al., (2014) reported the link between NF-B and 
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HIF-2 signalling in kidney cells where they found that NF-B induced HIF2 is 
responsible for the protective effects of renal cells against oxidative injuries. 
Although considerable evidences exist from various sources for the presence of 
cross talk between NF-B and HIF signalling the molecular mechanism behind 
this process has only been partly understood. Both NF-B and HIF signalling 
pathways demonstrate different degree of sensitivity under hypoxia and it is 
evident from various studies they are interdependent on each other.  
 
6.2 Rationale and aims of the study 
 
With the findings from chapter 5 that HIF1α and HIF2α did not play a significant 
role in GBM resistance to anticancer drugs, we looked out for a suitable factor 
that was elevated under hypoxic conditions and also plays a role in EMT, CSCs 
and chemoresistance. Extensive evidence suggests that aberrant NF-B 
activation could play a key role in various stages of tumour development by 
driving CSCs through EMT. Although a wealth of data is available to 
demonstrate the association between NF-B and GBM, very few studies have 
focussed on the role of NF-B mediated EMT in GBM. Especially in the case of 
GBM, studies always focus either on the relation between hypoxia and CSCs or 
hypoxia and NF-B the link between hypoxia-NF-B-EMT and CSCs is not 
studied well so far. In this study we aim to evaluate the role NF-B in hypoxia 
induced EMT signalling and generation of CSC phenotypes in cells grown as 
NS, SUS or HYP. We would also like to establish its role in resistance to 
anticancer drugs to find out whether NF-B functions as the driving force behind 
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chemoresistant GBM CSCs. There are possibilities that HIFs and NF-B can be 
either connected to each other or unrelated in their modes of actions. We aim to 
determine whether HIFs are the driving force behind enhanced NF-B activity or 
whether NF-B is expressed as a separate hypoxia responsive transcription 
factor. We would like to understand the mechanism of action of the interplay 
between the regulation of NF-B and HIF. By achieving the above mentioned 
aims we would like to ascertain whether NF-B could be the ultimate target to 
reverse chemoresistance in GBM.  
 
6.3 Experimental Design 
 
Detailed information on materials, products, manufacturers and methodologies 
used for the entire study has been described in chapter 2. The following are 
specific experimental designs and methods used for this part of the study. 
Although we studied the CSC and hypoxic characteristics using all three GBM 
cell lines U87, U251 and U373, due to the limitations of time, funding and 
resources we used only the U373MG GBM cell line for all the functional work 
related NF-B p65 ectopic overexpression.  
6.3.1 Determining NF-B activity in GBM spheres and hypoxic cells 
The high NF-B activity in NS, SUS and HYP cells from all GBM cell lines can 
be determined by analysing the nuclear translocation of NF-B-p65 subunit 
which is an indicator of the NF-B transcriptional activity. This can be done by 
western blot using nuclear protein extracts from all cells under study. ATT-GBM 
under NOR was used as a control for all samples of NS, SUS and HYP cells. 
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 6.3.2 Stable transfection U373GBM cells with NF-B-p65 
NF-B transcriptional activity is tightly controlled by various factors. In this study 
we aim to carry out ectopic overexpression of NF-B-p65 in GBM cell lines in 
order to compete with the action of NF-B repressor -α and thereby 
achieving high nuclear translocation of and eventually driving the target genes 
of NF-B signalling pathway. cDNA for NF-B-p65 was obtained from 
OriGeneTM, UK and recombinant vectors were constructed by inserting the 
cDNA into pcDNA3.1(+)/hygromycin mammalian expression vector. U373 GBM 
cells were cultured (1x106 cells/well) in 6 well plates without antibiotics 
overnight. 4ug of empty vector pcDNA3.1 and recombinant vector with NF-B-
p65 gene were introduced into the cells separately using LipofectamineTM 2000 
reagent. The transfected cells were incubated at 370C for 24 hours selected for 
7-10 days in a selective medium containing hygromycin 50ug/mL. Colonies of 
cells were picked up, enlarged and screened for over-expression of target gene 
in comparison with mock transfected clones using western blot. For the 
overexpression of NF-B-p65 confirmation was done by analysing the nuclear 
translocation of p65 using western blot from nuclear extract of transfected cells. 
At least two positive clones with high nuclear translocation of p65 were selected 
for each gene and subjected to further analysis. The mock transfected cells 
containing empty pcDNA3.1 vector was grown in parallel for all experiments and 
used as controls for HIFs expression. All cells were grown under the selecting 
medium containing hygromycin throughout culturing time.  
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6.3.3   Luciferase reporter gene assay for NF-B activity 
Any increase in NF-B transcriptional activity in GBM cells used in this study 
can be determined by luciferase reporter gene assay. Transfections of cells (1 × 
104/well) were cultured in 96-well were performed using Lipofectamine 2000 
reagent. The NF-B and pGL3-Basic luciferase reporter vectors were co-
transfected with pSV40-Renilla DNA,an internal control for normalization of the 
transcriptional activity of the reporter vectors. 24 hours after transfection, the 
cells were lysed and luciferase activity was determined using Dual Luciferase 
Assay kit protocol as mentioned in chapter 2.However this method cannot be 
used for NS and SUS sphere cells due to their suspended culture conditions.  
 
6.3.4 Analysis of CSC markers in NF-B-p65 transfected cells 
We already established the fact that NS, SUS and HYP cells have increased 
CSC characteristics (Chapter 3 and 4) possibly driven by HIFs (Chapter 5). In 
this study to establish whether these CSC characteristics are driven by NF-B 
signalling we analysed the p65 clones for their expression of CSC markers like 
ALDH, CD133, Sox2, Oct4 and Nanog using immuno-fluoresecence protocol for 
FACS as mentioned in chapter 2. Additional confirmation for the expression of 
Sox2, Oct4 and Nanog embryonic CSC markers was done by western blot 
analysis. If p65 transfected cells showed increased CSC characteristics than 
the control mock cells, then we can implicate that NF-B could be a key TF in 
driving the stemness in the NS, SUS and HYP cells in addition to HIFs. 
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6.3.5 Determining mesenchymal properties of NF-B-p65 clones 
If NF-B truly drives EMT signalling pathways and results in an EMT program, 
the positive clones should express high EMT markers. In other words the 
positive clones should be growing as mesenchymal phenotypes. In order to 
determine the mesenchymal properties, three important EMT markers like 
CD44, Vimentin and E-Cadherin to N-cadherin switching were tested for both 
p65 positive clones with Mock cells as control. CD44 cells surface marker 
expression was analysed using FACS flow cytometry protocol. The rest of the 
markers vimentin, E-cadherin and N-cadherin were analyzed by western blot to 
detect protein level expression. In addition cells that have undergone EMT and 
acquired a mesenchymal phenotype should display increased migratory and 
invasive characteristics. To confirm this we carried out in vitro wound healing 
assay (scratch assay) for migration and transwell matrigel invasion assay 
(Boyden chamber assay) to determine invasionfollowing the protocol mentioned 
in chapter 2. Briefly, the invasion rate of Mock and NF-B transfected cells that 
invaded through matrigel basement matrix was assessed according to the 
manufacturer‟s recommended protocol. 
 
6.3.6   MTT cytotoxicity assay for NF-B-p65 transfected cells 
The true aspect we are interested in for our study is the chemoresistance 
induced by CSCs. If cells transfected with NF-B activated EMT and resulted in 
CSC phenotypes they should also show the chemoresistant characteristics of 
CSCs. We aim to assess whether the cells with increased NF-B activity could 
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mimic the chemoresistant nature of CSCs. To determine the drug sensitivity, the 
cells were cultured in at a cell density of 2.5 x 103 cells/well in 96-well plate for 
overnight and exposed to anticancer drugs for another 120 hours before MTT 
assay. TMZ and other conventional anticancer drugs VCR, PAC and DOX were 
used in the same concentrations as used for sphere cell MTT assay and 
hypoxic conditions MTT assay. A parallel MTT assay was performed for mock 
transfected cells. 
 
6.4 Results 
 
6.4.1 High levels of NF-B was observed in both NS and SUS cells 
 
When compared to the ATT monolayer culture, both the NS cells and SUS cells 
isolated from all three GBM cell lines used in this study showed remarkable 
increase in the expression of NF-B p65 protein. Figure 6.1 shows the western 
blot analysis from whole protein of ATT, NS and SUS cells which clearly shows 
an increased expression of NF-B in NS and SUS in comparison to ATT cells. It 
can also be observed from Figure 6.1 that an increased nuclear translocation of 
NF-B p65 is evident by detection of NF-B proteins in the nuclear extracts of 
NS and SUS cells. In addition to this the NF-B inhibitory molecule IB-α is 
down regulated at the cytoplasmic level in NS and SUS samples which confirms 
the degradation of IB-proteins by IKK leading to increased nuclear 
translocation of NF-B in these cells. Tubulin and Nucleolin were used as 
loading control. 
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Figure 6.1 Western blot analysis of NF-B in GBM sphere cells: Western blot analysis 
shows that the sphere cells have increased expression and nuclear translocation of NF-B-p65 
and decreased expression of IB- in comparison to the ATT cells indicating high NF-B 
activity. Nucleolin was used as loading control.  
 
6.4.2 High levels of NF-B was observed in hypoxic cells 
 
Cells grown as ATT-HYP are tested for the increased expression and nuclear 
translocation of NF-B by western blot analysis. Figure 6.2 show that all three 
GBM cell lines grown under ATT-HYP conditions show a significant increase in 
the expression of NF-B p65 protein in the cytoplasm. In addition the western 
blot using nuclear extracts from these cultures showed significant nuclear 
translocation of NF-B p65 in comparison to their corresponding ATT-Normoxia 
cultures. Tubulin and Nucleolin were used as loading control.  
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Figure 6.2 Western blot analysis of NF-B in hypoxia cultured GBM cell lines: Western 
blot analysis shows that the hypoxic cultures have increased expression and nuclear 
translocation of NF-B in comparison to the normoxic cells. Nucleolin and tubulin were used as 
loading control. 
 
6.4.3 Stable transfection of U373 GBM cell line with NF-B-p65 
 
U373 GBM cell lines were transfected with pcDNA3.1/ NF-B-p65 recombinant 
vector and empty pcDNA3.1 vectors and clones were selected and enlarged in 
media containing 50ug/mL hygromycin. The selected clones were screened for 
overexpression of NF-B-p65 protein by western blot analysis in the 
cytoplasmic level using the mock transfected cells as control. Positive clones 
were selected enlarged and screened once again to select cells with high level 
of nuclear translocation of NF-B-p65 functional transcription factor using the 
nuclear extracts of selected cells.  Western blot results in Figure 6.3 shows the 
cytoplasmic and nuclear level NF-B-p65 protein expression in selected clones.  
The NF-B transcriptional activities of positive clones were verified using the 
luciferase reporter gene assay which is shown in figure 6.4. As seen in the 
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figure, when compared to mock two clones namely C1 and C4 had the highest 
p65 expression, nuclear translocation and transcriptional activity and were 
selected for further experiments.  
 
 
 
 
 
 
 
Fig 6.3 The expression status of NF-B-p65 protein in p65 transfected U373MG GBM cell 
lines. Western blot analysis shows increased expression and nuclear translocation of NF-B-
p65 protein in selected clones C1 and C4 in comparison to that of Mock transfected cells. 
Tubulin and Nucleolin was used as loading control. 
 
 
 
 
 
 
 
 
 
 
Fig 6.4 High NF-B transcriptional activity in NF-Bp65 transfected U373MG GBM cell 
lines. NFB transcriptional activity was determined by luciferase reporter gene assay. C1 and 
C4: p65 transfected clones. 
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6.4.4 NF-B p65 transfected clones displayed mesenchymal properties 
 
To establish the role of NF-B signalling in EMT we analysed all the EMT 
markers and invasive and migratory properties of p65 transfected positive 
clones C1 and C4 in comparison to the mock transfected cells. FACS analysis 
for the EMT cell surface marker CD44 showed a statistically significant increase 
in the expression of CD44 in C1 and C4 clones with high NF-B activity (Figure 
6.5). In addition expression of other mesenchymal proteins like N-cadherin and 
Vimentin also increased in p65 clones which is evident from the western blot 
results shown in Figure 6.6. Clones C1 and C4 with increased NF-B activity 
lost the epithelial marker E-cadherinvery similar to that of sphere cells and ATT-
HYP. Whereas in control mock transfected cells there was no loss of E-cadherin 
and hence they remain epithelial in nature. These results indicate that high NF-
B activity can transform the cells into a more mesenchymal phenotype which 
could be the reason behind EMT phenotypes leading to CSC characteristics. 
 
Further confirmation for the role of NF-B signalling in inducing EMT 
phenotypes was done by analysing the mesenchymal based migration and 
invasion potential of these p65 positive clones. The images taken using the 
inverted microscope for wound healing scratch assay were analysed using 
Image J software. This program measures the migratory distance and 
calculates the area and pixels for regions with no migrations as numerical value 
which enables us to calculate the percentage migration between p65positive 
clones and Mock cells. Results from the above analysis (Figure 6.7A and B) 
showed significant increase in the migratory potential of cells when there is high 
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NF-B activity. Invasion potential of these cells measured by matrigel invasion 
assay and the images taken from that experiment is shown in Figure 6.8. There 
is a clear increase in the invasion potential of p65 clones C1 and C4 in 
comparison to the mock cells. We also lysed the stained cells according to the 
protocol and measured the OD at 540nm using a multiwall plate reader. The 
results were given as invasion index (Figure 6.8 - bar chart) confirms the 
increased invasion potential of cells with increased NF-B activity. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.5 Expression of CD44 in NFB transfceted U373 GBM cell lines. FACS analysis using 
CD44-FITC conjugated antibody shows increased expression of CD44 cell surface marker in 
p65 transfected clones C1 and C4 in comparison with mock cells. n=6, **p<0.01 
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Fig 6.6 Expression of EMT markers inNFB transfected U373 GBM cell lines. The EMT 
markers were detected fromwhole cell lysates of NFB transfected clones and mock cells using 
western blotting assay. Tubulin was used as loading control. 
 
6.7 A) 
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6.7 B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.7 NFB enhances the migration potential of U373MG cells in vitro. A) Migration ability 
of NFB transfected U373 GBM cell line determined from the images (x100 magnification) of 
wound healing assay. The images show increased migration of NFB clones into the scratch 
when compared to the mock cells. B) Rate of migration (%) determined by analysis of wound 
healing assay images using image J software shows statistically significant increase in the 
migratory potential of NFB clones when compared to the mock cells.  n=8, **p=<0.01 
 
 
6.8 A) 
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6.8 B) 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.8  NFB enhances the invasive activity of U373MG cells in vitro. The invasive activity 
of the GBM cells was detected using matrigel Invasion assay. A) Morphology of the membrane 
penetrated GBM cells (40 magnification). B) Invasive index shows statistically significant 
increase in the invasive potential of NFB transfected clones in comparison to that of mock 
cells. n=6; **p<0.01 
 
6.4.5 High NF-B activity induces CSC characteristics in GBM cells 
 
In order to analyse if NF-B can play role in inducing CSC traits we tested the 
presence of CSC characteristics in NF-B p65 positive clones C1 and C4. For 
all the results below we used Mock as a control which was grown in parallel 
along with the p65 clones. As seen from the FACS analysis data in Figure 6.9 
p65 over expressing clones showed statistically significant increase in the 
expression level of universal CSC marker ALDH and neural progenitor marker 
CD133 when compared with mock transfected cells. In addition the expression 
of embryonic CSC markers namely Sox2, Oct4 and Nanog also increased 
remarkably in the p65 over expressing clones than the mock cells (Figure 6.10). 
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These proteins which are restricted to progenitor cells are important for stem 
cell maintenance, renewal and pluripotency. Results from western blot analysis 
for in Figure 6.11 also confirm the protein level expression of these embryonic 
markers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.9 High ALDH activity and CD133 expression were detected in NFB transfected 
U373MG cells. The ALDH activity and expression of CD133 were measured by ALDEFLUOR 
assay and CD133 immunostaining using FACS analysis, respectively. The bar chart displays 
percentage of ALDH and CD133 cell populations. n= 9, **p<0.01 
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Fig 6.10 Expression of Embryonic CSC markers in NFB transfected U373MG cells. The 
CSC markers were measured using FACS analysis. The bar chart below displays the 
statistically significant increase in all three embryonic CSC markers like SOX2, OCT4 and 
NANOG in NF-Bpositive clones. n=6 **p=<0.01 
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Fig 6.11 Western blot analysis of embryonic stem cell markers in NFB transfected 
U373MG cells.  Western blot analysis shows increased expression of embryonic stem cell 
proteins Sox2, Oct4 and Nanog in NFB transfected clones C1 and C4 in comparison to Mock. 
Tubulin was used as a loading control. 
 
 
6.4.6 NF-B induced multidrug resistance in GBM cells. 
 
From above results we know that NF-B activity can definitely induce EMT and 
results in CSCS characteristics. In addition previous result indicated that HIFs 
mediated signalling induced EMT and CSC phenotypes but not resistance. So 
we speculated that high NF-B activity may play an important role in promoting 
chemoresistant GBM CSCs. To determine this we measured the drug sensitivity 
of p65 positive clones compared to that of Mock cells using MTT analysis. The 
cells were exposed to drugs for a period of 120hrs and then subjected to MTT 
assay. In addition to increased CSC properties, the p65 positive clones C1 and 
C4 also displayed statistically significant resistance to the first line drug TMZ 
and other conventional drugs like VCR and PAC. However, high NF-B activity 
did not induce any significant resistance when treated with the drug DOX. As 
seen from the results shown in Figure 6.12 there is a clear difference between 
the drug sensitivity curves and the IC50 values of NF-B clones and Mock cells 
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treated with TMZ, VCR and PAC. But the IC50 values and sensitivity curve for 
DOX does not follow this resistance trend and has no change with NF-B 
activity. 
 
This indicates that additional mechanisms along with p65 may be involved in 
resistance to DOX.  These results indicate that elevated NF-B activity may 
play an important role in inducing CSC features and chemoresistance through 
NF-B signalling pathways in hypoxia induced EMT.  
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Fig 6.12  In vitro cytotoxicity of TMZ, VCR, PAC and DOX in NFB transfected U373MG 
cell lines. (A). Cell viability curves after the cells were exposed to different drugs for 120 hours 
and subjected to MTT cytotoxicity assay. B) The bar charts display IC50s of different drugs in 
the transfected cells. n=9 **p=<0.01 
 
6.5 Interplay between HIFs and NF-B signalling 
Since both HIFs and NF-B activities increased stemness in GBM cells, we 
were not able to confirm which is the master transcriptional factor in regulating 
hypoxia induced EMT and generating CSCs under hypoxic condition of NS and 
SUS cells. There are possibilities that HIFs and NF-B could be connected to 
each other or unrelated in their mode of actions. In addition, it is evident from 
literature that NF-B can regulate HIFs. The resistance pattern displayed by 
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HIFs did not match with the NS and SUS characteristics. Whereas NF-B was 
able to induce resistance to three out of four drugs that we tested and thus 
gaining a upper hand as an important TF. In order to determine whether HIFs 
are the driving force behind enhanced NF-B activity or whether NF-B is 
expressed as a separate hypoxia responsive transcription factor we had to use 
the HIF1α, HIF2α and NF-B p65 transfected U373 GBM cell lines and 
compared each other‟s expression between them. If HIF1α or HIF2α regulates 
NF-B activity, the transfected clones containing high HIF1α or HIF2α activity 
should have increased levels of NF-B nuclear translocation and transcriptional 
activity. We can determine this using western blot analysis of nuclear extracts 
from HIF transfected cells. In addition, any increase in NF-B transcriptional 
activity due to increased levels of HIF signalling in the HIF transfected clones 
can be determined using the luciferase reporter gene assay. Similarly if NF-B 
is the driving factor behind HIF1α or HIF2α, the p65 transfected clones with high 
NF-B activity should have increased nuclear translocation of HIF TFs in their 
nucleus. This can again be confirmed using western blot analysis of nuclear 
extracts from p65 transfected clones. This would help us to figure out among 
these three transcription factors which one could be the master regulator of 
hypoxia induced GBM CSCs that drives chemoresistance in GBM. Our results 
for the above experiment indicated that HIF1α positive clones C10 and C17 with 
high HIF signalling did not show any increase in the expression or nuclear 
translocation NF-B. Furthermore no change in NF-B transcriptional activity 
was observed in these clones as confirmed by reporter gene assay. Very similar 
results were obtained for HIF2α positive clones C14 and C26 with no increase 
in nuclear translocation or NF-B transcriptional activity (Figure 6.13). On the 
 251 
 
0.00
10.00
20.00
30.00
40.00
50.00
60.00
Mock C-10 C-17
R
e
la
ti
ve
 L
u
ci
fe
ra
se
u
n
it
s 
(R
LU
) 
U373-pCMV6-HIF1
Reporter gene assay for NFB activity
NFkB-Luciferase
0.00
20.00
40.00
60.00
80.00
100.00
120.00
Mock C-14 C-26
R
e
la
ti
ve
 L
u
ci
fe
ra
se
U
n
it
s 
(R
LU
)
U373-pCMV6-HIF2
Reporter gene assay for NFB activity
NFkB-Luciferase
other hand NF-B positive clones C1 and C4 showed increased nuclear 
translocation of both HIF1α and HIF2α indicating that NF-B could be drive 
HIFs protein expression (Figure 6.14). Direct evidence for the transcriptional 
level regulation can be achieved by performing a TF binding site analysis using 
online analytical tools. These results confirm that NF-B could possibly be the 
primary hypoxia response gene that drives HIF1α and HIF2α to induce 
stemness characteristics in GBM cells grown as spheres or under hypoxic 
conditions.  
 
 
 
 
 
 
 
 
 
Fig 6.13 NF-B activity in HIF1 and HIF2 transfected GBM cell lines. A) Western blot 
analysis and B) Luciferase reporter gene assay results show that both HIF1 and HIF2 
transfected U373 cells do not increase NF-B nuclear translocation and transcriptional activity.  
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Fig 6.14 High expression of HIF1and HIF2in NF-B transfected U373MG cells. Western 
blot analysis of nuclear extracts from NF-B transfected cells show increased nuclear 
translocation of HIF1 and HIF2in C1 and C4. Nucleolin was used a loading control. 
 
6.6 Interplay between NF-B and ALDH 
From the results of our previous chapters we identified that GBM sphere cells 
and Hypoxic cultures have increased ALDH activity. ALDHs are a family of 
detoxifying enzymes that contains 19 different isotypes and are known to play 
protective roles against toxic molecules and ROS. High ALDH has been 
recognized as a hallmark characteristic of CSCs in variety of cancers including 
GBM. Evidences from different cancers indicate that specific iso-enzymes of 
ALDH namely ALDH1A1, ALDH1A3 and ALDH3A1 are frequently associated 
with detoxification of drugs, like vincristine, paclitaxel, epirubicin and 
cyclophosphamide. It is hypothesized that multiple ALDH isoenzymes are 
coexpressed in the CSCs derived from the same cancers. In this study we 
aimed to identify whether the commonly mentioned ALDH isoenzymes play a 
role in ALDH activity and chemoresistance of GBM. Another important fact that 
we wanted to analyse was that both HIF1α and HIF2α transfected cell lines had 
increased ALDH activity. But neither of them showed multi drug resistance. So 
we wanted to find out whether ALDH truly play a role in chemoresistance of 
GBM CSCs. It has been speculated that NF-B can drive different members of 
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the ALDH family to aid in the maintenance of CSCs thereby increasing ALDH 
activity and chemoresistance of GBM CSCs. So we also wanted to analyse 
whether there is any relation between NF-B and ALDH expression in CSCs. 
Firstly Western blot analysis of three ALDH isoenzymes namely ALDH1A1, 
ALDH1A3 and ALDH3A1 was performed to analyse the expression of the above 
ALDH isoenzymes in GBM sphere cells and NF-B-p65 transfected clones. Our 
results from western blot analysis indicated that both NS and SUS cells isolated 
from all three GBM cell lines showed increased expression of ALDH1A3 and 
ALDH3A1 isoenzymes in comparison to their respective ATT-monolayer 
cultures. But much surprisingly the expression of ALDH1A1 was found to be low 
in both NS and SUS than the ATT cells (Figure 6.15).  
 
 
 
 
 
Fig 6.15 Expression of different ALDH isoenzymes in GBM sphere cells. Western blot 
analysis of whole cell lysates from ATT and sphere cells of the three GBM cell lines show 
increased expression of ALDH1A3 and ALDH3A1 and decreased expression of ALDH1A1 in 
NS and SUS cells. Tubulin was used as a loading control. 
 
Our results were contradictory to numerous research papers that mentioned 
ALDH1A1 as the key chemoresistance factor among ALDH enzymes (Kahlert et 
al., 2012; Wang et al., 2013; Duong et al., 2012; Song et al., 2014; Schaefer et 
al., 2012). When we tested the NF-B transfected cell lines for the above three 
ALDH enzymes we found that the expression pattern exactly matched with that 
 254 
 
of NS and SUS cells. Both NF-B clones C1 and C4 had increased ALDH1A3 
and ALDH3A1 but there was a downregulation of ALDH1A1 in these clones 
when compared to mock transfected cells (Figure 6.16).  
 
 
 
 
 
 
Fig 6.16 Expression of different ALDH isoenzymes in NFB transfected GBM cells. 
Western blot analysis of whole cell lysates from NF-B transfected GBM cells show an 
increased expression of ALDH1A3 and ALDH3A1 and decreased expression of ALDH1A1 in 
NF-B transfected cells. Tubulin was used as loading control. 
 
So in order to determine the role of ALDH in chemoresistance we 
overexpressed all the above isoenzymes in U373 GBM cell line by stable 
transfection. Three vectors pCDNA3.1(+)-ALDH1A1, pCDNA3.1(+)-ALDH1a3 
and pCMV6-ALDH3A1 were and their corresponding empty vectors were 
transfected in to U373 cell line by following the stable transfection protocol. 48 
clones were picked for each gene after selection with neomycin. The cells 
transfected with empty vectors were used as control and the positive clones 
were screened by western blot for the cells with highest protein level expression 
of the target genes. One mock transfected clone and two positive clones with 
high expression of the respective genes were picked out for each isoenzyme 
and any increase in ALDH activity was detected by routine ALDEFLUOR assay. 
The cytotoxicity of all the drugs used in our study TMZ, VCR, PAC and DOX 
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was tested using MTT cytotoxicity assay as mentioned above. Western blot 
results shown in Figure 6.17A shows the successful overexpression of all the 
above three ALDH isoenzymes in U373 GBM cell line. We also confirmed the 
increase in ALDH activity of these transfected clones Figure 6.17B and C. Our 
results show that any ALDH isoenzyme could increase the ALDH activity that 
can be detected by ALDEFLUOR, not just ALDH1A1, as mentioned by many 
research papers (Li et al., 2010; Sladek et al., 2002). As seen from the results 
shown in Figure 6.17 it was confirmed that both ALDH1A3 and ALDH3A1 which 
are highly expressed in GBM spheres and p65 clones can significantly increase 
the ALDH activity. We tested these ALDH transfected cells for their sensitivity to 
four drugs TMZ, VCR, PAC and DOX. The results of the MTT cytotoxicity assay 
are shown in Figure 16.18 (ALDH3A1) and Figure 16.19 (ALDH1A3) and Figure 
16.20 (ALDH1A1). The corresponding IC50 values are shown in Table below 
each cytotoxicity curve. It can be clearly seen from the results that the clones 
expressing high ALDH1A3 (C15 and C30) and ALDH3A1 (C30 and C39) 
showed significant resistance to the first line drug TMZ and other drugs VCR 
and PAC. But the resistance towards DOX was not statistically significant but a 
resistance trend could be observed with the IC50 values. This pattern of 
resistance is matching very well with NF-B transfected clones where 
resistance to DOX was not observed. Surprisingly the isoenzymeALDH1A1 
which was downregulated in both GBM spheres as well as p65 clones also 
showed significant increase in chemoresistance to all the four drugs tested. 
Especially ALDH1A1 transfected clones showed significantly higher resistance 
to DOX.  
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Fig 6.17 Stable transfection of ALDH isoenzymes in U373 GBM cell line. (A) Western blot 
analysis of ALDH1A3, ALDH3A1 and ALDH1A1 transfected U373 positive clones with 
increased expression of respective isoenzyme. Tubulin was used as a loading control. (B) High 
ALDH activity was detected by ALDEFLUOR assay in cells transfected with ALDH1A1, 
ALDH3A1 and ALDH1A3. (C) Bar chart represents percentage of cells with ALDH activity. n=6, 
**p<0.01 
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ALDH3A1 Mock Clone 30 Clone 39
Temozolomide
(M)
26.37
(2.47)
>5000 >5000
Vincristine
(nM)
2.00
(0.57)
19.99
(0.59)**
9.23
(1.75)**
Paclitaxel
(nM)
2.29
(0.69)
7.57
(2.11)**
15.27
(3.29)**
Doxorubicin
(nM)
16.77
(2.97)
23.75
(2.65)**
30.17
(4.12)**
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.18  In vitro cytotoxicity of TMZ, VCR, PAC and DOXin ALDH3A1 transfected 
U373MG cell lines. The cells were exposed to different drugs for 120 hours and subjected to 
MTT cytotoxicity assay.  
 
Table 6.1.  IC50s of TMZ, VCR, PAC and DOX in ALDH3A1 transfected U373MG cell lines  
 
 
 
 
 
 
 
The figures in the table represent the IC50 values. SD shown in parenthesis. N=9; **p<0.01  
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ALDH1A3 Mock Clone 15 Clone 30
Temozolomide
(M)
26.37 
(2.47)
867.88 
(135.9)**
642.37
(53.01)**
Vincristine
(nM)
2.00
(0.57)
6.47
(3.67)**
5.98
(2.73)**
Paclitaxel
(nM)
2.29
(0.69)
6.29
(0.63)**
5.17
(0.66)**
Doxorubicin
(nM)
16.77
(2.97)
22.05
(11.53)
24.90
(18.1)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.19  In vitro cytotoxicity of TMZ, VCR, PAC and DOXin ALDH1A3 transfected 
U373MG cell lines. The cells were exposed to different drugs for 120 hours and subjected to 
MTT cytotoxicity assay.  
 
Table 6.2. IC50s of TMZ, VCR, PAC and DOX in ALDH1A3 transfected U373MG cell lines 
 
 
 
 
 
 
 
 
The figures in the table represent the IC50 values. SD shown in parenthesis. N=9; **p<0.01 
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ALDH1A1 Mock Clone 30 Clone 39
Temozolomide
(M)
26.37
(2.47)
145.09
(15.62)**
107.30
(2.35)**
Vincristine
(nM)
2.00
(0.57)
14.86
(2.06)**
28.31
(7.86)**
Paclitaxel
(nM)
2.29
(0.69)
17.09
(4.38)**
13.91
(1.79)**
Doxorubicin
(nM)
16.77
(2.97)
254.59
(41.72)**
225.03
(35.49)**
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.20 In vitro cytotoxicity of TMZ, VCR, PAC and DOXin ALDH1A1 transfected U373MG 
cell lines. The cells were exposed to different drugs for 120 hours and subjected to MTT 
cytotoxicity assay. 
 
Table 6.3  IC50s of TMZ, VCR, PAC and DOXin ALDH1A1 transfected U373MG cell lines. 
 
 
 
 
 
 
 
 
The figures in the table represent the IC50 valuess. SD shown in parenthesis. N=9; **p<0.01 
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6.7 Discussion 
 
Extensive evidence in the past three decades have indicated that aberrant 
sustained activation of NF-B induces cell signalling implicated in various 
stages of tumourigenesis as well as in resistance to chemo-radiation therapy 
(Greten et al., 2004; Baldwin et al., 2001). NF-B is a key transcription factor 
involved in inflammatory responses of both innate and acquired immunity. The 
link between inflammation and cancer is a long known fact to biologists and has 
been established as the seventh hallmark of cancer. Accumulated evidence 
over many years suggests that many types of cancers have hypoxia induced 
chronic inflammation which is one of the very early stages in solid cancers. 
Thus NF-B activation could possibly be a response towards inflammation and 
is a well known anti-apoptotic factor. Hence it is speculated that NF-B is one of 
the primary hypoxia response genes recruited by tumour cells in order to avoid 
apoptosis and survive the hostile environment leading to tumour development 
(Coussens and Werb, 2002). NF-B is also shown to help tumour adaptation to 
hypoxia and survival by up-regulating VEGF to initiate neoangiogenesis and 
vascularization followed by tumour progression (Xie et al., 2010; Yoshida et al., 
1999).  
 
NF-B is an important transcription factor with more than 200 target genes. The 
nuclear translocation and transcriptional activity of NF-B p65 subunit is tightly 
regulated by a family of IB proteins that forms dimer with p65 and mask the 
nuclear localization sequence.  The stable transfected clones that we used in 
this study expressed high cytoplasmic levels of NF-B-p65 that could compete 
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with IκB-α activity and therefore has increased nuclear translocation of p65 
subunits. This in turn has enhanced the NF-B transcriptional activity as evident 
from our reporter gene results.  With confirmation of high NF-B activity in p65 
transfected clones we wanted to determine whether ectopic overexpression of 
p65 could activate EMT pathways. Our results clearly indicated a drop in 
epithelial marker E-Cadherin and an increase in mesenchymal markers. 
Moreover the p65 transfected cells displayed increased migratory and invasion 
potential along with CSC characteristics indicating that these cells clearly are 
mesenchymal phenotypes. The recruitment of NF-B plays a central role in 
cancer progression by regulating various aspects of EMT and metastasis 
(Huber et al., 2004). Several developmentally important transcription factors 
that are shown to induce EMT by repressing epithelial gene expression are 
regulated either directly or indirectly by NF-B.  
 
One of the most well-known transcription factors regulated by this way are the 
Snail and Slug (Nieto, 2002) which are direct inactivators of epithelial genes like 
E-cadherin, claudins, occludins, and muc1 (Ohkubo and Ozawa, 2004; 
Martinez-Estrada et al., 2006). They also enhance the expression of genes like 
fibronectin and metalloproteinase (MMPs) that are associated with a 
mesenchymal and invasive phenotype (Jorda et al., 2005). Snai1 transcription 
is directly activated by the NF-B which is evident by the presence of a NF-B 
binding region between -194 and -78 bp in the human SNAI1 promoter (Barbera 
et al., 2004). In addition, SNAI1 mRNA levels during EMT can be reversed by 
inhibition of NF-B signalling. Similar to Snail, Slug is also required for the EMT 
and also downregulates the expression of the epithelial claudins and occludins 
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genes (Kajita et al., 2004). Recent studies have identified that the Slug gene is 
a target for the aryl hydrocarbon receptor (AhR) which transcriptionally 
regulates slug only with co-expression of c-Rel.  Thus, NF-B may indirectly 
regulate the expression of Slug via the AhR (Shin et al., 2006; Belguise et al., 
2007).Twist is also part of the growing list of genes with a role in repression of 
E-cadherin and induction of EMT (Kang and Massague, 2004; Yang et al., 
2004).  Twist is an evolutionarily conserved NF-B target gene (Wang et al., 
1997; Kanegae et al., 1998; Takeda et al., 1999; Sosic et al., 2003). In 
Drosophila, twist is recognised as a direct transcriptional target of the NF-B 
protein (Pan et al., 1991). The expression of Vimentin in the p65 clones is a 
clear-cut evidence of mesenchymal phenotype because expression of vimentin 
is often described as the end stage progression of EMT pathway, which 
represents a completely dedifferentiated state in tumour cells that are highly 
proliferative and invasive (Satelli and Li, 2011). The vimentin promoter is 
comprised of a NF-B binding site between nucleotides -239 and -197 bp 
(Lilienbaum et al., 1990; Lilienbaum and Paulin, 1993). NF-B is responsible for 
the activation of promoter transcription of MMPs like MMP-9 and MMP-2 
(Himelstein et al., 1997; Yoshizaki et al., 2002; Vu and Werb, 2000) that 
enables rapid degradation of collagen in the basement membrane leading to 
tumour invasion and metastasis.  
 
Although many chemotherapeutic agents have been developed in the recent 
past for treating GBM patients, chemoresistance becomes the major obstacle to 
the cytotoxic effects of anti-cancer drugs. One of the important reasons behind 
this is the activation of NF-B in response to treatment with cytotoxic drugs.  
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NF-B is shown to induce resistance against a variety of chemotherapeutic 
agents like the topoisomerase I inhibitor SN38 and the topoisomerase II 
inhibitor, vinblastine, Doxorubicin, irinotecan, cyclophosphamide, docetaxel and 
many other drugs (Cusack et al., 1999). Our MTT results for the p65 transfected 
clones show an increase in chemoresistance to the first line GBM drug TMZ 
and other drugs like PAC and VCR. However we did not see any significant 
increase in resistance to DOX. This may be because of a different mechanism 
of resistance for DOX in GBM sphere cells which are significantly resistant to 
DOX. Like GBM sphere cells and HYP cultures the p65 clones are resistant to 
TMZ. But we did not find any evidence of MGMT protein expression even after 
several trials. This could be very likely due to TMZ resistance induced by NF-B 
being MGMT-independent. In addition, this can explain why some GBM patients 
who are MGMT-negative also develop resistance to TMZ (Gaspar et al., 2010). 
It has been reported that constitutive NF-B activation is a reason for tumour 
cells escaping apoptosis, which is also related to the development of drug 
resistance in cancer cells (Patel et al., 2000; Arltet al., 2001; Mabuchi et al., 
2004).  
 
It has been believed that the most important function of p53 tumour suppressor 
gene is its ability to induce apoptosis, and disruption of this process can 
promote tumour progression and chemoresistance (Tergaonkar et al., 2002). 
Activated NF-B inhibits chemotherapy-induced stabilization and activation of 
p53, which results in resistance to chemotherapy (Tergaonkar et al., 2002; 
Webster and Perkins, 1999). High NF-B directly blocks caspase activation or 
enhance the expression of genes encoding anti-apoptotic proteins to promote 
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cell survival. The expression of BCL-XL and BFL1 play important roles in the 
survival effect of NF-B in response to chemotherapeutic drugs in human lung 
carcinoma cell line (Cheng et al., 2000). In addition, recent studies have 
demonstrated that NF-B has a consensus-binding site for the human MDR1 
(Bentires-Aljet al., 2003). This finding further supports the vital role for NF-B in 
chemoresistance. All these data indicate that NF-B is a crucial target for 
cancer therapy and future cancer prevention.  
 
Our results from chapter 5 and chapter 6 show that both HIF1α and HIF2α as 
well as NF-B activities increased stemness in GBM cells. All three TFs induced 
EMT and resulted in a mesenchymal phenotype showing CSC characteristics, 
indicating the possibility that any of these transcription factors could play a role 
in regulating hypoxia induced EMT and generating CSCs under hypoxic 
condition of NS and SUS cells. There are other possibilities like a loop system 
existing between HIFs and NF-B or they could be totally unrelated in their 
mode of actions. There are many findings that indicate NF-B can regulate 
HIFs, but at the same time several findings also indicate that HIFs could 
regulate NF-B signalling (Melvin et al., 2011; Cockman et al., 2006; Devries et 
al., 2010). But the interesting results we obtained with chemoresistance which is 
an important characteristic GBM CSCs showed that the resistance pattern 
displayed by HIFs did not match with the NS and SUS characteristics. On the 
other hand NF-B was able to induce resistance to three out of four drugs and 
could be considered as an important TF. But that will not settle the question of 
master transcriptional regulator. In order to determine whether HIFs are the 
driving force behind enhanced NF-B activity or whether NF-B is expressed as 
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a separate hypoxia responsive transcription factor we analysed the expression 
of each of the above transcription factors under the influence of another using 
the HIF1α, HIF2α and NF-B p65 transfected U373 GBM cell lines.  
 
The interesting results obtained showed us clearly that neither HIF1α nor HIF2α 
regulated the NF-B activity, but the NF-B p65 transfected clones showed 
enhanced HIF1α and HIF2α activity.  In addition, results from the luciferase 
reporter gene assay clearly indicated that there is no increase in NF-B 
transcriptional activity due to increased levels of HIF signalling in the HIF 
transfected clones.This helped us to come to a conclusion that among these 
three transcription factors, NF-B could be the master regulator of hypoxia 
induced EMT and GBM CSCs that drives chemoresistance in GBM. It has been 
shown previously by many researchers that HIF-1α is required for the activation 
of NF-B. Scortegagna et al., showed that functional loss or deficiency of HIF-
1α decreases p65 expression and NF-B activation, whereas higher levels of 
HIF-1α resulted in the activation of NF-B through hyper phosphorylation of 
IκB and phosphorylation of p65 (Scortegagna et al., 2008).  
 
The molecular mechanism behind this process has been partly understood 
through several studies, which suggest HIF mediated regulation of IKK 
signalling which further then regulates canonical NF-B signalling. In particular, 
some studies has mentioned that IKK-β is activated by hypoxia and this 
activation is thought to be mediated by a PHD domain present in IKK-β, which 
are known targets for hydroxylation by PHD1 (Cummins et al., 2006; Oliver et 
al., 2009). But some other literature data support that fact that hypoxia regulates 
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the NF-B pathway through activation of IKK, specifically via IKK-β, without the 
involvement of any HIFs. In addition to IKK, FIH is also considered to regulate 
NF-B under hypoxic condition through hydroxylation of NF-B proteins such as 
p105 and IκB-α (Cockman et al., 2006). From the evidence listed above and 
various other studies it appears that hypoxic activation of NF-B pathway is 
partly dependent on HIF-1α. It is considered that functional HIF-1 proteins may 
directly interact with NF-B proteins, enhancing their binding at the promoter 
region of NF-B target genes (Cockman et al., 2006; Devries et al., 2010).  
 
Besides HIF-mediated activation of NF-B, evidences from large number of 
experimental studies indicate that NF-B could directly regulate HIF pathway in 
tumourigenesis. NF-B could control the expression of HIFs and its downstream 
signalling pathways within the tumour microenvironment because the promoter 
region of HIF1α gene contains an active NF-B binding site at 
position−178/−188. Any mutations introduced at this site of HIF-1α promoter 
region leads to the loss of hypoxia-induced HIF-1α activation (Bonello et al., 
200). Moreover, siRNAs mediated blocking of NF-B activity results in 
decreased HIF-1α activity. TNF-α induced activation of NF-B results in 
increased levels of HIF1α mRNA and protein (Belaiba et al., 2007; Van Uden et 
al., 2008). It has also been shown that NF-B up-regulates HIF-1 signalling 
pathway via IKK-β which is consistent with other recent findings that knockdown 
of IKK-β decreases HIF-1α activity (Jiang et al., 2010) suggesting he 
importance of IKK signalling HIF-1α activation. Even under the absence of 
hypoxia, cytokines especially TNF-α and IL-4 can also activate HIF-1α activity 
through NF-B dependent mechanism (Cockman et al., 2006; Jiang et al., 
 267 
 
2010). Therefore, it is speculated that NF-B drives HIF-1 signalling pathway to 
maintain the basal levels of HIF-1α under normoxia condition, and further 
increase the levels of HIF-1α under hypoxia. Another interesting study has 
shown that NF-B also can activate HIF-2α signalling through the interaction 
with IKK-γ which leads to recruitment of CBP/p300 for transcriptional activation 
of HIF-2α (Bracken et al., 2006). Furthermore, NF-B is also known to regulate 
HIF-3α, a negative regulator of HIF signalling pathway but the role of NF-B 
mediated HIF-3 signalling in the tumour microenvironment is not fully 
understood (Augstein et al., 2010). A recent clinical study in gastric cancer 
patients revealed that the expression of HIF-1α is positively connected with the 
expression of p65. The experiment showed that over-expression of IκB-αM 
which is a super-suppressive mutant form of IκB-α suppresses HIF-1α 
expression, angiogenesis, and tumour growth. This is consistent with earlier 
findings indicating that the HIF and NF-B pathways induce EMT in a p65 and 
HDAC dependant manner to contribute towards breast cancer metastasis 
(Nam, 2006; Bendinelli et al., 2009). Taken together, it is understood that the 
interplay between HIF and NF-B signalling pathways is crucial to promote 
tumour aggressiveness, but the precise molecular crosstalk between these 
complex pathways still requires profound investigation.  
 
ALDH is a well known CSC marker used for isolating CSCs from various solid 
tumours and haematological malignancies including GBM. The role of ALDH in 
drug resistance was mentioned in many studies involving sphere cell cultures 
and drug resistant cell lines (Magni et al., 1996, Moreb et al., 1998). Initially it 
was reported that the ALDH activity measured by ALDEFLUOR assay in CSCs 
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is due to a specific isoenzyme in the ALDH family known as ALDH1A1 (Storms 
et al., 1999). But later several other isoenzymes were also mentioned as factors 
for increasing ALDH activity and resistance in CSCs (Marcato et al., 2011; 
Brocker et al 2011). Although some studies mentioned ALDH1A1 as important 
resistance mediator in GBM to the first line drug TMZ (Schafer et al., 2012), our 
results showed that ALDH1A1 is down regulated in all NS and SUS cultures. 
Hence we investigated the presence of three commonly mentioned ALDH 
isotypes namely ALDH1A3 and ALDH3A1 in GBM sphere cells. We noted that 
whereas the ALDH1A3 and ALDH3A1 were highly increased in NS and SUS 
cultures as well as increased the ALDH activity in GBM CSCs. We were 
interested to know if NF-B is playing a master role in regulating various genes 
under hypoxia induced EMT, could it possibly be a regulator in inducing ALDH 
isoenzymes in GBM spheroids cultures. Our results showed that NF-B 
transfected clones C1 and C4 had decreased ALDH1A1 and increased 
ALDH1A3 and ALDH3A1 which matched precisely with the ALDH expression 
profile of GBM sphere cells. This indicates that in addition to the role of inducing 
EMT and mediating CSCs, NF-B plays an important role in regulating HIFs 
and ALDH isoenzymes under hypoxic conditions.  
 
NF-B also possibly regulates the ALDH activity and therefore could be the 
master regulator of hypoxia induced EMT and CSCs. But further studies are 
required to determine any direct involvement of NF-B in regulating ALDH 
genes. In order to investigate the role of these three ALDH isoenzymes in 
resistant nature of GBM spheroids we used transfected U373 GBM cells with 
expressing high amounts of ALDH1A1, ALDH1A3 and ALDH3A1. From the 
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above results we showed that any ALDH can increase the ALDH activity in 
GBM cells. These results indicate that regardless of the protein level of different 
isoenzymes the resistance to drugs largely depends on the enhanced ALDH 
activity rather than the subtype. It can be speculated that if one ALDH 
isoenzyme level drops the expression of any other isoenzyme could 
compensate the increase in ALDH activity and lead to resistance. For example 
although ALDH1A1 level is low in GBM sphere cells and NF-B transfected 
clones, forced overexpression of this isoenzyme leads to resistance. This 
proves that the presence of this isoenzyme will definitely increase resistance to 
the cancer cells as shown by many researchers. We have shown in chapter 3 
and 4 that GBM sphere cells and HYP cultures are resistant to DOX. However, 
the NF-B transfected clones, ALDH1A3 and ALDH3A1 expressing clones were 
not significantly resistant to DOX. But the ALDH1A1 expressing clones are 
significantly resistant to DOX. This gives us a hint that out of the 19 different 
members of the ALHD family, the presence of any other ALDH isoenzyme or a 
combination of many which are not tested in this study could possibly be the 
responsible factor for GBM sphere cells and HYP cell resistance to DOX.  
 
 Another factor is that these models used for our study are expressing ALDH 
isoenzyme at an extremely high level and the resistance achieved may be 
because of the presence of high level of enzymes that could easily detoxify the 
drugs. This also indicates the fact that ALDH activity not simply serves as a 
passive CSC marker but also could play a major diagnostic and prognostic role 
in GBM. Being a detoxification and antioxidant agent ALDH could play an 
important role in protecting the drug-tolerant CSC subpopulation from the 
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elevated levels of reactive oxygen species (ROS) in these cells, or potential 
toxic effects of drug induced ROS. Hence pharmacological inhibition 
of ALDH activity could lead to accumulation of ROS to very high toxic levels, 
resulting in DNA damage and apoptosis specifically within this CSC population. 
 
Since HIF transfected cell lines did not induce enough NF-B we can also 
hypothesise that lack of enough NF-B activity in these cells may be related to 
the lack of resistance which indirectly may indicate the lack of ALDH mediated 
resistance in these cells. But further experiments and confirmations are required 
to verify this reason behind the sensitivity of HIF transfected cells. But we can 
positively correlate these results with the resistance of NS and SUS cells 
because of the extremely high ALDH activity induced by hypoxia through 
activation of NF-B. Or it is very likely that the presence of other resistance 
factors like the ABC transporters or P-glycoprotein could also be present in the 
sphere cells that provide them with multi drug resistance. Even if that is the 
case, there is a wealth of literature indicating that NF-B regulates these MDR 
proteins in cancer cells. Hence targeting the overall enzyme activity of ALDH in 
addition to suppression of the master regulator NF-B could be a promising 
strategy to reverse the intrinsic chemoresistant nature of GBM cells as well to 
target CSCs. 
 
6.8 Conclusions 
To conclude we can say that NF-B is highly expressed under reduced oxygen 
environment in both GBM spheres and hypoxic cultures. The above findings 
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point out that the biological consequences of hypoxia largely depend on NF-B 
which includes regulation of HIFs which are the primary hypoxia response 
genes. NF-B could be the master regulator of EMT, stemness and 
chemoresistance and therefore responsible for the dedifferentiation of epithelial 
to mesenchymal phenotypes in GBM sphere cells and GBM hypoxic cultures. 
Various survival mechanisms and other anti-apototic pathways activated by NF-
B in addition to enhanced ALDH activity possibly driven by NF-B could be the 
key factors behind chemoresistant nature of GBM. Hence Targeting NF-B and 
ALDH activity could be a promising strategy to target CSCs and reverse 
chemoresistance in GBM. 
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Disulfiram targets hypoxia induced GBM 
CSCs by modulating NF-B pathway 
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7.1 Introduction 
Our results from all previous chapters have pointed out that the mesenchymal 
cells that are induced by hypoxia associated EMT process could be the 
chemoresistant tumour cell population that mimics CSCs in GBM sphere 
cultures. GBMs are extensively hypoxygenated tumours and it is very likely that 
in GBM patients this hypoxia induced mesenchymal phenotypes which display 
all characteristics of CSCs play a key role in the survival, invasion and 
resistance of GBM cells. Our findings of chapter 5 indicated that the biological 
consequences of hypoxia largely depend on NF-B which includes regulation of 
HIFs which are the primary hypoxia response genes. Hence, NF-B could be 
the master regulator of EMT, stemness and chemoresistance and therefore 
responsible for the dedifferentiation of epithelial to mesenchymal phenotypes in 
GBM sphere cells and GBM hypoxic cultures. Various survival mechanisms and 
other anti-apoptotic pathways activated by NF-B in addition to enhanced ALDH 
activity possibly driven by NF-B could be the key factors behind 
chemoresistant nature of GBM. Thus, targeting NF-B and ALDH activity could 
be a promising strategy to target CSCs and reverse chemoresistance in GBM.  
 
7.1.1 NF-B pathway as a therapeutic target in GBM 
Accumulated evidence over the past decade indicates that inhibiting NF-B 
activation results in reversal of chemoresistance in a variety of cancer cells 
(Wang et al., 1999; Patel et al., 2000; Jones et al., 2000; Arlt et al., 2001; 
Cusack et al., 2001; Flynn et al., 2003; Guo et al., 2004; Mabuchi et al., 2004; 
Banerjee et al., 2005; Kwon et al., 2006; Kim et al., 2006; Tapia et al., 2007; 
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Sors et al., 2008; Murtaza et al., 2009).  Although studies involved with the 
upstream or downstream inhibition of NF-B pathway employs several novel 
compounds designed with various systems and computational models, two 
mains strategies to block NF-B are well known: 1) IK inhibitors and 2) 
Proteasome inhibitors. Owing to the central role of IK-β in regulating NF-B 
activation through phosphorylation and degradation of I-B, a number of 
compounds such as IMD-0354, TPCA-1, IKI-1, PF-184, PS1145, etc were 
designed to inhibit IK-β. Other widely used NF-B inhibitors like BAY-11-7082 
and sulfasalazine suppresses both IK- and IK-β (Weber et al., 2000; 
Weitsman et al., 2006). A recent study involving a novel IK-β inhibitor EC-
70124 showed that blocking NF-B induces senescence in GBM stem cells 
(Nogueira et al., 2011). Another recent work by Zanotto-Filho et al., (2011) also 
showed that inhibition of NF-B pathway using a wide range of NF-B inhibitors 
like BAY-11-7082, MG132, parthenolide, Arsenic, Curcumin or by siRNA 
mediated knock down selectively enhanced cell death in GBM cells, worked 
synergistically with anticancer drugs and reversed chemoresistance in these 
GBM cells. Proteasome inhibitors are other effective NF-B inhibitors that act by 
interrupting the 26S proteasome degradation system. In the case of NF-B, the 
degradation of IΚ-Β by proteasomes in response to phosphorylation by IK 
leads to enhanced NF-B activation in tumour cells. Inhibition of the 26S 
proteasome will lead to stabilization of -Β thereby suppressing NF-B activity 
(Nakanishi and Toi., 2005).  Proteasome inhibitors such as bortezomib and 
MG132 are considered to be promising therapies because inhibition of the 
proteasome degradation results not only in the inhibition of NF-B pathway but 
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also a wide range of other targets leading to dysregulated cellular pathways and 
induction of apoptosis (Orlowski et al., 2002). Due to the successful and 
promising results from clinical trials which started 10 years ago, more than 5 
novel proteasome inhibitors have been introduced for clinical trials in 2012. But 
as with many other anticancer drugs, the proteasome inhibitors will also 
probably face the obstacle of resistance. Bortezomib an established 
proteasome inhibitor has already entered the decline phase due to resistance 
by MDR and other ABC drug efflux mediated resistance mechanisms (Orlowski 
and Kuhn, 2008; Lu and Wang., 2013). Additional mechanisms like mutations in 
the bortezomib binding sites of -5 proteasome subunit and overexpression of 
PSMB5 proteins are also thought to mediate resistance to proteasome inhibitors 
(Kale et al., 2012).  
 
Although inhibition of NF-κB through proteasome inhibitors might be beneficial, 
the high amounts of ABC efflux transporters, MGMT, p-glycoprotein and high 
ALDH activity present in GBM CSCs has to be tackled in addition to inhibition of 
NF-κB. None of the anticancer drugs, kinase inhibitors, proteasome inhibitors or 
angiogenesis inhibitors are promising for GBM. There is an urgent need for the 
development of new drugs that can target these multiple resistance 
mechanisms of GBM. With increasing incidence rates of GBM every year, we 
cannot afford to develop drugs that will cost around US$1 billion and take 
decades of research and testing. More than 25,000 FDA-approved drugs with 
well established safety and pharmacokinetic profiles are currently available on 
the market. Together with their derivatives they make a vast library of potential 
therapeutic compounds. Repurposing such old drugs for treatment of GBM 
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would reduce the time and cost for drug development to a greater extent. 
(Chong and Sullivan, 2007) 
 
7.1.2 Repurposing Disulfiram for GBM treatment 
 
Among several compounds which are repurposed into treatment of cancer, 
disulfram has the strongest evidence for potential anticancer activity (Cvek, 
2008). Disulfiram (DS) or tetraethylthiuram disulfide which is well known as 
Antabuse®, has been used for treatment of alcohol addiction for more than 60 
years. DS is considered to be a well tolerated drug with very little adverse side 
effects. At present two clinical trials for DS in GBM are in progress 
(www.clinicaltrails.gov, identifiers NCT01907165 and NCT01777919). Much of 
the seminal work on the anticancer property of DS comes from our group led by 
Prof. Weiguang Wang here at the University of Wolverhampton. The multiple 
anticancer activities of DS were demonstrated in several preclinical studies 
involving leukemia, melanoma, breast, and colon, prostate, cervical and lung 
cancers (Kast et al., 2013).  
 
Studies from our group and others report that DS is cytotoxic to GBM cell lines 
and inhibits self‐renewal of GBM CSCs. Multiple studies using in vitro models of 
GBM have demonstrated that DS targets GBM through proteasome and ALDH 
inhibition (Liu et al., 2012; Lovborg et al., 2006; Cvek., 2008). It is widely 
regarded that the resistant ALDH expressing CSC population in tumours are 
susceptible to inhibition by DS thereby eliminating tumours or sensitise them to 
conventional therapy including several anticancer agents. Recently it has also 
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been shown that DS inhibits the growth of TMZ‐resistant cells isolated from 
patients regardless of MGMT expression levels (Hothi et al., 2012; Triscott et 
al., 2012). Another study from Paranjpe et al. (2013) using T98G GBM cells that 
are resistant to TMZ has shown that DS can specifically inhibit MGMT protein in 
cell lines and xenografts implanted subcutaneously (Paranjpe et al., 2013). Choi 
et al. recently demonstrated that DS can effectively cross the BBB in mice and 
reduce atypical teratoid rhabdoid tumours (AT/RT) by targeting AT/RT CSCs 
(Choi et al., 2014). AT/RT is a very rare paediatric brain tumour and they 
reported that AT/RT CSCs were more sensitive to DS than clinically used drugs. 
DS was shown to remarkably reduce ALDH in vitro and in vivo and inhibit 
tumour cell proliferation in these tumours and prolonged the survival of mice 
with no adverse effects. Potential mechanisms of anti‐cancer activity by DS 
such as inhibition of MDR efflux proteins, ALDH, elevating ROS, proteasome 
inhibition and inhibition of NF-κB pathway have been discussed in detail in 
chapter 1. 
 
7.2 Rationale and aims of this study 
 
Although potential mechanisms of the anti-cancer activity of DS was described 
by our and various other groups, it is still not understood which are the primary, 
secondary or underlying targets of DS mediated anticancer effect. It is still not 
known which pathways are important to DS toxicity. Nishikawa et al., (2013) 
believe that ALDH inhibition is the primary mechanism, while other studies 
mention that proteasome inhibition followed by NF-κB inhibition is the key factor 
(Cvek., 2008). But a lot of uncertainties are still surrounding the role of ALDH in 
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chemoresistance. Some studies mention elevated ROS or interaction with 
mitochondria or inhibition of certain kinases as the reasons for DS induced 
cytotoxicity. Since DS and its metabolites diethyldithiocarbamates react with 
several proteins inside the cells and binds to many metal compounds present in 
enzymes, it is very difficult to determine the primary mechanism of action. In this 
study we would like show that DS-mediated cytotoxicity is largely dependent on 
Cu. Previous results from our group demonstrated the importance of using Cu 
in combination with DS for enhanced cytotoxicity of DS in different cancer cells 
including GBM. Preliminary in vitro results from our laboratory indicated that DS 
alone cannot successfully eliminate CSCs or resistant populations of GBM and 
other cancers. This is mainly because the CSC population possesses high 
ALDH activity and high antioxidant capacity which acts as ROS scavengers and 
reduce oxidative stress in addition to the antiapoptotic activity of NF-κB (Moreb 
et al., 2012). Therefore, inhibition of ALDHs and NF-κB by DS alone will not 
lead to enough ROS accumulation leading to cell death in CSCs. Although 
proteasome inhibition to target NF-κB and ALDH is effective in suppressing the 
non CSC cancer cells, we believe that an additional ROS trigger is required to 
induce apoptosis in CSCs. Cu plays a crucial role in the generation of reactive 
oxygen species (ROS) that induce apoptosis in cancer cells. The entry of Cu 
into cells is strictly regulated by the transmembrane Cu transporter protein Ctr1. 
DS is a strong divalent metal ion chelator, and hence form a complex with Cu 
that enhances the transport of Cu into cancer cells. DS/Cu is a very stronger 
ROS inducer than Cu or DS alone (Nobel et al., 1995). Free DS that enters the 
cells can also chelate with intracellular Cu (II), forming a DS/Cu complex and 
triggers ROS mediated apoptosis. Cancer tissues possess higher levels of Cu 
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in comparison to normal cells (Mulay et al., 1971; Yip et al., 2011) and thus high 
Cu concentration in tumour tissue under physiological conditions can be used to 
selectively target cancer cells with DS. In the in vitro part of this study we aim to 
reverse chemoresistance in GBM sphere cells and hypoxic cultures by inhibiting 
ALDH and NF-κB activity in addition to triggering ROS through addition of Cu. 
We want to demonstrate that DS/Cu complex induces cell death in both GBM 
CSC (NS and SUS) and non-CSC population and HYP cultures by intrinsic 
pathway of apoptosis. We also would like to test the cytotoxicity of DS/Cu on 
the NF-κB and ALDH transfected clones that were resistant to conventional 
anticancer drugs. Although the in vitro anticancer activity of DS/Cu has provided 
promising results for many cancers, there are very few successful cases 
reported in clinical trials. This inconsistency is mainly attributed to the very short 
half-life of DS in the bloodstream of approx 2-4 mins (Eneanya et al., 1981 and 
our unpublished data).  This would be a major drawback for GBM treatment as 
this time is not enough for DS to cross the BBB and hence reduce the 
bioavailability of DS in GBM tumours. Nanotechnology provides a cutting edged 
drug delivery system which may pave the path for translation of DS into cancer 
indication. Our previous study shows that liposome encapsulated DS 
demonstrated stronger anticancer efficacy in breast cancer model (Liu et al., 
2014). In this study, I examined a novel long circulating new formulation of poly 
(lactic- co-glycolic acid)-PLGA encapsulated disulfiram nano particles 
developed in our lab. In order to determine the efficiency of this PLGA-DS nano 
particles to cross the BBB, we used orthotopic xenograft mouse models of GBM 
generated using GFP tagged U87 cell lines.   To meet the requirement of Cu we 
used copper gluconate salt which is approved by FDA as a safe substance and 
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widely available as a dietary supplement. By achieving the above aims we 
would like to show that DS/Cu targets GBM CSCs and reverse 
chemoresistance by modulating hypoxia-NF-κB axis and is the first drug that 
can simultaneously suppress multiple mechanisms of GBM CSCs like MDR, 
NF-κB, proteasomes, ALDH and induce ROS to induce apoptosis. 
 
7.3 Experimental Design 
Detailed information on materials, products, manufacturers and methodologies 
used for the entire study has been described in chapter 2. The following are 
specific experimental designs and methods used for this part of the study.  
7.3.1   MTT cytotoxicity assay  
Three GBM cells lines U87 MG, U251MG and U373MG were cultured overnight 
in flat bottomed 96 well plates at a cell density of 5000 cells/well in triplicates. 
These ATT-Normoxia cells were then exposed to DS with doses ranging from 
1000nM serially diluted down to 7.8nM. A uniform dose of 10M Cu was 
maintained in all the wells. This is achieved by serially diluting DS in a 10M Cu 
containing medium. The cells were incubated at 37oC for 72hours. After 
incubation the cells were subjected to MTT analysis. The cell viability (%) at 
different concentrations was calculated and the corresponding IC50 values for 
DS/Cu were calculated. The same method was performed for ATT-HYP 
cultures in parallel.  
 
Similarly the cytotoxicity of DS/Cu on NF-κB-p65, ALDH1A3, ALDH1A1 and 
ALDH3A1 transfected clones was determined by MTT assay. All these clones 
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were seeded at cell number of 5000 cells/well in 96 well plates in parallel to 
their corresponding mock cells. The cells were treated with serially diluted DS 
and 10M Cu and MTT analysis was performed as mentioned above and the 
IC50 vales were calculated from cell viability (%) at different concentrations.  
The sphere cells NS and SUS from all three GBM cell lines used were 
trypsinised and reseeded in poly HEMA-coated 96-well flat bottom plates in 
their corresponding culture medium at a cell density of 5000 cells/well and 
cultured overnight. Since the cells were suspended they were grown overnight 
at a volume of 100 L/ well. They were then dosed with medium containing 
double strength DS dilutions (to make it 1x strength including already present 
100l medium) on top with another 100L. Again the concentration of Cu was 
kept at 10M. The cells were treated for 72 hours and MTT reagent was added 
to the wells. After incubation with MTT reagent, the plates were spun down at 
800 rpm for 5 mins in a plate centrifuge and media is discarded. The spheres 
which appear like purple crystals were dissolved by adding DMSO and the OD 
was measured using a plate reader. The % viability and corresponding IC50 
values for DS/Cu was calculated. 
 
7.3.2 Western blot analysis  
1x106 Cells of ATT, HYP, NS and SUS cells from all three cell lines were 
cultured in 25cm2 flasks under appropriate conditions overnight and treated with 
1M DS and 10M Cu  for 24 hours. After treatment the cells were collected, 
washed with PBS and stored as pellets. The whole cell protein in the treated 
cell pellets were extracted with RIPA buffer, quantified and separated by SDS 
PAGE. The expression levels of anti apoptotic protein Bcl2 and pro-apoptotic 
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protein Bax were analysed using appropriate primary and secondary antibodies 
as mentioned in the western blot section of chapter 2. In addition to the above 
apoptotic proteins, the expression level of NF-κB in these treated cells was also 
determined using appropriate NF-κB –p65 antibody.  
 
7.3.3 Sphere formation assay 
GBM NS and SUS sphere cells from all three GBM cell lines grown in poly-
HEMA coated 25cm2 flasks for 7 days were collected by trypsinization and were 
counted using a haemocytometer. For each group, 10000 cells were mixed in 
2mL medium in a 10mL tube. The cells were treated in the tube with 1M DS 
and 10M Cu for 4hours. DMSO was added to control tubes. After incubation, 
the cells were centrifuged and the drug containing medium was discarded. Cells 
were then washed twice with 1xPBS and resuspended into 2mL of fresh 
medium. Cells were then seeded into poly-HEMA-coated and 2-times water 
rinsed 6-well plate (2mL/well). Cells were cultured for 7 days and the spheres in 
all wells were photographed at x40 and x100 magnifications. Another 
experiment for long term treatment with DS/Cu was done with a similar protocol. 
The ATT cells of all three GBM cell lines were trypsinised and seeded in poly-
HEMA coated 6 well plates. They were left to form NS and SUS cells in the 6 
well plates for 7 days with intermittent feeding with fresh medium. After they 
formed spheres the medium was replaced with DS/Cu containing medium (DS 
1M and Cu 10M). One group of cells from the same plate was used a control. 
The cells were continually treated with DS/Cu 72 hours. After 72 hours the 
effect of DS/Cu on the NS and SUS cells were photographed.   
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7.3.4 Cytotoxicity of DS/Cu on a panel of normal cell lines 
MTT cytotoxicity assay was performed to determine the cytotoxicity of DS/Cu on 
normal cell lines. Different immortalized normal cell lines like NHA (Normal 
human astrocytes), MCF10A (normal breast), HECV (Human umbilical vein 
endothelial cell line), WI38 (Human lung fibroblasts), EA.hy926 (Human 
endothelial cell line) were experimented in parallel with three GBM cell lines 
U87, U251 and U373. About 5000 cells per well were treated with serially 
diluted DS (1M down to 7.8nM) and 10M Cu for 1 hour. After incubation for 1 
hr the drug containing medium was removed, and the cells were washed twice 
with 1xPBS and replaced with drug free medium. The cells were then incubated 
for 72 hrs and subjected to MTT analysis. The cell viability of normal cell lines at 
a concentration of DS1M /Cu 10M was compared with that of cancer cells. 
 
7.3.5 Preparation of PLGA-DSF nanoparticles 
We used a polyester named Poly(D,L-lactide-co-glycolide) (PLGA) to prepare a 
new formulation of DS loaded nanoparticles. Due to lack of time this part of the 
work was done with the help of Dr. Zhipeng Wang, post-doctoral research fellow 
in our group. The nanoparticles, loaded with DS, were prepared by an 
emulsion–solvent evaporation method. 200 mg of PLGA and 20, 40, 50, 100 or 
150mg DSF were dissolved in 10mL of dichloromethane, and then mixed with 
20mL of 2.5% PVA aqueous solution. This mixture was homogenized for 1 min 
by vortex and then sonicated using a microtip probe sonicator set at 70% power 
output (XL 2002 Sonicator® ultrasonic liquid processor) for 3, 4 or 5 min to 
produce the oil-in-water emulsion. The organic phase was evaporated for 5h at 
room temperature. The nanoparticles were recovered by ultracentrifugation 
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(10,000 rpm, 20 min, Hitachi). The nanoparticles were washed thrice with water. 
The purified nanoparticles were freeze-dried in 5% sucrose. In order to evaluate 
the surface morphology of the NPs, scanning electron microscopy was 
performed using a high resolution scanning electron microscope (JEOL JSM 
T330A). A drop of the nanoparticle samples were mounted on metal stubs and 
coated with a gold/palladium thin film by sputtering for 60 seconds, with a 15 
mA current, using a SPI Module sputter coater system. Images were obtained 
at an acceleration voltage of 15 kV.  
7.3.6 In vitro half-life of Disulfiram 
Liposome encapsulated DS was obtained from our collaborators in Shenyang 
Pharmaceutical University, China. 100μL of free DS, Lipo-DS, or PLGA-DS, all 
at the concentration of 3mg/mL, was added to 300μL of horse serum and 
shaken at 37oC. At different time intervals the Eppendorf tubes were collected 
and the proteins were precipitated by adding 300μL of absolute methanol. The 
supernatant was subjected to HPLC analysis. 
 
7.3.7 Effect of PLGA-DS nano particles on orthotopic GBM xenograft 
mouse models 
 
All experiments were done with the kind help of our collaborators in Prof. 
Xiuwu Bian’s lab at Third Military Medical University, Chongqing, China. 
Five-week-old female BALB/c Nu/Nu athymic nude mice (Biotechology & Cell 
Biology Shanghai, China) were housed under pathogen-free conditions 
according to Fourth Military Medical University (FMMU), China animal care 
guidelines and the animal experiments were reviewed and approved by the 
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Ethical Committee of FMMU. Nude mice were anesthetized with an 
intraperitoneal injection of 0.6 mL of a stock solution containing chloral hydrate 
(7 µl/g). The surgical site was shaved and prepared with 70% ethyl alcohol and 
iodine-containing solution. Intracranial injection was performed at the position of 
parietal midline with a double outer canthus connection intersection 0.5 cm at 
the right and rear bias. 2×105U87-Luciferase-GFPcells in 5 µl PBS were 
delivered using a 25μL micro-syringe drilled to a depth of 0.5cm. 10 days later, 
mice were randomly subdivided into three groups (8 mice/group) and treated 3 
times/week for 3 weeks, e.g. control, Cu-Glu 6mg/kg p.o.＋empty NPs i.v.，Cu-
Glu 6mg/kg p.o. plus PLGA-DSF 10mg/kg i.v. At the end of the experiment, 
mice were photographed by an in vivo imaging system, sacrificed and brains 
were removed, and subjected to further analysis. 
 
7.4 Results 
7.4.1 DS/Cu targets GBM CSCs in vitro 
Firstly we tested the toxicity of DS/Cu to ATT-normoxia cells to determine 
whether DS/Cu can eliminate the non-CSC population. From the results shown 
in Fig 7.1 it was very clear that DS/Cu comfortably eradicated the GBM cells at 
a very low concentration of nanomolar levels. The treatment was done for 
72hours. We have also tried short treatment of DS/Cu for all the three GBM cell 
lines. We found that just 1hour treatment of DS/Cu and then release will induce 
apoptosis in these cells but at a slightly higher concentration of DS. We treated 
the ATT-HYP cultures with DS/Cu which showed resistance towards all 
anticancer drugs tested in the previous experiments. The results shown in figure 
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U373 ATT
U87 ATT
U251 ATT
DS-1M/ Cu 10M-VE
7.1B clearly reveal that there is no resistance shown towards DS/Cu by ATT-
HYP cultures which is also evident from the very similar IC50 values for both 
NOR and HYP as shown in bar charts. In the other part of this study we tested 
the cytotoxicity of DS/Cu on GBM sphere cells isolated from U87, U251 and 
U373 cell lines. These spheres were proved to be highly resistant to all the four 
drugs that we tested earlier. But our MTT results for DS/Cu on these sphere 
cells did not show any evidence of resistance. DS/Cu was cytotoxic to these 
spheres at very low nanomolar levels after 72 hours treatment (Figure 7.2). We 
did not observe any significant difference in the cytotoxicity ranges between 
ATT and NS and SUS cells for DS/Cu treatment. However from the cytotoxicity 
curves shown in Fig 7.2 it is very clear that in all three cell lines tested there is a 
trend where the NS cultures were the most sensitive cells and the SUS cells 
needed a higher dose of DS. However the IC50 value calculated shows us that 
the dose of DS for SUS cells is around 1M DS which is still a very low dose 
given the fact that DS is generally a well tolerated drug with very little side 
effects.  
  A)  
 
 
 
 
 
 
  
 287 
 
0.00
200.00
400.00
600.00
800.00
1000.00
1200.00
U87 NOR U87 HYP
C
o
n
ce
n
tr
at
io
n
 o
f 
D
S 
-
n
M
 +
 C
u
 1
0
m
M
U87 NOR Vs HYP -DS/Cu IC50
-20.00
0.00
20.00
40.00
60.00
80.00
100.00
120.00
0.1 1 10 100 1000 10000
C
e
ll 
vi
ab
ili
ty
 (
%
)
Concentration of DS - nM + Cu 10M
U87 Nor Vs Hyp-DS/Cu
U87 NOR
U87 HYP
0.00
200.00
400.00
600.00
800.00
1000.00
1200.00
U251 NOR U251 HYP
C
o
n
ce
n
tr
at
io
n 
o
f D
S
-n
M
 +
 C
u
 1
0

M
U251 NOR vs HYP -DS/Cu IC50
-20.00
0.00
20.00
40.00
60.00
80.00
100.00
120.00
140.00
0.1 1 10 100 1000 10000
C
el
l v
ia
b
ili
ty
 (%
)
Concentration of DS-nM +Cu 10M 
U251 Nor Vs Hyp-DS/Cu
Normoxia
Hypoxia
-40.00
-20.00
0.00
20.00
40.00
60.00
80.00
100.00
120.00
140.00
0.1 1 10 100 1000 10000
C
e
ll 
V
ia
b
ili
ty
 (
%
)
Concentration of DS-nM + Cu 10M
U373 Nor Vs Hyp-DS/Cu
Normoxia
Hypoxia
0.00
200.00
400.00
600.00
800.00
1000.00
1200.00
U373 NOR U373 HYP
C
o
n
ce
n
tr
at
io
n 
o
f D
S-
n
M
 +
C
u
 1
0
M
U373 NOR Vs HYP- DS/Cu IC50
B)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1 DS/Cu induced cytotoxicity in GBM cell lines. A) Morphology of cells treated with 
1M DS and 10M Cu for 1hr and released for 72hr (40x magnification). B) In vitro 
cytotoxicity of DS/Cu on ATT-NOR and ATT-HYP GBM cell lines. Bar charts display IC50 
values of DS/Cu on normoxia and hypoxia cultures.  
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Figure 7.2 In vitro cytotoxicity of DS/Cu on GBM sphere cells. The cells were exposed to 
DS/Cu for 72 hrs and subjected to MTT analysis. Bar charts display the differences in IC50 
values of DS/Cu on ATT, NS and SUS cells.  
 
 289 
 
7.4.2 DS/Cu abolished the sphere forming ability of GBM cells 
 
The NS and SUS cells from GBM cell lines under culture for 7 days which 
expresses all CSC, EMT and chemoresistant characteristics were subjected to 
the sphere formation assay. Unlike the MTT cytotoxicity assay which treats 
these sphere cells in DS/Cu containing medium for 72 hrs the sphere formation 
assay exposes the cells to DS/Cu only for a short period of 4hrs. The cells were 
dissociated and exposed to a dose of 1M DS and 10M Cu for 4 hours. The 
cells were then removed from the drug containing medium and washed twice 
with PBS to remove any drugs present. The cells were reseeded into 
appropriate drug free medium and allowed to form spheres in polyHEMA coated 
6well plates. The results of this experiment is shown in figure 7.3.Our results 
shows that the untreated cells can form spheres again after dissociation of 
spheres and reseeding them back to suspended cultures. But the cells treated 
with DS/Cu for just four hours did not form any spheres even after 7 days 
incubation time indicating the effectiveness of DS/Cu against the cells with CSC 
characteristics. We observed that some of these cells were still alive with intact 
plasma membrane but they lost the ability to aggregate together and form 
spheres again. In addition the majority of cells underwent apoptosis. On the 
other hand we observed that DS alone or Cu alone did not affect the sphere 
formation indicating the importance of DS/Cu complex in targeting these cells. 
When we repeated the experiment in a modified manner by exposing the 
sphere cells without dissociation for 72 hours and without releasing the drug we 
observed that DS/Cu induced apoptosis and eradicated the spheres completely 
as shown in the last column of fig 7.3. 
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Figure 7.3 DS/Cu abolished sphere forming ability of GBM cells. NS and SUS cells were 
exposed to DS 1M/Cu 10M for 4 hrs and cultures in drug free medium for 7 days or 
continuously treated for 72 hrs w/o release to observe sphere formation. Images were taken at 
x40 magnification.  
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7.4.3 DS/Cu inhibits NF-κB and is cytotoxic to NF-κB and ALDH 
transfected GBM cells 
 
DS/Cu is a well known inhibitor of NF-B pathway through the inhibition of 
proteasomes (Cvek, 2008).  We performed western blot analysis of proteins 
collected from cells under all 4 culture conditions ATT, HYP, NS and SUS after 
treatment with DS1M/Cu10M for 24 hours. Our results indicated that 
treatment with DS/Cu significantly inhibits the NF-B protein levels in these cells 
(Fig 7.4). We also tested the cytotoxicity of DS/Cu towards the NF-B 
transfected clones which were previously shown to be resistant to different 
anticancer drugs. The cells were treated for one hour with DS/Cu. After 
exposure to DS/Cu the cells were washed with PBS twice and then replenished 
with fresh drug free medium. Our MTT results shown in figure 7.5 indicated that 
DS/Cu induced cell death in NF-B transfected clones and they did not show 
any signs of resistance to DS/Cu. After this short treatment DS probably 
inhibited both ALDH and NF-B in these clones that led to Cu mediated ROS 
accumulation leading to apoptosis.   
We also tested the cytotoxicity of DS/Cu on U373 cells transfected with three 
ALDH iso-enzymes namely ALDH1A1, ALDH1A3 and ALDH3A1. All these 
ALDH transfected cells were proved to show resistance to different drugs 
tested. We observed very similar results for this experiment where a short 1 hr 
exposure of these cells to DS/Cu induced cytotoxicity at low nanomolar levels 
as shown in fig 7.6. This could be again probably due to the inhibition of ALDH 
activity in these cells and paving way for ROS mediated apoptosis.  
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Fig 7.4 Expression status of NF-B-p65 protein in DS/Cu treated GBM cell lines. Western 
blot analysis shows reduced expression of NF-B-p65 protein after treatment with 1M DS and 
10M Cu for 24hrs. Tubulin was used as a loading control. 
 
 
 
 
 
 
 
 
 
 
Fig 7.5 In vitro cytotoxicity of DS/Cu on NF-B-p65-transfected GBM cell lines. The cells 
were exposed to DS/Cu for 1hr and cultured with drug free medium for 72hrs and subjected to 
MTT analysis. Bar chart displays differences in IC50 values of DS/Cu between Mock and NF-
B-p65 transfected clones. 
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Fig 7.6 In vitro cytotoxicity of DS/Cu on ALDH1A1, ALDH1A3 and ALDH3A1 transfected 
GBM cell lines. The cells were exposed to DS/Cu for 1hr and cultured with drug free medium 
for 72hrs and subjected to MTT analysis. Bar chart displays differences in IC50 values of DS/Cu 
between Mock and transfected clones. 
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7.4.4 DS/Cu induces Apoptosis in GBM cells 
From the above results we found that in addition to targeting non CSC-ATT 
cells, treatment with DS/Cu induces cell death and eliminates the resistant 
population in GBM spheres as well HYP cultures. We determined whether this 
cell death is induced through apoptosis by western blot analysis of Bax and 
Bcl2 proteins in ATT, HYP, NS and SUS treated with DS/Cu. The majority of 
cancer cells and resistant population express high level of anti-apoptotic protein 
Bcl2 and low level of pro-apoptotic protein Bax. The disturbance of this 
homeostatic balance is one of the reasons behind resistant nature of cells. The 
expression of Bcl2 is directly regulated by NF-B. On the other hand Bax can 
be activated by various factors including ROS. Our results (Figure 7.7) indicate 
that when the cells are treated with DS/Cu Bcl2 is suppressed and Bax is 
increased indicating that DS/Cu kill the cells by inducing intrinsic pathway of 
apoptosis.  
 
7.4.5 DS/Cu is less toxic to normal cells 
We hypothesised that by using copper in combination with DS we can 
selectively target GBM cells and CSCs because of the already high intracellular 
Cu levels in GBM cells. We performed MTT cytotoxicity assay with a panel of 
normal cell lines and three GBM cell lines in parallel. The results in Figure 7.8 
shows the cell viability (%) of normal cell lines in comparison to the three GBM 
cell lines at a dose of 1M DS and 10M Cu.  It is clearly evident that the 
normal cells had increased survival rates after treatment with DS/Cu than the 
GBM cells indicating the selective killing of GBM cells by DS/Cu.  
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Fig 7.7 Western blot analysis of alteration in BAX and BCL-2 in DS/Cu treated GBM cell 
lines. Western blot analysis shows the simultaneous inhibition of BCL2 and induction of BAX 
after treatment with 1M DS and 10MCu. Tubulin was used as a loading control. 
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Fig 7.8 DS/Cu is less toxic to normal cells. In vitro cytotoxicity of DS/Cu on a panel of normal 
and GBM cell lines. The cells were exposed to DS/Cu for 1hr and cultured with drug free 
medium for 72hrs and subjected to MTT analysis. The bar chart displays the difference in cell 
viability (%) between normal cells and GBM cells at a concentration of 1MDS+10M Cu. 
  
7.4.6 PLGA-DS nanoparticles have increased serum half-life than free DS  
 
We performed an in vitro assay for determining the half life of PLGA 
encapsulated DS by studying the release and stability of these nanoparticles in 
serum. The results shown in figure 7.9 clearly show that free DS disappears 
from the serum in less than 2 minutes time. We used a liposome encapsulated 
DS as a comparative tool for release studies. We can clearly see that LipoDS is 
stable in serum for about 2hrs. But this formulation usually produces bigger size 
particle and are not suitable for crossing BBB and also from the figure it is clear 
that the release of DS is not efficient with LipoDS. In addition two hours time 
may not be enough to increase the bioavailability in brain. The new PLGA 
nanoparticles formulation of DS significantly enhanced the half life of DS for 
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about 24 hours. The releasing efficiency of DS from the nanoparticles is good 
and high compared to that of LipoDS. Hence PLGA-DS NPs should be small 
enough and provide sufficient time to cross BBB and possibly enhance the 
bioavailability of DS in brain. 
 
 
 
 
 
 
 
Figure 7.9 Scanning electron micrograph of PLGA-DS Nanoparticles. SEM images of 
PLGA and PLGA-DS nanoparticles show an uniform size and shape of the nanoparticles 
indicating the high quality of synthesis.  
 
 
 
 
 
 
 
 
 
 
Figure 7.10 PLGA-Nanoparticle encapsulation increased the serum half life of DS. In vitro 
drug release studies analysed using HPLC indicate increased serum half life for PLGA-DS 
nanoparticles than free DS or lipoDS.  
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7.4.7 PLGA-DS NPs inhibits GBM in orthotopic xenograft mouse models 
 
The ability of DS/Cu to target GBM in vivo was examined using PLGA-DS-NPs 
and orthotopic xenograft mouse models of GBM. We administered a dose of 
PLGA-DS 10mg/kg intravenously along with 6mg/kg Copper gluconate orally. 
The GFP Luciferase tagged U87MG cells used for inducing tumours 
successfully generated tumours in all test animals 7.10A. The figure clearly 
indicates that tumours generally developed in both the hemispheres of the brain 
represented by a bright green fluorescence in the image. The treatment was 
done three times a week for 3 weeks. The results obtained are shown in figure 
7.10C which clearly shows that tumour almost disappeared in the group of mice 
treated with PLGA-DS NPs. The GFP imaging shows a small region of tumour 
in one of the treated animals but there is a significant reduction in tumour size. 
To show that the killing is not by Cu we had a separate group treated only with 
copper gluconate. The results clearly showed that Cu did not have any effect on 
the tumour in any of the animals. Figure7.10B. But since this was a very 
preliminary trial experiment involving less animals per group we did not 
measure all facts like survival rates and progression free survival. Based on this 
preliminary data we are conducting another big experiment at present involving 
more animals to gather detailed in vivo data on the effectiveness of our PLGA 
formulation against GBM. 
 
 
 
 
 299 
 
A)      B) 
 
 
 
 
 
 
 
 
 
 
 
  C) 
 
 
 
 
 
 
 
 
 
Figure 7.11 PLGA-DS-NPs inhibited GBM in orthotopic xenograft models. Tumour bearing 
mice were randomly subdivided into 3 groups (4 mice/group) A) control; B)  copper 
gluconate (CuGlu) 6 mg/kg p.o + Empty NPs i.v.; C) PLGA-DS NPs 10mg/kg i.v. + CuGlu 6 
mg/kg p.o; The drugs were administered 3 times/week for successive 3 weeks. The 
tumours were photographed using in vivo imaging system that detects green fluorescence 
produced by tumour cells expressing luciferase GFP.  
 300 
 
7.5 Discussion 
Currently available chemotherapeutic drugs improve the survival rate in GBM 
only by a small margin in combination with surgery and radiotherapy. This is 
due to various reasons like blood–brain barrier (BBB) limiting the access of 
drugs to brain and intrinsic resistance mechanisms of GBM cells to anticancer 
drugs. Therefore, there is an urgent need for the development of new drugs that 
effectively penetrate the BBB and target GBM cells. CSCs are one of the 
important reasons behind the failure of chemotherapy in GBM. We 
hypothesised and provided evidence that the CSCs isolated from GBM cell lines 
are highly resistant to anticancer drugs and these CSCs are probably induced 
by hypoxia through EMT. We showed that hypoxia also activates an important 
TF NF-B, which has been reported to be overexpressed in a diverse range of 
malignancies like leukemia, lymphoma, breast, colon, lung and ovarian cancers 
(Karin et al., 2002).   
 
The association between GBM and NF-B has been well known for many years 
through various studies indicating the upregulation of NF-B in response to 
various stresses in tumours including hypoxia. We showed that the transcription 
factor NF-B plays an important role in inducing CSCs through hypoxia induced 
EMT and therefore could be an important target in reversing chemoresistance in 
GBM. Although there are several NF-B specific inhibitors available in the 
market, many of them do not show promising results in clinical trials (Orlowski 
and Kuhn, 2008). This is because of other resistance mechanisms like p-gp, 
MDR, MRP that prevents the action of drugs. In addition NF-B also regulates 
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anti apoptotic mechanisms that enhance survival in GBM cells and GBM CSCs 
(Nogueira et al., 2011). Elevated ALDH activity displayed by GBM CSCs could 
be another factor for chemoresistance and we showed that NF-B also plays a 
role in regulating ALDH expression. Hence simultaneously suppressing multiple 
resistance mechanisms of these CSCs should be a promising approach and 
may improve the prognosis of GBM patients. Recently it has been reported that 
the anti-alcoholism drug DS and its dithiocarbamate derivatives are cytotoxic in 
vitro to a variety of cancer cells but not to normal cells and hence may have a 
potential in cancer therapy (Cvek et al., 2008).  
 
ALDH is well known for its involvement in detoxification of a wide range of 
aldehydes which otherwise generates high ROS inside the cells leading to DNA 
damage and cell death. ALDH is also known for its ROS scavenging activity 
reducing oxidative stress (Moreb et al., 2012). Cancer cells have high 
intracellular ROS levels due to increased metabolic rates. So any conventional 
drug that elevates the ROS levels can easily target the cancer cells. But the 
chemoresistant CSC population maintains very low ROS levels by increasing 
the ALDH activity which is a trademark characteristic of stem cells. ALDH 
activity has been recognized as a universal functional marker of CSCs and 
recent evidence suggests that ALDH may not only function as a surrogate 
marker but also be a target for therapeutic drugs (Skrott and Cvek, 2012). This 
is because stem cells use the high ALDH levels as a natural mechanism to 
avoid DNA damage by UV or other stress responses including anticancer drugs. 
Hence the conventional drugs that elevate the ROS levels simply do not target 
the CSCs.  As an anti alcoholism drug DS specifically inhibits ALDH enzymes 
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levels in patients‟ blood. Our results from chapter 5 shows that transfection of 
GBM cell lines with ALDH cDNA can induce chemoresistance to conventional 
anticancer drugs like TMZ, VCR, PAC and DOX. It has been reported by 
various researchers that knocking down ALDH genes could sensitize CSCs to 
chemotherapeutic drugs in prostate, ovarian, breast, GBM and lung cancer cell 
lines (Moreb et al., 2012). Our results also indicate that more than one ALDH 
isoenzymes are expressed together in the CSCs and the loss of ALDH activity 
by knocking down one ALDH could probably be compensated by another 
isoenzyme. Hence targeting a single ALDH isoenzyme may not be efficient in 
eliminating the CSC population.  
 
DS is a pan- ALDH inhibitor that suppresses ALDH activity rather than individual 
isoenzyme, and thus is an ideal agent to target ALDH in CSCs. Although 
targeting ALDH is one of the promising strategies to reverse chemoresistance in 
CSCs, that doesn‟t seem to be enough as CSCs have several other 
mechanisms of resistance which explains why many commercial ALDH 
inhibitors do not induce apoptosis in CSCs. This also explains why DS alone 
can inhibit ALDH but cannot produce any cytotoxic effects in CSCs. Results 
from our group have shown that the cytotoxicity of DS is highly copper (Cu)-
dependent. DS in combination with Cu enhances the cytotoxic effects of 
conventional anticancer drugs (Yip et al., 2011; Liu et al., 2012). My results from 
the sphere formation assay shown in figure 7.3 also indicate that DS alone or 
Cu alone does not affect the GBM spheres and hence leaving CSCs intact. But 
the combination of DS with Cu completely eradicates the sphere cell population. 
Similar results have been shown previously by our group in breast cancer; colon 
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cancer and GBM cell lines highlighting the importance of addition of Cu in DS 
cytotoxicity (Yip et al., 2011; Liu et al., 2012; Guo et al., 2010). Cu is an 
important trace element that plays a vital role in mitochondrial redox reactions 
and generates ROS that bring about apoptosis in cells. The transport of Cu into 
the cells is strictly regulated by the Cu transporting transmembrane protein Ctr1. 
DS is a strong chelator of metal ions, and can combine with Cu to form a DS/Cu 
complex. DS is known to enhance the transport of Cu into cancer cells by 
forming complex outside the cells or DS chelates intracellular Cu after 
penetrating into the cells forming a DS/Cu complex. DS/Cu is a much stronger 
inducer of ROS than Cu alone. (Nobel et al., 1995). So inhibition of ALDH by 
DS and generation of ROS by DS/Cu complex will lead to accumulation of ROS 
in CSCs thereby inducing apoptosis in these cells.  
 
But ROS generated by any mechanism is like a double-edged sword. It can also 
induce various anti-apoptotic mechanisms among which activation of NF-B is 
an important mechanism by which CSCs evade ROS mediated apoptosis (Liu 
et al., 2012). In addition to the role in hypoxia mediated EMT leading to CSCs, 
NF-B also plays an important role in survival of these CSC population (Liu et 
al., 2014). This is the reason why inhibition of NF-B is crucial for successful 
anticancer treatment. Consequently a compound that can simultaneously inhibit 
ALDH, inhibit NF-B and elevate ROS would significantly improve cytotoxic 
effects mediated by ROS. DS is a specific inhibitor of NF-B pathway by 
inhibiting the proteasome degradation pathway (Cvek, 2008). In addition to NF-
B pathway, proteasome degradation will also have an effect on various other 
cellular proteins causing a total imbalance and hence leading to cell death. Our 
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results after treatment with DS/Cu clearly show that NF-B protein levels are 
suppressed. Simultaneously BCL2 an anti-apoptotic factor and a direct target of 
NF-B were suppressed leading to enhanced pro-apoptotic protein BAX. BAX 
can also be induced by elevated ROS generated by DS/Cu complex leading to 
binding of voltage dependant anion channel in mitochondrial membrane leading 
to apoptosis (Skrott and Cvek, 2012). Moreover none of the NF-B transfected 
clones survived after treatment with DS/Cu. Very similarly the cells that are 
transfected with different ALDH cDNAs were also killed by DS/Cu treatment.  
 
In addition to these our results showed that DS/Cu selectively targets GBM cells 
and spares normal cells. This could be again because of the variations in Cu 
levels between normal cells, cancer cells and CSCs. Compared with normal 
tissues, high Cu levels present in cancer cells (Mulay et al., 1971; Yip et al., 
2011). DS transports Cu into the cells and elevate the Cu levels in the cells. At 
the same time inhibition of ALDH and NF-B will help the DS/Cu complex to 
accumulate ROS levels beyond the threshold limit thereby inducing cell death. 
But the Cu level in normal cells does not increase high enough to push the ROS 
beyond the threshold. The same strategy could possible apply between CSCs 
and normal stem cells leading to selective targeting of CSCs and cancer cells 
by DS/Cu. It has been previously shown that DS does not affect cells in the 
kidney, gut or bone marrow while potentiating the cytotoxic effects of 
conventional anticancer drugs (Hacker et al., 1982; Bodenner et al., 1986). The 
prospective clinical application of DS for treatment of GBM is hindered by the 
currently available oral formulation of DS which is unstable in the acidic gastric 
environment and has a very short half-life of less than 2mins. Even after a 
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500mg dose of DS, its metabolites cannot be detected in blood because of very 
low systemic concentration (Johansson, 1992). This short half-life may present 
a serious challenge for the use of DS in GBM treatment as the time is too short 
for the drug to cross BBB and accumulate in the brain environment. Therefore, 
we developed a new formulation of DS with longer half-life using PLGA-nano 
encapsulation technique that increased that increased the half life of DS up to 
24 hours.  This also will ensure that DS can cross BBB and sufficiently dose can 
reach the brain. We successfully tested this new formulation of PLGA-DS 
nanoparticles in orthotopic xenograft mouse models and achieved significant 
reduction in tumour levels of treated mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 7.12 Proposed mechanisms of selective killing of GBM cells by DS/Cu 
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It is very likely that DS/Cu eliminated the CSC population as well as non CSC 
population in the brain effectively thus reducing tumour size. Although we 
propose the mechanism to be simultaneous inhibition of resistance proteins, 
NF-B pathway and ALDH activity in addition to ROS elevation, there may be 
still many unknown mechanisms involved behind the success of DS/Cu. Further 
studies are required to confirm these findings. Once the DS/Cu and its 
formulations are fully characterized and tested, proper clinical trials are 
required. The prognosis for GBM patients still remains poor and development of 
drugs for BM is very slow. Hence repurposing of FDA approved drugs like DS 
with very little known side effects will cut down the cost and time required for 
development of new drugs besides providing therapeutic benefit for GBM 
patients.  
 
 
7.6  Conclusion 
To conclude we can say that DS/Cu effectively targets the CSC and non CSC 
population in GBM cells in vitro. The new formulation of PLGA encapsulated DS 
nanaoparticles with increased serum half life can effectively cross BBB and 
inhibits GBM in vivo. The possible mechanisms of action could be by 
simultaneous inhibition of NF-B and ALDH and increased generation of ROS 
by DS/Cu complex. DS/Cu is probably one of the best combinations of drugs 
that can efficiently target different CSC resistant mechanisms simultaneously. 
As an FDA approved drug with all clinical and preclinical data available, further 
studies with various formulations could quickly translate DS in to GBM 
therapeutics.  
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8. General Discussion  
 
GBM is the most common malignant primary brain tumour in adults, and has the 
worst prognosis among all human cancers. Even after aggressive treatment 
measures including surgery, radiotherapy and chemotherapy, the median 
survival among patients with GBM is only 12-15 months (Reardon and Arvold, 
2014). Only about 3-5% of patients have an overall survival rate of 2 years 
(Parsons et al., 2008). The reason behind such poor outcome is because most 
of the GBM patients develop a refractory disease with several characteristics 
that hinder therapeutic options and results in high rates of relapse. These 
include heterogeneity, highly infiltrative and invasive nature and presence of 
resistant population including CSCs. Currently available chemotherapeutic 
agents including the first line drug TMZ, increases survival only by a small 
margin however most patients develop resistance to these agents. This is partly 
due to the blood–brain barrier (BBB) which limits drug access and also because 
of the intrinsic resistance nature of GBM cells to many anticancer drugs 
(Sugiyama et al., 1999). Therefore, developments of new drugs that can cross 
the BBB and target GBM cells are of significant clinical importance for the 
treatment of GBM. While demand for better cancer therapies is high the rate of 
drug development is slow and expensive (average 15 years and US$1.5bn per 
drug) and only 5-25% of anticancer drugs in clinical development actually reach 
the market mainly due to toxicity of these agents (Walker et al., 2009). Hence 
the idea of finding new uses for existing drugs also known as „repurposing‟ has 
emerged in recent years. Because of the already existing safety profiles and 
pharmacokinetics information, any newly identified use of old drugs can be 
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quickly translated to phase-II clinical trials within two years and at a low cost of 
$17m (Marshall, 2011; Chong and Sullivan, 2007).  The drug we used in this 
study Disulfiram, the old anti-alcoholism drug is one best example for a 
repurposed drug which has been reported to have significant potential in cancer 
therapy.  
 
Previously published research from our group in different cancers has already 
shown various mechanisms of DS induced cytotoxicity. These include inhibition 
of ALDH, inhibition of proteasome, inhibition of NF-B pathway, targeting MDR 
p-gp, and inducing ROS-MAPK pathway of apoptosis. In the body DS is 
metabolised into DTC which is shown to chelate with metal ions like Cu or Zn to 
form complexes that can elevate the ROS in cells. Our published data also 
revealed the importance of Cu in DS mediated cytotoxicity (Yip et al., 2011; Liu 
et al., 2012). DS/Cu was also shown to sensitise the cancer cells and potentiate 
the cytotoxic effects of other conventional anticancer drugs (Liu et al., 2012; 
Triscott et al., 2012; Yip et al., 2011; Liu et al., 2013; Liu et al., 2014; Chen et 
al., 2006). In this study I intended to repurpose DS for GBM treatment by 
understanding the in vitro and in vivo efficiency of DS in targeting GBM cells, 
specifically GBM CSCs.  
 
In order to do this, it is indispensable to have a complete understanding about 
the role and mechanisms of GBM CSCs mediated resistance of GBM. GBM 
CSCs are a very small population of cancer cells expressing CSC markers that 
promotes therapeutic resistance. Although there is wealth of evidence 
supporting the role of GBM CSCS in initiation, progression and relapse of GBM 
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there is a still an ongoing debate concerning the origin and nature of GBM 
CSCs. It is still unclear whether GBM CSCs are derived from neural progenitor 
cells or from differentiated cells. I was interested to fully elucidate the the nature 
of GBM CSCs and their resistance mechanisms. Many research groups 
mentioned that GBM CSCs are a special group of cells that can be isolated only 
from fresh tumour samples of GBM from patients. Additionally it was claimed 
that isolation of GBM CSCs also required specific low attachment spheroid 
growth conditions and special growth factor-supplemented serum-free selective 
growth medium which was is adapted from the normal neural stem cell culture 
system. This method is widely accepted as a gold standard method to keep the 
CSCs in an undifferentiated state under in vitro conditions. It is also referred 
that serum free conditions will purge the differentiated progenies, and 
selectively enrich the CSC population (Lee et al., 2006). The major pitfalls of the 
serum-free enrichment system are that it is very expensive, it differs from the 
physiological conditions and there is no clear evidence for source of the CSCs 
growing in sphere culture. Another factor to consider is that CSCs once 
exposed to serum will differentiate irreversibly in to their progenies. 
Researchers supporting this selection hypothesis do not use established cell 
lines as a source for CSCs. But on the other hand several studies also reported 
the isolation of CSCs from established cell lines of GBM. They showed all CSC 
characteristics including initiation of tumour in animal models (Charafe-Jauffret 
et al., 2009; Kondo et al., 2004; Collins, 2005; Setoguchi, 2004).  
  
Our results in this study also demonstrated that when the cells from established 
GBM cell lines such as U87, U251 and U373 are grown as NS in selective 
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media they form spheres and exhibit several CSC characteristics such as 
CD133, ALDH, Sox2, Oct4, and Nanog. If this is the case it appears like most of 
the established cell lines have a residual population of CSCs that can be 
enriched and activated by this growth factor enriched medium under specific 
growth conditions. But on the other hand we also demonstrated that growing 
these cell lines as spheres in normal DMEM+10% serum conditions also 
induced better spheres and enhanced all the above mentioned CSC 
characteristics. Therefore we concluded that stemness in GBM CSCs is not 
determined by the culture medium and hence serum free culture system is not 
mandatory for GBM CSC culture. 
 
We found that hypoxia is the common factor that existed in all GBM sphere 
cultures. Many recent studies have elucidated that intra-tumoural hypoxia 
induces CSCs phenotypes in tumour via epithelial-to-mesenchymal transition 
(EMT) (Batlle et al., 2000; Yee et al., 2010; Polyak and Weinberg, 2009; 
Salnikov et al., 2012). We provided substantial evidence for EMT that occurred 
in both NS and SUS cultures indicating that culture medium or the source of the 
initial GBM does not affect the formation of GBM CSCs in sphere cultures. 
Instead it is the mesenchymal phenotypes which are induced by hypoxia are the 
true culprits in driving resistance. We provided evidence for the above 
statement by showing that cells grown as attached monolayers under hypoxia in 
normal medium acquired mesenchymal phenotype and eventually CSC 
properties without growing them as spheres. This transition into CSC like 
phenotypes also led to remarkable increase in the chemoeresistance towards 
various drugs which indicated that accumulated hypoxia could be the key 
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reason behind chemoresistance in GBM. This transition to mesenchymal 
phenotype also played an important role in enhancing the migration invasion 
and metastatic potential of these cells. This can also apply to physiological 
conditions of GBM in patients where tumour cells experience extensive hypoxia 
in the central region of the tumour bulk. Under such hypoxic conditions added to 
several other microenvironmental stresses the fully differentiated GBM cells 
could reprogram themselves to mesenchymal cells to facilitate migration, 
metastasis or to produce growth factors to initiate angiogenesis in order to 
survive and escape the hostile environment. Unlike the NSCs, the monolayer-
cultured non-CSCs and sphere-cultured CSCs are interconvertible by oxygen 
concentrations (Biddle et al., 2011; Chen et al., 2012). Hypoxic stress induces 
EMT and the cells can migrate out of the tumour and follow another program 
called MET where the mesenchymal cells become differentiated epithelial cells. 
This could be the reason why when grown as spheres, established cell lines get 
converted to mesenchymal phenotype and revert back to the epithelial 
phenotype when they are adhered back to monolayer culture. Physiologically 
this could be a very important mechanism that happens in all solid tumours 
where cells constantly under hypoxic stress are undergoing EMT to move away 
from the hostile environment and undergo MET to establish in the new region. 
This could be the possible reason why GBMs has multiple spots of local 
metastasis or highly infiltrative in nature that leaves the tumour with no margins 
(Szeto et al., 2009). The survival signalling pathways activated for this 
interconversion adds up to the already existing intrinsic resistance rendering 
chemotherapy useless. But we also had questions to ourselves about how 
some people can isolate NS CSCs from fresh samples. This is probably 
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because they are enriching the already existing mesenchymal or CSC 
phenotypes induced by physiological hypoxia in the primary tumour. Thus we 
concluded that GBM sphere cell culture using selective medium or normal 
medium could provide a suitable model for studying this hypoxia induced 
resistant cells. Although under physiological conditions there are a lot of other 
microenvironmental factors that play their role in chemoresistance to drugs, 
these sphere cell cultures from GBM cell lines could provide us with 
physiologically relevant model for studying drug uptake, resistance mechanisms 
and EMT phenotypes.  
 
After establishing the fact that hypoxia is the key driver of CSCs and resistance 
in GBM sphere cells I analysed the possibilities of various transcription factors 
which are likely to be involved in activating various signalling pathways leading 
to this hypoxia induced EMT programme eventually to chemoresistant GBM 
CSCs. We had to do this because we had to understand who the master driver 
under hypoxic conditions is and whether DS/Cu can target this upstream 
activator of CSCs in order to inhibit CSC population. If not upstream we wanted 
to analyse what are the downstream regulators that are activated and I also 
wanted to understand if DS/Cu can blocking these important factors. Hypoxia 
inducible factors (HIFs) are master transcriptional regulators under hypoxic 
conditions (Rohwer and Cramer, 2011). In this study we analysed the role of 
two HIFs namely HIF1 and HIF2. The DNA binding and the transcriptional 
activity depends of these ubiquitously expressed proteins depend largely on 
nuclear translocation of HIF subunits. These elements are tightly regulated 
and constantly degraded by PHDs which prevents nuclear localization under 
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high concentrations by of O2. So in order to study them we used U373MG cell 
line transfected with HIF1 and HIF2 cDNA that drastically increased the 
cytoplasmic proteins levels of HIFs and compete with the PHDs ultimately 
leading to increased HIF1 or HIF2 signalling pathways. Both HIF1 and HIF2 
will be activated under reduced O2 environment which directly or indirectly 
activates the expression of hundred of genes. Some of these targets overlap 
between these two factors due to the similarities in their DNA binding sequence. 
Therefore the biological consequences of hypoxia in cells largely depend on 
which HIF is active at any given time and what targets are being regulated by 
them (Heddleston et al., 2010). Our results demonstrated that increased 
expression of both HIF1 and HIF2 could play vital roles in driving the EMT 
programme. We found that expression of HIF2 induced resistance to TMZ. 
However we did not find significant evidence to confirm the involvement of both 
HIFs in multidrug resistance which is a clinically important characteristic of GBM 
CSCs. But we cannot deny the fact that both HIF1 and HIF2 are crucial for 
EMT, CSCs, tumour motility and invasion suggesting that pharmacological 
inhibition of these factors in addition to suppression of chemoresistance factors 
holds great promise in targeting GBM CSCs. 
 
However NF-B, another key transcription factor, is also highly up-regulated in 
hypoxia induced CSCs and is proved to be playing an important role in cancer 
chemoresistance (Cummins et al., 2005). NF-B is a key TF involved in various 
normal and pathological conditions of cells and is widely associated with several 
diseases. Although the link between inflammation, NF-B and cancer has been 
studied for decades, the detailed molecular mechanisms and pathways linking 
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hypoxia, NF-B and CSCs are not fully elucidated. There is also a large amount 
of literature evidence that suggest that HIFs can activate NF-B through 
interaction with components of NF-B pathway (Yeramian et al., 2011; 
Cummins et al., 2006).  While there are some evidences which suggest that NF-
B could be the factor activating HIFs (Bonello et al., 2007). In my study the 
activation of NF-B was observed in all sphere cell models and in cells under 
hypoxic conditions. This suggested that NFB which is known to be a TF for 
more than 200 genes could play an important role in determination of CSC 
traits. But there are no clear insights on how HIFs and NF-B together 
orchestrates the anti-apoptotic signalling, chemo-radiation resistance and 
maintenance of stemness in GBM CSC phenotypes. In order to study this in 
detail, I transfected the U373MG cell line with NFB p65 cDNA in order to 
enhance the cytoplasmic levels of NF-B that can compete with IkB and gain 
nuclear translocation. NF-B pathway activation was also confirmed in this p65 
transfected cells. Our results revealed that the NF-B p65 transfected clones 
induced EMT pathway to convert these cells to a mesenchymal phenotype, 
expressed high levels of stem cell markers and displayed evidence of multidrug 
resistance to drugs like TMZ, PAC and VCR. In order to establish the link 
between HIFs and NF-B, we analysed the nuclear translocation and 
transcriptional activity of NF-B in HIF1 and HIF2 transfected cells. None of 
the HIF transfected clones had increased NF-B activity indicating that neither 
HIF1 nor HIF2 could be direct drivers of NF-B p65. On the other hand we 
found that NF-B transfected clones significantly enhanced the expression and 
nuclear translocation of both HIF1 and HIF2 indicating that NF-B could be a 
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direct driver of these genes.  Therefore we concluded that NFB could possible 
play the master role in regulating hypoxia induced EMT, stemness and 
chemoresistance by activating various genes directly or through activation of 
HIF signalling. In addition to NF-B mediated resistance factors all CSCs 
possess high levels of ALDH activity which is a universal stem cell marker and 
has been implicated with chemoresistance for many types of cancers (Sladek et 
al., 2002; Liu et al., 2014). ALDHs are a group of detoxification enzymes that 
has 19 different isoforms. High ALDH expressing cells have been associated 
with enhanced xenograft tumour formation in mice and chemotherapeutic 
resistance by cell detoxification leading to resistance towards drugs like 
cyclophosphamide, cisplatin, docetaxel, temozolomide and doxorubicin (Sladek 
et al., 2002). Initially, ALDH1A1 was thought to be the isoform associated with 
the CSC phenotype, but later several other phenotypes are also shown to play 
a role in resistance (Marcato et al., 2011). Since DS is a specific inhibitor of 
ALDH we thought that ALDH inhibition could be the reason behind the ability of 
DS to reverse chemoresistance and induce cytotoxicity. So this means that 
ALDH as reported by many others could be the important target in reversing 
chemoresistance of GBM CSCs. We screened our GBM sphere cells for the 
expression of three commonly mentioned ALDH isoenzymes namely ALDH1A1, 
ALDH3A1 and ALDH1A3. We found that GBM sphere cells had increased 
expression of ALDH1A3 and ALDH3A1 but had clearly downregulated 
expression of ALDH1A1 in comparison to that of non-CSC GBM cells. Since 
NF-B clones were resistant to drugs and displayed enhanced ALDH activity, 
we screened them for the above three isotypes. Excitingly, the same pattern of 
ALDH expression in GBM spheres was reproduced in NF-B transfected 
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clones. Although we couldn‟t provide detailed or direct evidence for NF-B in 
transcription of ALDH genes we hypothesised that NF-B may play a key role in 
regulatory link in this pattern of ALDH expression. In order to find out whether 
ALDH isoforms play any role in chemoresistance of GBM CSCs we transfected 
the U373MG cell line with cDNAs of all the three ALDH isoforms and selected 
the clones with very high expression of these isoenzymes. We tested these 
ALDH clones for chemoresistance and found that all the ALDH isoenzymes 
induced resistance towards drugs like TMZ, PAC, VCR and DOX. We 
concluded that regardless of the isoenzyme the high ALDH enzyme activity 
induced by the presence of high levels of any isoform could be the reason 
behind chemoresistance driven by ALDH. We also pointed out that if any one 
isoform is targeted, the presence of another isoform could still maintain the 
ALDH activity to retain chemoresistance. Due to redundancy in activity by some 
isoforms it very difficult to pinpoint or target independent isotype. Hence 
targeting the whole ALDH activity rather than subtype is a better strategy to 
target CSCs.  
 
DS is able to suppress GBM tumour development through multiple 
mechanisms. As a single compound DS is shown to be a inhibitor of drug 
resistance proteins like P-gp and MRP-1. It is a well established proteasome 
inhibitor that leads to inhibition of NF-B pathway. DS is also known to be a pan 
ALDH inhibitor that suppresses ALDH activity (Liu et al., 2014). Several pieces 
of evidences from our research group and various other groups working on 
repurposing DS for cancer treatment have provided solid evidences to prove 
that DS could be the drug that has the ability to simultaneously target multiple 
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chemoresistance mechanisms. Data from our research group provides 
convincing evidences that the cytotoxicity of DS is dependent forming 
complexes with Cu or other metal ions like Zn (Liu et al., 2014). We chose Cu 
because it plays a critical role in redox reactions and in generates free radicals 
in combination with DS (Turnlund et al., 1998). Cu has a very long history in 
cancer treatment with records early as 400 B.C. (Gelarie, 1913; Hieger, 1926). 
Cu exists in two forms in the body, oscillating between the cuprous (Cu1+) and 
cupric (Cu2+) forms, with Cu2+ found widely. The transport of Cu into the cells 
is strictly regulated by Ctr1, a Cu transporter protein (Kim et al., 2008). Hence 
treatment with Cu alone does not result in cytotoxicity which is clearly evident 
from our previously published results as well as results shown in treatment of 
GBM CSCs in this study. Copper initiates oxidative damage through generation 
of the most powerful oxidising hydroxyl radicals (OH) from hydrogen peroxide 
(H2O2). Hydroxyl radicals are capable of reacting with every biological molecule 
resulting in DNA damage and apoptosis through accumulation of ROS.  Not 
only DS and but also it metabolic derivative, DTC can form a complex Cu. In 
fact it was shown the enhancement of Cu levels in the cells was achieved by 
transport of Cu into the cells by DS/Cu complex in a Ctr1 independent 
mechanism (Cen et al., 2002; Cen et al, 2004).  
 
But it is well understood that GBM tissues possess significantly higher (approx 
44-fold) levels of Cu owing to their high metabolic rate and a high need for Cu in 
redox reactions than the surrounding normal brain tissues (Margalioth et al, 
1983; Yoshida et al, 1993). Therefore additional Cu intake by DS/Cu could push 
the generation of ROS in GBM cells beyond the threshold limit thereby inducing 
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oxidative damage and apoptosis. This enables us to develop a strategy to 
selectively target GBM cells sparing normal brain tissue. Since brain is a highly 
delicate organ, selective killing by any anticancer drug is a vital requirement and 
DS can effectively achieve this with the strategy involving Cu. My results using 
a panel of normal cell lines compared to that of cancer cell lines demonstrated 
that DS/Cu is highly cytotoxic to GBM cells but less toxic to normal cells. In 
addition DS/Cu can kill GBM cells at very low nanomolar levels and hence we 
can target tumour cells without any system toxicity or worsening side effects 
which is extremely rare or impossible to be achieved by any present day 
anticancer drugs. 
 
Although all the above mentioned mechanisms of DS/Cu apply for GBM cells 
the major aim of my work was to see the anti-GBM CSCs effect of DS/Cu. My in 
vitro data comparing the NS and SUS sphere cells of GBM showed that there is 
no big difference in the cytotoxicity ranges of DS/Cu on these cells and the 
results are very much comparable. In addition we found that DS/Cu treatment 
abolishes NF-B in ATT, HYP and in sphere cells indicating that NF-B could 
be one of the primary targets. As mentioned earlier the possible mechanism of 
DS/Cu cytotoxicity on these cells could be by elevating ROS levels. But we 
need to consider that cells possessing CSC characteristics are known for their 
very low ROS levels due to high ALDH activity. Being a well known pan ALDH 
inhibitor DS/Cu comfortably induced cell death in GBM CSCs because elevation 
of ROS is possible by bringing the ALDH down. The ALDH transfected GBM 
cells that showed resistance to all drugs tested earlier did not show any form of 
resistance to DS/Cu treatment. It is known that elevated ROS levels also 
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activate NF-B pathway and anti-apoptotic machinery related to it. But DS/Cu 
being an effective inhibitor of NF-B pathway this mechanism of evasion by 
CSCs simply does not work. Earlier work by our group in breast cancer, colon 
cancer and GBM has shown that in addition to ALDH and NF-B inhibition and 
accumulation of ROS, treatment with DS/Cu resulted in the persistent activation 
of JNK and p38 MAPK pathways that promote ROS-induced apoptosis in all 
these cancer cells (Liu et al., 2012., Liu et al., 2014; Junttila et al., 2008). ROS 
is known to activate ERK pathway downstream that plays essential role in 
survival and proliferation. But the ROS generated by DS/Cu did not activate the 
ERK pathway. ROS-activated JNK and p38 pathways induce apoptosis via 
mitochondrial apoptotic pathways in which the balance between pro-apoptotic 
BAX and anti-apoptotic BCL2 plays a major decisive role (Junttila et al., 2008).  
From my results from the untreated GBM cells including ATT, HYP, NS and 
SUS it well understood that the balance between BAX/BCL2 is inclined towards 
resistance of apoptosis where BCL2 expression is higher. In fact very high 
BCL2 expression was noted in the sphere cells and HYP cells compared to the 
non CSC counterparts indicating their resistant nature. The treatment with 
DS/Cu reversed this balance to express more BAX and suppress BCL2. It is 
also known that BCL2 is a direct target of NF-B pathway (Gloire et al., 2006). 
So it is evident that inhibition of NF-B pathway by DS/Cu resulted in 
suppression of BCL2 leading to BAX increase by ROS.  
.  
Although DS shows remarkable anticancer activity in vitro its clinical application 
in patients is highly limited by its bio-instability. The half-life of DS in the blood 
stream is only less than 4 minutes due to its rapid degradation and extensive 
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metabolic conversion (Cobby et al., 1977). Therefore an effective delivery 
system was required to protect DS in bloodstream that can extend its half life to 
provide enough time to cross the BBB and reach the GBM tissue. Our 
collaborators in Shenyang Pharmaceutical University, China developed a 
liposome encapsulated DS that improved the half life of DS to about 2 hours. 
But for GBM we had practical problems of delivering Lipo DS because of its size 
and probably insufficient time to reach the brain. So we had to think about 
further increasing the half life and decreasing the size of the delivering 
substance. Dr. Zhipeng Wang, post-doctoral research fellow in our group 
recently developed PLGA- coated DS nanoparticles which extended the half life 
up to 24 hours and are relatively small particles measuring in the nanometer 
ranges. We tested on orthotopic GBM xenograft mouse models. The results 
demonstrated that DS has remarkable potential of eliminating GBM tumours in 
the animal models.  The results were achieved with very low dose of 10mg/kg 
dose of PLGA-DS and 6mg/kg of oral copper gluconate supplement. The 
normal dose of free DS used for alcoholism treatment ranges between 300-
500mg.  We are continuing further experiments to have an enlarged animal 
study to demonstrate the effectiveness of PLGA-DS- nanoparticles.  
 
The tumour microenvironment plays a vital role in promoting the progression of 
GBM. My data suggest that hypoxic microenvironment could result in 
heterogeneous population due to interconversions and transitions between 
different cell phenotypes.   Further studies are required to understand the 
molecular mechanism of hypoxia induced CSCs and its relevance to 
physiological tumour conditions. The role of NF-B and HIFs has to be studied 
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in further details using techniques that can functionally knock out or knock down 
these genes and other important factors involved in the origin of GBM CSCs. 
We also aim to do chemical inhibitor studies to block the above pathways 
individually to further understand the relationship between hypoxia, NF-B and 
CSCs. If NF-B acts as a master regulator of hypoxia induced stemness and 
resistance, it will be interesting to see whether inhibition of NF-B in hypoxic 
cultures will stop the cells from being converted to mesenchymal phenotypes. 
Further studies are ongoing to analyse all 19 isoforms of ALDH in GBM CSCs 
to understand the regulators of these isoenzymes. 
 
In order to successfully treat tumours like GBM novel combination therapies 
targeting different phenotypes in different regions of the tumour 
microenvironment are necessary. Formulating the existing drugs in 
nanoparticles (NPs) will have unique advantages in delivering multiple 
anticancer drugs to tumour sites without systemic side effects. In addition it is 
possible to change existing pharmacokinetics and bio-distribution of drugs using 
NPs. There are several attempts made by researchers to formulate DS into gold 
NPS, lipid nanoemulsions, dendrimer NPS, polymeric micelles, etc. Since 
PLGA-DS NPs are working in vivo will do further analysis using these NPs. 
However our lab is also generated polymeric micelle NPs of DS. It will be very 
interesting to compare the effectiveness of both these NPS to select the best 
delivery system with high efficiency and low toxicity for the treatment of GBM. 
 
In summary, GBM contains CSC population that are highly resistant to 
anticancer drugs. These CSCs are probably hypoxia induced EMT phenotypes 
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with acquired mesenchymal characteristics that results in aggressive, 
chemoresistant and infiltrating nature of GBM.  NF-B along with HIF signalling 
orchestrates the various signalling pathways leading to EMT programme under 
hypoxic conditions and hence are important targets in eradicating GBM CSCs. 
ALDH activity resulting from the acquisition of CSC characteristics also play a 
major role in chemoresistance. DS is a specific inhibitor of NF-B pathway and 
a pan ALDH inhibitor.  DS forms a complex in combination with Cu, which was 
highly cytotoxic to GBM cells, hypoxic cells and also chemoresistant GBM 
CSCs. DS has a very short half life in blood stream which limits its clinical 
applications as an anticancer drug.  The new formulation of PLGA-DS- 
nanoparticles developed in our lab with extended half life significantly reduced 
GBM in xenograft models of GBM at very low doses in combination with oral 
copper gluconate. This also indicated that the new formulation effectively 
crossed the BBB. DS is a safe, well-understood, FDA approved drug that has 
been used in the anti-alcoholism clinic for over 60 years. DS does not show any 
systemic toxicity or severe side effects because of the low toxicity to normal 
cells. We have demonstrated that DS has excellent anticancer activity in a wide 
range of cancers, including the most aggressive form of colon, breast, and liver 
cancer and triple negative breast cancer.  Hence DS should be translated to 
clinics at the earliest at least for treatment of tumours like GBM where there are 
no successful therapeutic options at present.   
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